0001171520-11-000047.txt : 20110121 0001171520-11-000047.hdr.sgml : 20110121 20110121155620 ACCESSION NUMBER: 0001171520-11-000047 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20110115 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20110121 DATE AS OF CHANGE: 20110121 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HEMACARE CORP /CA/ CENTRAL INDEX KEY: 0000801748 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090] IRS NUMBER: 953280412 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-15223 FILM NUMBER: 11541445 BUSINESS ADDRESS: STREET 1: 15350 SHERMAN WAY STREET 2: SUITE 350 CITY: VAN NUYS STATE: CA ZIP: 91406 BUSINESS PHONE: 818-226-1968 MAIL ADDRESS: STREET 1: 15350 SHERMAN WAY STREET 2: SUITE 350 CITY: VAN NUYS STATE: CA ZIP: 91406 8-K 1 eps4055.htm HEMACARE CORPORATION

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of the earliest event reported): January 15, 2011

HEMACARE CORPORATION

(Exact name of registrant as specified in its charter)

California 000-15223 95-3280412
(State or other jurisdiction
of incorporation or organization)
(Commission
File Number)
(I.R.S. Employer
Identification No.)

 

15350 Sherman Way, Suite 350, Van Nuys, CA 91406

(Address of principal executive offices) (Zip Code)

 

(818) 226-1968

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[_] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[_] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[_] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 
 

Item 1.01 Change in Registrant’s Certifying Accountant

Effective as of January 15, 2011, HemaCare Corporation (the “Company”) entered into a letter agreement (the “Amendment”) with Wells Fargo Bank (the “Bank’), pursuant to which the parties amended that certain Credit Agreement, dated December 4, 2009 (the “Credit Agreement”), by and among the Company, the Bank and Coral Blood Services, Inc. (“Coral”), and the Bank waived the Company’s existing defaults under the Credit Agreement.

Under the Credit Agreement, as amended by the Amendment, outstanding borrowings, including outstanding advances and letters of credit, shall not at any time exceed the amount of cash collateral in a segregated, blocked deposit account maintained by the Company and/or Coral with the Bank, in which Bank has been granted a security interest of first priority to secure all present and future indebtedness of the Company to the Bank. The Company has pledged $660,000 in cash to the Bank, and the Company has outstanding letters of credit for an aggregate of $660,000 under the Credit Agreement.

In connection with the Amendment, the Company also entered into a First Modification To Promissory Note, and a Security Agreement Specific Rights to Payment, as modified by the Addendum attached thereto, each dated as of January 15, 2011.

The foregoing summary of the Amendment is qualified in its entirety by the actual agreements attached hereto as Exhibits 10.6 through 10.8 and incorporated herein by reference.

Item 8.01. Other Events

Included with this Current Report are Exhibits 10.1 through 10.5, which exhibits the Company is filing in response to a comment letter the Company received from the Securities Exchange Commission. The exhibits consist of material contracts previously filed by the Company with its periodic reports. The material contracts, as previously filed, omitted certain exhibits, schedules or other attachments thereto. The Company is filing the material contracts in their entirety as exhibits to this Current Report.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits.

The following exhibits are filed herewith:

Exhibit

Number Description

10.1 * Employment Agreement dated August 29, 2006, between HemaCare Corporation and Joseph Mauro.

10.2 * Employment Agreement dated August 29, 2006, between HemaCare Corporation and Valentin Adia.

2
 

 

10.3 Letter agreement dated August 29, 2006, among HemaCare Corporation, Teragenix Corporation, Dr. Lawrence Feldman and Dr. Karen Raben.

10.4 Assignment for the Benefit of Creditors made as of December 4, 2007.

10.5 Settlement Agreement and Mutual General Release entered into as of August 26, 2008, between HemaCare Corporation and Joseph Mauro and Valentin Adia.

10.6 Amendment to Credit Agreement, dated as of January 15, 2011, among Wells Fargo Bank, HemaCare Corporation and Coral Blood Services, Inc.

10.7 First Modification to Promissory Note, dated as of January 15, 2011, between HemaCare Corporation, Coral Blood Services, Inc. and Wells Fargo Bank.

10.8 Security Agreement Specific Rights to Payment, dated January 15, 2011, between HemaCare Corporation and Wells Fargo Bank, with addendum.

_________________

* Management contract and/or compensatory plan or arrangement.

3
 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:   January 21, 2011   HEMACARE CORPORATION
     
  By Lisa Bacerra,
    Chief Financial Officer

 

4
 

EXHIBIT INDEX

Exhibit

Number Description

10.1 * Employment Agreement dated August 29, 2006, between HemaCare Corporation and Joseph Mauro.

10.2 * Employment Agreement dated August 29, 2006, between HemaCare Corporation and Valentin Adia.

10.3 Letter agreement dated August 29, 2006, among HemaCare Corporation, Teragenix Corporation, Dr. Lawrence Feldman and Dr. Karen Raben.

10.4 Assignment for the Benefit of Creditors made as of December 4, 2007.

10.5 Settlement Agreement and Mutual General Release entered into as of August 26, 2008, between HemaCare Corporation and Joseph Mauro and Valentin Adia.

10.6 Amendment to Credit Agreement, dated as of January 15, 2011, among Wells Fargo Bank, HemaCare Corporation and Coral Blood Services, Inc.

10.7 First Modification to Promissory Note, dated as of January 15, 2011, between HemaCare Corporation, Coral Blood Services, Inc. and Wells Fargo Bank.

10.8 Security Agreement Specific Rights to Payment, dated January 15, 2011, between HemaCare Corporation and Wells Fargo Bank, with addendum.

_________________

* Management contract and/or compensatory plan or arrangement.

 

 

5

EX-10.1 2 ex10-1.htm

Exhibit 10.1

EMPLOYMENT AGREEMENT

This Employment Agreement (this “Agreement”) is entered into as of August 29, 2006 (the “Effective Date”), by and between Teragenix Corporation, a Florida corporation (the “Company”), and Joseph Mauro (“Executive”) (together, the “Parties”).

INTRODUCTION

WHEREAS, the shareholders of the Company and HemaCare Corporation, a California corporation (“HemaCare”) are entering into that certain Stock Purchase Agreement of even date herewith (the “Stock Purchase Agreement”);

WHEREAS, it is a condition to the consummation of the transactions contemplated by the Stock Purchase Agreement that the Company and Executive enter into this Agreement; and

WHEREAS, the Company desires to employ Executive as of the Effective Date and Executive desires to accept employment with the Company on the terms and conditions set forth below.

NOW, THEREFORE, in consideration of the foregoing recital and the respective covenants and agreements of the Parties contained in this document, the Company and Executive agree as follows:

1.                                       Employment.

(a)                                  Title; Duties.  During the Term, Executive will serve as Division President of the Company, and will report directly to HemaCare’s President and Chief Executive Officer (“CEO”).  Executive shall have such duties consistent with that of a President that may from time to time be designated or assigned to Executive pursuant to the directives of HemaCare’s President and CEO.  Executive shall perform faithfully the duties assigned to him to the best of his ability.

(b)                                 Other Activities.  During the Term, Executive shall devote his entire productive business time and attention to his duties on the Company’s behalf except for sick leave, vacations and approved leaves of absence; provided, however, that nothing in this Agreement shall prohibit Executive from (i) serving as a director of any entity or business enterprise which is not in direct competition with the business of the Company or any present or future affiliate of the Company and which does not create a real or perceived conflict of interest, (ii) otherwise participating in educational, welfare, social, religious and civic organizations or (iii) making any investments (other than “passive investments,” as defined below) in the securities of any entity or business enterprise which is not in direct competition with the business of the Company or any present or future affiliate of the Company and which does not create a real or perceived conflict of interest; provided, that Executive obtains the prior approval of the CEO with respect to any position described in clause (i) of this Section 1(b) and any investment (other than any “passive investments”) described in clause (iii) of this Section 1(b), which approval shall not be unreasonably withheld, delayed or conditioned.  An investment shall be considered a “passive investment” to the extent that such securities (x) are actively traded on a United States national securities exchange, on the NASDAQ National Market System or Small Cap Market System, on the OTC Bulletin Board, or on any foreign securities exchange, and (y) represent, at the time such investment is made, less than five percent (5%) of the aggregate voting power of such entity or business enterprise.

2.                                       Employment Term.  Subject to Section 9, Executive’s employment hereunder shall be for a term of thirty-six (36) months commencing on the Effective Date and expiring at the close of business on the day prior to the thirty-six (36) month anniversary of the Effective Date (the “Term”).  This Agreement shall automatically renew for successive one (1) year periods following the initial Term and any extensions thereof, if applicable, unless either party provides written notice to the other party not less than ninety (90) days prior to the end of the then-existing Term, that such party does not desire the Term to automatically renew, in which event this Agreement shall terminate as of the last day of the then-existing Term.

  

3.                                       Place of Employment.  Executive’s services shall be performed at the Company’s principal executive offices located at 5440 NW 33rd Avenue, Suite 108, Ft. Lauderdale, Florida 33309 or such other place as the Company and Executive shall mutually agree.

4.                                       Salary.  For all services rendered by Executive hereunder and all covenants and conditions undertaken by him pursuant to this Agreement, the Company shall pay, and Executive shall accept, as full compensation, the amounts set forth in this Section 4.

a.                                       Base Salary.  For all services to be rendered by Executive pursuant to this Agreement, the Company agrees to pay Executive a base salary (the “Base Salary”) of One Hundred and Seventy-Five Thousand Dollars ($175,000.00) on an annualized basis.  The Base Salary shall be paid in accordance with the Company’s regular payroll practices.  All amounts payable shall be reduced by standard withholding and other authorized deductions.  The Company, in its sole discretion, may increase (but not decrease) the Base Salary from time to time, provided, however, that commencing January 1, 2008, the Base Salary shall increase at a minimum level of 3% per annum during each year of the Term.

b.                                      Bonus.  Executive shall be eligible for a bonus of up to 20% of the Base Salary (the “Bonus”), starting in calendar year 2007, upon the achievement of specific goals and objectives, as determined in the sole discretion of HemaCare’s President and Chief Executive Officer.  The Bonus structure will put 100% of Executive’s Bonus potential at risk each year.  Executive must be employed by the Company at the time of payment to be eligible to receive any Bonus.

c.                                       Car Allowance.  During the Term, Executive shall receive a car allowance equal to $1,250 per month.

d.                                      Life Insurance.  The Company agrees to pay a whole life insurance policy for the Employee with a face amount equal to one times Executive’s salary.

e.                                       Deductions.  The Company shall deduct from the compensation described in Sections 4(a) and 4(b) any federal, state or local withholding taxes, social security contributions and any other amounts which may be required to be deducted or withheld by the Company pursuant to any federal, state or local laws, rules or regulations.

f.                                         Disability Adjustment.  Any compensation otherwise payable to Executive pursuant to Sections 4(a) and 4(b) in respect of any period during which Executive is Disabled (as defined in Section 9(d)) shall be reduced by any amounts payable to Executive for loss of earnings or the like under any insurance plan or policy sponsored by the Company.

5.                                       Expenses.  The Company shall from time to time pay or reimburse Executive for the reasonable and necessary expenses incurred by Executive in connection with the performance of his duties hereunder if (a) such expenses have been previously approved by the Company or reimbursement is otherwise appropriate in accordance with the Company’s established policies and (b) the Company receives such verification thereof as the Company may require in order to qualify such expenses as deductible business expenses.

6.                                       Other Benefits.  In addition to his compensation provided by the foregoing, so long as Executive is employed by the Company, Executive shall be entitled to all of the benefits available (a) generally to Company employees pursuant to Company programs, and/or (b) to senior level executives at the Company, including, by way of illustration, personal leave, paid holidays, sick leave, profit-sharing, retirement, disability, dental, vision, group sickness, accident or health insurance programs or equity incentive plans of the Company which may now or hereafter be in effect, or in any other or additional such programs which may be established by the Company, as and to the extent any such programs are or may from time to time be in effect, as determined by the Company.  The Company shall implement and maintain a health and medical plan as soon as is reasonably practical after the execution of this Agreement and maintain such plan throughout the Term.  The Company shall have the right to amend, reduce or completely terminate any or all such plans by duly authorized action respecting all employees covered by such plans as a group.

2

 

7.                                       Vacations and Holidays.  During each calendar year, Executive shall accrue compensated personal time off (“PTO”) at the rate of twenty-nine (29) days per year.  If Executive’s earned but unused PTO reaches forty-eight (48) days, Executive will not continue to accrue additional PTO time until he uses sufficient PTO to fall below this maximum amount.  Thereafter, Executive shall start earning PTO benefits again until the forty-eight (48) day maximum is again reached.  Any accrued but unused PTO time will be paid to Executive on a pro rata basis at termination of employment for any reason.  Executive shall not be compensated for holidays (other than as part of the PTO system).

8.                                       Other Activities.  Executive shall, during the term of his employment by the Company, devote all of his working time and efforts to the business and affairs of the Company and its subsidiaries and to the diligent and faithful performance of the duties assigned to him pursuant to this Agreement.

9.                                       Termination.  The Company may terminate Executive’s employment for any reason or no reason, with or without Cause (as defined below), with the consequences described in Section 10 of this Agreement.  Executive may terminate his employment with Good Reason (as defined below) by giving the Company thirty (30) days’ advance written notice.  Upon termination of Executive’s employment with the Company, Executive’s rights under any applicable benefit plans shall be determined under the provisions of those plans.

a.                                       Death.  Executive’s employment shall terminate immediately in the event of his death.

b.                                      Cause.  Subject to Executive’s failure to cure a breach in the manner and time described below, the Company may terminate Executive’s employment for Cause immediately. As used in this Agreement, the term “for Cause” shall be limited to a termination for the following acts by Executive:  (i) misappropriation or embezzlement of the funds or property of the Company or any subsidiary, falsification of any Company or subsidiary documents or records or any unauthorized attempt by the Executive to take any business or business opportunities of the Company or any subsidiary for his or her own personal gain; (ii) Executive’s failure or inability to perform any material duties contemplated by this Agreement for a period of thirty (30) days, except in the event that the Executive is determined to have a Disability (as defined in Section 9(d)) or in the event of Executive’s death; (iii) grossly negligent, reckless or willful misconduct or insubordination in connection with Executive’s performance of his duties; (iv) any material breach by Executive of any agreement (including this Agreement or the Confidentiality Agreement (as defined in Section 11)) between Executive and the Company; (v) Executive’s conviction (including any plea of guilty or nolo contendere) of any felony, any misdemeanor involving dishonesty or fraud, or any other criminal act that impairs or could impair Executive’s ability to perform his or her duties; (vi) the Executive’s material violation of Company policies, including, without limitation, policies on prohibition of unlawful harassment or (vii) any illegal drug or illegal substance abuse, illegal drug or illegal substance addiction, or chronic addiction to alcohol on the part of Executive, other than any use of medication prescribed by a doctor.  The determination of Cause shall be made by HemaCare’s President and Chief Executive Officer in her reasonable discretion.  Anything herein to the contrary notwithstanding, as to any termination based upon clause (iii) above, the Company shall give the Executive written notice prior to terminating this Agreement of the Executive’s employment, setting forth a general description of the grounds for termination and the conduct required to cure such grounds for termination.  The Executive shall have thirty (30) days from the receipt of such notice within which to cure any such grounds for termination to the satisfaction of the Company, which shall be determined by the Company in its reasonable discretion.

c.                                       Termination by Executive for “Good Reason”.  Subject to the provisions outlined below, at any time after the date Executive commences employment under this Agreement, upon thirty (30) days’ advance written notice to the Company of his intent to terminate the Agreement, Executive shall have the right to terminate his employment under this Agreement for “Good Reason”.  For purposes of this Agreement, “Good Reason” is defined as any one of the following:  (i) the Company fails to comply with the provisions hereof governing compensation and benefits to Executive, (ii) the Company moves the Company’s office location in violation of Section 3, (iii) the Company fails to maintain Executive in the position of Division President (or a comparable position) described in Section 1 or materially diminishes his duties or responsibilities in such positions, (iv) the Company materially breaches any other provision of this Agreement or any other written agreement with Executive, or (v) conduct by the Company occurs that would cause Executive to commit fraudulent acts or would expose Executive to criminal liability; provided, however, that it shall not constitute Good Reason unless Executive shall have provided the Company with written notice of its alleged actions constituting Good Reason (which notice shall specify in reasonable detail the particulars of such Good Reason) and the Company has not cured any such alleged Good Reason within thirty (30) days of the Company’s receipt of such written notice.

3

 

d.                                      Disability.  The Company may terminate Executive’s employment for Disability by giving Executive three (3) days’ advance written notice.  For all purposes under this Agreement, “Disability” shall mean that Executive, at the time such notice is given, has been unable to substantially perform his duties under this Agreement for a period of not less than three (3) consecutive months (or after four (4) months in the aggregate during a twelve-month period, whether consecutive or not) as the result of his incapacity due to physical or mental illness.  A determination of Disability shall be made by the Board in consultation with a physician reasonably satisfactory to Executive (or his representative) and the Company, and Executive shall cooperate with the efforts to make such determination. Any such determination shall be conclusive and binding on the Parties for the purposes of this Agreement.

10.                                 Termination Benefits.  Upon the termination of Executive’s employment, Executive shall be entitled to receive:

a.                                       Death or Disability.  Executive shall be entitled to the following:

(i)                  Payment of any Base Salary accrued but unpaid as of the date of death or termination for Disability;

(ii)               Payments in accordance with any disability insurance policy maintained by the Company and payment of Base Salary to the extent required to ensure that Executive receives the full amount of Base Salary through the combined payments under disability insurance (whether pursuant to a disability insurance policy provided by the Company, or pursuant to state disability benefits) and salary payments from the Company, for the remainder of the Term;

(iii)            Reimbursement for any unpaid expenses incurred in accordance with Section 5; and

(iv)           Payment of any and all earnouts, or other consideration amounts that the Company is obligated to pay pursuant to the Stock Purchase Agreement (but only if actually earned, and such amounts shall be paid on the date(s) provided in the Stock Purchase Agreement), and any bonuses earned as of the date of termination pursuant to Section 4(b) of this Agreement.

b.                                      Termination for Cause.  Executive shall be entitled to receive on the date of termination any accrued but unpaid salary and shall be reimbursed for any reimbursable expenses pursuant to Section 5 that have not been reimbursed prior to such termination.

c.                                       Termination by Company Other than for Cause.  In the event the Company terminates Executive’s employment other than for Cause, Executive shall be entitled to the following:

(i)                  Payment of any Base Salary accrued but unpaid as of the date of termination;

(ii)               An amount equal to Executive’s monthly Base Salary in effect on the date of termination for a period equal to the greater of the remainder of the Term or twelve (12) months;

(iii)            The Company will pay to continue Executive’s health insurance coverage (i.e., make COBRA payments) following the date of termination other than for Cause until the earlier of (A) the greater of (1) the remainder of the Term or (2) twelve (12) months, and (B) until Executive obtains full-time employment, provided that such coverage remains available with respect to Executive; and

(iv)           Payment of any and all earnouts, or other consideration amounts payable by the Company pursuant to the Stock Purchase Agreement, whether earned or unearned, within thirty (30) days of the date of termination, and any bonuses earned as of the date of termination pursuant to Section 4(b) of this Agreement.

4
 
 

d.                                      Termination by Executive for “Good Reason”.  A termination for Good Reason shall have the same consequences as provided in Section 10(c) for a termination other than for Cause.

of employment by Executive on his own initiative, other than a termination due to death or Disability or for Good Reason, shall have the same consequences as provided in Section 10(b) for a termination for Cause.

f.                                         Other Benefits.  Except as expressly set forth herein or pursuant to the terms of the Company’s written employee benefit plans and policies in effect at the time of such termination, Executive shall not be entitled to any pay or benefits upon his termination.

11.                                 Proprietary Information and Inventions Agreement.  Executive has signed a Proprietary Information and Inventions Agreement (the “Confidentiality Agreement”) substantially in the form attached hereto as Exhibit A.  Executive hereby represents and warrants to the Company that he has complied with all of the obligations under the Confidentiality Agreement and agrees to continue to abide by the terms of the Confidentiality Agreement and further agrees that the provisions of the Confidentiality Agreement shall survive any termination of this Agreement and/or Executive’s employment relationship with the Company.

12.                                 Indemnification.  During the Term, the Company shall indemnify Executive and hold Executive harmless from and against all claims, actions, suits, proceedings, liabilities, damages, fines, costs and expenses (including, without limitation, reasonable attorneys’ fees and expenses) (collectively, “Losses”) which may be incurred by Executive in connection with the performance of his duties hereunder, to the fullest extent permitted by applicable law and to the same extent provided to any other senior executive officer of the Company, except with respect to any Losses suffered by Executive in connection with the transactions contemplated by the Stock Purchase AgreementExpenses advanced to Executive under this Section 12 shall be repaid by Executive on demand if and to the extent such advanced expenses are found not to be lawfully indemnifiable by a competent tribunal.

13.                                 Exclusive Agreement.  Executive represents and warrants that his employment by the Company as described herein does not and shall not conflict with and is not and will not be constrained by any prior employment or consulting agreement, arrangement or relationship, whether written or oral.  Executive agrees not to make any unauthorized disclosure or use, on behalf of the Company, of any confidential information belonging to any of Executive’s former employers.  Executive represents that he is not in unauthorized possession or control of any materials containing confidential and proprietary or private information of a third party.

14.                                 Assignment.  This Agreement and all rights under this Agreement shall be binding upon and inure to the benefit of and be enforceable by the Parties hereto and their respective personal or legal representatives, executors, administrators, heirs, distributees, devisees, legatees, successors and assigns.  Neither this Agreement nor any right or obligation of Executive under this Agreement may be assigned or transferred by Executive to any other person or entity without the prior written consent of the Company.  The Company may assign this Agreement; provided, however, that such assignment will not relieve the Company of its obligations hereunder.

15.                                 Notices.  For purposes of this Agreement, notices and other communications provided for in this Agreement shall be in writing and shall be delivered personally or sent by United States certified mail, return receipt requested, postage prepaid, addressed as follows:

  If to Executive: Joseph Mauro
    12590 Little Palm Lane
    Boca Raton, FL 33428
    Facsimile No.:                      561-488-2584
     
  If to the Company: c/o Judi Irving
    HemaCare Corporation
    21101 Oxnard Street
    Woodland Hills, CA 91367

 

 
5
 

or to such other address or the attention of such other person as the recipient party has previously furnished to the other party in writing in accordance with this Section 15.  Such notices or other communications shall be effective upon the earlier of delivery or three days after they have been mailed as provided above.

16.                                 Integration.  This Agreement, and Exhibit A hereto, represent the entire agreement and understanding between the Parties as to the subject matter hereof and supersede all prior or contemporaneous agreements whether written or oral.  No waiver, alteration, or modification of any of the provisions of this Agreement shall be binding unless in writing and signed by duly authorized representatives of the Parties hereto.

17.                                 Waiver.  Failure or delay on the part of either Party hereto to enforce any right, power, or privilege hereunder shall not be deemed to constitute a waiver thereof.  Additionally, a waiver by either Party of a breach of any promise hereof by the other Party shall not operate as or be construed to constitute a waiver of any subsequent breach by such other Party.

18.                                 Severability.  Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had never been contained herein.

19.                                 Headings.  The headings of the Sections contained in this Agreement are for reference purposes only and shall not in any way affect the meaning or interpretation of any provision of this Agreement.

20.                                 Applicable Law.  This Agreement shall be governed by and construed in accordance with the internal substantive laws, and not the choice of law rules, of the State of Florida.

21.                                 Counterparts; Facsimile.  This Agreement may be executed in one or more counterparts and via facsimile, none of which need contain the signature of more than one party hereto, and each of which shall be deemed to be an original, and all of which together shall constitute a single agreement.

22.                                 Arbitration.

a.                                       The Company and Executive agree that any dispute or controversy arising out of or relating to any interpretation, construction, performance, termination or breach of this Agreement or Executive’s employment with the Company or termination of such employment, will be settled by final and binding arbitration by a single arbitrator to be held in Los Angeles County, California, in accordance with the National Rules for the Resolution of Employment Disputes of the American Arbitration Association (“AAA Rules”) then in effect.  Without limiting any other provision herein, this Section 22 shall survive the termination of Executive’s employment with the Company and will apply to any claim, dispute, or controversy that arises during or after the termination of Executive’s employment with the Company.  Executive and the Company agree that the agreement to arbitrate under this Section 22 is subject to and enforceable under the provisions of the Federal Arbitration Act (the “FAA”), 9 U.S.C. § § I, et seq.  The arbitrator selected shall have the authority to grant Executive or the Company or both all remedies otherwise available by law, including injunctions.

b.                                      Notwithstanding anything to the contrary in the AAA Rules, the arbitration shall provide (i) for written discovery and depositions adequate to give the Parties access to documents and witnesses that are essential to the dispute and (ii) for a written decision by the arbitrator that includes the essential findings and conclusions upon which the decision is based.  Consistent with applicable law, Executive and the Company shall each bear his or its own costs and attorneys’ fees incurred in conducting the arbitration and, except in such disputes where Executive asserts a claim under a state or federal statute prohibiting discrimination in employment, a claim for wrongful termination in violation of public policy, or a claim involving enforcement of rights under any statute enacted for a public reason (the “Excepted Claims”), shall split equally the fees and administrative costs charged by the arbitrator and AAA.  In disputes where Executive asserts an Excepted Claim against the Company, Executive shall be required to pay only the AAA filing fee to the extent such filing fee does not exceed the fee to file a complaint in state or federal court and the Company shall pay the balance of the arbitrator’s fees and administrative costs.

6
 

c.                                       The decision of the arbitrator will be final, conclusive and binding on the Parties to the arbitration.  The prevailing party in the arbitration, as determined by the arbitrator, shall be entitled to recover his or its reasonable attorneys’ fees and costs, including the costs or fees charged by the arbitrator and AAA.  In disputes where Executive asserts an Excepted Claim, reasonable attorneys’ fees shall be awarded by the arbitrator based on the same standard as such fees would be awarded if the Excepted Claim had been asserted in state or federal court.  Judgment may be entered on the arbitrator’s decision in any court having jurisdiction.

The parties hereby acknowledge that they have voluntarily negotiated the terms of this Agreement, including, without limitation, this Section 22, have consulted with counsel concerning such terms, and voluntarily agree to them.

         
  /s/ J I   /s/ J M  
  Company’s Initials   Executive’s Initials  

 

23.                                 Advice of Counsel.  The Parties represent and agree that they have carefully read and fully understand all of the provisions of this Agreement, and the terms and conditions set forth herein, and that they are voluntarily entering into this Agreement.  The Parties affirm that, prior to execution of this Agreement, they have consulted with counsel concerning the terms and conditions set forth herein or have had the opportunity to do so.

24.                                 Survival of Certain Terms.  The provisions of Sections 9, 10, 11, 14 and 22 of this Agreement shall survive the termination of this Agreement; provided, however, that the survival of such provisions after the termination of this Agreement shall in no way constitute an extension of the Term.  Except as set forth in the prior sentence, all other rights and obligations of the Parties shall cease upon termination of this Agreement.

[Rest of page intentionally left blank]

7
 

IN WITNESS WHEREOF, each of the Parties has executed this Employment Agreement, in the case of the Company by its duly authorized officer, as of the day and year first above written.

  TERAGENIX CORPORATION
     
     
  By: /s/ Judi Irving
  Title: Chief Executive Officer
     
     
  EXECUTIVE
     
     
  By: /s/ Joseph Mauro
    Joseph Mauro

 

S-1
 

EXHIBIT A

EMPLOYEE PROPRIETARY INFORMATION
AND INVENTIONS AGREEMENT

In consideration of my employment by _____________ (the "Company") and the compensation I receive from the Company, I agree that:

1. Proprietary Information. I understand that the Company possesses and will possess Proprietary Information that is important to its business. "Proprietary Information" is information (whether conveyed orally, in writing or otherwise) that was or will be developed, created, or discovered by or on behalf of the Company, or that became or will become known by, or was or is conveyed to the Company, that has or could have commercial value in the Company's business, unless (a) the information is or becomes publicly known through lawful means; or (b) the information is disclosed to me without confidential or proprietary restriction by a third party who rightfully possesses the information (without confidential or proprietary restriction) and who did not learn of it directly or indirectly from the Company.

Proprietary Information includes, without limitation, any Company Inventions (as defined below) and any information relating to (i) client/customer lists, vendor lists or other lists or compilations containing client, customer or vendor information; (ii) information about products, proposed products, research, product development, techniques, processes, costs, profits, markets, marketing plans, strategies, forecasts, sales or commissions; (iii) plans for the future development or new product concepts; (iv) manufacturing techniques or processes, documents, books, papers, drawings, schematics, models, sketches, computer programs, databases or other data, including electronic data recorded or retrieved by any means; (v) the compensation, performance and terms of employment of other employees; (vi) all other information that has been or will be given to me in confidence by the Company (or any affiliate); (vii) software in various stages of development, and any designs, drawings, schematics, specifications, techniques, models, data, source code, algorithms, object code, documentation, diagrams, flow charts, research development, processes and procedures relating to any software; and (viii) any information that the Company obtains from another party that it treats as proprietary or designates as Proprietary Information.

At all times, both during my employment with the Company and after my termination, I will not, directly or indirectly, use, make available, sell, disclose or otherwise communicate to any third party, other than in my assigned duties for the benefit of the Company, any Proprietary Information. I am aware that the unauthorized disclosure of Proprietary Information may be highly prejudicial to the Company's interests, an invasion of privacy, and an improper disclosure of trade secrets. Without limiting the foregoing, I shall not make copies of, or otherwise reproduce, Proprietary Information unless authorized by the Company for reproduction.

2. Company Materials. "Company Materials" are documents or other media or tangible items that contain or embody Proprietary Information or any other information concerning the business, operations or plans of the Company, whether such documents have been prepared by me or by others. "Company Materials" include, without limitation, blueprints, drawings, photographs, charts, graphs, notebooks, customer lists, computer software, media or printouts, sound recordings and other printed, typewritten or handwritten documents, as well as samples, prototypes, models, products and the like.

 
 

 

3. Intellectual Property.

3.1 All Proprietary Information and all right, title and interest in and to any patents, patent rights, copyrights, trademark rights, mask work rights, trade secret rights, and all other intellectual and industrial property and proprietary rights that currently exist or may exist in the future anywhere in the world (collectively, "Rights") in connection therewith shall be the sole property of the Company. I hereby assign to the Company any Rights I may have or acquire in such Proprietary Information.

3.2 I acknowledge and agree that I have no expectation of privacy with respect to the Company's telecommunications, networking or information processing systems (including, without limitation, stored company files, e-mail messages and voice messages) and that my activity and any files or messages on or using any of those systems may be monitored at any time without notice. I further agree that any property situated on the Company's premises and owned by the Company, including disks and other storage media, filing cabinets or other work areas, is subject to inspection by Company personnel at any time with or without notice. All Company Materials shall be the sole property of the Company. I agree that during my employment with the Company, I will not remove any Company Materials from the business premises of the Company or deliver any Company Materials to any person or entity outside the Company, except as I am required to do in connection with performing the duties of my employment. I recognize that the unauthorized taking of any Proprietary Information may be a crime under the Cal. Penal Code §499c or comparable laws of other states or the United States, and may also result in civil liability under Sections 3426.1 through 3426.11 of the California Civil Code, or comparable laws of other states. I further agree that, immediately upon the termination of my employment by me or by the Company for any reason, or for no reason, or during my employment if so requested by the Company, I will return all Company Materials, apparatus, equipment and other physical property, or any reproduction of such property, excepting only (a) my personal copies of records relating to my compensation; (b) my personal copies of any materials previously distributed generally to stockholders of the Company; and (c) my copy of this Employee Proprietary Information and Inventions Agreement (the "Agreement").

3.3 I agree that all "Inventions" (which term includes patentable or non-patentable inventions, original works of authorship, derivative works, trade secrets, trademarks, copyrights, service marks, mask works, discoveries, patents, technology, algorithms, computer software, application programming interfaces, protocols, formulas, compositions, ideas, designs, processes, techniques, know-how, data and all improvements, rights and claims related to the foregoing), which I have made, conceived, reduced to practice or developed, and which I make, conceive, reduce to practice or develop (in whole or in part, either alone or jointly with others) during my employment and in connection with the business of the Company, shall be the sole property of the Company to the maximum extent permitted by Section 2870 of the California Labor Code. I hereby assign, without further consideration, all such Inventions ("Company Inventions") to the Company (free and clear of all liens and encumbrances), and the Company shall be the sole owner of all Rights in connection therewith. No assignment in this Agreement shall extend to Inventions, the assignment of which is prohibited by Labor. Code Section 2870, which states:

2
 

 

Any provision in an employment agreement which provides that an employee shall assign, or offer to assign, any of his or her rights in an invention to his or her employer shall not apply to an invention that the employee developed entirely on his or her own time without using the employer's equipment, supplies, facilities, or trade secret information except for those inventions that either:

1. Relate at the time of conception or reduction to practice of the invention to the employer's business, or actual or demonstrably anticipated research or development of the employer.

2. Result from any work performed by the employee for the employer.

I acknowledge that all original works of authorship which have been made and which are made by me (in whole or in part, either alone or jointly with others) within the scope of my employment and which are protectable by copyright are "works made for hire," as defined in the United States Copyright Act (17 USCA, Section 101). I have not disclosed and will not disclose Inventions covered by this Section 3.3 to any person outside the Company, unless I am requested to do so by management personnel of the Company.

3.4 I have maintained and agree to maintain adequate and current written records on the development of all Company Inventions and have disclosed and agree to disclose promptly to the Company all Company Inventions and relevant records, which records will remain the sole property of the Company. I further agree that all information and records pertaining to any idea, process, trademark, service mark, invention, technology, computer program, original work or authorship, design, formula, discovery, patent, or copyright that I do not believe to be a Company Invention, but is conceived, developed, or reduced to practice by me (in whole or in part, either alone or jointly with others) during my employment, shall be promptly disclosed to the Company (such disclosure to be received in confidence). The Company shall examine such information to determine if in fact the ideas, process, or invention, etc., constitutes a Company Invention and is therefore subject to assignment under Section 3.3. I will also disclose to the Company all Inventions conceived, reduced to practice, used, sold, exploited or developed by me (in whole or in part, either alone or jointly with others) within one (1) year of the termination of my employment with the Company ("Presumed Inventions"); such disclosures shall be received by the Company in confidence, to the extent they are not assigned to the Company in Section 3.3, and do not extend such assignment. Because of the difficulty of establishing when any Presumed Invention is first conceived or developed by me, or whether it results from access to Proprietary Information or the Company's equipment, facilities, and data, I agree that all Presumed Inventions and all Rights associated therewith shall be presumed to be Company Inventions and therefore assignable to the Company_ I can rebut this presumption, if I prove that a Presumed Invention is not a Company Invention.

3
 

 

3.5 I agree to perform, during and after my employment, all acts deemed necessary or desirable by the Company to permit and assist it, at the Company's expense, in evidencing, perfecting, recording, obtaining, maintaining, defending and enforcing Rights and/or my assignment with respect to such Company Inventions in any and all countries. Such acts may include, without limitation, execution of documents and assistance or cooperation in legal proceedings. Should the Company be unable to secure my signature on any document necessary to apply for, prosecute, obtain, enforce or defend any Rights relating to any assigned Invention, whether due to my mental or physical incapacity or any other cause, I hereby irrevocably designate and appoint the Company and its duly authorized officers and agents, as my agents and attorneys-in-fact, with full power of substitution, to act for and in my behalf and instead of me, to execute and file any documents and to do all other lawfully permitted acts to further the above purposes with the same legal force and effect as if executed by me.

3.6 Any assignment of copyright hereunder (and any ownership of a copyright as a work made for hire) includes all rights of paternity, integrity, disclosure and withdrawal and any other rights that may be known as or referred to as "moral rights" (collectively, "Moral Rights"). To the extent such Moral Rights cannot be assigned under applicable law and to the extent the following is allowed by the laws in the various countries where Moral Rights exist, I hereby waive such Moral Rights and consent to any action of the Company that would violate such Moral Rights in the absence of such waiver and consent. I will confirm any such waivers and consents from time to time as requested by the Company.

3.7 I agree that I will not incorporate in any way, or permit to be incorporated in any way, any Inventions made, conceived, reduced to practice or developed by me (in whole or in part, either alone or jointly with others) either: (a) prior to or (b) outside the scope of my engagement as an independent contractor for the Company ("Prior Inventions"). Notwithstanding the foregoing, I hereby grant the Company a royalty-free, nonexclusive, perpetual, irrevocable, transferable, worldwide license (with rights to sublicense through multiple tiers of sublicense) to practice all Rights relating to any Prior Inventions (or other Inventions that are not assigned or assignable to Company hereunder) that become incorporated in any way, or I permit to be incorporated in any way, in any Company Inventions or any other Company technology or products.

3.8 I understand that nothing in this Agreement is intended to expand the scope of protection provided me by Sections 2870 through 2872 of the California Labor Code.

4. Former Employer Information. I agree that I will not, during my employment with the Company, improperly use or disclose any confidential information, proprietary information or trade secrets of my former or concurrent employers. I agree that I will not bring onto the premises of the Company any document or any property belonging to my former employers unless consented to in writing by them. I represent and warrant that I have returned all property and confidential information belonging to all prior employers.

5. Prior Actions and Knowledge. I represent and warrant that from the time of my first contact or communication with the Company, I have held in strict confidence all Proprietary Information and have not and will not: (a) disclose any Proprietary Information or deliver any Company Materials to anyone outside of the Company, or (b) use, copy, publish, or summarize any Proprietary Information or remove any Company Materials from the business premises of the Company, except to the extent necessary and appropriate to carry out my responsibilities as an employee of the Company, or (c) improperly use or disclose any confidential information, proprietary information or trade secrets of my former or concurrent employers or any other third party, or (d) bring onto the premises of the Company any document or any property belonging .to my former employers unless consented to in writing by them.

4
 

 

6. No Conflict with Obligations to Third Parties. I represent that my performance of all the terms of this Agreement has not breached and will not breach any agreement to keep in confidence proprietary or confidential information acquired by me in confidence or in trust prior to my employment with the Company_ I have not entered into, and I agree I will not enter into, any agreement either written or oral in conflict herewith or in conflict with my employment with the Company. The performance of this Agreement does not and will not violate any applicable law, rule or regulation or any proprietary or other right of any third party.

7. Remedies; Waiver. I recognize that nothing in this Agreement is intended to limit any remedy of the Company under the California Uniform Trade Secrets Act. I recognize that my violation of this Agreement could cause the Company irreparable harm, the amount of which may be extremely difficult to estimate, making any remedy at law or in damages inadequate. Therefore, I agree that the Company shall have the right to apply to any court of competent jurisdiction for an order restraining any breach or threatened breach of this Agreement and for any other relief the Company deems appropriate. This right shall be in addition to any other remedy available to the Company. I ALSO ACKNOWLEDGE AND UNDERSTAND THAT I SHALL NOT, UNDER ANY CIRCUMSTANCE, HAVE ANY RIGHT TO SEEK OR ATTEMPT TO SEEK ANY INJUNCTIVE RELIEF AGAINST THE COMPANY WITH RESPECT TO ANY BREACH OR THREATENED BREACH OF THIS AGREEMENT, AND I HEREBY WAIVE ANY AND ALL SUCH RIGHTS AGAINST THE COMPANY.

8. Survival. I agree that my obligations under Sections 1, 3, and 7 through 15 of this Agreement shall continue in effect after termination of my employment, regardless of the reason or reasons for termination, and whether such termination is voluntary or involuntary on my part, and that the Company is entitled to communicate my obligations under this Agreement to any future employer or potential employer of mine.

9. Controlling Law; Venue; Severability. I agree that the sole jurisdiction and venue for actions related to the subject matter hereof shall be the state and federal courts located in the County of Los Angeles, California. I further agree that if one or more provisions of this Agreement are held to be illegal or unenforceable under applicable California law, such illegal or unenforceable portion(s) shall be limited or excluded from this Agreement to the minimum extent required so that this Agreement shall otherwise remain in full force and effect and enforceable in accordance with its terms.

10. Successors and Assigns. This Agreement shall be binding upon me, my heirs, executors, assigns, and administrators and shall inure to the benefit of the Company, its subsidiaries, successors and assigns. The failure, whether purposeful or otherwise, to exercise in any instance any right, power or privilege under this Agreement or under law shall not constitute a waiver of any other right, power or privilege, nor of the same right, power or privilege in any other instance.

5
 

11. Entire Agreement/Modification. The terms of this Agreement (including all attached Exhibits, which are incorporated herein by this reference) are the final expression of my agreement with respect to its subject matter and may not be contradicted by evidence of any prior or contemporaneous agreement. This Agreement can only be modified by a subsequent written agreement executed by an officer of the Company.

12. Integration. This Agreement supersedes all, and may not be contradicted by evidence of any, other prior and contemporaneous agreements and statements on these subjects. If any practices, policies, or procedures of the Company, now or in the future, that apply to me are inconsistent with the terms hereof, the provisions of this Agreement shall control unless changed in writing by the Company.

13. Employment at Will. This Agreement is not an employment agreement. Except as set forth in my employment agreement, if any, the Company may terminate my employment with it at any time, with or without cause.

14. Construction. This Agreement shall be construed as a whole, according to its fair meaning, and not in favor of or against any party. By way of example and not limitation, this Agreement shall not be construed against the party responsible for any language in this Agreement. The headings of the paragraphs hereof are inserted for convenience only, and do not constitute part of and shall not be used to interpret this Agreement.

15. Rights Cumulative. The rights and remedies provided hereby to the Company are cumulative, and the exercise of any right or remedy by the Company, whether pursuant hereto, to any other agreement, or to law, shall not preclude or waive the Company's right to exercise any or all other rights and remedies.

6
 

I HAVE READ THIS AGREEMENT CAREFULLY AND I UNDERSTAND AND ACCEPT THE OBLIGATIONS WHICH IT IMPOSES UPON ME WITHOUT RESERVATION. I HAVE HAD THE OPPORTUNITY TO CONSULT LEGAL COUNSEL IN REGARD TO THIS AGREEMENT AND AM FULLY AWARE OF ITS LEGAL EFFECT. I HAVE ENTERED INTO THIS AGREEMENT FREELY AND VOLUNTARILY AND BASED ON MY OWN JUDGMENT. NO PROMISES OR REPRESENTATIONS HAVE BEEN MADE TO ME TO INDUCE ME TO SIGN THIS AGREEMENT.

 

Date:      
      Employee Signature

 

Accepted and Agreed to:

 

By:    
Name:    
Title:    

 

7


 

EX-10.2 3 ex10-2.htm

Exhibit 10.2

EMPLOYMENT AGREEMENT

This Employment Agreement (this “Agreement”) is entered into as of August 29, 2006 (the “Effective Date”), by and between Teragenix Corporation, a Florida corporation (the “Company”), and Valentin Adia (“Executive”) (together, the “Parties”).

INTRODUCTION

WHEREAS, the shareholders of the Company and HemaCare Corporation, a California corporation (“HemaCare”) are entering into that certain Stock Purchase Agreement of even date herewith (the “Stock Purchase Agreement”);

WHEREAS, it is a condition to the consummation of the transactions contemplated by the Stock Purchase Agreement that the Company and Executive enter into this Agreement; and

WHEREAS, the Company desires to employ Executive as of the Effective Date and Executive desires to accept employment with the Company on the terms and conditions set forth below.

NOW, THEREFORE, in consideration of the foregoing recital and the respective covenants and agreements of the Parties contained in this document, the Company and Executive agree as follows:

1. Employment.

(a) Title; Duties.  During the Term, Executive will serve as Vice President, Business Development of the Company, and will report directly to the Company’s Division President (the “Company President”).  Executive shall have such duties consistent with that of a Vice President, Business Development that may from time to time be designated or assigned to Executive pursuant to the directives of the Company President.  Executive shall perform faithfully the duties assigned to him to the best of his ability.

(b) Other Activities.  During the Term, Executive shall devote his entire productive business time and attention to his duties on the Company’s behalf except for sick leave, vacations and approved leaves of absence; provided, however, that nothing in this Agreement shall prohibit Executive from (i) serving as a director of any entity or business enterprise which is not in direct competition with the business of the Company or any present or future affiliate of the Company and which does not create a real or perceived conflict of interest, (ii) otherwise participating in educational, welfare, social, religious and civic organizations or (iii) making any investments (other than “passive investments,” as defined below) in the securities of any entity or business enterprise which is not in direct competition with the business of the Company or any present or future affiliate of the Company and which does not create a real or perceived conflict of interest; provided, that Executive obtains the prior approval of HemaCare’s President and Chief Executive Officer (“CEO”) with respect to any position described

 

 

in clause (i) of this Section 1(b) and any investment (other than any “passive investments”) described in clause (iii) of this Section 1(b), which approval shall not be unreasonably withheld, delayed or conditioned.  An investment shall be considered a “passive investment” to the extent that such securities (x) are actively traded on a United States national securities exchange, on the NASDAQ National Market System or Small Cap Market System, on the OTC Bulletin Board, or on any foreign securities exchange, and (y) represent, at the time such investment is made, less than five percent (5%) of the aggregate voting power of such entity or business enterprise.

2. Employment Term.  Subject to Section 9, Executive’s employment hereunder shall be for a term of thirty-six (36) months commencing on the Effective Date and expiring at the close of business on the day prior to the thirty-six (36) month anniversary of the Effective Date (the “Term”).  This Agreement shall automatically renew for successive one (1) year periods following the initial Term and any extensions thereof, if applicable, unless either party provides written notice to the other party not less than ninety (90) days prior to the end of the then-existing Term, that such party does not desire the Term to automatically renew, in which event this Agreement shall terminate as of the last day of the then-existing Term.

3. Place of Employment.  Executive’s services shall be performed at the Company’s principal executive offices located at 5440 NW 33rd Avenue, Suite 108, Ft. Lauderdale, Florida  33309 or such other place as the Company and Executive shall mutually agree.

4. Salary.  For all services rendered by Executive hereunder and all covenants and conditions undertaken by him pursuant to this Agreement, the Company shall pay, and Executive shall accept, as full compensation, the amounts set forth in this Section 4.

a. Base Salary.  For all services to be rendered by Executive pursuant to this Agreement, the Company agrees to pay Executive a base salary (the “Base Salary”) of One Hundred and Twenty-Five Thousand Dollars ($125,000.00) on an annualized basis.  The Base Salary shall be paid in accordance with the Company’s regular payroll practices.  All amounts payable shall be reduced by standard withholding and other authorized deductions.  The Company, in its sole discretion, may increase (but not decrease) the Base Salary from time to time, provided, however, that commencing January 1, 2008, the Base Salary shall increase at a minimum level of 3% per annum during each year of the Term.

b. Bonus.  Executive shall be eligible for a bonus of up to 16% of the Base Salary (the “Bonus”), starting in calendar year 2007, upon the achievement of specific goals and objectives, as determined in the sole discretion of HemaCare’s President and CEO and the Company President.  The Bonus structure will put 100% of Executive’s Bonus potential at risk each year.  Executive must be employed by the Company at the time of payment to be eligible to receive any Bonus.

c. Car Allowance.  During the Term, Executive shall receive a car allowance equal to $1,250 per month.

d. Life Insurance.  The Company agrees to pay a whole life insurance policy for the Employee with a face amount equal to one times Executive’s salary.

2
 

e. Deductions.  The Company shall deduct from the compensation described in Sections 4(a) and 4(b) any federal, state or local withholding taxes, social security contributions and any other amounts which may be required to be deducted or withheld by the Company pursuant to any federal, state or local laws, rules or regulations.

f. Disability Adjustment.  Any compensation otherwise payable to Executive pursuant to Sections 4(a) and 4(b) in respect of any period during which Executive is Disabled (as defined in Section 9(d)) shall be reduced by any amounts payable to Executive for loss of earnings or the like under any insurance plan or policy sponsored by the Company.

5. Expenses.  The Company shall from time to time pay or reimburse Executive for the reasonable and necessary expenses incurred by Executive in connection with the performance of his duties hereunder if (a) such expenses have been previously approved by the Company or reimbursement is otherwise appropriate in accordance with the Company’s established policies and (b) the Company receives such verification thereof as the Company may require in order to qualify such expenses as deductible business expenses.

6. Other Benefits.  In addition to his compensation provided by the foregoing, so long as Executive is employed by the Company, Executive shall be entitled to all of the benefits available (a) generally to Company employees pursuant to Company programs, and/or (b) to senior level executives at the Company, including, by way of illustration, personal leave, paid holidays, sick leave, profit-sharing, retirement, disability, dental, vision, group sickness, accident or health insurance programs or equity incentive plans of the Company which may now or hereafter be in effect, or in any other or additional such programs which may be established by the Company, as and to the extent any such programs are or may from time to time be in effect, as determined by the Company.  The Company shall implement and maintain a health and medical plan as soon as is reasonably practical after the execution of this Agreement and maintain such plan throughout the Term.  The Company shall have the right to amend, reduce or completely terminate any or all such plans by duly authorized action respecting all employees covered by such plans as a group.

7. Vacations and Holidays.  During each calendar year, Executive shall accrue compensated personal time off (“PTO”) at the rate of twenty-nine (29) days per year.  If Executive’s earned but unused PTO reaches forty-eight (48) days, Executive will not continue to accrue additional PTO time until he uses sufficient PTO to fall below this maximum amount.  Thereafter, Executive shall start earning PTO benefits again until the forty-eight (48) day maximum is again reached.  Any accrued but unused PTO time will be paid to Executive on a pro rata basis at termination of employment for any reason.  Executive shall not be compensated for holidays (other than as part of the PTO system).

8. Other Activities.  Executive shall, during the term of his employment by the Company, devote all of his working time and efforts to the business and affairs of the Company and its subsidiaries and to the diligent and faithful performance of the duties assigned to him pursuant to this Agreement.

9. Termination.  The Company may terminate Executive’s employment for any reason or no reason, with or without Cause (as defined below), with the consequences described in Section 10 of this Agreement.  Executive may terminate his employment with Good Reason (as defined below) by giving the Company thirty (30) days’ advance written notice.  Upon termination of Executive’s employment with the Company, Executive’s rights under any applicable benefit plans shall be determined under the provisions of those plans.

3
 

 

a. Death.  Executive’s employment shall terminate immediately in the event of his death.

b. Cause.  Subject to Executive’s failure to cure a breach in the manner and time described below, the Company may terminate Executive’s employment for Cause immediately. As used in this Agreement, the term “for Cause” shall be limited to a termination for the following acts by Executive:  (i) misappropriation or embezzlement of the funds or property of the Company or any subsidiary, falsification of any Company or subsidiary documents or records or any unauthorized attempt by the Executive to take any business or business opportunities of the Company or any subsidiary for his or her own personal gain; (ii) Executive’s failure or inability to perform any material duties contemplated by this Agreement for a period of thirty (30) days, except in the event that the Executive is determined to have a Disability (as defined in Section 9(d)) or in the event of Executive’s death; (iii) grossly negligent, reckless or willful misconduct or insubordination in connection with Executive’s performance of his duties; (iv) any material breach by Executive of any agreement (including this Agreement or the Confidentiality Agreement (as defined in Section 11)) between Executive and the Company; (v) Executive’s conviction (including any plea of guilty or nolo contendere) of any felony, any misdemeanor involving dishonesty or fraud, or any other criminal act that impairs or could impair Executive’s ability to perform his or her duties; (vi) the Executive’s material violation of Company policies, including, without limitation, policies on prohibition of unlawful harassment or (vii) any illegal drug or illegal substance abuse, illegal drug or illegal substance addiction, or chronic addiction to alcohol on the part of Executive, other than any use of medication prescribed by a doctor.  The determination of Cause shall be made by HemaCare’s President and CEO in her reasonable discretion.  Anything herein to the contrary notwithstanding, as to any termination based upon clause (iii) above, the Company shall give the Executive written notice prior to terminating this Agreement of the Executive’s employment, setting forth a general description of the grounds for termination and the conduct required to cure such grounds for termination.  The Executive shall have thirty (30) days from the receipt of such notice within which to cure any such grounds for termination to the satisfaction of the Company, which shall be determined by the Company in its reasonable discretion.

c. Termination by Executive for “Good Reason”.  Subject to the provisions outlined below, at any time after the date Executive commences employment under this Agreement, upon thirty (30) days’ advance written notice to the Company of his intent to terminate the Agreement, Executive shall have the right to terminate his employment under this Agreement for “Good Reason”.  For purposes of this Agreement, “Good Reason” is defined as any one of the following:  (i) the Company fails to comply with the provisions hereof governing compensation and benefits to Executive, (ii) the Company moves the Company’s office location in violation of Section 3, (iii) the Company fails to maintain Executive in the position of Division President (or a comparable position) described in Section 1 or materially diminishes his duties or responsibilities in such positions, (iv) the Company materially breaches any other provision of this Agreement or any other written agreement with Executive, or (v) conduct by the Company occurs that would cause Executive to commit fraudulent acts or would expose Executive to criminal liability; provided, however, that it shall not constitute Good Reason unless Executive shall have provided the Company with written notice of its alleged actions constituting Good Reason (which notice shall specify in reasonable detail the particulars of such Good Reason) and the Company has not cured any such alleged Good Reason within thirty (30) days of the Company’s receipt of such written notice.

4
 

d. Disability.  The Company may terminate Executive’s employment for Disability by giving Executive three (3) days’ advance written notice.  For all purposes under this Agreement, “Disability” shall mean that Executive, at the time such notice is given, has been unable to substantially perform his duties under this Agreement for a period of not less than three (3) consecutive months (or after four (4) months in the aggregate during a twelve-month period, whether consecutive or not) as the result of his incapacity due to physical or mental illness.  A determination of Disability shall be made by the Board in consultation with a physician reasonably satisfactory to Executive (or his representative) and the Company, and Executive shall cooperate with the efforts to make such determination. Any such determination shall be conclusive and binding on the Parties for the purposes of this Agreement.

10. Termination Benefits.  Upon the termination of Executive’s employment, Executive shall be entitled to receive:

a.   Death or Disability.  Executive shall be entitled to the following:

(i) Payment of any Base Salary accrued but unpaid as of the date of death or termination for Disability;

(ii) Payments in accordance with any disability insurance policy maintained by the Company and payment of Base Salary to the extent required to ensure that Executive receives the full amount of Base Salary through the combined payments under disability insurance (whether pursuant to a disability insurance policy provided by the Company, or pursuant to state disability benefits) and salary payments from the Company, for the remainder of the Term;

(iii) Reimbursement for any unpaid expenses incurred in accordance with Section 5; and

(iv) Payment of any and all earnouts, or other consideration amounts that the Company is obligated to pay pursuant to the Stock Purchase Agreement (but only if actually earned, and such amounts shall be paid on the date(s) provided in the Stock Purchase Agreement), and any bonuses earned as of the date of termination pursuant to Section 4(b) of this Agreement.

b. Termination for Cause.  Executive shall be entitled to receive on the date of termination any accrued but unpaid salary and shall be reimbursed for any reimbursable expenses pursuant to Section 5 that have not been reimbursed prior to such termination.

5
 

c. Termination by Company Other than for Cause.  In the event the Company terminates Executive’s employment other than for Cause, Executive shall be entitled to the following:

(i) Payment of any Base Salary accrued but unpaid as of the date of termination;

(ii) An amount equal to Executive’s monthly Base Salary in effect on the date of termination for a period equal to the greater of the remainder of the Term or twelve (12) months;

(iii) The Company will pay to continue Executive’s health insurance coverage (i.e., make COBRA payments) following the date of termination other than for Cause until the earlier of (A) the greater of (1) the remainder of the Term or (2) twelve (12) months, and (B) until Executive obtains full-time employment, provided that such coverage remains available with respect to Executive; and

(iv) Payment of any and all earnouts, or other consideration amounts payable by the Company pursuant to the Stock Purchase Agreement, whether earned or unearned, within thirty (30) days of the date of termination, and any bonuses earned as of the date of termination pursuant to Section 4(b) of this Agreement.

d. Termination by Executive for “Good Reason”.  A termination for Good Reason shall have the same consequences as provided in Section 10(c) for a termination other than for Cause.

e. Voluntary Termination by Executive.  A termination of employment by Executive on his own initiative, other than a termination due to death or Disability or for Good Reason, shall have the same consequences as provided in Section 10(b) for a termination for Cause.

f. Other Benefits.  Except as expressly set forth herein or pursuant to the terms of the Company’s written employee benefit plans and policies in effect at the time of such termination, Executive shall not be entitled to any pay or benefits upon his termination.

11. Proprietary Information and Inventions Agreement.  Executive has signed a Proprietary Information and Inventions Agreement (the “Confidentiality Agreement”) substantially in the form attached hereto as Exhibit A.  Executive hereby represents and warrants to the Company that he has complied with all of the obligations under the Confidentiality Agreement and agrees to continue to abide by the terms of the Confidentiality Agreement and further agrees that the provisions of the Confidentiality Agreement shall survive any termination of this Agreement and/or Executive’s employment relationship with the Company.

12. Indemnification.  During the Term, the Company shall indemnify Executive and hold Executive harmless from and against all claims, actions, suits, proceedings, liabilities, damages, fines, costs and expenses (including, without limitation, reasonable attorneys’ fees and expenses) (collectively, “Losses”) which may be incurred by Executive in connection with the performance of his duties hereunder, to the fullest extent permitted by applicable law and to the same extent provided to any other senior executive officer of the Company, except with respect to any Losses suffered by Executive in connection with the transactions contemplated by the Stock Purchase AgreementExpenses advanced to Executive under this Section 12 shall be repaid by Executive on demand if and to the extent such advanced expenses are found not to be lawfully indemnifiable by a competent tribunal.

6
 

13. Exclusive Agreement.  Executive represents and warrants that his employment by the Company as described herein does not and shall not conflict with and is not and will not be constrained by any prior employment or consulting agreement, arrangement or relationship, whether written or oral.  Executive agrees not to make any unauthorized disclosure or use, on behalf of the Company, of any confidential information belonging to any of Executive’s former employers.  Executive represents that he is not in unauthorized possession or control of any materials containing confidential and proprietary or private information of a third party.

14. Assignment.  This Agreement and all rights under this Agreement shall be binding upon and inure to the benefit of and be enforceable by the Parties hereto and their respective personal or legal representatives, executors, administrators, heirs, distributees, devisees, legatees, successors and assigns.  Neither this Agreement nor any right or obligation of Executive under this Agreement may be assigned or transferred by Executive to any other person or entity without the prior written consent of the Company.  The Company may assign this Agreement; provided, however, that such assignment will not relieve the Company of its obligations hereunder.

15. Notices.  For purposes of this Agreement, notices and other communications provided for in this Agreement shall be in writing and shall be delivered personally or sent by United States certified mail, return receipt requested, postage prepaid, addressed as follows:

If to Executive: Valentin Adia
  10752 Oak Lake Way
  Boca Raton, FL 33498
  Facsimile No.: 561-482-3757
   
If to the Company: c/o Judi Irving
  HemaCare Corporation
  21101 Oxnard Street
  Woodland Hills, CA 91367

 

or to such other address or the attention of such other person as the recipient party has previously furnished to the other party in writing in accordance with this Section 15.  Such notices or other communications shall be effective upon the earlier of delivery or three days after they have been mailed as provided above.

16. Integration.  This Agreement, and Exhibit A hereto, represent the entire agreement and understanding between the Parties as to the subject matter hereof and supersede all prior or contemporaneous agreements whether written or oral.  No waiver, alteration, or modification of any of the provisions of this Agreement shall be binding unless in writing and signed by duly authorized representatives of the Parties hereto.

7
 

17. Waiver.  Failure or delay on the part of either Party hereto to enforce any right, power, or privilege hereunder shall not be deemed to constitute a waiver thereof.  Additionally, a waiver by either Party of a breach of any promise hereof by the other Party shall not operate as or be construed to constitute a waiver of any subsequent breach by such other Party.

18. Severability.  Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had never been contained herein.

19. Headings.  The headings of the Sections contained in this Agreement are for reference purposes only and shall not in any way affect the meaning or interpretation of any provision of this Agreement.

20. Applicable Law.  This Agreement shall be governed by and construed in accordance with the internal substantive laws, and not the choice of law rules, of the State of Florida.

21. Counterparts; Facsimile.  This Agreement may be executed in one or more counterparts and via facsimile, none of which need contain the signature of more than one party hereto, and each of which shall be deemed to be an original, and all of which together shall constitute a single agreement.

22. Arbitration.

a. The Company and Executive agree that any dispute or controversy arising out of or relating to any interpretation, construction, performance, termination or breach of this Agreement or Executive’s employment with the Company or termination of such employment, will be settled by final and binding arbitration by a single arbitrator to be held in Los Angeles County, California, in accordance with the National Rules for the Resolution of Employment Disputes of the American Arbitration Association (“AAA Rules”) then in effect.  Without limiting any other provision herein, this Section 22 shall survive the termination of Executive’s employment with the Company and will apply to any claim, dispute, or controversy that arises during or after the termination of Executive’s employment with the Company.  Executive and the Company agree that the agreement to arbitrate under this Section 22 is subject to and enforceable under the provisions of the Federal Arbitration Act (the “FAA”), 9 U.S.C. § § I, et seq.  The arbitrator selected shall have the authority to grant Executive or the Company or both all remedies otherwise available by law, including injunctions.

b. Notwithstanding anything to the contrary in the AAA Rules, the arbitration shall provide (i) for written discovery and depositions adequate to give the Parties access to documents and witnesses that are essential to the dispute and (ii) for a written decision by the arbitrator that includes the essential findings and conclusions upon which the decision is based.  Consistent with applicable law, Executive and the Company shall each bear his or its own

8
 

 

costs and attorneys’ fees incurred in conducting the arbitration and, except in such disputes where Executive asserts a claim under a state or federal statute prohibiting discrimination in employment, a claim for wrongful termination in violation of public policy, or a claim involving enforcement of rights under any statute enacted for a public reason (the “Excepted Claims”), shall split equally the fees and administrative costs charged by the arbitrator and AAA.  In disputes where Executive asserts an Excepted Claim against the Company, Executive shall be required to pay only the AAA filing fee to the extent such filing fee does not exceed the fee to file a complaint in state or federal court and the Company shall pay the balance of the arbitrator’s fees and administrative costs.

c. The decision of the arbitrator will be final, conclusive and binding on the Parties to the arbitration.  The prevailing party in the arbitration, as determined by the arbitrator, shall be entitled to recover his or its reasonable attorneys’ fees and costs, including the costs or fees charged by the arbitrator and AAA.  In disputes where Executive asserts an Excepted Claim, reasonable attorneys’ fees shall be awarded by the arbitrator based on the same standard as such fees would be awarded if the Excepted Claim had been asserted in state or federal court.  Judgment may be entered on the arbitrator’s decision in any court having jurisdiction.

The parties hereby acknowledge that they have voluntarily negotiated the terms of this Agreement, including, without limitation, this Section 22, have consulted with counsel concerning such terms, and voluntarily agree to them.

  /s/ J I   /s/ V A  
  Company’s Initials   Executive’s Initials  

 

23. Advice of Counsel.  The Parties represent and agree that they have carefully read and fully understand all of the provisions of this Agreement, and the terms and conditions set forth herein, and that they are voluntarily entering into this Agreement.  The Parties affirm that, prior to execution of this Agreement, they have consulted with counsel concerning the terms and conditions set forth herein or have had the opportunity to do so.

24. Survival of Certain Terms.  The provisions of Sections 9, 10, 11, 14 and 22 of this Agreement shall survive the termination of this Agreement; provided, however, that the survival of such provisions after the termination of this Agreement shall in no way constitute an extension of the Term.  Except as set forth in the prior sentence, all other rights and obligations of the Parties shall cease upon termination of this Agreement.

[Rest of page intentionally left blank]

9
 

IN WITNESS WHEREOF, each of the Parties has executed this Employment Agreement, in the case of the Company by its duly authorized officer, as of the day and year first above written.

  TERAGENIX CORPORATION
     
     
  By: /s/ Judi Irving  
  Title: Chief Executive Officer  
     
     
  EXECUTIVE
     
     
  By: /s/ Valentin Adia  
    Valentin Adia
S-1
 

EXHIBIT A

EMPLOYEE PROPRIETARY INFORMATION
AND INVENTIONS AGREEMENT

In consideration of my employment by _____________ (the "Company") and the compensation I receive from the Company, I agree that:

1. Proprietary Information. I understand that the Company possesses and will possess Proprietary Information that is important to its business. "Proprietary Information" is information (whether conveyed orally, in writing or otherwise) that was or will be developed, created, or discovered by or on behalf of the Company, or that became or will become known by, or was or is conveyed to the Company, that has or could have commercial value in the Company's business, unless (a) the information is or becomes publicly known through lawful means; or (b) the information is disclosed to me without confidential or proprietary restriction by a third party who rightfully possesses the information (without confidential or proprietary restriction) and who did not learn of it directly or indirectly from the Company.

Proprietary Information includes, without limitation, any Company Inventions (as defined below) and any information relating to (i) client/customer lists, vendor lists or other lists or compilations containing client, customer or vendor information; (ii) information about products, proposed products, research, product development, techniques, processes, costs, profits, markets, marketing plans, strategies, forecasts, sales or commissions; (iii) plans for the future development or new product concepts; (iv) manufacturing techniques or processes, documents, books, papers, drawings, schematics, models, sketches, computer programs, databases or other data, including electronic data recorded or retrieved by any means; (v) the compensation, performance and terms of employment of other employees; (vi) all other information that has been or will be given to me in confidence by the Company (or any affiliate); (vii) software in various stages of development, and any designs, drawings, schematics, specifications, techniques, models, data, source code, algorithms, object code, documentation, diagrams, flow charts, research development, processes and procedures relating to any software; and (viii) any information that the Company obtains from another party that it treats as proprietary or designates as Proprietary Information.

At all times, both during my employment with the Company and after my termination, I will not, directly or indirectly, use, make available, sell, disclose or otherwise communicate to any third party, other than in my assigned duties for the benefit of the Company, any Proprietary Information. I am aware that the unauthorized disclosure of Proprietary Information may be highly prejudicial to the Company's interests, an invasion of privacy, and an improper disclosure of trade secrets. Without limiting the foregoing, I shall not make copies of, or otherwise reproduce, Proprietary Information unless authorized by the Company for reproduction.

2. Company Materials. "Company Materials" are documents or other media or tangible items that contain or embody Proprietary Information or any other information concerning the business, operations or plans of the Company, whether such documents have been prepared by me or by others. "Company Materials" include, without limitation, blueprints, drawings, photographs, charts, graphs, notebooks, customer lists, computer software, media or printouts, sound recordings and other printed, typewritten or handwritten documents, as well as samples, prototypes, models, products and the like.

 
 

 

3. Intellectual Property.

3.1 All Proprietary Information and all right, title and interest in and to any patents, patent rights, copyrights, trademark rights, mask work rights, trade secret rights, and all other intellectual and industrial property and proprietary rights that currently exist or may exist in the future anywhere in the world (collectively, "Rights") in connection therewith shall be the sole property of the Company. I hereby assign to the Company any Rights I may have or acquire in such Proprietary Information.

3.2 I acknowledge and agree that I have no expectation of privacy with respect to the Company's telecommunications, networking or information processing systems (including, without limitation, stored company files, e-mail messages and voice messages) and that my activity and any files or messages on or using any of those systems may be monitored at any time without notice. I further agree that any property situated on the Company's premises and owned by the Company, including disks and other storage media, filing cabinets or other work areas, is subject to inspection by Company personnel at any time with or without notice. All Company Materials shall be the sole property of the Company. I agree that during my employment with the Company, I will not remove any Company Materials from the business premises of the Company or deliver any Company Materials to any person or entity outside the Company, except as I am required to do in connection with performing the duties of my employment. I recognize that the unauthorized taking of any Proprietary Information may be a crime under the Cal. Penal Code §499c or comparable laws of other states or the United States, and may also result in civil liability under Sections 3426.1 through 3426.11 of the California Civil Code, or comparable laws of other states. I further agree that, immediately upon the termination of my employment by me or by the Company for any reason, or for no reason, or during my employment if so requested by the Company, I will return all Company Materials, apparatus, equipment and other physical property, or any reproduction of such property, excepting only (a) my personal copies of records relating to my compensation; (b) my personal copies of any materials previously distributed generally to stockholders of the Company; and (c) my copy of this Employee Proprietary Information and Inventions Agreement (the "Agreement").

3.3 I agree that all "Inventions" (which term includes patentable or non-patentable inventions, original works of authorship, derivative works, trade secrets, trademarks, copyrights, service marks, mask works, discoveries, patents, technology, algorithms, computer software, application programming interfaces, protocols, formulas, compositions, ideas, designs, processes, techniques, know-how, data and all improvements, rights and claims related to the foregoing), which I have made, conceived, reduced to practice or developed, and which I make, conceive, reduce to practice or develop (in whole or in part, either alone or jointly with others) during my employment and in connection with the business of the Company, shall be the sole property of the Company to the maximum extent permitted by Section 2870 of the California Labor Code. I hereby assign, without further consideration, all such Inventions ("Company Inventions") to the Company (free and clear of all liens and encumbrances), and the Company shall be the sole owner of all Rights in connection therewith. No assignment in this Agreement shall extend to Inventions, the assignment of which is prohibited by Labor. Code Section 2870, which states:

2
 

 

Any provision in an employment agreement which provides that an employee shall assign, or offer to assign, any of his or her rights in an invention to his or her employer shall not apply to an invention that the employee developed entirely on his or her own time without using the employer's equipment, supplies, facilities, or trade secret information except for those inventions that either:

1. Relate at the time of conception or reduction to practice of the invention to the employer's business, or actual or demonstrably anticipated research or development of the employer.

2. Result from any work performed by the employee for the employer.

I acknowledge that all original works of authorship which have been made and which are made by me (in whole or in part, either alone or jointly with others) within the scope of my employment and which are protectable by copyright are "works made for hire," as defined in the United States Copyright Act (17 USCA, Section 101). I have not disclosed and will not disclose Inventions covered by this Section 3.3 to any person outside the Company, unless I am requested to do so by management personnel of the Company.

3.4 I have maintained and agree to maintain adequate and current written records on the development of all Company Inventions and have disclosed and agree to disclose promptly to the Company all Company Inventions and relevant records, which records will remain the sole property of the Company. I further agree that all information and records pertaining to any idea, process, trademark, service mark, invention, technology, computer program, original work or authorship, design, formula, discovery, patent, or copyright that I do not believe to be a Company Invention, but is conceived, developed, or reduced to practice by me (in whole or in part, either alone or jointly with others) during my employment, shall be promptly disclosed to the Company (such disclosure to be received in confidence). The Company shall examine such information to determine if in fact the ideas, process, or invention, etc., constitutes a Company Invention and is therefore subject to assignment under Section 3.3. I will also disclose to the Company all Inventions conceived, reduced to practice, used, sold, exploited or developed by me (in whole or in part, either alone or jointly with others) within one (1) year of the termination of my employment with the Company ("Presumed Inventions"); such disclosures shall be received by the Company in confidence, to the extent they are not assigned to the Company in Section 3.3, and do not extend such assignment. Because of the difficulty of establishing when any Presumed Invention is first conceived or developed by me, or whether it results from access to Proprietary Information or the Company's equipment, facilities, and data, I agree that all Presumed Inventions and all Rights associated therewith shall be presumed to be Company Inventions and therefore assignable to the Company_ I can rebut this presumption, if I prove that a Presumed Invention is not a Company Invention.

3
 

 

3.5 I agree to perform, during and after my employment, all acts deemed necessary or desirable by the Company to permit and assist it, at the Company's expense, in evidencing, perfecting, recording, obtaining, maintaining, defending and enforcing Rights and/or my assignment with respect to such Company Inventions in any and all countries. Such acts may include, without limitation, execution of documents and assistance or cooperation in legal proceedings. Should the Company be unable to secure my signature on any document necessary to apply for, prosecute, obtain, enforce or defend any Rights relating to any assigned Invention, whether due to my mental or physical incapacity or any other cause, I hereby irrevocably designate and appoint the Company and its duly authorized officers and agents, as my agents and attorneys-in-fact, with full power of substitution, to act for and in my behalf and instead of me, to execute and file any documents and to do all other lawfully permitted acts to further the above purposes with the same legal force and effect as if executed by me.

3.6 Any assignment of copyright hereunder (and any ownership of a copyright as a work made for hire) includes all rights of paternity, integrity, disclosure and withdrawal and any other rights that may be known as or referred to as "moral rights" (collectively, "Moral Rights"). To the extent such Moral Rights cannot be assigned under applicable law and to the extent the following is allowed by the laws in the various countries where Moral Rights exist, I hereby waive such Moral Rights and consent to any action of the Company that would violate such Moral Rights in the absence of such waiver and consent. I will confirm any such waivers and consents from time to time as requested by the Company.

3.7 I agree that I will not incorporate in any way, or permit to be incorporated in any way, any Inventions made, conceived, reduced to practice or developed by me (in whole or in part, either alone or jointly with others) either: (a) prior to or (b) outside the scope of my engagement as an independent contractor for the Company ("Prior Inventions"). Notwithstanding the foregoing, I hereby grant the Company a royalty-free, nonexclusive, perpetual, irrevocable, transferable, worldwide license (with rights to sublicense through multiple tiers of sublicense) to practice all Rights relating to any Prior Inventions (or other Inventions that are not assigned or assignable to Company hereunder) that become incorporated in any way, or I permit to be incorporated in any way, in any Company Inventions or any other Company technology or products.

3.8 I understand that nothing in this Agreement is intended to expand the scope of protection provided me by Sections 2870 through 2872 of the California Labor Code.

4. Former Employer Information. I agree that I will not, during my employment with the Company, improperly use or disclose any confidential information, proprietary information or trade secrets of my former or concurrent employers. I agree that I will not bring onto the premises of the Company any document or any property belonging to my former employers unless consented to in writing by them. I represent and warrant that I have returned all property and confidential information belonging to all prior employers.

5. Prior Actions and Knowledge. I represent and warrant that from the time of my first contact or communication with the Company, I have held in strict confidence all Proprietary Information and have not and will not: (a) disclose any Proprietary Information or deliver any Company Materials to anyone outside of the Company, or (b) use, copy, publish, or summarize any Proprietary Information or remove any Company Materials from the business premises of the Company, except to the extent necessary and appropriate to carry out my responsibilities as an employee of the Company, or (c) improperly use or disclose any confidential information, proprietary information or trade secrets of my former or concurrent employers or any other third party, or (d) bring onto the premises of the Company any document or any property belonging .to my former employers unless consented to in writing by them.

4
 

 

6. No Conflict with Obligations to Third Parties. I represent that my performance of all the terms of this Agreement has not breached and will not breach any agreement to keep in confidence proprietary or confidential information acquired by me in confidence or in trust prior to my employment with the Company_ I have not entered into, and I agree I will not enter into, any agreement either written or oral in conflict herewith or in conflict with my employment with the Company. The performance of this Agreement does not and will not violate any applicable law, rule or regulation or any proprietary or other right of any third party.

7. Remedies; Waiver. I recognize that nothing in this Agreement is intended to limit any remedy of the Company under the California Uniform Trade Secrets Act. I recognize that my violation of this Agreement could cause the Company irreparable harm, the amount of which may be extremely difficult to estimate, making any remedy at law or in damages inadequate. Therefore, I agree that the Company shall have the right to apply to any court of competent jurisdiction for an order restraining any breach or threatened breach of this Agreement and for any other relief the Company deems appropriate. This right shall be in addition to any other remedy available to the Company. I ALSO ACKNOWLEDGE AND UNDERSTAND THAT I SHALL NOT, UNDER ANY CIRCUMSTANCE, HAVE ANY RIGHT TO SEEK OR ATTEMPT TO SEEK ANY INJUNCTIVE RELIEF AGAINST THE COMPANY WITH RESPECT TO ANY BREACH OR THREATENED BREACH OF THIS AGREEMENT, AND I HEREBY WAIVE ANY AND ALL SUCH RIGHTS AGAINST THE COMPANY.

8. Survival. I agree that my obligations under Sections 1, 3, and 7 through 15 of this Agreement shall continue in effect after termination of my employment, regardless of the reason or reasons for termination, and whether such termination is voluntary or involuntary on my part, and that the Company is entitled to communicate my obligations under this Agreement to any future employer or potential employer of mine.

9. Controlling Law; Venue; Severability. I agree that the sole jurisdiction and venue for actions related to the subject matter hereof shall be the state and federal courts located in the County of Los Angeles, California. I further agree that if one or more provisions of this Agreement are held to be illegal or unenforceable under applicable California law, such illegal or unenforceable portion(s) shall be limited or excluded from this Agreement to the minimum extent required so that this Agreement shall otherwise remain in full force and effect and enforceable in accordance with its terms.

10. Successors and Assigns. This Agreement shall be binding upon me, my heirs, executors, assigns, and administrators and shall inure to the benefit of the Company, its subsidiaries, successors and assigns. The failure, whether purposeful or otherwise, to exercise in any instance any right, power or privilege under this Agreement or under law shall not constitute a waiver of any other right, power or privilege, nor of the same right, power or privilege in any other instance.

5
 

11. Entire Agreement/Modification. The terms of this Agreement (including all attached Exhibits, which are incorporated herein by this reference) are the final expression of my agreement with respect to its subject matter and may not be contradicted by evidence of any prior or contemporaneous agreement. This Agreement can only be modified by a subsequent written agreement executed by an officer of the Company.

12. Integration. This Agreement supersedes all, and may not be contradicted by evidence of any, other prior and contemporaneous agreements and statements on these subjects. If any practices, policies, or procedures of the Company, now or in the future, that apply to me are inconsistent with the terms hereof, the provisions of this Agreement shall control unless changed in writing by the Company.

13. Employment at Will. This Agreement is not an employment agreement. Except as set forth in my employment agreement, if any, the Company may terminate my employment with it at any time, with or without cause.

14. Construction. This Agreement shall be construed as a whole, according to its fair meaning, and not in favor of or against any party. By way of example and not limitation, this Agreement shall not be construed against the party responsible for any language in this Agreement. The headings of the paragraphs hereof are inserted for convenience only, and do not constitute part of and shall not be used to interpret this Agreement.

15. Rights Cumulative. The rights and remedies provided hereby to the Company are cumulative, and the exercise of any right or remedy by the Company, whether pursuant hereto, to any other agreement, or to law, shall not preclude or waive the Company's right to exercise any or all other rights and remedies.

6
 

I HAVE READ THIS AGREEMENT CAREFULLY AND I UNDERSTAND AND ACCEPT THE OBLIGATIONS WHICH IT IMPOSES UPON ME WITHOUT RESERVATION. I HAVE HAD THE OPPORTUNITY TO CONSULT LEGAL COUNSEL IN REGARD TO THIS AGREEMENT AND AM FULLY AWARE OF ITS LEGAL EFFECT. I HAVE ENTERED INTO THIS AGREEMENT FREELY AND VOLUNTARILY AND BASED ON MY OWN JUDGMENT. NO PROMISES OR REPRESENTATIONS HAVE BEEN MADE TO ME TO INDUCE ME TO SIGN THIS AGREEMENT.

 

Date:      
      Employee Signature

 

Accepted and Agreed to:

 

By:    
Name:    
Title:    

 

7

EX-10.3 4 ex10-3.htm

Exhibit 10.3

May 8, 2006

Teragenix Corporation

5440 NW 33rd Avenue, Suite 108

Ft. Lauderdale, FL 33309

HemaCare Corporation

21101 Oxnard Street

Woodland Hills, California 91367

Re:  Agreement to Replace Promissory Note

Dear Joe and Judi:

Reference is made to the following:

1. Promissory Note in the principal amount of $450,000, dated November 11, 2005, issued by Teragenix Corporation (“Teragenix”) to the order of Lawrence Feldman (the “Existing Note”); and

2. Non-Binding Letter of Intent dated March 10, 2006 between HemaCare Corporation (“HemaCare”) and Teragenix (the “LOI”).

The LOI sets forth the proposed terms for the acquisition of 100% of the outstanding capital stock of Teragenix by HemaCare (the “Acquisition”).  One of the terms of the Acquisition is the replacement of the Existing Note with a new subordinated promissory note in the principal amount of $250,000, the form of which is attached hereto as Exhibit “A” (the “New Note”).  In furtherance of their desire to proceed with the Acquisition, Teragenix and HemaCare have requested that the undersigned agree to replace the Existing Note with the New Note.  The replacement of the Existing Note with the New Note would occur concurrently with the closing of the Acquisition.

In consideration of the shorter time to maturity in the New Note relative to the Existing Note and the obligation of Teragenix to pay interest annually in the New Note, as well as the benefits which the undersigned expects Teragenix to realize as a result of the consummation of the Acquisition, the undersigned hereby agrees to accept, concurrently with the closing of the Acquisition, the New Note in substitution for the Existing Note and agrees to the terms of the New Note as reflected on Exhibit “A”.

 
 

 

Letter to Teragenix and HemaCare

May 8, 2006

This letter agreement constitutes the entire agreement among the undersigned, Teragenix and HemaCare with respect to the subject matter hereof and may be amended or modified only in a written agreement among such parties.  This letter agreement may be executed in any number of counterparts and by different parties on separate counterparts.  Each of such counterparts shall be deemed to be an original, and all of such counterparts, taken together, shall constitute but one and the same agreement.  Delivery of an executed counterpart of this letter by telefacsimile shall be equally effective as delivery of a manually executed counterpart.

[signature page to follow]

 

2
 

 

Letter to Teragenix and HemaCare

May 8, 2006

 

Sincerely,

 

/s/ Lawrence Feldman  
Lawrence Feldman

 

Acknowledged and Agreed:

TERAGENIX CORPORATION

 

By:   /s/ Joseph Mauro  

Title:  President

 

HEMACARE CORPORATION

 

By:   /s/ Judi Irving  

Title:  President & CEO

3
 

EXHIBIT “A”

Form of New Note

 

AMENDED AND RESTATED SUBORDINATED PROMISSORY NOTE

$250,000.00   Fort Lauderdale, Florida
    August 29, 2006

 

FOR VALUE RECEIVED, TERAGENIX CORPORATION, a Florida corporation (the “Payor”), promises to pay to the order of LAWRENCE FELDMAN (the “Payee”) at 777 17th Street, Miami Beach, FL 33139-1854, the principal sum of TWO HUNDRED FIFTY THOUSAND DOLLARS ($250,000), together with interest from the date hereof at a rate equal to 7% simple interest per annum.

1.             Payments of Principal and Interest; Time of the Essence.  Principal under this note shall be due and payable in four (4) equal, consecutive, annual installments in the amount of SIXTY TWO THOUSAND FIVE HUNDRED DOLLARS ($62,500) on each anniversary of the date of this note commencing on the first anniversary and continuing through the fourth anniversary, at which time all principal that remains unpaid shall be due and payable in full.  Accrued but unpaid interest to the date of each principal payment shall be due and payable on such date and any remaining accrued but unpaid interest shall be due and payable concurrently with the final principal payment under this note.  Time is of the essence.

2.             Prepayment.  Subject to the terms of Section 5 below, this note may be prepaid in whole or in part at any time without premium or penalty.

3.              Acceleration after Default; Default Interest Rate.  If any payment remains unpaid after the same shall become due, the entire principal sum shall forthwith become due at the option of the holder of this note.  While this note is in default, it shall bear interest at the maximum rate of 10% per annum.

4.             Florida Documentary Stamp Tax. Florida documentary stamp tax required by law in the amount of $2,450 has been paid directly to the Florida Department of Revenue.

5.             Subordination to Senior Debt.  The Payee, by acceptance of this note, agrees that the payment of the principal and interest of this note is subordinated to the extent and as provided below and undertakes, as a condition to the right to receive any payments hereunder, to execute such subordination agreements as may be requested by the Senior Lenders (as defined below) from time to time.

(a)  As used herein, the term “Senior Debt” shall mean any and all indebtedness of the Payor and all of its subsidiaries (collectively, the “Company”) owed to Senior Lenders together with (i) all complete or partial refinancings of such indebtedness, (ii) any amendments, restatements, extensions, modifications, amendments, renewals or substitutions with respect to the foregoing, (iii) interest, reasonable attorney fees, other fees and other sums payable in respect thereof, and (iv) any interest accruing thereon after the commencement of a bankruptcy proceeding, without regard to whether or not such interest is an allowed claim in such proceeding.  The term “Senior Lenders” shall mean any institutional lender or lenders providing one or more senior secured credit facilities to the Company.  Senior Debt shall be considered to be outstanding whenever any loan or loan commitment remains outstanding under a loan agreement entered into with a Senior Lender.

4
 

 

(b)  Except as specifically permitted in Section 5(c) below, the Payee, by acceptance of this note, agrees that the Payee will not ask, demand, sue for, accept, or receive payment from the Payor, by set-off or in any other manner, either in whole or in part, of any of the principal of or interest accrued on the indebtedness evidenced by this note (the “Subordinated Indebtedness”).

(c)  The Payor shall pay or cause to be paid to the Payee the Subordinated Indebtedness as set forth in Section 1 (and Section 3 with respect to interest after default) above, except that the Payor shall not be required or permitted to make any payment on the Subordinated Indebtedness if an event of default exists with respect to the Senior Debt until such time as such event of default has been cured or waived by the Senior Lender.  The Payor may make prepayments of this note only upon receipt of written consent thereto from the Senior Lender.

6.              Miscellaneous.  Should it become necessary to collect this note through an attorney, the Payor hereby agrees to pay all costs of collection, including a reasonable attorney’s fee.  Said reasonable attorney’s fee shall include fees for services rendered in all appellate proceedings.  The Payor waives presentment for payment and protest for nonpayment of this note; agrees to an extension of the time of payment of this note, without notice; and agrees that any such extensions will not release the Payor’s liability hereon.

7.             Choice of Law.  This note will be interpreted, construed and enforced in accordance with the laws of the State of Florida, without giving effect to the application of the principles pertaining to conflicts of laws.

8.             Amendment and Restatement of Note.  This note amends, restates, replaces and supercedes that that certain Promissory Note (“Prior Note”) dated November 11, 2005, in the principal amount of $450,000, issued by the Payor to the order of the Payee, which Prior Note upon Payor’s execution and delivery of this Note to Payee shall be null, void and of no further legal force or effect.

 

9.             WAIVER OF JURY TRIAL.  THE PAYOR HEREBY, AND THE PAYEE BY ACCEPTANCE OF THIS NOTE, KNOWINGLY, VOLUNTARILY AND INTENTIONALLY WAIVE THE RIGHT EITHER MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION BASED HEREON, OR ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS NOTE AND ANY AGREEMENT CONTEMPLATED TO BE EXECUTED IN CONJUNCTION HEREWITH OR ANY COURSE OF CONDUCT, COURSE OR DEALING, STATEMENTS (WHETHER VERBAL OR WRITTEN) OR ACTIONS OF EITHER PARTY.  THIS PROVISION IS A MATERIAL INDUCEMENT FOR THE PAYEE ACCEPTING THIS NOTE.

  TERAGENIX CORPORATION
     
     
  By: /  
    Joseph L Mauro, President

 

5

EX-10.4 5 ex10-4.htm

Exhibit 10.4

ASSIGNMENT FOR THE BENEFIT OF CREDITORS

THIS ASSIGNMENT, made this 4th day of December, 2007, between HemaCare Bioscience, Inc., a Florida corporation, with its principal place of business at 5440 NW 33rd Street, Suite 108, Fort Lauderdale, Florida, 33309, hereinafter "ASSIGNOR," and PHIL VON KAHLE, whose address is Michael Moecker & Associates, Inc., 6861 S.W. 196 Avenue, Suite 201-04, Pembroke Pines, Florida 33332, hereinafter "ASSIGNEE."

WHEREAS, the Assignor has been engaged in the business of providing biotechnology services.

WHEREAS, the ASSIGNOR is indebted to creditors as set forth in Schedule A annexed hereto, is unable to pay its debts as they become due, and is desirous of providing for the payment of its debts, so far as it is possible by an assignment of all of its assets for that purpose. 

NOW THEREFORE, the ASSIGNOR, in consideration of the ASSIGNEE's acceptance of this Assignment, and for other good and valuable consideration, hereby grants, assigns, conveys, transfers, and sets over unto the ASSIGNEE, his successors and assigns, all of its assets, except such assets as are exempt by law from levy and sale under an execution including, but not limited to, all real property, fixtures, goods, stock inventory, equipment, furniture, furnishings, accounts receivable, bank deposits, cash, promissory notes, cash value and proceeds of insurance policies, claims and demands belonging to the ASSIGNOR, wherever such assets may be located, hereinafter the "ESTATE," as which assets are, to the best knowledge and belief of the ASSIGNOR, set forth on Schedule B annexed hereto. 

The ASSIGNEE shall take possession and administer the ESTATE in accordance with the provisions of Chapter 727, Florida Statutes, and shall liquidate the assets of the ESTATE with reasonable dispatch and convert the ESTATE into money, collect all claims and demands hereby assigned as may be collectible, and pay and discharge all reasonable expenses, costs, and disbursements in connection with the execution and administration of this Assignment from the proceeds of such liquidation and collections.

The ASSIGNEE shall then pay and discharge in full, to the extent that funds are available in the ESTATE after payment of administrative expenses, costs, and disbursements, all of the debts and liabilities now due from the ASSIGNOR, including interest on such debts and liabilities. If funds of the ESTATE shall not be sufficient to pay such debts and liabilities in full, then the ASSIGNEE shall pay from funds of the ESTATE such debts and liabilities, on a pro rata basis and in proportion to their priority as set forth in Florida Statutes § 727.114. 

In the event that all debts and liabilities are paid in full, any funds of the ESTATE remaining shall be returned to the ASSIGNOR. 

To accomplish the purposes of this Assignment, the ASSIGNOR hereby appoints the ASSIGNEE its true and lawful attorney, irrevocable, with full power and authority to all acts and things which may be necessary to execute the Assignment hereby created; to demand and recover from all persons all assets of the ESTATE; to sue for the recovery of such assets; to execute, acknowledge, and deliver all necessary deeds, instruments, and conveyances; and to appoint one or more attorneys under him to assist him in carrying out his duties hereunder. 

The ASSIGNOR hereby authorizes the ASSIGNEE to sign the name of the ASSIGNOR to any check draft, promissory note, or other instrument in writing which is payable to the order of the ASSIGNOR, or to sign the name of the ASSIGNOR to any instrument in writing, whenever it shall be necessary to do so, to carry out the purposes of this Assignment.

The ASSIGNEE hereby accepts the trust created by the Assignment, and agrees with the ASSIGNOR that the ASSIGNEE will faithfully and without delay carry out his duties under this Assignment for the Benefit of Creditors.

-Page 1-
 

 

Dated this 4th day of December, 2007.

 

WITNESSES:   ASSIGNOR:
(As to Assignor)   HEMACARE BIOSCIENCE, INC.,
    a Florida corporation
       
       
/s/ Robert S. Chilton   By: /s/ Julian Steffenhagen
(Sign)     (Sign) Julian Steffenhagen
Robert S. Chilton     Title:  President
(Print)      
       
       
/s/ Zaira Licona      
(Sign)      
Zaira Licona      
(Print)      

 

-Page 2-
 

 

  (As to Assignee)   ASSIGNEE:
       
       
  /s/ Norma Castellon   By     /s/ Phil von Kahle
(Sign)               Phil von Kahle
  Norma Castellon      
(Print)      
       
       
  /s/ R. Prazda      
(Sign)      
  R. Prazda      
(Print)      

 

 

STATE OF )
  ) ss:
COUNTY OF )

 

The foregoing instrument was acknowledged before me this 6th day of December, 2007 by Phil von Kahle. He/she is personally known to me or has produced __________________________ as identification.

 

 

    /s/ Nadira Joseph
  [STAMP] NOTARY PUBLIC, STATE OF FLORIDA AT LARGE
  Print Name: Nadira Joseph

 

My Commission Expires: 11-15-09

Commission No: DD491124

 

-Page 3-
 

 

SCHEDULE A

CREDITOR LIST

1. List all secured creditors showing:

 

Name Address Amount Collateral Whether or not
disputed?
Corneriea Bank 333 Vkiest Santa Clara St
San Jose CA
2,500,000   N
Valentin Ada 10752 Oak Lake Way
Boca Itaton, FL 3:i498
46,200   N
Lawrence Feldman 177 117' St.
Miami Beach, FL
250,000   N
Joseph Mauro 12590 Little Palm Lane
Boca Raton, FL 33428
153,800   N
Karen Rabin 7000 SW 62 Ave. PH S
South Miami, FL
250,000   N

 

2. List all wages owed showing:

 

Name Address Amount Whether or not disputed?
none      

 

3. Consumer deposits:

 

Name Address Amount Whether or not disputed?
Sequenorn 3595 .John Hopkins Court
San Diego, CA 92 121
44,357 N

 

4. List fill taxes owed showing:

 

Name Address Amount Whether or not disputed?

Broward County

 

PO Box 29009
Fort Lauderdale, FL 33301
4,773.84 N

 

5. List all unsecured claims showing:

 

Name Address Amount Whether or not disputed?
Accounts Payable;
See Exhibit A-5
  349,203,92 N
Commerce Center
Development Corp.
c/o Andrew Dector
Shapiro Blasi
7777 Glades Rd., Ste 400
Boca Raton, 1,'l, 33434
Unknown Y

HemaCare Attn: Jay Steficnhagen

Corporation

Attn: Jay Steffenhagen
15350 Sherman Way,
Suite 350
Van Nuys, CA 91406
4,507,326.17 N

 

6. List ail owners or shareholders showing:

 

Name Address Percent of
Ownership
Hemacare Corporation 15350 Sherman Way, Ste. 350 100%
Van Nuys, CA 91406    

 

7. List all pending litigation and opposing counsel of record:

 

Style Parties Opposing Counsel of Record
None    

 

-Page 4-
 

Schedule   A-5
HemaCare BioScience
Accounts Payable
11/9/2007

 

Vendor ID Vendor Name Document Date   Document Number Current
Trx Amount
  Address 1 Address 2 City State Zip Code
ABBOTTDIAGNOSTI Abbott Diagnostics 10/22/2007   923133148 $34.86   PO Box 100997   Atlanta GA 30384-0997
ABBOTTDIAGNOSTI Abbott Diagnostics 10/22/2007   923130777 $669.48   PO Box 100997   Atlanta GA 30384-0997
AFLAC Aflac 10/28/2007   621347 $223.10   1932 Wynnton Road   Columbus GA 31999-0797
ASSOCIATIONCIRB Association CIRBA 5/14/2007   TERA-HBV-2004-70 $1,200.00   Cote d'Ivoire        
ASTARTEBIOLOGIC Astarte Biologics, LLC 9/25/2007   2800 $7,650.00   P.O. Box 2308   Redmond WA 98073
ATT AT & T 10/19/2007   654-733-4744 OCT-07 $321.04   PO Box 70529   Charlotte NC 28272-0529
ATT AT & T 10/19/2007   954-733-6505 OCT-07 $525.76   PO Box 70529   Charlotte NC 28272-0529
ATT AT & T 10/16/2007   954 Q32-49190011805 $625.00   PO Box 70529   Charlotte NC 28272-0529
BOCARATONCOMMUN Boca Raton Community Hospital 1/30/2007   8 RANDOM SAMPLES $16.00   800 Meadow Road   Boca Raton FL 33486
BOCARATONCOMMUN Boca Raton Community Hospital 2/22/2007   28 RANDOM SAMPLES $28.00   800 Meadow Road   Boca Raton FL 33486
BOCARATONCOMMUN Boca Raton Community Hospital 3/28/2007   17 CSF $34.00   800 Meadow Road   Boca Raton FL 33486
BOCARATONCOMMUN Boca Raton Community Hospital 2/23/2007   9 D-DIMER $36.00   800 Meadow Road   Boca Raton FL 33486
BOCARATONCOMMUN Boca Raton Community Hospital 2/23/2007   21 CSF $42.00   800 Meadow Road   Boca Raton FL 33486
BOCARATONCOMMUN Boca Raton Community Hospital 2/12/2007   58 RANDOM SAMPLES $58.00   800 Meadow Road   Boca Raton FL 33486
BOCARATONCOMMUN Boca Raton Community Hospital 1/30/2007   88 RANDOM SAMPLES $88.00   800 Meadow Road   Boca Raton FL 33486
BOCARATONCOMMUN Boca Raton Community Hospital 2/22/2007   45 CSF SAMPLES $90.00   800 Meadow Road   Boca Raton FL 33486
BOCARATONCOMMUN Boca Raton Community Hospital 1/17/2007   119 RANDOM HOSP $119.00   800 Meadow Road   Boca Raton FL 33486
BOCARATONCOMMUN Boca Raton Community Hospital 3/28/2007   33 D-DIMER $132.00   800 Meadow Road   Boca Raton FL 33486
BOCARATONCOMMUN Boca Raton Community Hospital 1/17/2007   139 RANDOM HOSP $139.00   800 Meadow Road   Boca Raton FL 33486
BOCARATONCOMMUN Boca Raton Community Hospital 4/18/2007   175 RHS $175.00   800 Meadow Road   Boca Raton FL 33486
BOCARATONCOMMUN Boca Raton Community Hospital 4/18/2007   175 RHS - 2 $175.00   800 Meadow Road   Boca Raton FL 33486
BOCARATONCOMMUN Boca Raton Community Hospital 2/22/2007   46 D-DIMER $184.00   800 Meadow Road   Boca Raton FL 33486
BROWARDCOUNTYRE Broward County Revenue Collection 11/6/2007   3C000-08-376550 $4,773.84   Government Center Annex 115 S. Andrews Ave. Rm A-100 Fort Lauderdale FL 33301
CADEPTOFHEALTHP CA Dept of Health-PHFE 4/2/2007   615 ANTI-HTLV I/II $3,075.00   13200 Crossroads Parkway North Suite #135 City of Industry CA 91746
CENTRENATLDETRA Centre Natl De Transfusion-Dr Konate-WIRE 1/10/2007   100 HIV-2 SPECIMENS $36,500.00   co Seidou KONATE KM 4 Bd de Marseille Cote d'Ivoire    
CENTRODEIMUNOLO Centro de Imunologia E Imunogenetica S/C 5/2/2007   NEED INV - A $750.00   Rua Peixoto Gomide   51512 Andar   01409-001
CENTRODEIMUNOLO Centro de Imunologia E Imunogenetica S/C 5/2/2007   NEED INV - B $750.00   Rua Peixoto Gomide   51512 Andar   01409-001
CENTRODEIMUNOLO Centro de Imunologia E Imunogenetica S/C 5/8/2007   NEED INV - D $1,425.00   Rua Peixoto Gomide   51512 Andar   01409-001
CENTRODEIMUNOLO Centro de Imunologia E Imunogenetica S/C 5/2/2007   NEED INV - C $1,875.00   Rua Peixoto Gomide   51512 Andar   01409-001
CURELINEINC Cureline, Inc. 10/1/2007   061-266-01 $3,501.60   393 East Grand Ave., Suite 1   South San Francisco CA 94080
DHLWORLDWIDEEXP DHL World Wide Express 10/22/2007   0030887967 $611.61   P.O. BOX 277264   ATLANTA GA 30384-7264
DHLWORLDWIDEEXP DHL World Wide Express 10/15/2007   0030769378 $1,468.07   P.O. BOX 277264   ATLANTA GA 30384-7264
DIAMEDIXCORPORA Diamedix Corporation 10/10/2007   DMX 398379 $241.48   2140 North Miami Avenue   Miami FL 33127
DIASORIN Dia-Sorin Inc. 10/10/2007   5244258 $291.77   NW 8678,  P.O.Box 1450 Customer# 50621-1 Minneapolis MN 55485-8678
DIASORIN Dia-Sorin Inc. 10/22/2007   5244988 $411.67   NW 8678,  P.O.Box 1450 Customer# 50621-1 Minneapolis MN 55485-8678
DISCOVERYCLINIC Discovery Clinical Research 3/22/2007   DO NOT PAY- 1 $125.00   1613 N Harrison Parkway   Sunrise FL 33323
DISCOVERYCLINIC Discovery Clinical Research 3/27/2007   DO NOT PAY - 2 $125.00   1613 N Harrison Parkway   Sunrise FL 33323
DISCOVERYCLINIC Discovery Clinical Research 4/27/2007   DO NOT PAY- 3 $125.00   1613 N Harrison Parkway   Sunrise FL 33323
DISCOVERYCLINIC Discovery Clinical Research 5/4/2007   DO NOT PAY- 4 $125.00   1613 N Harrison Parkway   Sunrise FL 33323
DISCOVERYCLINIC Discovery Clinical Research 4/10/2007   DO NOT PAY- 2 $250.00   1613 N Harrison Parkway   Sunrise FL 33323
DISCOVERYCLINIC Discovery Clinical Research 5/3/2007   DO NOT PAY - 4 $250.00   1613 N Harrison Parkway   Sunrise FL 33323
DISCOVERYCLINIC Discovery Clinical Research 5/9/2007   DO NOT PAY - 5 $250.00   1613 N Harrison Parkway   Sunrise FL 33323
DISCOVERYCLINIC Discovery Clinical Research 4/24/2007   DO NOT PAY - 3 $375.00   1613 N Harrison Parkway   Sunrise FL 33323
DONALDZELLERMD Donald Zeller, MD 10/20/2007   OCTOBER 2007 $1,000.00   24 Saranac Road   Sea Ranch Lakes FL 33308
EXAKTTECHNOLOGI Exakt Technologies, Inc. 10/11/2007   0014380-IN $131.52   7002 N. Broadway Extension   Oklahoma City OK 73116-9006
EXAKTTECHNOLOGI Exakt Technologies, Inc. 10/18/2007   0014464-IN $3,160.36   7002 N. Broadway Extension   Oklahoma City OK 73116-9006
FEDEX FedEx 10/17/2007   8-150-86504 $20.00   P.O.Box 94515   Palatine IL 60094-4515
FEDEX FedEx 10/25/2007   8-154-44222 $27.75   P.O.Box 94515   Palatine IL 60094-4515
FEDEX FedEx 10/16/2007   8-150-37411 $45.39   P.O.Box 94515   Palatine IL 60094-4515
FEDEX FedEx 10/23/2007   8-153-33078 $77.06   P.O.Box 94515   Palatine IL 60094-4515
FEDEX FedEx 10/9/2007   8-147-06302 $256.61   P.O.Box 94515   Palatine IL 60094-4515
FEDEX FedEx 10/16/2007   8-150-16193 $292.67   P.O.Box 94515   Palatine IL 60094-4515
FEDEX FedEx 10/9/2007   2-306-49877 $572.37   P.O.Box 94515   Palatine IL 60094-4515
FEDEX FedEx 10/16/2007   2-319-61744 $675.25   P.O.Box 94515   Palatine IL 60094-4515
FEDEX FedEx 10/23/2007   2-332-70862 $719.44   P.O.Box 94515   Palatine IL 60094-4515
FISHERSCIENTIFI Fisher Scientific 10/15/2007   3397321 $304.82   PO Box#404705 Atlanta , GA 30384-4705 Acct#   685336-001
FISHERSCIENTIFI Fisher Scientific 10/18/2007   3491886 $1,590.00   PO Box#404705 Atlanta , GA 30384-4705 Acct#   685336-001
FISHERSCIENTIFI Fisher Scientific 10/12/2007   3367380 $2,622.64   PO Box#404705 Atlanta , GA 30384-4705 Acct#   685336-001
FLORIDACERTIFIC Florida Certification Services, Inc. 10/1/2007   879 $480.00   Att: Accounts Receivable 7645 NW 38 Court Sunrise FL 33351
FUNDACIONCARDIO Fundacion Cardiovascular De Colombia-WIRE 5/10/2007   5169 - 1 $750.00   Calle 155-A #23-58 Tercer Piso Floridablanca, Santander Columbia    
FUNDACIONCARDIO Fundacion Cardiovascular De Colombia-WIRE 5/10/2007   5169 - 2 $1,200.00   Calle 155-A #23-58 Tercer Piso Floridablanca, Santander Columbia    
FUNDACIONCARDIO Fundacion Cardiovascular De Colombia-WIRE 5/11/2007   5169 - 3 $1,500.00   Calle 155-A #23-58 Tercer Piso Floridablanca, Santander Columbia    
FUNDACIONCARDIO Fundacion Cardiovascular De Colombia-WIRE 5/11/2007   5169 - 4 $2,400.00   Calle 155-A #23-58 Tercer Piso Floridablanca, Santander Columbia    
FUNDACIONCARDIO Fundacion Cardiovascular De Colombia-WIRE 5/14/2007   5169 - 5 $3,150.00   Calle 155-A #23-58 Tercer Piso Floridablanca, Santander Columbia    
GULFCOASTREGION Gulf Coast Regional Blood Center 9/30/2007   07-HEM-212 $2,430.00   PO Box#200601   Houston TX 77216-0601
GULFCOASTREGION Gulf Coast Regional Blood Center 9/30/2007   07-HEM-211 $2,565.00   PO Box#200601   Houston TX 77216-0601
GUYPERRINWIRE Guy Perrin-WIRE 4/30/2007   07-120B.01 $2,401.65            
HEMAGEN Hemagen 10/10/2007   0075333-IN $581.40   PO Box#37218   Baltimore MD 21297-3218
INDEPENDENTINVE Independent Investigational Review Board, Inc. 10/19/2007   15843 $100.00   6738 West Sunrise Blvd. Suite 102 Plantation FL 33313
INDEPENDENTINVE Independent Investigational Review Board, Inc. 10/12/2007   15768 $150.00   6738 West Sunrise Blvd. Suite 102 Plantation FL 33313
INDEPENDENTINVE Independent Investigational Review Board, Inc. 10/29/2007   15902 $150.00   6738 West Sunrise Blvd. Suite 102 Plantation FL 33313
INDEPENDENTINVE Independent Investigational Review Board, Inc. 10/12/2007   15770 $250.00   6738 West Sunrise Blvd. Suite 102 Plantation FL 33313
INDEPENDENTINVE Independent Investigational Review Board, Inc. 10/12/2007   15771 $350.00   6738 West Sunrise Blvd. Suite 102 Plantation FL 33313
INDEPENDENTINVE Independent Investigational Review Board, Inc. 9/16/2007   15511 $650.00   6738 West Sunrise Blvd. Suite 102 Plantation FL 33313
INDEPENDENTINVE Independent Investigational Review Board, Inc. 9/24/2007   15579 $750.00   6738 West Sunrise Blvd. Suite 102 Plantation FL 33313
INDEPENDENTINVE Independent Investigational Review Board, Inc. 10/29/2007   15898 $750.00   6738 West Sunrise Blvd. Suite 102 Plantation FL 33313
INDEPENDENTINVE Independent Investigational Review Board, Inc. 9/24/2007   15581 $900.00   6738 West Sunrise Blvd. Suite 102 Plantation FL 33313
INDEPENDENTINVE Independent Investigational Review Board, Inc. 10/3/2007   15686 $900.00   6738 West Sunrise Blvd. Suite 102 Plantation FL 33313
INDEPENDENTINVE Independent Investigational Review Board, Inc. 10/29/2007   15896 $900.00   6738 West Sunrise Blvd. Suite 102 Plantation FL 33313
INDEPENDENTINVE Independent Investigational Review Board, Inc. 10/29/2007   15895 $900.00   6738 West Sunrise Blvd. Suite 102 Plantation FL 33313
INDEPENDENTINVE Independent Investigational Review Board, Inc. 10/19/2007   15837 $1,750.00   6738 West Sunrise Blvd. Suite 102 Plantation FL 33313
INTEGRATEDSECUR Integrated Security Systems 11/1/2007   SRVCE041706 $26.50   1876 N.W. 7 Street   Miami FL 33125
INTEGRATEDSECUR Integrated Security Systems 12/1/2007   SRVCE042189 $26.50   1876 N.W. 7 Street   Miami FL 33125
IRL IRL 3/15/2006   1 RA $5.00   PO Box#281612   Atlanta GA 30384-1612
IRL IRL 9/14/2006   1 FREE T4 $5.00   PO Box#281612   Atlanta GA 30384-1612
IRL IRL 9/14/2006   2 RA $10.00   PO Box#281612   Atlanta GA 30384-1612
IRL IRL 3/15/2006   3 MYOGLOBIN $15.00   PO Box#281612   Atlanta GA 30384-1612
IRL IRL 3/21/2006   5 PTH SPECS $20.00   PO Box#281612   Atlanta GA 30384-1612
IRL IRL 6/5/2006   8   MYOGLOBIN $40.00   PO Box#281612   Atlanta GA 30384-1612
IRL IRL 3/15/2006   9 CORTISOL $45.00   PO Box#281612   Atlanta GA 30384-1612
IRL IRL 9/14/2006   11 MYOGLOBIN $55.00   PO Box#281612   Atlanta GA 30384-1612
IRL IRL 6/5/2006   12 PTH $60.00   PO Box#281612   Atlanta GA 30384-1612
IRL IRL 6/5/2006   14 FREE T4 $70.00   PO Box#281612   Atlanta GA 30384-1612
IRL IRL 6/5/2006   25 DSDNA ANTIBODY $125.00   PO Box#281612   Atlanta GA 30384-1612
IRL IRL 9/14/2006   30 AMYLASE $150.00   PO Box#281612   Atlanta GA 30384-1612
IRL IRL 6/5/2006   33 CA 19 - 9 $165.00   PO Box#281612   Atlanta GA 30384-1612
IRL IRL 9/14/2006   35 CARBAMAZEPINE $175.00   PO Box#281612   Atlanta GA 30384-1612
IRL IRL 9/14/2006   41 INSULIN $205.00   PO Box#281612   Atlanta GA 30384-1612
IRL IRL 9/14/2006   41 CA-125 $205.00   PO Box#281612   Atlanta GA 30384-1612
IRL IRL 6/5/2006   43 CEA $215.00   PO Box#281612   Atlanta GA 30384-1612
IRL IRL 6/5/2006   50 FERRITIN $250.00   PO Box#281612   Atlanta GA 30384-1612
IRL IRL 9/14/2006   73 FERRITIN $365.00   PO Box#281612   Atlanta GA 30384-1612
JOHNGRESSARD John Gressard 9/15/2007   OCTOBER 2007 $620.00   5440 NW 33RD AVENUE, SUITE 108   FT. LAUDERDALE FL 33309
JOSEPH L. MAURO Joseph L. Mauro 9/15/2007   OCTOBER 2007 $1,250.00   5440 NW 33rd Avenue Suite #108 Fort Lauderdale FL 33309
KEYSTONEBIO Keystone Bio 10/22/2007   1611 $20,639.50   21 North York Road   Hatboro PA 19040
KEYSTONEBIO Keystone Bio 9/24/2007   1570 $27,455.00   21 North York Road   Hatboro PA 19040
LABORATORYCORPO Laboratory Corp of America 3/15/2007   NEED INV - 5 $12.50   PO Box#12140   Burlington NC 27216-2140
LABORATORYCORPO Laboratory Corp of America 3/5/2007   NEED INV - 4 $75.00   PO Box#12140   Burlington NC 27216-2140
LABORATORYCORPO Laboratory Corp of America 3/15/2007   NEED INV - 6 $150.00   PO Box#12140   Burlington NC 27216-2140
LABORATORYCORPO Laboratory Corp of America 1/8/2007   NEED INV - 1 $850.00   PO Box#12140   Burlington NC 27216-2140
LABORATORYCORPO Laboratory Corp of America 3/2/2007   NEED INV - 3 $550.00   PO Box#12140   Burlington NC 27216-2140
LABORATORYCORPO Laboratory Corp of America 3/7/2007   NEED INV - 2 $1,080.00   PO Box#12140   Burlington NC 27216-2140
LEHIGHVALLEYHOS Lehigh Valley Hospital 4/18/2007   1143SEPSISID#'S45,46 $960.00   1240 S Cedar Crest Blvd. Suite# 212 Allentown PA 18103
OMEGAENGINEERIN Omega Engineering, Inc. 10/5/2007   473099 $156.35   PO Box#740496   Atlanta GA 30374-0496
ORTHO CLINICAL Ortho Clinical Diagnostics 9/5/2007   27077948 $29,525.24   Lock Box 10 P.O. Box # 406663 Atlanta GA 30384-6663
ORTHO CLINICAL Ortho Clinical Diagnostics 8/16/2007   27063198 $44,330.40   Lock Box 10 P.O. Box # 406663 Atlanta GA 30384-6663
OTD OTD 10/22/2007   35793 $308.32   3620 NE 5th Avenue   Oakland Park FL 33334
OTD OTD 10/15/2007   35681 $432.66   3620 NE 5th Avenue   Oakland Park FL 33334
OTD OTD 10/8/2007   35565 $520.47   3620 NE 5th Avenue   Oakland Park FL 33334
PHARMAEMARKETLL Pharma eMarket, LLC 10/22/2007   9964 $88.00   PO Box#8500   Philadelphia PA 19178-3486
PHARMAEMARKETLL Pharma eMarket, LLC 10/15/2007   9930 $4,312.00   PO Box#8500   Philadelphia PA 19178-3486
QIAGENINC Qiagen Inc. 10/4/2007   92640907 $178.01   File#54370   Los Angelos CA 90074-4370
QIAGENINC Qiagen Inc. 10/4/2007   92640906 $222.76   File#54370   Los Angelos CA 90074-4370
RABENFELDMANMD Raben & Feldman, MD 9/6/2006   10 MATCH SETS $2,000.00            
RABENFELDMANMD Raben & Feldman, MD 9/18/2006   11 MATCH SETS $2,000.00            
RAPS RAPS 10/24/2007   ID # 32007 $75.00   co SunTrust Lockbox Dept RAPS PO Box#79546 Baltimore MD 21279-0546
REDCROSSNICARAG Red Cross Nicaragua-Dr. Rene Berrios-WIRE 8/27/2007   1SLE UNIT $200.00   Kilometro 7 Carretera Sur   Reparto Belmonte    
REDCROSSNICARAG Red Cross Nicaragua-Dr. Rene Berrios-WIRE 8/27/2007   1 CHAGAS $200.00   Kilometro 7 Carretera Sur   Reparto Belmonte    
REDCROSSNICARAG Red Cross Nicaragua-Dr. Rene Berrios-WIRE 9/6/2007   724 SYPHILLIS RN#478 $250.00   Kilometro 7 Carretera Sur   Reparto Belmonte    
REDCROSSNICARAG Red Cross Nicaragua-Dr. Rene Berrios-WIRE 6/8/2007   RN#4622 TERA-ID-0003 $300.00   Kilometro 7 Carretera Sur   Reparto Belmonte    
REDCROSSNICARAG Red Cross Nicaragua-Dr. Rene Berrios-WIRE 8/31/2007   558 CHAGAS RN#4790 $1,100.00   Kilometro 7 Carretera Sur   Reparto Belmonte    
REDCROSSNICARAG Red Cross Nicaragua-Dr. Rene Berrios-WIRE 5/17/2007   PENDING TEST RESULTS $1,200.00   Kilometro 7 Carretera Sur   Reparto Belmonte    
REDCROSSNICARAG Red Cross Nicaragua-Dr. Rene Berrios-WIRE 8/27/2007   10 UNITS PO#4521-1 $1,500.00   Kilometro 7 Carretera Sur   Reparto Belmonte    
REDCROSSNICARAG Red Cross Nicaragua-Dr. Rene Berrios-WIRE 6/8/2007   RN#4623 TERA-ID-0003 $2,000.00   Kilometro 7 Carretera Sur   Reparto Belmonte    
REDCROSSNICARAG Red Cross Nicaragua-Dr. Rene Berrios-WIRE 5/7/2007   12 CHAGAS UNITS $2,400.00   Kilometro 7 Carretera Sur   Reparto Belmonte    
REDCROSSNICARAG Red Cross Nicaragua-Dr. Rene Berrios-WIRE 4/4/2007   112 RANDOM DONORS $2,800.00   Kilometro 7 Carretera Sur   Reparto Belmonte    
REDCROSSNICARAG Red Cross Nicaragua-Dr. Rene Berrios-WIRE 7/5/2007   13 SLE 24 SAMPLES $3,000.00   Kilometro 7 Carretera Sur   Reparto Belmonte    
REDCROSSNICARAG Red Cross Nicaragua-Dr. Rene Berrios-WIRE 4/4/2007   144 RANDOM DONORS $3,600.00   Kilometro 7 Carretera Sur   Reparto Belmonte    
REDCROSSNICARAG Red Cross Nicaragua-Dr. Rene Berrios-WIRE 4/4/2007   144 RANDOM SAMPLES $3,600.00   Kilometro 7 Carretera Sur   Reparto Belmonte    
REDCROSSNICARAG Red Cross Nicaragua-Dr. Rene Berrios-WIRE 4/6/2007   175 RANDOM DONORS $4,375.00   Kilometro 7 Carretera Sur   Reparto Belmonte    
REDCROSSNICARAG Red Cross Nicaragua-Dr. Rene Berrios-WIRE 4/16/2007   374 RANDOM DONORS $9,350.00   Kilometro 7 Carretera Sur   Reparto Belmonte    
REDCROSSNICARAG Red Cross Nicaragua-Dr. Rene Berrios-WIRE 3/29/2007   400 RANDOM DONORS $10,000.00   Kilometro 7 Carretera Sur   Reparto Belmonte    
RICOHAMERICASCO Ricoh Americas Corp-formerly Lanier 10/23/2007   93202492 $67.60   14820 Palmetto Frontage Road   Miami Lakes FL 33016
RICOHAMERICASCO Ricoh Americas Corp-formerly Lanier 10/13/2007   07650616 $443.68   14820 Palmetto Frontage Road   Miami Lakes FL 33016
RICOHAMERICASCO Ricoh Americas Corp-formerly Lanier 10/27/2007   93315359 $646.12   14820 Palmetto Frontage Road   Miami Lakes FL 33016
ROCHE Roche 10/8/2007   96590047 $6,589.34   Dept AT 952243   Atlanta GA 31192-2243
SIEMENSMEDICALS Siemens Medical Solutions (formerly DPC) 10/13/2007   2319883 $327.54   P.O. BOX 121102   DALLAS TX 75312-1102
SIEMENSMEDICALS Siemens Medical Solutions (formerly DPC) 10/4/2007   2313489 $8,640.63   P.O. BOX 121102   DALLAS TX 75312-1102
STANLEYJALEXAND Stanley J. Alexander 10/23/2007   PROT.#HEMA-RH-0064 $1,915.55   5 West Sycamore Avenue   Arcadia CA 91006
STAPLES Staples Business Advantage 9/29/2007   3091720468 $430.31   500 Staples Drive   Framingham MA 01702
TENNESSEEBLOODS Tennessee Blood Services 10/31/2007   43091 $43.00   Harold Stamey 807 Poplar Ave. Memphis TN 38105
TENNESSEEBLOODS Tennessee Blood Services 10/23/2007   43039 $66.00   Harold Stamey 807 Poplar Ave. Memphis TN 38105
TENNESSEEBLOODS Tennessee Blood Services 10/1/2007   42872 $70.00   Harold Stamey 807 Poplar Ave. Memphis TN 38105
TENNESSEEBLOODS Tennessee Blood Services 10/29/2007   43066 $89.00   Harold Stamey 807 Poplar Ave. Memphis TN 38105
TENNESSEEBLOODS Tennessee Blood Services 10/4/2007   42910 $170.00   Harold Stamey 807 Poplar Ave. Memphis TN 38105
TENNESSEEBLOODS Tennessee Blood Services 10/8/2007   42928 $170.00   Harold Stamey 807 Poplar Ave. Memphis TN 38105
TENNESSEEBLOODS Tennessee Blood Services 10/30/2007   43078 $181.00   Harold Stamey 807 Poplar Ave. Memphis TN 38105
TENNESSEEBLOODS Tennessee Blood Services 10/24/2007   43049 $192.50   Harold Stamey 807 Poplar Ave. Memphis TN 38105
TENNESSEEBLOODS Tennessee Blood Services 10/22/2007   43024 $468.50   Harold Stamey 807 Poplar Ave. Memphis TN 38105
TENNESSEEBLOODS Tennessee Blood Services 9/29/2007   42862 $1,220.00   Harold Stamey 807 Poplar Ave. Memphis TN 38105
TMOBILE T-Mobile 10/24/2007   954-554-5790 OCT07 $445.34   PO Box 742596   Cincinnati OH 45274-2596
UNIVERSITYOFMIA University of Miami 9/28/2007   09-28-2007 $30,850.00   School of Medicine - CFLD 1500 N.W. 12th Avenue, Suite #1101 Miami FL 33136
VALENTINAADIA Valentin A. Adia 9/15/2007   OCTOBER 2007 $1,250.00   5440 NW 33RD AVENUE SUITE 108 FORT LAUDERDALE FL 33309
VIRGINIAMEDICAL Virginia Medical Research 5/17/2007   1385-B $198.00   915 First Colonial Road Suite# 101 Virginia Beach VA 23454
VIRGINIAMEDICAL Virginia Medical Research 10/9/2007   1619 $210.00   915 First Colonial Road Suite# 101 Virginia Beach VA 23454
VIRGINIAMEDICAL Virginia Medical Research 10/9/2007   1618 $270.00   915 First Colonial Road Suite# 101 Virginia Beach VA 23454
WORLDCOURIER World Courier 10/23/2007   473627 $889.80   P.O. BOX 62277   BALTIMORE MD 21264-2277
XOCOMMUNICATION XO Communications 10/12/2007   0219185813 $141.59   14239 Collections Center Drive   Chicago IL 60693
          $349,203.92            

 

 
 

SCHEDULE B

 

LIST OF ASSETS

List each category of assets and for each give approximate value obtainable for the asset on the date of assignment, and address where asset is located.

NOTE: All assts listed at book value. Approximate value obtainable not known to Assignor.

I. Nonexempt Property

  Description and Location Liquidation Value at Date of Assignment

1. Legal description and street address of real estate, including leasehold interests:

None

2. Fixtures:

  Furniture & Fixtures $    7,050,21
  Leasehold Improvements $ 20,965.06
  See Exhibit B-2  

3. Cash and hank accounts:

  Comerica Bank $ 76,264.00

4. Inventory:

  Sets attached Exhibit B-4 $348,754.00

5. Accounts receivable:

  See attached Exhibit B-5 $450,957.97

6. Equipment:

  Computer Equipment $ 38,026.89
  Machinery & Equipment $ 70,928.37
  See attached Exhibit B-2  

7. Prepaid expenses, including deposits, insurance, rents, and utilities:

  Mohammed Abel-Blamid $ 15,500.00
  Red Cross Nicaragua-Dr. Rene Berrios $ 9,960.00

8. Other, including loans to third parties, claims, and choses in action:

None

IL. Exempt Properly

  Description and Location Liquidation Value at Date of Assignment

None

 

-Page 5-
 

Schedule B-2    TERAGENIX
FIXED ASSET DETAILS
10/31/2007 GL #6150 / 1520-1640

 

    Date 1825   Teragenix Original Acc Depn     HemaCare Acquired Monthly Acc Depn Sep to Dec   Depreciation Expense     Acc. Depn. Net Book Value
Asset Prop Description Acquired Life Method Cost 8/29/2006   Life Cost Depn 2006   Jan-07 28-Feb Mar-07 Apr-07 May-07 Jun-07 Jul-07 Aug-07 Sep-07 Oct-07   Total   2007 2007
Computers                                                      
21 Server 12/10/1999 5 S/L 1,622.00 1,622.00   5 -                             -   - -
47 Eltron TLP Printer 3/21/2000 5 S/L 634.00 634.00   5 -                             -   - -
48 Lab Computer 12/13/2000 5 S/L 1,295.00 1,295.00   5 -                             -   - -
49 Office Laptop Computer 12/24/2000 5 S/L 4,661.00 4,661.00   5 -                             -   - -
53 Computer Additions 9/30/2001 5 S/L 25,041.00 24,596.13   5 444.87 7.41 29.64   7.41 7.41 7.41 7.41 7.41 7.41 7.41 7.41 7.41 7.41   74.10   103.74 341.13
61 Computer CPU 12/6/2002 5 S/L 1,125.00 842.51   5 282.49 4.71 18.84   4.71 4.71 4.71 4.71 4.71 4.71 4.71 4.71 4.71 4.71   47.10   65.94 216.55
63 Laptop (2) - Val & Joe 4/29/2003 5 S/L 3,911.00 2,603.04   5 1,307.96 21.80 87.2   21.80 21.80 21.80 21.80 21.80 21.80 21.80 21.80 21.80 21.80   218.00   305.20 1,002.76
64 Laptop - Amanda 4/15/2003 5 S/L 1,227.00 826.88   5 400.13 6.67 26.68   6.67 6.67 6.67 6.67 6.67 6.67 6.67 6.67 6.67 6.67   66.70   93.38 306.75
65 Computer - Joe 12/1/2003 5 S/L 2,180.00 1,196.60   5 983.40 16.39 65.56   16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39   163.90   229.46 753.94
66 Monitors 2 Flat 12/11/2003 5 S/L 2,912.00 1,598.40   5 1,313.60 21.89 87.56   21.89 21.89 21.89 21.89 21.89 21.89 21.89 21.89 21.89 21.89   218.90   306.46 1,007.14
67 Computer Equipment 5/1/2003 5 S/L 6,415.00 4,269.61   5 2,145.39 35.76 143.04   35.76 35.76 35.76 35.76 35.76 35.76 35.76 35.76 35.76 35.76   357.60   500.64 1,644.75
87 New Computer 7/21/2004 5 S/L 1,863.48 774.40   5 1,089.08 18.15 72.6   18.15 18.15 18.15 18.15 18.15 18.15 18.15 18.15 18.15 18.15   181.50   254.10 834.98
92 Computers 1/10/2005 5 S/L 4,150.00 1,378.77   5 2,771.23 46.19 184.76   46.19 46.19 46.19 46.19 46.19 46.19 46.19 46.19 46.19 46.19   461.90   646.66 2,124.57
93 2 monitors 1/17/2005 5 S/L 847.98 281.73   5 566.25 9.44 37.76   9.44 9.44 9.44 9.44 9.44 9.44 9.44 9.44 9.44 9.44   94.40   132.16 434.09
94 Computers Teralab 2/1/2005 5 S/L 1,172.65 370.05   5 802.60 13.38 53.52   13.38 13.38 13.38 13.38 13.38 13.38 13.38 13.38 13.38 13.38   133.80   187.32 615.28
95 Scanner 1/17/2005 5 S/L 732.75 243.44   5 489.31 8.16 32.64   8.16 8.16 8.16 8.16 8.16 8.16 8.16 8.16 8.16 8.16   81.60   114.24 375.07
96 30 " LCD TV 1/18/2005 5 S/L 1,231.08 409.01   5 822.07 13.70 54.8   13.70 13.70 13.70 13.70 13.70 13.70 13.70 13.70 13.70 13.70   137.00   191.80 630.27
98 Software 4/1/2005 5 S/L 2,093.02 590.73   5 1,502.29 25.04 100.16   25.04 25.04 25.04 25.04 25.04 25.04 25.04 25.04 25.04 25.04   250.40   350.56 1,151.73
99 Laptop for Irak 4/1/2005 5 S/L 1,515.96 427.85   5 1,088.11 18.14 72.56   18.14 18.14 18.14 18.14 18.14 18.14 18.14 18.14 18.14 18.14   181.40   253.96 834.15
100 3 servers 8/22/2005 5 S/L 15,750.39 3,132.76   5 12,617.63 210.29 841.16   210.29 210.29 210.29 210.29 210.29 210.29 210.29 210.29 210.29 210.29   2,102.90   2,944.06 9,673.57
103 15 in Color Computer Monitor 8/16/2005 5 S/L 1,708.63 339.84   5 1,368.79 22.81 91.24   22.81 22.81 22.81 22.81 22.81 22.81 22.81 22.81 22.81 22.81   228.10   319.34 1,049.45
104 24 port ethernet switch 1/19/2005 5 S/L 620.32 206.09   5 414.23 6.90 27.6   6.90 6.90 6.90 6.90 6.90 6.90 6.90 6.90 6.90 6.90   69.00   96.60 317.63
105 Rack Unwire, 13mm 6/3/2005 5 S/L 1,107.10 312.46   5 794.64 13.24 52.96   13.24 13.24 13.24 13.24 13.24 13.24 13.24 13.24 13.24 13.24   132.40   185.36 609.28
106 Rack Unwire, 13mm 6/3/2005 5 S/L 1,107.10 312.46   5 794.64 13.24 52.96   13.24 13.24 13.24 13.24 13.24 13.24 13.24 13.24 13.24 13.24   132.40   185.36 609.28
107 CDW Computer Centers, Inc. 11/8/2005 5 S/L 1,863.59 339.61   5 1,523.98 25.40 101.6   25.40 25.40 25.40 25.40 25.40 25.40 25.40 25.40 25.40 25.40   254.00   355.60 1,168.38
108 CDW Computer Centers, Inc. 12/7/2005 5 S/L 1,795.01 327.11   5 1,467.90 24.46 97.84   24.46 24.46 24.46 24.46 24.46 24.46 24.46 24.46 24.46 24.46   244.60   342.44 1,125.46
109 Joe-laptop 12/31/05 5 S/L 3,061.55 404.84   5 2,656.71 44.28 177.12   44.28 44.28 44.28 44.28 44.28 44.28 44.28 44.28 44.28 44.28   442.80   619.92 2,036.79
110 HP Direct 12/31/05 5 S/L 1,756.97 232.34   5 1,524.63 25.41 101.64   25.41 25.41 25.41 25.41 25.41 25.41 25.41 25.41 25.41 25.41   254.10   355.74 1,168.89
111 2 Zebra printer f/lab & 5 software licenses 12/31/05 5 S/L 4,181.45 552.93   5 3,628.52 60.48 241.92   60.48 60.48 60.48 60.48 60.48 60.48 60.48 60.48 60.48 60.48   604.80   846.72 2,781.80
112 Cisco Equipment 3/31/06 5 S/L 1,782.86 235.76   5 1,547.10 25.79 103.16   25.79 25.79 25.79 25.79 25.79 25.79 25.79 25.79 25.79 25.79   257.90   361.06 1,186.04
113 Dell Computer 5/19/06 5 S/L 478.20 56.85   5 421.35 7.02 28.08   7.02 7.02 7.02 7.02 7.02 7.02 7.02 7.02 7.02 7.02   70.20   98.28 323.07
114 Recorder, 12 input mono ethernet 1/17/2007 5         5 2,045.00 34.08     34.08 34.08 34.08 34.08 34.08 34.08 34.08 34.08 34.08 34.08   340.80   340.80 1,704.20
                                                       
  Total Computer Equipment GL #1620     99,843.09 55,074.20     46,813.89 780.23 2,984.60   780.23 780.23 780.23 780.23 780.23 780.23 780.23 780.23 780.23 780.23 # 7,802.30   10,786.90 36,026.99
                                                       
Furniture & Fixtures   2555                                                
8 Office Furniture 11/19/1998 7 S/L 3,593.00 3,593.00   7 0.00 - 0   - - - - - - - - - -   -   - 0.00
22 Compact Refrigerator 2/10/1999 7 S/L 117.00 117.00   7 - - 0   - - - - - - - - - -   -   - -
23 Office Chairs 4/15/1999 7 S/L 214.00 214.00   7 - - 0   - - - - - - - - - -   -   - -
24 Exec Leather Chair 4/29/1999 7 S/L 106.00 106.00   7 - - 0   - - - - - - - - - -   -   - -
25 Dry Erase Board 4/29/1999 7 S/L 48.00 48.00   7 - - 0   - - - - - - - - - -   -   - -
26 Desk 5/24/1999 7 S/L 212.00 212.00   7 - - 0   - - - - - - - - - -   -   - -
27 Microwave 6/14/1999 7 S/L 74.00 74.00   7 - - 0   - - - - - - - - - -   -   - -
28 Desk 6/15/1999 7 S/L 85.00 85.00   7 - - 0   - - - - - - - - - -   -   - -
29 Bookcase 7/26/1999 7 S/L 200.00 200.00   7 - - 0   - - - - - - - - - -   -   - -
30 Lateral File 10/21/1999 7 S/L 180.00 180.00   7 - - 0   - - - - - - - - - -   -   - -
44 Furniture 6/30/1999 7 S/L 750.00 750.00   7 - - 0   - - - - - - - - - -   -   - -
54 F & F Additions 9/30/2001 7 S/L 19,003.00 11,841.58   7 7,161.42 85.26 341.04   85.26 85.26 85.26 85.26 85.26 85.26 85.26 85.26 85.26 85.26   852.60   1,193.64 5,967.78
  Misc. Office Supllies 11/15/2004 7 S/L 830.99 217.32   7 613.67 7.31 29.24   7.31 7.31 7.31 7.31 7.31 7.31 7.31 7.31 7.31 7.31   73.10   102.34 511.33
101 Rack Mount Mini 8/22/2005 7 S/L 799.20 113.86   7 685.34 8.16 32.64   8.16 8.16 8.16 8.16 8.16 8.16 8.16 8.16 8.16 8.16   81.60   114.24 571.10
                                                       
                                                       
                                                       
  Total Furniture & Fixtures GL #1520     26,212.19 17,751.76     8,460.43 100.73 402.92   100.73 100.73 100.73 100.73 100.73 100.73 100.73 100.73 100.73 100.73 # 1,007.30   1,410.22 7,050.21
                                                       
Leasehold Improvements on Lease ending 8/31/06 (Extended to 8/31/09)                                                
58 Security System 9/1/2001 5 S/L 26,625.00                                            
59 Office Buildout 9/1/2001 5 S/L 51,274.00                                            
68 Teralab, buildout 6/30/2003 3.2mo S/L 10,628.00                                            
75 Office Buildout 3/30/2004 2.5mo S/L 1,100.00                                            
75 Office Buildout 4/30/2004 2.4mo S/L 2,350.00                                            
77 Plumbing 4/30/2004 2.4mo S/L 3,150.00                                            
78 Cabinets 4/30/2004 2.4mo S/L 3,365.36                                            
79 Counter Tops 4/30/2004 2.4mo S/L 3,777.80                                            
80 Electric Work 4/30/2004 2.4mo S/L 1,450.00                                            
81 Flooring 4/30/2004 2.4mo S/L 1,921.18                                            
82 Walls and Doors 6/1/2004 2.2mo S/L 1,500.00                                            
83 Deposit for 2 new doors and removal of cabinets in office 11/12/2004 1.10mo S/L 600.00                                            
84 Final Pymt for 2 new doors and removal of cabinets in office 11/15/2004 1.10mo S/L 600.00                                            
85 New carpet for CRS Office 11/17/2004 1.10mo S/L 319.18                                            
86 New border in back office 11/29/2004 1.10mo S/L 125.00     36 mos                                      
86 Sub total, leasehold improvement       108,785.52 86,959.72   3.00 21,825.80 606.27 2425.08   606.27 606.27 606.27 606.27 606.27 606.27 606.27 606.27 606.27 606.27   6,062.70   8,487.78 13,338.02
87 Carpet 2/12/2007           31.00 2,611.84 84.25         84.25 84.25 84.25 84.25 84.25 84.25 84.25 84.25   674.00   674.00 1,937.84
88 Leasehold improvements, 2/16/2007           31.00 3,200.00 103.23         103.23 103.23 103.23 103.23 103.23 103.23 103.23 103.23   825.84   825.84 2,374.16
89 Lobby, logo sign 2/23/2007           31.00 1,172.36 37.82         37.82 37.82 37.82 37.82 37.82 37.82 37.82 37.82   302.56   302.56 869.80
90 Security System 3/12/2007           30.00 2,931.56 97.72             97.72 97.72 97.72 97.72 97.72 97.72   586.32   586.32 2,345.24
                                                       
  Total leasehold improvement GL #1640             31,741.56 929.29 2,425.08   606.27 606.27 831.57 831.57 929.29 929.29 929.29 929.29 929.29 929.29   8,451.42   10,876.50 20,865.06
                                                       
Machinery & Equipment   2555                                                
11 Medical Equipment 9/14/1998 7 S/L 3,409.00 3,409.00   7 (0.00) - 0   - - - - - - - - - -   -   - (0.00)
36 Freezer 3/30/1999 7 S/L 459.79 459.79   7 - - 0   - - - - - - - - - -   -   - -
37 Refrigerator 3/30/1999 7 S/L 136.61 136.61   7 - - 0   - - - - - - - - - -   -   - -
38 Typewriter 3/30/1999 7 S/L 84.79 84.79   7 - - 0   - - - - - - - - - -   -   - -
40 Used Bio Hood 8/12/1999 7 S/L 1,300.00 1,300.00   7 - - 0   - - - - - - - - - -   -   - -
42 Walk-in Freezer 10/4/1999 7 S/L 1,590.00 1,590.00   7 - - 0   - - - - - - - - - -   -   - -
43 Freezer 10/29/1999 7 S/L 470.39 470.39   7 - - 0   - - - - - - - - - -   -   - -
46 Medical Equipment 6/30/1999 7 S/L 2,708.92 2,708.92   7 - - 0   - - - - - - - - - -   -   - -
51 Below Zero Freezer 6/12/2000 7 S/L 6,145.00 6,145.00   7 - - 0   - - - - - - - - - -   -   - -
52 Lab Freezer 10/31/2000 7 S/L 548.00 456.46   7 91.54 1.09 4.36   1.09 1.09 1.09 1.09 1.09 1.09 1.09 1.09 1.09 1.09   10.90   15.26 76.28
55 Machinery Additions 8/1/2001 7 S/L 5,940.00 4,311.29   7 1,628.71 19.39 77.56   19.39 19.39 19.39 19.39 19.39 19.39 19.39 19.39 19.39 19.39   193.90   271.46 1,357.25
56 Telephone System 9/30/2001 7 S/L 12,388.00 8,696.34   7 3,691.66 43.95 175.8   43.95 43.95 43.95 43.95 43.95 43.95 43.95 43.95 43.95 43.95   439.50   615.30 3,076.36
57 Walk-in Freezer 9/30/2001 7 S/L 34,498.00 24,217.49   7 10,280.51 122.39 489.56   122.39 122.39 122.39 122.39 122.39 122.39 122.39 122.39 122.39 122.39   1,223.90   1,713.46 8,567.05
60 Equipment - 2 Zebras and Centrifuge 5/2/2002 7 S/L 12,097.00 7,483.97   7 4,613.03 54.92 219.68   54.92 54.92 54.92 54.92 54.92 54.92 54.92 54.92 54.92 54.92   549.20   768.88 3,844.15
62 Lab Equipment 7/25/2002 7 S/L 1,590.00 926.89   7 663.11 7.89 31.56   7.89 7.89 7.89 7.89 7.89 7.89 7.89 7.89 7.89 7.89   78.90   110.46 552.65
69 Copier 7/1/2003 7 S/L 7,102.00 3,210.08   5 3,891.92 64.87 259.48   64.87 64.87 64.87 64.87 64.87 64.87 64.87 64.87 64.87 64.87   648.70   908.18 2,983.74
70 Lab Barcode Scanner 4/24/2003 7 S/L 1,167.00 555.27   7 611.73 7.28 29.12   7.28 7.28 7.28 7.28 7.28 7.28 7.28 7.28 7.28 7.28   72.80   101.92 509.81
71 Lab Zebra Printer 5/2/2003 7 S/L 1,277.00 607.60   7 669.40 7.97 31.88   7.97 7.97 7.97 7.97 7.97 7.97 7.97 7.97 7.97 7.97   79.70   111.58 557.82
72 Lab RMS Cobas Equip 6/4/2003 7 S/L 10,322.00 4,788.39   7 5,533.61 65.88 263.52   65.88 65.88 65.88 65.88 65.88 65.88 65.88 65.88 65.88 65.88   658.80   922.32 4,611.29
74 Lab Conco 3 ft Hood 9/17/2003 7 S/L 5,278.78 2,228.96   7 3,049.82 36.31 145.24   36.31 36.31 36.31 36.31 36.31 36.31 36.31 36.31 36.31 36.31   363.10   508.34 2,541.48
76 Fisher Scientific 2/5/2004 7 S/L 2,620.80 966.19   7 1,654.61 19.70 78.8   19.70 19.70 19.70 19.70 19.70 19.70 19.70 19.70 19.70 19.70   197.00   275.80 1,378.81
83 Chest Freezer 5/1/2004 7 S/L 6,495.00 2,162.51   7 4,332.49 51.58 206.32   51.58 51.58 51.58 51.58 51.58 51.58 51.58 51.58 51.58 51.58   515.80   722.12 3,610.37
84 Fridge for Teralab 6/1/2004 7 S/L 1,378.00 442.40   7 935.60 11.14 44.56   11.14 11.14 11.14 11.14 11.14 11.14 11.14 11.14 11.14 11.14   111.40   155.96 779.64
85 Phone System 6/1/2004 7 S/L 4,050.99 1,300.55   7 2,750.44 32.74 130.96   32.74 32.74 32.74 32.74 32.74 32.74 32.74 32.74 32.74 32.74   327.40   458.36 2,292.08
86 DPC-Immulite 1000 6/30/2004 7 S/L 41,000.00 13,162.83   7 27,837.17 331.39 1325.56   331.39 331.39 331.39 331.39 331.39 331.39 331.39 331.39 331.39 331.39   3,313.90   4,639.46 23,197.71
89 Roche Diagnostics Corporation 9/2/2004 7 S/L 10,660.00 3,041.62   7 7,618.38 90.69 362.76   90.69 90.69 90.69 90.69 90.69 90.69 90.69 90.69 90.69 90.69   906.90   1,269.66 6,348.72
90 Datel Corporation 10/29/2004 7 S/L 40.00 10.94   7 29.06 0.35 1.4   0.35 0.35 0.35 0.35 0.35 0.35 0.35 0.35 0.35 0.35   3.50   4.90 24.16
91 Alliance Medical Consultants, Inc. 11/15/2004 7 S/L 4,770.00 1,247.45   7 3,522.55 41.94 167.76   41.94 41.94 41.94 41.94 41.94 41.94 41.94 41.94 41.94 41.94   419.40   587.16 2,935.39
102 Test Tube Rack 9/1/2005 7 S/L 747.78 106.54   7 641.24 7.63 30.52   7.63 7.63 7.63 7.63 7.63 7.63 7.63 7.63 7.63 7.63   76.30   106.82 534.42
103 Ritz Camera 6/5/2006 7 S/L 638.99 22.58   7 616.41 7.34 29.36   7.34 7.34 7.34 7.34 7.34 7.34 7.34 7.34 7.34 7.34   73.40   102.76 513.65
104 Costco 6/13/2006 7 S/L 803.65 28.39   7 775.26 9.23 36.92   9.23 9.23 9.23 9.23 9.23 9.23 9.23 9.23 9.23 9.23   92.30   129.22 646.04
                                                       
  Total Machinery & Equipment GL #1540     181,717.49 96,279.24     85,438.25 1,035.67 4,142.68   1,035.67 1,035.67 1,035.67 1,035.67 1,035.67 1,035.67 1,035.67 1,035.67 1,035.67 1,035.67 # 10,356.70   14,499.38 70,938.87
                                                       
          416,558.29 256,064.93     172,454.12 2,845.92 9,955.28   2,522.90 2,522.90 2,748.20 2,748.20 2,845.92 2,845.92 2,845.92 2,845.92 2,845.92 2,845.92 # 27,617.72   37,573.00 134,881.12

 

 
 

Schedule B-4              HemaBioscience
Inventory / Inventory Allowance
9/30/2007    

 

      Volume       12 Month Sales (Volume)        
Item Number Item Description Base U Of M 9/30/2007   Asset Value ($) Ave
Cost
10/1/06 to 5/22/07 5/23/07 to 9/30/07   Total Excess Inventory (Units) Reserve / Excess ($)   Asset Book Value
1 PSA ML 751.20   2,231.06 2.97 18.30 45.00   63.30 687.90 2,043.06   188.00
2 TSH ML 1,278.20   3,783.47 2.96 9.10 53.30   62.40 1,215.80 3,598.77   184.70
6 Anti-HIV 2 ML 2,924.40   51,498.68 17.61 2,821.20 449.00   3,270.20 - -   51,498.68
7 Osteoporosis ML 228.20   419.89 1.84       - 228.20 419.89   (0.00)
8 Human Serum ML 18,486.30   24,231.94 1.31 7,405.50 12,992.50   20,398.00 - -   24,231.94
10 Anti-HTLV I/II ML 43,454.80   27,572.39 0.63 3,164.20 317.00   3,481.20 39,973.60 25,183.37   2,389.02
11 Anti-HTLV I ML 1,354.50   650.16 0.48   2,415.40   2,415.40 - -   650.16
12 Anti-HTLV II ML 4.10   27.88 6.80       - 4.10 27.88   -
13 SLE ML 18,131.20   30,981.85 1.71 1,695.60 1,401.60   3,097.20 15,034.00 25,708.14   5,273.71
16 Cholesterol ML 268.80   2,110.08 7.85       - 268.80 2,110.08   -
26 Hashimoto's Thyroiditis ML 9.70   169.02 17.42   2.00   2.00 7.70 134.13   34.89
27 Human Urine ML 1,004.80   10.05 0.01       - 1,004.80 10.05   (0.00)
29 Anti-HIV 1/2 ML 30,865.80   5,555.84 0.18 764.60 528.00   1,292.60 29,573.20 5,323.18   232.66
30 dsDNA Antibody ML 6.00   17.93 2.99 22.60 33.90   56.50 - -   17.93
31 SSA Antibody ML 0.50   - - 761.00 2.00   763.00 - -   -
32 RNP Antibodies ML -   - - 4.60 101.50   106.10 - -   -
35 Hyperthyroidism ML 59.30   703.89 11.87       - 59.30 703.89   0.00
37 SCL-70 Antibody ML 12.90   500.75 38.82 21.50 12.00   33.50 - -   500.75
38 Thyroglobulin Antibody (TgAb) ML 9,475.50   7,390.89 0.78 36.80 3.30   40.10 9,435.40 7,359.61   31.28
40 Anti-EBV VCA IgG ML 2,330.60   442.81 0.19 3.60 2.80   6.40 2,324.20 441.60   1.21
48 Triglyceride ML 73.60   - -   1.00   1.00 72.60 -   -
49 Jo-1 Antiboyd ML 5.00   - - 653.00 7.00   660.00 - -   -
63 Anti-HBs ML 11,585.60   10,299.58 0.89 206.60     206.60 11,379.00 10,127.31   172.27
64 Anti-HBc IgM ML 28.20   210.80 7.48 2,538.50 795.60   3,334.10 - -   210.80
83 Anti-Rubella IgG ML 1,101.20   1,475.61 1.34   4.00   4.00 1,097.20 1,470.25   5.36
85 Syphillis-Primary (untreated) ML 1,045.80   627.48 0.60 73.50 11.00   84.50 961.30 576.78   50.70
91 Total T4 ML 37.00   242.35 6.55       - 37.00 242.35   -
92 T3 Uptake ML 1.10   12.53 11.39       - 1.10 12.53   (0.00)
93 Total T3 ML 719.50   4,292.81 5.97 219.90     219.90 499.60 2,982.61   1,310.20
101 FTA/ABS ML 82.00   187.78 2.29       - 82.00 187.78   -
162 Bilirubin (Total) ML 274.60   260.87 0.95       - 274.60 260.87   -
171 Human Plasma (EDTA-K3) ML 16,050.90   14,072.16 0.88 14,555.60 2,390.30   16,945.90 - -   14,072.16
172 Human Plasma (Lithium Heparin) ML 66.70   250.13 3.75   600.00   600.00 - -   250.13
174 Human Plasma (Sodium Citrate) ML 80,494.80   22,538.54 0.28 10,507.07 1,121.00   11,628.07 68,866.73 19,282.68   3,255.86
175 Human Plasma (Sodium Heparin) ML 3,022.90   1,900.56 0.63 229.90 1,620.20   1,850.10 1,172.80 738.86   1,161.70
176 Anti-Rubella IgM ML 662.00   123.00 0.19   20.80   20.80 641.20 121.83   1.17
178 H. Pylori ML 5,232.10   4,865.85 0.93 77.50 241.00   318.50 4,913.60 4,569.65   296.20
184 Anti-CMV IgM ML 197.80   1,242.18 6.28 64.20 15.00   79.20 118.60 744.81   497.37
197 HIVAg ML 10,932.10   7,215.19 0.66 104.00     104.00 10,828.10 7,146.55   68.64
199 Anti-HCV ML 206,572.40   93,055.03 0.45 7,507.30 5,769.30   13,276.60 193,295.80 86,983.11   6,071.92
225 Anti-Toxoplasmosis IgG ML 86.20   84.48 0.98 72.30 5.70   78.00 8.20 8.04   76.44
226 Anti-HSV 1 IgG ML 891.70   891.70 1.00 16.30 9.20   25.50 866.20 866.20   25.50
227 Anti-HSV 2 IgG ML 154.10   204.95 1.33 28.70 3.90   32.60 121.50 161.60   43.35
247 Anti-Toxoplasmosis IgM ML 16.40   49.69 3.03 252.60 2.90   255.50 - -   49.69
251 Anti-EBV NA IgM ML -   - -       - - -   -
252 Anti-HSV 1 IgM ML 122.80   2,603.36 21.20   28.10   28.10 94.70 2,007.64   595.72
253 Anti-HSV 2 IgM ML 122.50   388.33 3.17   14.90   14.90 107.60 341.09   47.24
261 FREE T4 ML 773.20   2,721.66 3.52 100.70 3.50   104.20 669.00 2,354.88   366.78
262 Tobramycin ML 107.30   690.92 6.44 16.80     16.80 90.50 582.82   108.10
263 Anti-CMV IgG ML 185.20   703.76 3.80 6.00     6.00 179.20 680.96   22.80
264 HBeAg ML 128.50   116.94 0.91 1,048.80     1,048.80 - -   116.94
266 Total Protein ML 135.50   271.00 2.00       - 135.50 271.00   -
297 H. Pylori (IgA) ML 53.30   - -   2.00   2.00 51.30 -   -
298 H. Pylori (IgG) ML 57.90   145.33 2.51       - 57.90 145.33   (0.00)
299 H. Pylori (IgM) ML 1.00   - -       - 1.00 -   -
305 Anti-HBc Total ML 77,113.00   4,626.78 0.06 304.50 267.20   571.70 76,541.30 4,592.48   34.30
310 Anti-Mumps IgG ML 16,243.50   4,223.31 0.26       - 16,243.50 4,223.31   -
317 Anti-VZV IgG ML 108.20   59.51 0.55 206.90     206.90 - -   59.51
322 Anti-HAV IgM ML 1,205.70   12,028.00 9.98 884.00 4,794.30   5,678.30 - -   12,028.00
325 Hemophilia ML 3.00   16.92 5.64       - 3.00 16.92   -
333 Anti-Rubeola IgG ML 104.70   - -       - 104.70 -   -
336 Anti-Dengue IgG ML 677.90   393.18 0.58 325.10     325.10 352.80 204.62   188.56
351 Pregnancy - 1st Trimester ML 1,014.90   4,556.16 4.49 30.00 486.90   516.90 498.00 2,236.02   2,320.14
352 Pregnancy - 2nd Trimester ML 1,841.10   8,540.72 4.64   228.50   228.50 1,612.60 7,482.46   1,058.26
353 Pregnancy - 3rd Trimester ML 3,167.50   14,364.81 4.54 15.10 239.60   254.70 2,912.80 13,224.11   1,140.70
370 Anti-Measles IgG ML 3,527.20   670.17 0.19       - 3,527.20 670.17   (0.00)
388 HBeAb ML 50.40   1.51 0.03       - 50.40 1.51   0.00
391 FREE T3 ML 633.00   3,923.71 6.20 891.70 56.70   948.40 - -   3,923.71
400 ALT ML 417.90   87.76 0.21       - 417.90 87.76   (0.00)
402 Anti-Measles IgM ML 90.70   495.22 5.46       - 90.70 495.22   0.00
410 Acute HBV ML 147.20   4,359.55 29.62 105.80     105.80 41.40 1,226.27   3,133.28
417 Anti-Mumps IgM ML 18.20   125.22 6.88       - 18.20 125.22   (0.00)
418 Anti-VZV IgM ML 106.20   663.75 6.25       - 106.20 663.75   -
421 Hepatocellular Carcinoma ML 9.00   - - 55.00 12.00   67.00 - -   -
429 Anti-HBs Vaccinated ML -   - -       - - -   -
446 Anti-HIV 1 ML 68,252.20   116,355.92 1.70 7,863.30 1,292.10   9,155.40 59,096.80 100,464.56   15,891.36
447 Anti-HAV Total ML 1,257.20   2,137.24 1.70       - 1,257.20 2,137.24   -
448 Acute HAV ML 941.80   24,147.75 25.64 418.70 94.50   513.20 428.60 10,989.30   13,158.45
456 Hospital Patient Sera ML 51.00   306.51 6.01       - 51.00 306.51   -
472 Amylase ML 46.80   194.22 4.15       - 46.80 194.22   -
501 Anti-HSV 1/2 IgM ML 4.70   26.32 5.60       - 4.70 26.32   -
502 CA 19 - 9 ML 22.40   170.91 7.63 76.20     76.20 - -   170.91
535 Hemolysed ML 7,592.20   3,409.76 0.45 15.50 1,503.00   1,518.50 6,073.70 2,733.17   676.59
536 Hypogonadism ML 95.00   416.10 4.38       - 95.00 416.10   -
537 Vitamin B12 ML 24.20   15.25 0.63       - 24.20 15.25   (0.00)
538 Hospital Sample (Non-Cancer Associated) ML 16.80   11.93 0.71       - 16.80 11.93   (0.00)
542 HBV Vaccinated ML 6,316.40   5,747.92 0.91 95.10     95.10 6,221.30 5,661.38   86.54
543 Rheumatoid Factor ML 5,658.30   38,605.84 6.82 5,335.40 1,406.80   6,742.20 - -   38,605.84
544 Pediatric ML 707.10   28,043.59 39.66       - 707.10 28,043.59   (0.00)
546 Human Plasma ML 15,868.80   11,584.22 0.73 583,180.01 146.20   583,326.21 - -   11,584.22
547 HCV-PCR ML 10,949.70   3,722.90 0.34 349.40 2.00   351.40 10,598.30 3,603.42   119.48
548 Anti-D ML 6.90   - -       - 6.90 -   -
549 Myoglobin ML 29.10   72.17 2.48       - 29.10 72.17   (0.00)
550 Troponin I ML 171.10   1,136.34 6.64 1,267.20 860.00   2,127.20 - -   1,136.34
552 PTH (C-Terminal) ML 69.80   166.12 2.38       - 69.80 166.12   0.00
554 Diagnostic Specimen ML 139.00   861.80 6.20 64.70 3.70   68.40 70.60 437.72   424.08
555 HBsAg ML 137,507.50   81,457.77 0.59 6,418.10 3,288.40   9,706.50 127,801.00 75,402.59   6,055.18
556 Cardiac Specimen ML 42.60   135.47 3.18 3.10     3.10 39.50 125.61   9.86
558 Chagas ML 29,478.80   25,219.27 0.86 5,891.70 7,107.90   12,999.60 16,479.20 14,172.11   11,047.16
562 HIV-PCR ML 2,593.10   1,504.00 0.58 65.70     65.70 2,527.40 1,465.89   38.11
563 High Risk-Brazil ML 367.10   124.81 0.34       - 367.10 124.81   0.00
565 Breast Cancer ML 5,056.20   20,224.80 4.00 757.90 109.10   867.00 4,189.20 16,756.80   3,468.00
567 Syphillis-Secondary(untreated) ML 31.60   - - 17.60     17.60 14.00 -   -
572 HIV-1 Seroconversion Panel ML 6,855.70   2,810.84 0.41       - 6,855.70 2,810.84   (0.00)
573 ANA-Homogenous Pattern ML 3.80   - -       - 3.80 -   -
580 PTH (Intact) ML 42.40   148.83 3.51   55.20   55.20 - -   148.83
581 SSA/SSB Antibody ML -   - -   10.00   10.00 - -   -
582 Leishmania ML 1,064.80   8,249.00 7.75   94.00   94.00 970.80 7,523.70   725.30
584 Centromere Antibody ML 2.00   - - 1.00 4.10   5.10 - -   -
585 HCV-Genotype 1a ML 78.50   - -       - 78.50 -   -
586 HCV-Genotype 2a ML 54.00   140.00 2.59   190.00   190.00 - -   140.00
587 HCV-Genotype 3a ML 5.00   - - 10.00     10.00 - -   -
589 HCV-Genotype 5a ML 178.00   4,227.50 23.75 642.40 308.20   950.60 - -   4,227.50
590 HCV-Genotype 6a ML 355.30   106.59 0.30 1.10     1.10 354.20 106.26   0.33
592 ANA ML 1,610.80   4,639.10 2.88 366.30 86.20   452.50 1,158.30 3,335.90   1,303.20
593 Fibrocystic Breast Disease ML 77.20   - -       - 77.20 -   -
594 Breast Cancer (Pre-Treatment) ML 101.10   657.15 6.50       - 101.10 657.15   -
607 Lipemic ML 18,121.00   5,073.88 0.28   905.70   905.70 17,215.30 4,820.28   253.60
609 Patient Specimen ML 40.40   - -       - 40.40 -   -
610 Colon Cancer-Active ML 94.80   262.60 2.77 5.30     5.30 89.50 247.92   14.68
611 Lung Cancer-Active ML 281.80   701.68 2.49 9.10     9.10 272.70 679.02   22.66
612 Patient-Multiple Matrices ML 69.40   86.06 1.24       - 69.40 86.06   (0.00)
613 BPH ML 609.60   2,365.25 3.88       - 609.60 2,365.25   (0.00)
614 Prostate Cancer (Pre-Treatment) ML 10.80   31.21 2.89       - 10.80 31.21   0.00
615 Ovarian Cancer ML 700.70   2,648.65 3.78 423.50     423.50 277.20 1,047.82   1,600.83
616 Benign Gynelogical Condition ML 108.00   519.48 4.81       - 108.00 519.48   -
620 Syphillis-Primary(treated) ML 141.70   450.00 3.18       - 141.70 450.61   (0.61)
621 RPR ML 30,636.90   11,029.28 0.36 84.20 207.70   291.90 30,345.00 10,924.20   105.08
623 HIV-2 ML 4,527.90   45,296.02 10.00 1,739.30 927.40   2,666.70 1,861.20 18,612.00   26,684.02
624 HCV-Genotype 2a/2c ML 231.30   1,311.47 5.67 0.40     0.40 230.90 1,309.20   2.27
627 CEA ML 873.20   1,329.60 1.52 270.80     270.80 602.40 915.65   413.95
628 CA-125 ML 81.30   240.20 2.95 170.20 4.10   174.30 - -   240.20
631 Human Plasma (CPDA) ML 3,754.80   2,102.69 0.56 1,034.50 249.30   1,283.80 2,471.00 1,383.76   718.93
633 HCV-Genotype 4 ML 3,017.10   8,840.10 2.93   2.00   2.00 3,015.10 8,834.24   5.86
635 Albumin ML 55.10   517.39 9.39       - 55.10 517.39   (0.00)
637 CMV ML 517.60   1,704.54 3.29 0.90 6.90   7.80 509.80 1,677.24   27.30
638 EBV ML 61.10   13.29 0.22 78.20 75.50   153.70 - -   13.29
639 Benign Breast Disease ML 958.60   2,463.60 2.57       - 958.60 2,463.60   0.00
640 Mononucleosis ML 8.10   48.20 5.95       - 8.10 48.20   (0.01)
641 Chlamydia IgM ML 2.90   - -       - 2.90 -   -
643 HIV-Venezuela ML 5,087.30   2,492.78 0.49 282.40 13.00   295.40 4,791.90 2,348.03   144.75
659 HIV-Nicaragua ML 17.70   116.64 6.59       - 17.70 116.64   0.00
663 HBV-Venezuela ML 9,289.90   4,087.56 0.44 338.00 2.00   340.00 8,949.90 3,937.96   149.60
679 HBV-Nicaragua ML 25,478.90   5,095.78 0.20 270.00 371.90   641.90 24,837.00 4,967.40   128.38
683 HCV-Venezuela ML 346.70   228.82 0.66 9.50     9.50 337.20 222.55   6.27
702 HIV-O ML 781.30   9,789.69 12.53 45.00     45.00 736.30 9,225.84   563.85
703 Anti-EBV IgM ML 1.00   5.21 5.21       - 1.00 5.21   -
708 c-ANCA ML 13.40   1.34 0.10       - 13.40 1.34   -
709 p-ANCA ML 8.80   50.07 5.69 253.20     253.20 - -   50.07
714 Pregnancy-Serial ML 45.00   1,105.20 24.56       - 45.00 1,105.20   -
716 Rheumatoid Arthritis ML 149.60   872.00 5.83 304.80 21.30   326.10 - -   872.00
718 High Risk-Hepatitis(US) ML 5.90   39.24 6.65       - 5.90 39.24   (0.00)
719 HCV NAT+/Ab- ML 17.40   6.26 0.36   2.00   2.00 15.40 5.54   0.72
720 High Risk-Senegal ML 533.60   602.97 1.13       - 533.60 602.97   (0.00)
721 High Risk-South Africa ML 322.30   354.53 1.10       - 322.30 354.53   -
723 Prostate Cancer ML 2,299.80   8,900.23 3.87 565.20 289.80   855.00 1,444.80 5,591.38   3,308.85
724 Syphillis ML 51,393.40   15,812.84 0.31 8,569.60 1,780.30   10,349.90 41,043.50 12,723.49   3,089.35
725 HBsAg-Senegal ML 173.80   45.19 0.26 10.20     10.20 163.60 42.54   2.65
731 Cardiac Serial Panel ML 8.30   24.15 2.91 1.50     1.50 6.80 19.79   4.36
732 Bladder CA ML 1,126.10   3,918.83 3.48       - 1,126.10 3,918.83   (0.00)
733 High Risk-Egypt ML 130.30   512.08 3.93       - 130.30 512.08   (0.00)
734 High Risk-Hong Kong ML 273.20   - -       - 273.20 -   -
740 HIV-1 (Subtype G) ML 2.40   20.50 8.54 26.60     26.60 - -   20.50
742 Parvovirus IgG ML 1.60   11.02 6.89       - 1.60 11.02   0.00
743 HCV Serial Set ML 199.70   4,305.53 21.56       - 199.70 4,305.53   0.00
747 HIV-Nigeria ML 1,293.30   879.44 0.68 19.80 26.80   46.60 1,246.70 847.76   31.68
756 HCV-Egypt ML 2,005.00   1,583.95 0.79 11.00 179.80   190.80 1,814.20 1,433.22   150.73
762 HBV-Egypt ML 685.20   3,090.25 4.51       - 685.20 3,090.25   0.00
763 HBV-Senegal ML 673.80   - - 167.30 14.10   181.40 492.40 -   -
765 HBV-China ML 250.20   - - 81.90     81.90 168.30 -   -
777 Cirrhosis ML 7.00   12.11 1.73       - 7.00 12.11   -
778 Hemodialysis ML 132.20   277.62 2.10   60.00   60.00 72.20 151.62   126.00
782 Endometriosis ML 566.60   2,051.09 3.62       - 566.60 2,051.09   0.00
783 Ulcerative Colitis ML 192.50   1,128.99 5.86 54.20 174.30   228.50 - -   1,128.99
785 Hematospermia ML 1.10   5.54 5.04       - 1.10 5.54   0.00
788 HIV-Africa ML 13,741.40   19,229.26 1.40 887.90 62.40   950.30 12,791.10 17,907.54   1,321.72
791 HBV-Africa ML 817.90   - -   65.00   65.00 752.90 -   -
795 HCV-Genotype 3e ML 8.10   - -       - 8.10 -   -
796 High Risk ML 34.20   21.55 0.63       - 34.20 21.55   (0.00)
797 Icteric ML 3,437.50   446.88 0.13       - 3,437.50 446.88   (0.00)
800 Hemoglobin ML 175.60   - - 15.40     15.40 160.20 -   -
802 Match Patient Set ML 7,220.60   9,603.40 1.33 6,191.50 3,313.50   9,505.00 - -   9,603.40
803 HCV Thera-Conversion Panel ML 1,208.70   - -       - 1,208.70 -   -
804 High Risk-Ivory Coast ML 10,208.00   11,535.04 1.13   89.20   89.20 10,118.80 11,434.24   100.80
805 Pancreatic CA ML 135.80   698.01 5.14 45.80 1.00   46.80 89.00 457.46   240.55
807 HIV-1 (Subtype B) ML 238.30   1,491.76 6.26 33.00     33.00 205.30 1,285.18   206.58
815 Pregnancy Specimen ML 1,416.20   1,869.38 1.32       - 1,416.20 1,869.38   0.00
816 HIV Mutation ML 4,568.20   3,197.74 0.70 770.60 123.30   893.90 3,674.30 2,572.01   625.73
817 Stomach CA ML 293.70   772.43 2.63 1.00     1.00 292.70 769.80   2.63
819 RBC (ALT/HBc) ML 0.80   7.57 9.46       - 0.80 7.57   (0.00)
823 Angiosarcoma ML 9.70   31.33 3.23       - 9.70 31.33   0.00
824 Thyroid Cancer ML 34.00   131.58 3.87       - 34.00 131.58   -
827 HBV NAT+/Ab- ML 3,453.70   379.91 0.11       - 3,453.70 379.91   (0.00)
828 HIV NAT+/Ab- ML 1,555.30   357.72 0.23       - 1,555.30 357.72   (0.00)
831 Monoclonal Gammopathy ML 611.90   1,597.06 2.61 197.50 30.50   228.00 383.90 1,001.98   595.08
832 Multiple Myeloma ML 1,624.90   4,611.87 2.84 289.70 219.50   509.20 1,115.70 3,168.59   1,443.28
834 Fresh Frozen Plasma (Human) ML 2,148.40   - -       - 2,148.40 -   -
836 Male Homosexual ML 431.70   - -       - 431.70 -   -
838 Elevated IgG ML 276.60   785.54 2.84   30.00   30.00 246.60 700.34   85.20
839 Elevated IgM ML 348.60   1,819.69 5.22 23.80 30.20   54.00 294.60 1,537.81   281.88
841 CK-MB ML 44.00   - -       - 44.00 -   -
843 Non-Viral Liver Disease ML 4.10   147.35 35.94 43.50 50.20   93.70 - -   147.35
844 HCV Patient-Match Set ML 252.70   886.98 3.51 1.10     1.10 251.60 883.12   3.86
847 Beta-HCG ML 81.20   207.87 2.56       - 81.20 207.87   0.00
848 FSH ML 643.00   1,009.51 1.57       - 643.00 1,009.51   -
849 Prolactin ML 535.60   637.36 1.19 32.50     32.50 503.10 598.69   38.67
850 Cortisol ML 51.20   295.37 5.77 16.00     16.00 35.20 203.10   92.27
851 Human Serum (Male) ML 576.50   541.91 0.94 0.10     0.10 576.40 541.82   0.09
852 Human Serum (Female) ML 1,732.70   1,784.68 1.03 4.20 4.00   8.20 1,724.50 1,776.24   8.44
853 Post Menopausal Female ML 1,775.00   1,491.00 0.84   412.10   412.10 1,362.90 1,144.84   346.16
855 HIV-Cote D'Ivoire ML 6,775.80   1,897.22 0.28 451.10 153.20   604.30 6,171.50 1,728.02   169.20
856 HBV-Cote D'Ivoire ML 14,033.70   11,226.96 0.80 5.60 772.60   778.20 13,255.50 10,604.40   622.56
857 HCV-Cote D'Ivoire ML 3,194.50   1,245.86 0.39       - 3,194.50 1,245.86   (0.00)
859 HBV Match Set ML 7,654.60   49,222.20 6.43 111.70 817.20   928.90 6,725.70 43,246.25   5,975.95
860 Anti-HAV IgG ML 75.30   313.25 4.16       - 75.30 313.25   (0.00)
861 CA 15-3 ML 129.50   50.16 0.39 221.60 4.00   225.60 - -   50.16
862 Autoimmune ML 45.10   810.00 17.96 78.90     78.90 - -   810.00
865 Flu Vaccine Recipient ML 496.90   472.06 0.95   54.50   54.50 442.40 420.28   51.78
866 Vancomycin ML 689.30   3,260.39 4.73 16.30     16.30 673.00 3,183.29   77.10
867 Carbamazepine ML 241.80   1,501.97 6.21 128.60     128.60 113.20 702.97   799.00
868 Dilantin ML 278.20   851.29 3.06       - 278.20 851.29   0.00
869 Digoxin ML 492.90   1,276.61 2.59       - 492.90 1,276.61   0.00
870 Theophylline ML 6.40   41.58 6.50 4.00     4.00 2.40 15.60   25.98
874 Coumadin ML 900.80   1,873.66 2.08       - 900.80 1,873.66   0.00
875 Phenobarbital ML 5.10   44.00 8.63 16.80     16.80 - -   44.00
876 Valproic Acid ML 335.50   2,206.10 6.58 52.74     52.74 282.76 1,860.56   345.54
877 Gentamycin ML 134.10   1,139.39 8.50 83.40     83.40 50.70 430.95   708.44
878 Depakene ML 2.00   5.74 2.87       - 2.00 5.74   -
879 Amiodarone ML 4.00   11.48 2.87       - 4.00 11.48   -
880 Gabapentin (Neurontin) ML 2.00   5.72 2.86       - 2.00 5.72   -
882 Elevated IgA ML 94.20   68.77 0.73 27.90     27.90 66.30 48.40   20.37
883 Multiple Transfusion ML 195.70   467.72 2.39 104.60 71.00   175.60 20.10 48.04   419.68
885 IgE Allergic ML 782.70   164.37 0.21       - 782.70 164.37   (0.00)
886 Progesterone ML 759.90   1,770.57 2.33       - 759.90 1,770.57   (0.00)
887 HCV Seroconversion Panel ML 6,133.10   2,085.25 0.34 1,277.50 9.00   1,286.50 4,846.60 1,647.84   437.41
888 HBsAg Seroconversion Panel ML 10,316.70   2,682.34 0.26 3.00 1.00   4.00 10,312.70 2,681.30   1.04
890 HBsAg (AY) ML 7.20   63.22 8.78       - 7.20 63.22   (0.00)
895 Multiple Lymphoma ML 20.90   30.10 1.44       - 20.90 30.10   (0.00)
896 Renal Insufficiency ML 24.10   51.33 2.13       - 24.10 51.33   0.00
897 Hemolytic Anemia ML 36.90   80.07 2.17       - 36.90 80.07   0.00
898 Aplastic Anemia ML 36.50   70.08 1.92       - 36.50 70.08   -
899 Chronic Lymphocytic Leukemia ML 2,042.90   4,759.96 2.33 14.10     14.10 2,028.80 4,727.10   32.86
900 Acute Lymphocytic Leukemia ML 67.80   128.82 1.90       - 67.80 128.82   -
901 Ascites Fluid ML 4.70   - -       - 4.70 -   -
903 Myelodysplastic Syndrome ML 408.50   833.34 2.04       - 408.50 833.34   -
905 Leutinizing Hormone ML 823.90   1,252.33 1.52       - 823.90 1,252.33   (0.00)
906 Testicular CA ML 3.70   26.31 7.11       - 3.70 26.31   (0.00)
907 Crohn's Disease ML 231.20   1,589.06 6.87 551.27 240.50   791.77 - -   1,589.06
908 Celiac Disease ML 34.10   91.73 2.69       - 34.10 91.73   (0.00)
910 Mycoplasma IgG ML 40.30   94.71 2.35       - 40.30 94.71   (0.00)
911 Mycoplasma IgM ML 4.80   0.38 0.08       - 4.80 0.38   0.00
916 Acute Myelocytic Leukemia ML 79.10   289.51 3.66       - 79.10 289.51   (0.00)
917 Chronic Myelocytic Leukemia ML 169.20   379.01 2.24       - 169.20 379.01   (0.00)
919 Liver Cancer - Secondary ML 8.90   19.76 2.22 3.40     3.40 5.50 12.21   7.55
920 Melanoma ML 322.60   864.57 2.68 1.10     1.10 321.50 861.62   2.95
921 HCV Mutation ML 454.90   250.20 0.55       - 454.90 250.20   (0.00)
922 CHF - Class I ML 61.80   499.34 8.08 13.80 90.20   104.00 - -   499.34
923 CHF - Class II ML 224.70   1,580.43 7.03 12.10 246.60   258.70 - -   1,580.43
924 CHF - Class III ML 492.10   2,861.20 5.81 11.40 107.20   118.60 373.50 2,170.04   691.16
925 CHF - Class IV ML 7.50   71.93 9.59   3.20   3.20 4.30 41.24   30.69
926 Breast Cancer Tissue (FFPE) ML 94.00   4,115.32 43.78       - 94.00 4,115.32   -
927 Benign Nevi (FFPE) ML 2.00   64.74 32.37       - 2.00 64.74   -
928 Melanoma (FFPE) ML 48.00   471.84 9.83       - 48.00 471.84   -
929 Cardiac Matched Set ML 42.10   200.82 4.77   0.90   0.90 41.20 196.52   4.30
930 HBV (Genotype G) ML 810.60   1,296.96 1.60 1.50     1.50 809.10 1,294.56   2.40
932 Triple Infection ML 66.40   - -       - 66.40 -   -
934 Lipid Profile ML 113.20   320.36 2.83       - 113.20 320.36   (0.00)
935 Alcoholic Hepatitis ML 7.60   13.07 1.72   5.90   5.90 1.70 2.92   10.15
936 Multiparity ML 1,443.20   7,194.67 4.99   73.40   73.40 1,369.80 6,835.30   359.37
937 NTX ML 57.40   37.31 0.65       - 57.40 37.31   -
938 Human Papillomavirus ML 2.00   134.58 67.29       - 2.00 134.58   -
939 Grave's Disease ML 20.90   62.91 3.01       - 20.90 62.91   (0.00)
940 Diabetes ML 760.90   4,230.60 5.56 107.30     107.30 653.60 3,634.02   596.58
941 HAMA ML 116.20   - -   6.00   6.00 110.20 -   -
943 Hypergammaglobulin IgG ML 34.90   35.95 1.03       - 34.90 35.95   (0.00)
946 Fibromyalgia ML 1,315.90   12,803.71 9.73       - 1,315.90 12,803.71   (0.00)
947 MCTD ML 159.80   556.10 3.48       - 159.80 556.10   0.00
948 Scleroderma ML 88.20   303.41 3.44       - 88.20 303.41   (0.00)
949 Vasculitis ML 124.30   459.91 3.70       - 124.30 459.91   -
950 Chlamydia trachomatis (pos.) ML 751.10   2,831.65 3.77       - 751.10 2,831.65   (0.00)
951 Neisseria gonorrhoeae ML 326.00   2,555.84 7.84   67.30   67.30 258.70 2,028.21   527.63
952 Human Urine (Male) ML 2,211.90   552.98 0.25       - 2,211.90 552.98   (0.00)
956 Non-Chronic Heart Failure ML 509.40   2,913.77 5.72       - 509.40 2,913.77   (0.00)
960 Lyme (European) IgM ML 197.70   472.50 2.39 584.50 521.90   1,106.40 - -   472.50
961 Parvo B-19 DNA+ ML 822.20   9,841.73 11.97 4.00     4.00 818.20 9,793.85   47.88
962 HBV DNA+ ML 118.80   510.84 4.30       - 118.80 510.84   -
965 Hypertension ML 64.00   816.64 12.76       - 64.00 816.64   -
966 HIV-Indonesia ML 935.60   271.32 0.29 8.00 1.00   9.00 926.60 268.71   2.61
967 HBV-Indonesia ML 3,777.90   1,246.71 0.33 1.00 32.30   33.30 3,744.60 1,235.72   10.99
968 HCV-Indonesia ML 4,236.20   889.60 0.21 96.90 19.00   115.90 4,120.30 865.26   24.34
970 COPD ML 14.60   218.42 14.96       - 14.60 218.42   (0.00)
971 Human Female Urine ML 1,320.00   330.00 0.25       - 1,320.00 330.00   -
973 HBV/HCV co-infected ML 2,831.20   1,811.97 0.64       - 2,831.20 1,811.97   (0.00)
974 HBV Precore Mutation ML 63.00   - -       - 63.00 -   -
977 Chlamydia IgG ML 8.40   23.02 2.74       - 8.40 23.02   (0.00)
978 HBV ML 1,253.90   8,902.69 7.10 14.60     14.60 1,239.30 8,799.03   103.66
980 HCV Genotype Panel (HCVGTP-002a) ML 90.00   - -       - 90.00 -   -
984 DNA, Total ML 59.00   - -       - 59.00 -   -
987 Anti-Gliadin IgG ML 30.20   420.69 13.93 0.50 1.80   2.30 27.90 388.65   32.04
988 Anti-Gliadin IgA ML 7.10   151.09 21.28 0.50     0.50 6.60 140.45   10.64
989 Labor and Delivery ML 58.80   939.62 15.98       - 58.80 939.62   0.00
990 Lyme (European) ML 568.80   904.39 1.59 2.00 2.00   4.00 564.80 898.03   6.36
992 Chlamydia IgA ML 5.50   22.83 4.15       - 5.50 22.83   (0.00)
993 Anti-Cardiolipin IgG/IgM ML 2.50   14.68 5.87       - 2.50 14.68   (0.00)
994 Chronic HCV ML 253.90   2,442.52 9.62       - 253.90 2,442.52   (0.00)
995 HIV and HCV coinfection ML 7,573.40   4,165.37 0.55 49.00     49.00 7,524.40 4,138.42   26.95
997 Human Plasma (EDTA-K2) ML 11.00   161.81 14.71       - 11.00 161.81   -
998 HCV-Thailand ML 13,414.90   15,158.84 1.13 160.30 662.60   822.90 12,592.00 14,228.96   929.88
1000 Anti-Smith ML 10.00   56.90 5.69       - 10.00 56.90   -
1001 HIVDRP-002a ML 770.00   24,116.40 31.32       - 770.00 24,116.40   -
1002 Homocysteine ML 20.70   57.34 2.77       - 20.70 57.34   (0.00)
1003 HIV/HBV Co-Infection ML 2,688.80   2,097.26 0.78       - 2,688.80 2,097.26   0.00
1004 HBV/HCV SCP ML 3,897.30   3,663.46 0.94 24.00     24.00 3,873.30 3,640.90   22.56
1005 HIV-Netherlands ML 2.60   16.98 6.53       - 2.60 16.98   (0.00)
1010 Esophogeal CA ML 267.90   959.08 3.58       - 267.90 959.08   0.00
1011 Rectal CA ML 449.00   1,917.23 4.27 4.00     4.00 445.00 1,900.15   17.08
1012 Anemia ML 990.20   6,296.84 6.36 10.00 25.00   35.00 955.20 6,075.07   221.77
1013 Lung/Breast CA ML 13.20   12.54 0.95       - 13.20 12.54   -
1014 Colorectal CA ML 132.00   564.96 4.28 2.20 4.10   6.30 125.70 538.00   26.96
1015 Non-Hodgkins Lymphoma ML 1,901.20   4,353.75 2.29 117.50     117.50 1,783.70 4,084.67   269.08
1016 HBV-Thailand ML 2,402.20   5,645.17 2.35       - 2,402.20 5,645.17   -
1023 Cervical CA ML 10.50   24.99 2.38       - 10.50 24.99   -
1024 HBV NAT Seroconversion ML 7,987.10   1,198.07 0.15 16.00 6.00   22.00 7,965.10 1,194.77   3.30
1028 Head &Neck CA ML 192.70   672.52 3.49       - 192.70 672.52   0.00
1029 Lung/Ovarian CA ML 2.90   14.53 5.01 1.10     1.10 1.80 9.02   5.51
1030 Larynx CA ML 4.00   20.04 5.01       - 4.00 20.04   -
1031 Colon/Lung CA ML 5.30   20.03 3.78       - 5.30 20.03   0.00
1032 Stomach/Colon CA ML 8.20   40.10 4.89       - 8.20 40.10   (0.00)
1033 Endometrial CA ML 145.60   396.03 2.72 7.50     7.50 138.10 375.63   20.40
1034 Breast/Lung CA ML 5.50   40.10 7.29       - 5.50 40.10   (0.01)
1035 Bronchial CA ML 6.40   17.34 2.71       - 6.40 17.34   0.00
1037 Colon/Breast CA ML 4.70   20.02 4.26       - 4.70 20.02   0.00
1038 Colon/Rectal CA ML 15.10   54.66 3.62       - 15.10 54.66   0.00
1039 Colon/Bladder CA ML 7.00   14.98 2.14       - 7.00 14.98   -
1040 Prostate/Colon CA ML 5.10   16.73 3.28       - 5.10 16.73   (0.00)
1041 Endocrine CA ML 3.90   20.05 5.14       - 3.90 20.05   (0.00)
1043 Interstitial Cystitis ML 1,637.20   5,926.66 3.62       - 1,637.20 5,926.66   0.00
1046 Preeclampsia (3rd trimester) ML 52.00   81.64 1.57 3.20 1.10   4.30 47.70 74.89   6.75
1047 Prostatitis (chronic) ML 321.00   927.69 2.89       - 321.00 927.69   -
1048 Prostatitis (acute) ML 307.70   910.79 2.96       - 307.70 910.79   0.00
1049 Kidney CA ML 273.50   741.19 2.71 16.60     16.60 256.90 696.20   44.98
1052 HCVGTP-004b ML 24.00   - - 9.00     9.00 15.00 -   -
1054 Cryptosporidium ML 10.00   12.50 1.25       - 10.00 12.50   -
1055 Human Stool ML 1,757.00   1,739.43 0.99       - 1,757.00 1,739.43   -
1056 HBV (Genotype H) ML 1,056.90   327.64 0.31       - 1,056.90 327.64   (0.00)
1057 Parvo B-19 ML 9.30   - -       - 9.30 -   -
1059 Cyclosporas ML 176.30   648.78 3.68       - 176.30 648.78   0.00
1060 HIV-Thailand ML 5,633.00   7,491.89 1.33 181.60 232.10   413.70 5,219.30 6,941.67   550.22
1062 HCVGTP-005a ML 30.00   - - 150.00 15.00   165.00 - -   -
1063 Osteoarthritis ML 946.40   6,435.52 6.80   5.00   5.00 941.40 6,401.52   34.00
1074 Geriatric Specimen ML 284.60   523.66 1.84       - 284.60 523.66   0.00
1075 Estradiol ML 77.10   184.27 2.39       - 77.10 184.27   (0.00)
1076 Syphillis IgG ML 52.20   185.83 3.56       - 52.20 185.83   0.00
1077 Syphillis IgM ML 238.00   968.66 4.07       - 238.00 968.66   -
1080 HCV (NS5 single band) ML 223.20   399.53 1.79 18.90 482.50   501.40 - -   399.53
1081 CT and GC positive ML 52.20   363.31 6.96       - 52.20 363.31   0.00
1082 Cyclosporine ML 318.70   1,389.53 4.36       - 318.70 1,389.53   0.00
1083 AST ML 1.20   - -       - 1.20 -   -
1084 Tacrolimus ML 626.90   2,695.67 4.30       - 626.90 2,695.67   -
1085 Lung Cancer (Pre-Treatment) ML 14.00   156.66 11.19       - 14.00 156.66   -
1090 BUN ML 237.90   485.32 2.04       - 237.90 485.32   (0.00)
1091 Testosterone ML 150.60   1,255.02 8.33       - 150.60 1,254.50   0.52
1093 HCVGTP-004c ML 45.00   - - 67.50     67.50 - -   -
1094 Primary hyperparathyroidism ML 85.30   1,126.81 13.21       - 85.30 1,126.81   0.00
1096 Psoriasis ML 1.10   - -       - 1.10 -   -
1097 HCVGTP-002c ML 780.00   - - 45.00     45.00 735.00 -   -
1098 BNP ML 218.80   822.69 3.76 11.90 238.00   249.90 - -   822.69
1100 West Nile Virus ML 1.60   71.57 44.73       - 1.60 71.57   (0.00)
1104 Quinidine ML 4.40   13.16 2.99       - 4.40 13.16   (0.00)
1105 Colon CA ML 2,527.50   10,160.55 4.02 217.40 73.10   290.50 2,237.00 8,992.74   1,167.81
1106 Lung CA ML 3,643.80   13,664.25 3.75 38.20 88.10   126.30 3,517.50 13,190.63   473.62
1107 Triple Infection - HIV, HCV and HBV ML 268.30   187.81 0.70       - 268.30 187.81   -
1108 Lyme Acute Infection ML 809.20   946.76 1.17   294.60   294.60 514.60 602.08   344.68
1110 Multiparity Panel ML 920.00   - -       - 920.00 -   -
1111 Polycythermia ML 49.30   163.18 3.31       - 49.30 163.18   0.00
1112 Thalassemia ML 20.30   25.17 1.24       - 20.30 25.17   0.00
1113 Astrocytoma ML 6.00   12.54 2.09       - 6.00 12.54   -
1114 Urethral CA ML 4.40   12.50 2.84       - 4.40 12.50   (0.00)
1115 Leiomyosarcoma ML 3.50   12.53 3.58       - 3.50 12.53   -
1116 Gastrointestinal CA ML 3.00   14.91 4.97       - 3.00 14.91   -
1117 HCV (c-22 single band) ML 256.10   494.27 1.93   208.00   208.00 48.10 92.83   401.44
1119 HBVSCP-002a ML 211.50   - -       - 211.50 -   -
1120 HBVSCP-003a ML 210.00   - - 37.50     37.50 172.50 -   -
1123 HEV ML 951.60   1,256.11 1.32 7.70 7.90   15.60 936.00 1,235.52   20.59
1125 ToRCH IgM ML 1,957.80   450.29 0.23 1,234.10 18.60   1,252.70 705.10 162.17   288.12
1126 Allergy Sample ML 22.10   61.44 2.78       - 22.10 61.44   (0.00)
1127 HGV ML 95.70   556.02 5.81   5.00   5.00 90.70 526.97   29.05
1128 Phenytoin ML 174.60   1,163.46 6.66 98.40     98.40 76.20 507.49   655.97
1129 Bacterial Cystitis ML 705.20   2,193.17 3.11       - 705.20 2,193.17   0.00
1130 Down's Syndrome ML 78.50   3,667.52 46.72       - 78.50 3,667.52   -
1131 Amikacin ML 100.80   495.94 4.92       - 100.80 495.94   (0.00)
1134 HCVSCP-002a ML 120.00   - -   7.50   7.50 112.50 -   -
1135 Myloidysplasia ML 149.60   251.33 1.68       - 149.60 251.33   (0.00)
1136 Uterine Cancer ML 32.40   127.33 3.93       - 32.40 127.33   0.00
1137 Liver CA ML 0.60   1.79 2.99 7.40 5.10   12.50 - -   1.79
1138 Renal CA ML 48.70   128.57 2.64       - 48.70 128.57   (0.00)
1139 Hemachromotosis ML 62.70   174.93 2.79       - 62.70 174.93   0.00
1140 HIV/HBV/HCV Triple Infection ML 284.00   377.72 1.33       - 284.00 377.72   -
1143 Sepsis ML 4,513.10   7,381.34 1.64 6,395.00 3,014.10   9,409.10 - -   7,381.34
1145 Leukemia ML 64.60   162.79 2.52       - 64.60 162.79   0.00
1147 HBV/HGV co-infected ML 10.00   457.20 45.72       - 10.00 457.20   -
1148 D-Dimer ML 545.10   1,967.81 3.61       - 545.10 1,967.81   0.00
1149 LDL ML 175.20   562.39 3.21       - 175.20 562.39   0.00
1150 Brain CA ML 6.80   25.02 3.68       - 6.80 25.02   0.00
1151 Islets of Langshans CA ML 36.00   75.24 2.09       - 36.00 75.24   -
1152 HCV/RPR+ ML 1,678.10   184.59 0.11       - 1,678.10 184.59   0.00
1153 IgE-trees ML 0.50   - -       - 0.50 -   -
1154 IgE-weeds ML 0.70   - -       - 0.70 -   -
1155 IgE-food ML 4.10   - -       - 4.10 -   -
1156 HIV & Syphilis Positive ML 17.80   - -       - 17.80 -   -
1157 Psoriatic Arthritis ML 3.10   - -       - 3.10 -   -
1158 Hairy Cell Leukemia ML 19.60   62.52 3.19       - 19.60 62.52   0.00
1159 Unspecified Leukemia ML 3.40   12.51 3.68       - 3.40 12.51   0.00
1160 Anal CA ML 56.30   237.59 4.22       - 56.30 237.59   (0.00)
1161 Prolymphocytic Leukemia ML 2.90   12.53 4.32       - 2.90 12.53   (0.00)
1162 Myeloma IgM ML 13.00   24.28 1.87   5.90   5.90 7.10 13.28   11.00
1163 Preeclampsia ML 12.20   258.27 21.17 37.20 15.70   52.90 - -   258.27
1164 Appendix CA ML 10.00   25.10 2.51       - 10.00 25.10   -
1165 Sarcoma ML 46.80   150.23 3.21       - 46.80 150.23   (0.00)
1166 Pituitary Gland CA ML 6.60   12.54 1.90       - 6.60 12.54   -
1167 Mesothelioma ML 8.90   25.10 2.82       - 8.90 25.10   (0.00)
1168 Thymus CA ML 14.60   56.36 3.86       - 14.60 56.36   (0.00)
1169 Tracheal CA ML 5.60   12.54 2.24       - 5.60 12.54   0.00
1170 Syphillis-Secondary(treated) ML 104.40   - -       - 104.40 -   -
1171 Acute MI ML 0.60   2.50 4.17 1.30     1.30 - -   2.50
1174 HBc IgM Panel (Lot# 50011) ML 1,360.00   - - 20.00     20.00 1,340.00 -   -
1175 Glioblastoma ML 33.90   87.46 2.58       - 33.90 87.46   0.00
1176 Small Intestine CA ML 5.00   12.55 2.51       - 5.00 12.55   -
1177 Gall Bladder CA ML 41.00   175.07 4.27       - 41.00 175.07   -
1178 Tongue CA ML 18.60   56.36 3.03       - 18.60 56.36   (0.00)
1179 Merkel Cell CA ML 7.50   25.05 3.34       - 7.50 25.05   -
1180 Islets of Langerhans CA ML 10.50   64.68 6.16       - 10.50 64.68   -
1181 HIV-1 Worldwide Subtype Panel (Lot#50051) ML 1,008.00   - - 90.00 18.00   108.00 900.00 -   -
1185 MGUS ML 60.90   87.70 1.44       - 60.90 87.70   (0.00)
1186 Paraprotien ML 33.20   37.85 1.14       - 33.20 37.85   (0.00)
1188 Gioblastoma ML 3.40   12.51 3.68       - 3.40 12.51   0.00
1189 Abdominal CA ML 5.50   98.45 17.90       - 5.50 98.45   -
1190 Peritoneal CA ML 5.00   16.45 3.29 10.20     10.20 - -   16.45
1191 Multiple CA (Renal,Breast,Thyroid,Prostate) ML 2.50   12.53 5.01       - 2.50 12.53   (0.01)
1192 Brain Oligodendioglioma ML 2.90   12.53 4.32       - 2.90 12.53   (0.00)
1193 Breast CA (Male) ML 7.00   30.52 4.36       - 7.00 30.52   -
1194 Lip CA ML 1.80   12.53 6.96       - 1.80 12.53   (0.00)
1199 Pelvic CA ML 7.40   31.30 4.23       - 7.40 31.30   0.00
1200 Biliary CA ML 8.10   62.61 7.73       - 8.10 62.61   0.00
1201 Fallopian CA ML 4.00   25.04 6.26 1.00     1.00 3.00 18.78   6.26
1205 HBV Genotype Panel (Lot# 60011) ML 870.00   - - 240.00     240.00 630.00 -   -
1206 HIV-2 Monospecific Panel (Lot#60021) ML 40.00   - - 30.00     30.00 10.00 -   -
1214 EBV IgM ML 1.00   - -       - 1.00 -   -
1215 Ferritin ML 190.50   771.53 4.05       - 190.50 771.53   (0.00)
1218 CRP ML 161.00   1,000.00 6.21       - 161.00 999.81   0.19
1219 Anti-Cardiolipin ML 2.50   12.50 5.00   3.60   3.60 - -   12.50
1220 Semen ML 32.60   - - 127.00     127.00 - -   -
1221 Hemoglobin A1c ML 495.00   1,453.23 2.94       - 495.00 1,455.30   (2.07)
1222 Random Donors ML 3,248.70   10,402.50 3.20 13,226.90 1,397.70   14,624.60 - -   10,402.50
1227 Irritable Bowel Syndrome ML 587.20   5,613.33 9.56       - 587.20 5,613.63   (0.30)
1232 Insulin ML 61.60   256.87 4.17       - 61.60 256.87   0.00
1234 Random Hospital Sample ML 383.40   329.72 0.86 3,195.20     3,195.20 - -   329.72
1235 HBsAg(False Positive) ML 3,856.70   2,468.29 0.64       - 3,856.70 2,468.29   (0.00)
1240 CSF ML 90.00   46.00 0.51 368.50 114.00   482.50 - -   46.00
1241 DHEA-S ML 42.50   328.86 7.74 257.10     257.10 - -   328.86
1243 Normal Human Serum ML 731.20   914.00 1.25 14,395.20 3,242.10   17,637.30 - -   914.00
1245 Hyperglobulinemia ML 619.60   1,456.06 2.35 446.60     446.60 173.00 406.55   1,049.51
1247 Adenocarcinoma (FFPE) ML 3.00   - - 3.00     3.00 - -   -
1248 Wilson Disease ML -   - -   17.20   17.20 - -   -
1250 Whole Blood ML 150.00   - -   110.00   110.00 40.00 -   -
1254 Elevated IgE ML 29.50   - - 29.50     29.50 - -   -
1256 Cystic Fibrosis DNA ML 0.10   - - 0.10     0.10 - -   -
1257 PM/SCL ML 1.20   - - 0.40     0.40 0.80 -   -
1258 HCV-Genotype 6 ML 109.80   3,856.18 35.12 35.80 1.00   36.80 73.00 2,563.76   1,292.42
1259 HBc IgM ML -   - - 4,035.40 1,762.80   5,798.20 - -   -
1260 HAV IgM ML -   - - 1.90 2,908.20   2,910.10 - -   -
1262 WHOLE BLOOD TEMPUS TUBES EA -   - - 20.00 35.00   55.00 - -   -
1263 Factor V Mutation ML 59.30   563.94 9.51       - 59.30 563.94   0.00
1264 Pregnancy (Rh-) ML 91.30   565.82 6.20 292.70 305.10   597.80 - -   565.82
1265 Cadaveric Specimen ML 386.10   4,440.03 11.50 741.30 2,123.10   2,864.40 - -   4,440.03
1266 Mono IgM ML 25.80   - -   178.50   178.50 - -   -
1267 Dengue ML 1,167.30   8,027.08 6.88 32.70 74.70   107.40 1,059.90 7,292.11   734.97
1268 HCV GTP (Lot#70021) ML 522.00   - - 6.00     6.00 516.00 -   -
1273 Anti-HBc IgM (pooled) ML -   - -       - - -   -
1274 Normal Human Match Sets ML 324.70   1,217.63 3.75   3,678.00   3,678.00 - -   1,217.63
1275 Stroke ML 6.30   1,499.94 238.09       - 6.30 1,499.97   (0.03)
1276 Dermamyositis ML -   - -   10.00   10.00 - -   -
1277 B2GP1 IgG ML -   - -   100.00   100.00 - -   -
1278 Fibrillarin ML -   - -       - - -   -
1279 PCNA ML -   - -   40.80   40.80 - -   -
1280 RNA Pol  I/III ML -   - -       - - -   -
1281 Polyclonal Gammopathy ML 10.50   - -   30.00   30.00 - -   -
1286 Hypercholesterolemia ML 48.10   - -       - 48.10 -   -
1287 Malaria ML 289.00   2,250.00 7.79       - 289.00 2,251.31   (1.31)
                             
                             
                             
                             
  Total           -   1,292,137.00   1,372,322.33 - 744,634.29 88,283.60   832,917.89 1,103,848.29 1,017,286.92   355,035.41
      Per GL #1310   1,372,322.33         -        
  Difference - GL #5150 / #1310   (0.00)   Inventory Reserve Per GL #1360 Hemacare 545,718.94    
                      Hembioscience 471,567.98    
                      Total 1,017,286.92    
                             
                Difference - GL #5150 / #1360 -    
                             
                Net / total adj. - add'l COGS=> 0.00    

 
 

HemaBioscience
Inventory Valuation
9/30/2007  

 

        Volume                               Receipts from 5/22/2007 to 6/30/2007      
Item Number   Item Description Base U Of M 9/30/2007   Qty Unit Cost Qty Unit Cost Qty Unit Cost Qty Unit Cost Qty Unit Cost Qty Unit Cost Qty Unit Cost Qty Unit Cost Qty Unit Cost Qty Unit Cost Qty Unit Cost Qty Unit Cost Qty Unit Cost Qty Unit Cost Qty Unit Cost Qty Unit Cost Qty Unit Cost Qty Unit Cost Qty Unit Cost Qty Unit Cost Qty Unit Cost Qty Unit Cost Qty Unit Cost Qty Unit Cost Total Qty   Extended Amount
1   PSA ML 751.20                                                                                               751 2.97 751.20 - 2,231.06
2   TSH ML 1,278.20                                                                                               1,278 2.96 1,278.20 - 3,783.47
6   Anti-HIV 2 ML 2,924.40                                                                                               2,924 17.61 2,924.40 - 51,498.68
7   Osteoporosis ML 228.20                                                                                               228 1.84 228.20 - 419.89
8   Human Serum ML 18,486.30                                       20.00 3.75 144.00 3.75 152.00 3.75 152 3.75 144 3.75 192 3.75 899 1.33 1 4.33 299 1.34 1 2.34                 16,482 1.19 18,486.30 - 24,231.94
10   Anti-HTLV I/II ML 43,454.80   1 3.16 149.2 3.33 1 0.65 1204 0.56 1 2.28 1294 0.52 1 23.07 2,413 0.55 1.00 23.07 942.40 0.57 1.00 2.83 2,488.40 0.54 1 6.26 1,789 0.60 1 6.42 1,131 0.59 1 7.53 1,296 0.52 1 1.29 41 11.88 1 11.73 1,235 0.54 1 8.04 29,460 0.64 43,454.80 - 27,572.39
11   Anti-HTLV I ML 1,354.50                                                                                               1,355 0.48 1,354.50 - 650.16
12   Anti-HTLV II ML 4.10                                                                                               4 6.80 4.10 - 27.88
13   SLE ML 18,131.20       1 4.41 391.9 5.73 1 1.7 793.2 0.25 1 7.92 97.9 7.58 212 7.03 1.00 7.53 499.70 5.70 503.90 5.95 22.00 5.43 1 5.54 463 6.46 1 8.37 81 6.11 1 5.70 179 6.26 1 5.71 37 6.61 1 6.75         14,842 1.04 18,131.20 - 30,981.85
16   Cholesterol ML 268.80                                                                                               269 7.85 268.80 - 2,110.08
26   Hashimoto's Thyroiditis ML 9.70                                               2.00 75.00                                             8 2.47 9.70 - 169.02
27   Human Urine ML 1,004.80                                                                                               1,005 0.01 1,004.80 - 10.05
29   Anti-HIV 1/2 ML 30,865.80                                                                                               30,866 0.18 30,865.80 - 5,555.84
30   dsDNA Antibody ML 6.00                                               0.50 -                                             6 3.26 6.00 - 17.93
31   SSA Antibody ML 0.50                                                                                               1 - 0.50 - -
32   RNP Antibodies ML -                                                                                               -   - - -
35   Hyperthyroidism ML 59.30                                                                                               59 11.87 59.30 - 703.89
37   SCL-70 Antibody ML 12.90                                               10.00 50.00                                             3 0.26 12.90 - 500.75
38   Thyroglobulin Antibody (TgAb) ML 9,475.50                                                                                               9,476 0.78 9,475.50 - 7,390.89
40   Anti-EBV VCA IgG ML 2,330.60                                                                                               2,331 0.19 2,330.60 - 442.81
48   Triglyceride ML 73.60                                                                                               74 - 73.60 - -
49   Jo-1 Antiboyd ML 5.00                                                                                               5 - 5.00 - -
63   Anti-HBs ML 11,585.60                                               1,294.00 0.52 1 2.12 1,239 0.54 1 5.89 1,337 0.50 1 6.40 1,325 0.50 1 12.45 4,721 1.19             1,665 1.19 11,585.60 - 10,299.58
64   Anti-HBc IgM ML 28.20   1 0                                         27.20 7.75                                             -   28.20 - 210.80
83   Anti-Rubella IgG ML 1,101.20                                                                                               1,101 1.34 1,101.20 - 1,475.61
85   Syphillis-Primary (untreated) ML 1,045.80                                                                                               1,046 0.60 1,045.80 - 627.48
91   Total T4 ML 37.00                                                                                               37 6.55 37.00 - 242.35
92   T3 Uptake ML 1.10                                                                                               1 11.39 1.10 - 12.53
93   Total T3 ML 719.50   1 5.79 49.6 5.73 1 5.95 47.5 5.98                             11.40 4.84 1 4.82 215 5.52 1 5.96 42 5.99 1 6.02 349 6.31                     -   719.50 - 4,292.81
101   FTA/ABS ML 82.00                                                                                               82 2.29 82.00 - 187.78
162   Bilirubin (Total) ML 274.60                                                                                               275 0.95 274.60 - 260.87
171   Human Plasma (EDTA-K3) ML 16,050.90   204 3.75 92 3.75 148 3.75 156 3.75                             899.00 1.33 1 4.33                                         14,551 0.73 16,050.90 - 14,072.16
172   Human Plasma (Lithium Heparin) ML 66.70   48 3.75 18.7 3.75                                                                                     - 0.71 66.70 - 250.13
174   Human Plasma (Sodium Citrate) ML 80,494.80                                                                                               80,495 0.28 80,494.80 - 22,538.54
175   Human Plasma (Sodium Heparin) ML 3,022.90                                               899.00 1.33 1 4.33                                         2,123 0.33 3,022.90 - 1,900.56
176   Anti-Rubella IgM ML 662.00                                               650.00 -                                             12 10.25 662.00 - 123.00
178   H. Pylori ML 5,232.10                                                                                               5,232 0.93 5,232.10 - 4,865.85
184   Anti-CMV IgM ML 197.80                                                                                               198 6.28 197.80 - 1,242.18
197   HIVAg ML 10,932.10                                                                                               10,932 0.66 10,932.10 - 7,215.19
199   Anti-HCV ML 206,572.40                                               3,949.10 0.47 1 18.92                                         202,622 0.45 206,572.40 - 93,055.03
225   Anti-Toxoplasmosis IgG ML 86.20                                                                                               86 0.98 86.20 - 84.48
226   Anti-HSV 1 IgG ML 891.70                                                                                               892 1.00 891.70 - 891.70
227   Anti-HSV 2 IgG ML 154.10                                                                                               154 1.33 154.10 - 204.95
247   Anti-Toxoplasmosis IgM ML 16.40                                                                                               16 3.03 16.40 - 49.69
251   Anti-EBV NA IgM ML -                                                                                               -   - - -
252   Anti-HSV 1 IgM ML 122.80                                                                                               123 21.20 122.80 - 2,603.36
253   Anti-HSV 2 IgM ML 122.50                                                                                               123 3.17 122.50 - 388.33
261   FREE T4 ML 773.20                                                                                               773 3.52 773.20 - 2,721.66
262   Tobramycin ML 107.30   1 7.37 11 7.33                                     78.00 6.45                                             17 5.77 107.30 - 690.92
263   Anti-CMV IgG ML 185.20                                                                                               185 3.80 185.20 - 703.76
264   HBeAg ML 128.50                                                                                               129 0.91 128.50 - 116.94
266   Total Protein ML 135.50                                                                                               136 2.00 135.50 - 271.00
297   H. Pylori (IgA) ML 53.30                                                                                               53 - 53.30 - -
298   H. Pylori (IgG) ML 57.90                                                                                               58 2.51 57.90 - 145.33
299   H. Pylori (IgM) ML 1.00                                                                                               1 - 1.00 - -
305   Anti-HBc Total ML 77,113.00                                                                                               77,113 0.06 77,113.00 - 4,626.78
310   Anti-Mumps IgG ML 16,243.50                                                                                               16,244 0.26 16,243.50 - 4,223.31
317   Anti-VZV IgG ML 108.20                                                                                               108 0.55 108.20 - 59.51
322   Anti-HAV IgM ML 1,205.70   2.9 0                                         1,202.80 10.00                                             -   1,205.70 - 12,028.00
325   Hemophilia ML 3.00                                                                                               3 5.64 3.00 - 16.92
333   Anti-Rubeola IgG ML 104.70                                                                                               105 - 104.70 - -
336   Anti-Dengue IgG ML 677.90                                                                                               678 0.58 677.90 - 393.18
351   Pregnancy - 1st Trimester ML 1,014.90   1 6.48 78.4 6.55 49 7.03                 578 5.13 1.00 2.81                                                         307 2.35 1,014.90 - 4,556.16
352   Pregnancy - 2nd Trimester ML 1,841.10   1 6.37 76.2 6.57 53.6 8                 1,321 5.11 1.00 1.22                                                         389 2.20 1,841.10 - 8,540.72
353   Pregnancy - 3rd Trimester ML 3,167.50   1 7.02 71.3 6.83 52.5 7.3                 2,100 5.01 1.00 10.00                                                         942 3.14 3,167.50 - 14,364.81
370   Anti-Measles IgG ML 3,527.20                                                                                               3,527 0.19 3,527.20 - 670.17
388   HBeAb ML 50.40                                                                                               50 0.03 50.40 - 1.51
391   FREE T3 ML 633.00   1 6.76 9.3 6.8                     8 6.41             1.20 4.55 1 4.54 7 6.33 1 6.32                                 605 6.19 633.00 - 3,923.71
400   ALT ML 417.90                                                                                               418 0.21 417.90 - 87.76
402   Anti-Measles IgM ML 90.70                                                                                               91 5.46 90.70 - 495.22
410   Acute HBV ML 147.20                               26 33.71 1.00 33.65                                                         121 28.71 147.20 - 4,359.55
417   Anti-Mumps IgM ML 18.20                                                                                               18 6.88 18.20 - 125.22
418   Anti-VZV IgM ML 106.20                                                                                               106 6.25 106.20 - 663.75
421   Hepatocellular Carcinoma ML 9.00                                                                                               9 - 9.00 - -
429   Anti-HBs Vaccinated ML -                                                                                               - - - - -
446   Anti-HIV 1 ML 68,252.20                               57 14.58 2.00 14.66 1.00 14.62     1,414.50 0.44 1 2.62                                         66,777 1.72 68,252.20 - 116,355.92
447   Anti-HAV Total ML 1,257.20                                                                                               1,257 1.70 1,257.20 - 2,137.24
448   Acute HAV ML 941.80                                                                                               942 25.64 941.80 - 24,147.75
456   Hospital Patient Sera ML 51.00                                                                                               51 6.01 51.00 - 306.51
472   Amylase ML 46.80                                                                                               47 4.15 46.80 - 194.22
501   Anti-HSV 1/2 IgM ML 4.70                                                                                               5 5.60 4.70 - 26.32
502   CA 19 - 9 ML 22.40                                                                                               22 7.63 22.40 - 170.91
535   Hemolysed ML 7,592.20   15 1.17                                         299.00 1.17 1 0.17 179 0.39 1 0.19 317 0.99 1 1.37 370 0.94 1 2.67                 6,409 0.36 7,592.20 - 3,409.76
536   Hypogonadism ML 95.00                                                                                               95 4.38 95.00 - 416.10
537   Vitamin B12 ML 24.20                                                                                               24 0.63 24.20 - 15.25
538   Hospital Sample (Non-Cancer Associated) ML 16.80                                                                                               17 0.71 16.80 - 11.93
542   HBV Vaccinated ML 6,316.40                                                                                               6,316 0.91 6,316.40 - 5,747.92
543   Rheumatoid Factor ML 5,658.30   1 11.35 1108 6.22 1 8.92 4.6 8.93 1 4.9 585.3 7.68 1 8.56 357 8.37 718.00 6.06 74.70 15.06 8.60 8.72 8.00 6.94 1 6.98 56 8.19 1 7.95 289 6.20 1 7.58 120 - 22 5.34 1 5.38 43 7.87 48 8.61 76 6.57 2,132 6.99 5,658.30 - 38,605.84
544   Pediatric ML 707.10                                                                                               707 39.66 707.10 - 28,043.59
546   Human Plasma ML 15,868.80                                                                                               15,869 0.73 15,868.80 - 11,584.22
547   HCV-PCR ML 10,949.70                                                                                               10,950 0.34 10,949.70 - 3,722.90
548   Anti-D ML 6.90                                                                                               7 - 6.90 - -
549   Myoglobin ML 29.10                                                                                               29 2.48 29.10 - 72.17
550   Troponin I ML 171.10   1 6.17 149 6.67                 1 6.19 20 6.38                                                             (0)   171.10 - 1,136.34
552   PTH (C-Terminal) ML 69.80                                                                                               70 2.38 69.80 - 166.12
554   Diagnostic Specimen ML 139.00                                                                                               139 6.20 139.00 - 861.80
555   HBsAg ML 137,507.50   1 8.83 1042 0.51 1 11.59 1301 0.51 1 18.16 2058 0.72     633 9.46 1.00 10.87 1,172.30 0.57 1.00 6.78 1,353.00 1.62 1 8.14 4,029 0.46 1 21.61                                 125,913 0.54 137,507.50 - 81,457.77
556   Cardiac Specimen ML 42.60                                                                                               43 3.18 42.60 - 135.47
558   Chagas ML 29,478.80   1 6.69 464.3 6.77 1 2.78 616.3 0.32 1 0.4 1506 0.73     1,340 0.89 1.00 7.04         2,120.80 0.94 1 6.45                                         23,426 0.75 29,478.80 - 25,219.27
562   HIV-PCR ML 2,593.10                                                                                               2,593 0.58 2,593.10 - 1,504.00
563   High Risk-Brazil ML 367.10                                                                                               367 0.34 367.10 - 124.81
565   Breast Cancer ML 5,056.20                                                                                               5,056 4.00 5,056.20 - 20,224.80
567   Syphillis-Secondary(untreated) ML 31.60                                                                                               32 - 31.60 - -
572   HIV-1 Seroconversion Panel ML 6,855.70                                                                                               6,856 0.41 6,855.70 - 2,810.84
573   ANA-Homogenous Pattern ML 3.80                                                                                               4 - 3.80 - -
580   PTH (Intact) ML 42.40                                               19.00 1.88 1 1.78                                         22 4.97 42.40 - 148.83
581   SSA/SSB Antibody ML -                                                                                               - 50.00 - - -
582   Leishmania ML 1,064.80   279.4 7.49                         160 7.44 1.00 8.11         155.60 6.70 1 7.48 90 6.62 1 6.85                                 377 8.77 1,064.80 - 8,249.00
584   Centromere Antibody ML 2.00   1.1 0 1 0                                                                                     (0) - 2.00 - -
585   HCV-Genotype 1a ML 78.50                                                                                               79   78.50 - -
586   HCV-Genotype 2a ML 54.00   1 2.2 53 2.6                                                                                     -   54.00 - 140.00
587   HCV-Genotype 3a ML 5.00                                                                                               5 - 5.00 - -
589   HCV-Genotype 5a ML 178.00                                                                                               178 23.75 178.00 - 4,227.50
590   HCV-Genotype 6a ML 355.30                                                                                               355 0.30 355.30 - 106.59
592   ANA ML 1,610.80                                                                                               1,611 2.88 1,610.80 - 4,639.10
593   Fibrocystic Breast Disease ML 77.20                                                                                               77 - 77.20 - -
594   Breast Cancer (Pre-Treatment) ML 101.10                                                                                               101 6.50 101.10 - 657.15
607   Lipemic ML 18,121.00                                                                                               18,121 0.28 18,121.00 - 5,073.88
609   Patient Specimen ML 40.40                                                                                               40 - 40.40 - -
610   Colon Cancer-Active ML 94.80                                                                                               95 2.77 94.80 - 262.60
611   Lung Cancer-Active ML 281.80                                                                                               282 2.49 281.80 - 701.68
612   Patient-Multiple Matrices ML 69.40                                                                                               69 1.24 69.40 - 86.06
613   BPH ML 609.60                                                                                               610 3.88 609.60 - 2,365.25
614   Prostate Cancer (Pre-Treatment) ML 10.80                                                                                               11 2.89 10.80 - 31.21
615   Ovarian Cancer ML 700.70                                                                                               701 3.78 700.70 - 2,648.65
616   Benign Gynelogical Condition ML 108.00                                                                                               108 4.81 108.00 - 519.48
620   Syphillis-Primary(treated) ML 141.70   1 13.43 32.8 13.31                                                                                     108 - 141.70 - 450.00
621   RPR ML 30,636.90                                                                                               30,637 0.36 30,636.90 - 11,029.28
623   HIV-2 ML 4,527.90                                               4,384.90 10.33                                             143   4,527.90 - 45,296.02
624   HCV-Genotype 2a/2c ML 231.30                                                                                               231 5.67 231.30 - 1,311.47
627   CEA ML 873.20                                               1.10 3.64                                             872 1.52 873.20 - 1,329.60
628   CA-125 ML 81.30                                               0.50 2.67 1 2.66                                         80 2.96 81.30 - 240.20
631   Human Plasma (CPDA) ML 3,754.80                                                                                               3,755 0.56 3,754.80 - 2,102.69
633   HCV-Genotype 4 ML 3,017.10                                                                                               3,017 2.93 3,017.10 - 8,840.10
635   Albumin ML 55.10                                                                                               55 9.39 55.10 - 517.39
637   CMV ML 517.60   1 7.29 12.7 7.3 1 8.18 64 7.88             15 8.38 1.00 8.45         21.40 8.37 1 8.38 41 8.27 1 8.45 27 7.51 1 7.48 22 8.89 1 8.86 5 0.89             302   517.60 - 1,704.54
638   EBV ML 61.10   22 0                                                                                         39 0.34 61.10 - 13.29
639   Benign Breast Disease ML 958.60                                                                                               959 2.57 958.60 - 2,463.60
640   Mononucleosis ML 8.10                                                                                               8 5.95 8.10 - 48.20
641   Chlamydia IgM ML 2.90                                                                                               3 - 2.90 - -
643   HIV-Venezuela ML 5,087.30                                                                                               5,087 0.49 5,087.30 - 2,492.78
659   HIV-Nicaragua ML 17.70                                                                                               18 6.59 17.70 - 116.64
663   HBV-Venezuela ML 9,289.90                                                                                               9,290 0.44 9,289.90 - 4,087.56
679   HBV-Nicaragua ML 25,478.90                                                                                               25,479 0.20 25,478.90 - 5,095.78
683   HCV-Venezuela ML 346.70                                                                                               347 0.66 346.70 - 228.82
702   HIV-O ML 781.30                                                                                               781 12.53 781.30 - 9,789.69
703   Anti-EBV IgM ML 1.00                                                                                               1 5.21 1.00 - 5.21
708   c-ANCA ML 13.40                                                                                               13 0.10 13.40 - 1.34
709   p-ANCA ML 8.80                                                                                               9 5.69 8.80 - 50.07
714   Pregnancy-Serial ML 45.00                                                                                               45 24.56 45.00 - 1,105.20
716   Rheumatoid Arthritis ML 149.60                                               30.90 7.92 117 5.28 1 5.66                                     0 5.66 149.60 - 872.00
718   High Risk-Hepatitis(US) ML 5.90                                                                                               6 6.65 5.90 - 39.24
719   HCV NAT+/Ab- ML 17.40                                                                                               17 0.36 17.40 - 6.26
720   High Risk-Senegal ML 533.60                                                                                               534 1.13 533.60 - 602.97
721   High Risk-South Africa ML 322.30                                                                                               322 1.10 322.30 - 354.53
723   Prostate Cancer ML 2,299.80                                                                                               2,300 3.87 2,299.80 - 8,900.23
724   Syphillis ML 51,393.40   1 9.54 1002 0.24                                     1,154.50 0.25 1 11.37                                         49,235 0.31 51,393.40 - 15,812.84
725   HBsAg-Senegal ML 173.80                                                                                               174 0.26 173.80 - 45.19
731   Cardiac Serial Panel ML 8.30                                                                                               8 2.91 8.30 - 24.15
732   Bladder CA ML 1,126.10                                                                                               1,126 3.48 1,126.10 - 3,918.83
733   High Risk-Egypt ML 130.30                                                                                               130 3.93 130.30 - 512.08
734   High Risk-Hong Kong ML 273.20                                                                                               273 - 273.20 - -
740   HIV-1 (Subtype G) ML 2.40                                                                                               2 8.54 2.40 - 20.50
742   Parvovirus IgG ML 1.60                                                                                               2 6.89 1.60 - 11.02
743   HCV Serial Set ML 199.70                                                                                               200 21.56 199.70 - 4,305.53
747   HIV-Nigeria ML 1,293.30                                                                                               1,293 0.68 1,293.30 - 879.44
756   HCV-Egypt ML 2,005.00                                                                                               2,005 0.79 2,005.00 - 1,583.95
762   HBV-Egypt ML 685.20                                                                                               685 4.51 685.20 - 3,090.25
763   HBV-Senegal ML 673.80                                                                                               674 - 673.80 - -
765   HBV-China ML 250.20                                                                                               250 - 250.20 - -
777   Cirrhosis ML 7.00                                                                                               7 1.73 7.00 - 12.11
778   Hemodialysis ML 132.20                                                                                               132 2.10 132.20 - 277.62
782   Endometriosis ML 566.60                                                                                               567 3.62 566.60 - 2,051.09
783   Ulcerative Colitis ML 192.50   1 5.99 61.4 6.01 1 4.16 28.3 4.27                             60.30 6.12 1 5.96                                         40 6.43 192.50 - 1,128.99
785   Hematospermia ML 1.10                                                                                               1 5.04 1.10 - 5.54
788   HIV-Africa ML 13,741.40                               1,288 0.62 1.00 1.32                                                         12,452 1.48 13,741.40 - 19,229.26
791   HBV-Africa ML 817.90                                                                                               818 - 817.90 - -
795   HCV-Genotype 3e ML 8.10                                                                                               8 - 8.10 - -
796   High Risk ML 34.20                                                                                               34 0.63 34.20 - 21.55
797   Icteric ML 3,437.50                                                                                               3,438 0.13 3,437.50 - 446.88
800   Hemoglobin ML 175.60                                                                                               176 - 175.60 - -
802   Match Patient Set ML 7,220.60                                                                                               7,221 1.33 7,220.60 - 9,603.40
803   HCV Thera-Conversion Panel ML 1,208.70                                                                                               1,209 - 1,208.70 - -
804   High Risk-Ivory Coast ML 10,208.00                                                                                               10,208 1.13 10,208.00 - 11,535.04
805   Pancreatic CA ML 135.80                                                                                               136 5.14 135.80 - 698.01
807   HIV-1 (Subtype B) ML 238.30                                                                                               238 6.26 238.30 - 1,491.76
815   Pregnancy Specimen ML 1,416.20                                                                                               1,416 1.32 1,416.20 - 1,869.38
816   HIV Mutation ML 4,568.20                                                                                               4,568 0.70 4,568.20 - 3,197.74
817   Stomach CA ML 293.70                                                                                               294 2.63 293.70 - 772.43
819   RBC (ALT/HBc) ML 0.80                                                                                               1 9.46 0.80 - 7.57
823   Angiosarcoma ML 9.70                                                                                               10 3.23 9.70 - 31.33
824   Thyroid Cancer ML 34.00                                                                                               34 3.87 34.00 - 131.58
827   HBV NAT+/Ab- ML 3,453.70                                                                                               3,454 0.11 3,453.70 - 379.91
828   HIV NAT+/Ab- ML 1,555.30                                                                                               1,555 0.23 1,555.30 - 357.72
831   Monoclonal Gammopathy ML 611.90                                                                                               612 2.61 611.90 - 1,597.06
832   Multiple Myeloma ML 1,624.90                                               134.00 8.89 1 8.74                                         1,490 2.29 1,624.90 - 4,611.87
834   Fresh Frozen Plasma (Human) ML 2,148.40                                                                                               2,148 - 2,148.40 - -
836   Male Homosexual ML 431.70                                                                                               432 - 431.70 - -
838   Elevated IgG ML 276.60                                                                                               277 2.84 276.60 - 785.54
839   Elevated IgM ML 348.60                                                                                               349 5.22 348.60 - 1,819.69
841   CK-MB ML 44.00                                                                                               44 - 44.00 - -
843   Non-Viral Liver Disease ML 4.10                                                                                               4 35.94 4.10 - 147.35
844   HCV Patient-Match Set ML 252.70                                                                                               253 3.51 252.70 - 886.98
847   Beta-HCG ML 81.20                                                                                               81 2.56 81.20 - 207.87
848   FSH ML 643.00                                                                                               643 1.57 643.00 - 1,009.51
849   Prolactin ML 535.60                                                                                               536 1.19 535.60 - 637.36
850   Cortisol ML 51.20   1 7.37 11 7.33                                                                                     39 5.29 51.20 - 295.37
851   Human Serum (Male) ML 576.50                                                                                               577 0.94 576.50 - 541.91
852   Human Serum (Female) ML 1,732.70                                                                                               1,733 1.03 1,732.70 - 1,784.68
853   Post Menopausal Female ML 1,775.00                                                                                               1,775 0.84 1,775.00 - 1,491.00
855   HIV-Cote D'Ivoire ML 6,775.80                                                                                               6,776 0.28 6,775.80 - 1,897.22
856   HBV-Cote D'Ivoire ML 14,033.70                                                                                               14,034 0.80 14,033.70 - 11,226.96
857   HCV-Cote D'Ivoire ML 3,194.50                                                                                               3,195 0.39 3,194.50 - 1,245.86
859   HBV Match Set ML 7,654.60   1 10.12 26.2 10.11 1 8.95 296.4 8.32                                                                             7,330 6.34 7,654.60 - 49,222.20
860   Anti-HAV IgG ML 75.30                                                                                               75 4.16 75.30 - 313.25
861   CA 15-3 ML 129.50                                               1.30 3.08                                             128 0.36 129.50 - 50.16
862   Autoimmune ML 45.10                                                                                               45 17.96 45.10 - 810.00
865   Flu Vaccine Recipient ML 496.90                                                                                               497 0.95 496.90 - 472.06
866   Vancomycin ML 689.30                                                                                               689 4.73 689.30 - 3,260.39
867   Carbamazepine ML 241.80   1 7.63 89 7.33                                     112.40 6.40 1 6.64 38 3.02                                     0 3.02 241.80 - 1,501.97
868   Dilantin ML 278.20                                                                                               278 3.06 278.20 - 851.29
869   Digoxin ML 492.90                                                                                               493 2.59 492.90 - 1,276.61
870   Theophylline ML 6.40                                               2.00 7.33 1 7.34 3 5.76                                     0   6.40 - 41.58
874   Coumadin ML 900.80                                                                                               901 2.08 900.80 - 1,873.66
875   Phenobarbital ML 5.10                                               4.10 8.63 1 8.62                                         -   5.10 - 44.00
876   Valproic Acid ML 335.50                                               69.50 6.71 1 6.65                                         265 6.54 335.50 - 2,206.10
877   Gentamycin ML 134.10   1 7.37 11 7.33                                     15.00 6.60 29 6.56 1 6.45                                     77 9.81 134.10 - 1,139.39
878   Depakene ML 2.00                                                                                               2 2.87 2.00 - 5.74
879   Amiodarone ML 4.00                                                                                               4 2.87 4.00 - 11.48
880   Gabapentin (Neurontin) ML 2.00                                                                                               2 2.86 2.00 - 5.72
882   Elevated IgA ML 94.20                                                                                               94 0.73 94.20 - 68.77
883   Multiple Transfusion ML 195.70                                                                                               196 2.39 195.70 - 467.72
885   IgE Allergic ML 782.70                                                                                               783 0.21 782.70 - 164.37
886   Progesterone ML 759.90                                                                                               760 2.33 759.90 - 1,770.57
887   HCV Seroconversion Panel ML 6,133.10                                                                                               6,133 0.34 6,133.10 - 2,085.25
888   HBsAg Seroconversion Panel ML 10,316.70                                                                                               10,317 0.26 10,316.70 - 2,682.34
890   HBsAg (AY) ML 7.20                                                                                               7 8.78 7.20 - 63.22
895   Multiple Lymphoma ML 20.90                                                                                               21 1.44 20.90 - 30.10
896   Renal Insufficiency ML 24.10                                                                                               24 2.13 24.10 - 51.33
897   Hemolytic Anemia ML 36.90                                                                                               37 2.17 36.90 - 80.07
898   Aplastic Anemia ML 36.50                                                                                               37 1.92 36.50 - 70.08
899   Chronic Lymphocytic Leukemia ML 2,042.90                                                                                               2,043 2.33 2,042.90 - 4,759.96
900   Acute Lymphocytic Leukemia ML 67.80                                                                                               68 1.90 67.80 - 128.82
901   Ascites Fluid ML 4.70                                                                                               5 - 4.70 - -
903   Myelodysplastic Syndrome ML 408.50                                                                                               409 2.04 408.50 - 833.34
905   Leutinizing Hormone ML 823.90                                                                                               824 1.52 823.90 - 1,252.33
906   Testicular CA ML 3.70                                                                                               4 7.11 3.70 - 26.31
907   Crohn's Disease ML 231.20   1 6.15 19.2 6.19                     82 6.04 1.00 5.93                                                         128 7.52 231.20 - 1,589.06
908   Celiac Disease ML 34.10                                                                                               34 2.69 34.10 - 91.73
910   Mycoplasma IgG ML 40.30                                                                                               40 2.35 40.30 - 94.71
911   Mycoplasma IgM ML 4.80                                                                                               5 0.08 4.80 - 0.38
916   Acute Myelocytic Leukemia ML 79.10                                                                                               79 3.66 79.10 - 289.51
917   Chronic Myelocytic Leukemia ML 169.20                                                                                               169 2.24 169.20 - 379.01
919   Liver Cancer - Secondary ML 8.90                                                                                               9 2.22 8.90 - 19.76
920   Melanoma ML 322.60                                                                                               323 2.68 322.60 - 864.57
921   HCV Mutation ML 454.90                                                                                               455 0.55 454.90 - 250.20
922   CHF - Class I ML 61.80                                                                                               62 8.08 61.80 - 499.34
923   CHF - Class II ML 224.70                                               103.00 5.19 1 5.43                                         121 8.62 224.70 - 1,580.43
924   CHF - Class III ML 492.10                                               414.80 5.19 1 7.19                                         76 9.19 492.10 - 2,861.20
925   CHF - Class IV ML 7.50                                                                                               8 9.59 7.50 - 71.93
926   Breast Cancer Tissue (FFPE) ML 94.00                                                                                               94 43.78 94.00 - 4,115.32
927   Benign Nevi (FFPE) ML 2.00                                                                                               2 32.37 2.00 - 64.74
928   Melanoma (FFPE) ML 48.00                                                                                               48 9.83 48.00 - 471.84
929   Cardiac Matched Set ML 42.10                                                                                               42 4.77 42.10 - 200.82
930   HBV (Genotype G) ML 810.60                                                                                               811 1.60 810.60 - 1,296.96
932   Triple Infection ML 66.40                                                                                               66 - 66.40 - -
934   Lipid Profile ML 113.20                                                                                               113 2.83 113.20 - 320.36
935   Alcoholic Hepatitis ML 7.60                                                                                               8 1.72 7.60 - 13.07
936   Multiparity ML 1,443.20                               1,288 5.24 1.00 1.93                                                         154 2.88 1,443.20 - 7,194.67
937   NTX ML 57.40                                                                                               57 0.65 57.40 - 37.31
938   Human Papillomavirus ML 2.00                                                                                               2 67.29 2.00 - 134.58
939   Grave's Disease ML 20.90                                                                                               21 3.01 20.90 - 62.91
940   Diabetes ML 760.90                                                                                               761 5.56 760.90 - 4,230.60
941   HAMA ML 116.20                                                                                               116 - 116.20 - -
943   Hypergammaglobulin IgG ML 34.90                                                                                               35 1.03 34.90 - 35.95
946   Fibromyalgia ML 1,315.90                                                                                               1,316 9.73 1,315.90 - 12,803.71
947   MCTD ML 159.80                                                                                               160 3.48 159.80 - 556.10
948   Scleroderma ML 88.20                                                                                               88 3.44 88.20 - 303.41
949   Vasculitis ML 124.30                                                                                               124 3.70 124.30 - 459.91
950   Chlamydia trachomatis (pos.) ML 751.10                                                                                               751 3.77 751.10 - 2,831.65
951   Neisseria gonorrhoeae ML 326.00                                                                                               326 7.84 326.00 - 2,555.84
952   Human Urine (Male) ML 2,211.90                                                                                               2,212 0.25 2,211.90 - 552.98
956   Non-Chronic Heart Failure ML 509.40                                                                                               509 5.72 509.40 - 2,913.77
960   Lyme (European) IgM ML 197.70                                                                                               198 2.39 197.70 - 472.50
961   Parvo B-19 DNA+ ML 822.20                                                                                               822 11.97 822.20 - 9,841.73
962   HBV DNA+ ML 118.80                                                                                               119 4.30 118.80 - 510.84
965   Hypertension ML 64.00                                                                                               64 12.76 64.00 - 816.64
966   HIV-Indonesia ML 935.60                                                                                               936 0.29 935.60 - 271.32
967   HBV-Indonesia ML 3,777.90                                                                                               3,778 0.33 3,777.90 - 1,246.71
968   HCV-Indonesia ML 4,236.20                                                                                               4,236 0.21 4,236.20 - 889.60
970   COPD ML 14.60                                                                                               15 14.96 14.60 - 218.42
971   Human Female Urine ML 1,320.00                                                                                               1,320 0.25 1,320.00 - 330.00
973   HBV/HCV co-infected ML 2,831.20                                                                                               2,831 0.64 2,831.20 - 1,811.97
974   HBV Precore Mutation ML 63.00                                                                                               63 - 63.00 - -
977   Chlamydia IgG ML 8.40                                                                                               8 2.74 8.40 - 23.02
978   HBV ML 1,253.90                                                                                               1,254 7.10 1,253.90 - 8,902.69
980   HCV Genotype Panel (HCVGTP-002a) ML 90.00                                                                                               90   90.00 - -
984   DNA, Total ML 59.00                                                                                               59 - 59.00 - -
987   Anti-Gliadin IgG ML 30.20                                                                                               30 13.93 30.20 - 420.69
988   Anti-Gliadin IgA ML 7.10                                                                                               7 21.28 7.10 - 151.09
989   Labor and Delivery ML 58.80                                                                                               59 15.98 58.80 - 939.62
990   Lyme (European) ML 568.80                                                                                               569 1.59 568.80 - 904.39
992   Chlamydia IgA ML 5.50                                                                                               6 4.15 5.50 - 22.83
993   Anti-Cardiolipin IgG/IgM ML 2.50                                                                                               3 5.87 2.50 - 14.68
994   Chronic HCV ML 253.90                                                                                               254 9.62 253.90 - 2,442.52
995   HIV and HCV coinfection ML 7,573.40                                                                                               7,573 0.55 7,573.40 - 4,165.37
997   Human Plasma (EDTA-K2) ML 11.00                                                                                               11 14.71 11.00 - 161.81
998   HCV-Thailand ML 13,414.90                                                                                               13,415 1.13 13,414.90 - 15,158.84
1000   Anti-Smith ML 10.00                                                                                               10 5.69 10.00 - 56.90
1001   HIVDRP-002a ML 770.00                                                                                               770 31.32 770.00 - 24,116.40
1002   Homocysteine ML 20.70                                                                                               21 2.77 20.70 - 57.34
1003   HIV/HBV Co-Infection ML 2,688.80                                                                                               2,689 0.78 2,688.80 - 2,097.26
1004   HBV/HCV SCP ML 3,897.30                                                                                               3,897 0.94 3,897.30 - 3,663.46
1005   HIV-Netherlands ML 2.60                                                                                               3 6.53 2.60 - 16.98
1010   Esophogeal CA ML 267.90                                                                                               268 3.58 267.90 - 959.08
1011   Rectal CA ML 449.00                                                                                               449 4.27 449.00 - 1,917.23
1012   Anemia ML 990.20                                               635.60 8.84 1 6.30                                         354 1.90 990.20 - 6,296.84
1013   Lung/Breast CA ML 13.20                                                                                               13 0.95 13.20 - 12.54
1014   Colorectal CA ML 132.00                                                                                               132 4.28 132.00 - 564.96
1015   Non-Hodgkins Lymphoma ML 1,901.20                                                                                               1,901 2.29 1,901.20 - 4,353.75
1016   HBV-Thailand ML 2,402.20                                                                                               2,402 2.35 2,402.20 - 5,645.17
1023   Cervical CA ML 10.50                                                                                               11 2.38 10.50 - 24.99
1024   HBV NAT Seroconversion ML 7,987.10                                                                                               7,987 0.15 7,987.10 - 1,198.07
1028   Head &Neck CA ML 192.70                                                                                               193 3.49 192.70 - 672.52
1029   Lung/Ovarian CA ML 2.90                                                                                               3 5.01 2.90 - 14.53
1030   Larynx CA ML 4.00                                                                                               4 5.01 4.00 - 20.04
1031   Colon/Lung CA ML 5.30                                                                                               5 3.78 5.30 - 20.03
1032   Stomach/Colon CA ML 8.20                                                                                               8 4.89 8.20 - 40.10
1033   Endometrial CA ML 145.60                                                                                               146 2.72 145.60 - 396.03
1034   Breast/Lung CA ML 5.50                                                                                               6 7.29 5.50 - 40.10
1035   Bronchial CA ML 6.40                                                                                               6 2.71 6.40 - 17.34
1037   Colon/Breast CA ML 4.70                                                                                               5 4.26 4.70 - 20.02
1038   Colon/Rectal CA ML 15.10                                                                                               15 3.62 15.10 - 54.66
1039   Colon/Bladder CA ML 7.00                                                                                               7 2.14 7.00 - 14.98
1040   Prostate/Colon CA ML 5.10                                                                                               5 3.28 5.10 - 16.73
1041   Endocrine CA ML 3.90                                                                                               4 5.14 3.90 - 20.05
1043   Interstitial Cystitis ML 1,637.20                                                                                               1,637 3.62 1,637.20 - 5,926.66
1046   Preeclampsia (3rd trimester) ML 52.00                                                                                               52 1.57 52.00 - 81.64
1047   Prostatitis (chronic) ML 321.00                                                                                               321 2.89 321.00 - 927.69
1048   Prostatitis (acute) ML 307.70                                                                                               308 2.96 307.70 - 910.79
1049   Kidney CA ML 273.50                                                                                               274 2.71 273.50 - 741.19
1052   HCVGTP-004b ML 24.00                                                                                               24 - 24.00 - -
1054   Cryptosporidium ML 10.00                                                                                               10 1.25 10.00 - 12.50
1055   Human Stool ML 1,757.00                                                                                               1,757 0.99 1,757.00 - 1,739.43
1056   HBV (Genotype H) ML 1,056.90                                                                                               1,057 0.31 1,056.90 - 327.64
1057   Parvo B-19 ML 9.30                                                                                               9 - 9.30 - -
1059   Cyclosporas ML 176.30                                                                                               176 3.68 176.30 - 648.78
1060   HIV-Thailand ML 5,633.00                                                                                               5,633 1.33 5,633.00 - 7,491.89
1062   HCVGTP-005a ML 30.00                                                                                               30 - 30.00 - -
1063   Osteoarthritis ML 946.40                                                                                               946 6.80 946.40 - 6,435.52
1074   Geriatric Specimen ML 284.60                                                                                               285 1.84 284.60 - 523.66
1075   Estradiol ML 77.10                                                                                               77 2.39 77.10 - 184.27
1076   Syphillis IgG ML 52.20                                                                                               52 3.56 52.20 - 185.83
1077   Syphillis IgM ML 238.00                                                                                               238 4.07 238.00 - 968.66
1080   HCV (NS5 single band) ML 223.20                                                                                               223 1.79 223.20 - 399.53
1081   CT and GC positive ML 52.20                                                                                               52 6.96 52.20 - 363.31
1082   Cyclosporine ML 318.70                                                                                               319 4.36 318.70 - 1,389.53
1083   AST ML 1.20                                                                                               1 - 1.20 - -
1084   Tacrolimus ML 626.90                                                                                               627 4.30 626.90 - 2,695.67
1085   Lung Cancer (Pre-Treatment) ML 14.00                                                                                               14 11.19 14.00 - 156.66
1090   BUN ML 237.90                                                                                               238 2.04 237.90 - 485.32
1091   Testosterone ML 150.60   1 8.98 15.6 9.04                     131 8.33 1.00 8.77                                                         2 2.51 150.60 - 1,255.02
1093   HCVGTP-004c ML 45.00                                                                                               45 - 45.00 - -
1094   Primary hyperparathyroidism ML 85.30                                                                                               85 13.21 85.30 - 1,126.81
1096   Psoriasis ML 1.10                                                                                               1   1.10 - -
1097   HCVGTP-002c ML 780.00                                                                                               780 - 780.00 - -
1098   BNP ML 218.80                                                                                               219 3.76 218.80 - 822.69
1100   West Nile Virus ML 1.60                                                                                               2 44.73 1.60 - 71.57
1104   Quinidine ML 4.40                                                                                               4 2.99 4.40 - 13.16
1105   Colon CA ML 2,527.50                                                                                               2,528 4.02 2,527.50 - 10,160.55
1106   Lung CA ML 3,643.80                                                                                               3,644 3.75 3,643.80 - 13,664.25
1107   Triple Infection - HIV, HCV and HBV ML 268.30                                                                                               268 0.70 268.30 - 187.81
1108   Lyme Acute Infection ML 809.20                                               809.20 1.17                                             -   809.20 - 946.76
1110   Multiparity Panel ML 920.00                                                                                               920 - 920.00 - -
1111   Polycythermia ML 49.30                                                                                               49 3.31 49.30 - 163.18
1112   Thalassemia ML 20.30                                                                                               20 1.24 20.30 - 25.17
1113   Astrocytoma ML 6.00                                                                                               6 2.09 6.00 - 12.54
1114   Urethral CA ML 4.40                                                                                               4 2.84 4.40 - 12.50
1115   Leiomyosarcoma ML 3.50                                                                                               4 3.58 3.50 - 12.53
1116   Gastrointestinal CA ML 3.00                                                                                               3 4.97 3.00 - 14.91
1117   HCV (c-22 single band) ML 256.10                                                                                               256 1.93 256.10 - 494.27
1119   HBVSCP-002a ML 211.50                                                                                               212 - 211.50 - -
1120   HBVSCP-003a ML 210.00                                                                                               210 - 210.00 - -
1123   HEV ML 951.60                                                                                               952 1.32 951.60 - 1,256.11
1125   ToRCH IgM ML 1,957.80                                                                                               1,958 0.23 1,957.80 - 450.29
1126   Allergy Sample ML 22.10                                                                                               22 2.78 22.10 - 61.44
1127   HGV ML 95.70                                                                                               96 5.81 95.70 - 556.02
1128   Phenytoin ML 174.60   1 6.76 71.4 6.53                                     58.40 6.67 1 6.47 28 6.88                                     15 6.88 174.60 - 1,163.46
1129   Bacterial Cystitis ML 705.20                                                                                               705 3.11 705.20 - 2,193.17
1130   Down's Syndrome ML 78.50                                                                                               79 46.72 78.50 - 3,667.52
1131   Amikacin ML 100.80                                                                                               101 4.92 100.80 - 495.94
1134   HCVSCP-002a ML 120.00                                                                                               120 - 120.00 - -
1135   Myloidysplasia ML 149.60                                                                                               150 1.68 149.60 - 251.33
1136   Uterine Cancer ML 32.40                                                                                               32 3.93 32.40 - 127.33
1137   Liver CA ML 0.60                                                                                               1 2.99 0.60 - 1.79
1138   Renal CA ML 48.70                                                                                               49 2.64 48.70 - 128.57
1139   Hemachromotosis ML 62.70                                                                                               63 2.79 62.70 - 174.93
1140   HIV/HBV/HCV Triple Infection ML 284.00                                                                                               284 1.33 284.00 - 377.72
1143   Sepsis ML 4,513.10                               809 3.16 1.00 3.24         2,090.50 1.10 1 20.45 929 1.98 1 1.17 682 0.97   1.20                         0 0.74 4,513.10 - 7,381.34
1145   Leukemia ML 64.60                                                                                               65 2.52 64.60 - 162.79
1147   HBV/HGV co-infected ML 10.00                                                                                               10 45.72 10.00 - 457.20
1148   D-Dimer ML 545.10                                                                                               545 3.61 545.10 - 1,967.81
1149   LDL ML 175.20                                                                                               175 3.21 175.20 - 562.39
1150   Brain CA ML 6.80                                                                                               7 3.68 6.80 - 25.02
1151   Islets of Langshans CA ML 36.00                                                                                               36 2.09 36.00 - 75.24
1152   HCV/RPR+ ML 1,678.10                                                                                               1,678 0.11 1,678.10 - 184.59
1153   IgE-trees ML 0.50                                                                                               1 - 0.50 - -
1154   IgE-weeds ML 0.70                                                                                               1 - 0.70 - -
1155   IgE-food ML 4.10                                                                                               4 - 4.10 - -
1156   HIV & Syphilis Positive ML 17.80                                                                                               18 - 17.80 - -
1157   Psoriatic Arthritis ML 3.10                                                                                               3 - 3.10 - -
1158   Hairy Cell Leukemia ML 19.60                                                                                               20 3.19 19.60 - 62.52
1159   Unspecified Leukemia ML 3.40                                                                                               3 3.68 3.40 - 12.51
1160   Anal CA ML 56.30                                                                                               56 4.22 56.30 - 237.59
1161   Prolymphocytic Leukemia ML 2.90                                                                                               3 4.32 2.90 - 12.53
1162   Myeloma IgM ML 13.00                               6 -                                                             7 3.42 13.00 - 24.28
1163   Preeclampsia ML 12.20                                                                                               12 21.17 12.20 - 258.27
1164   Appendix CA ML 10.00                                                                                               10 2.51 10.00 - 25.10
1165   Sarcoma ML 46.80                                                                                               47 3.21 46.80 - 150.23
1166   Pituitary Gland CA ML 6.60                                                                                               7 1.90 6.60 - 12.54
1167   Mesothelioma ML 8.90                                                                                               9 2.82 8.90 - 25.10
1168   Thymus CA ML 14.60                                                                                               15 3.86 14.60 - 56.36
1169   Tracheal CA ML 5.60                                                                                               6 2.24 5.60 - 12.54
1170   Syphillis-Secondary(treated) ML 104.40                                                                                               104 - 104.40 - -
1171   Acute MI ML 0.60                                                                                               1 4.17 0.60 - 2.50
1174   HBc IgM Panel (Lot# 50011) ML 1,360.00                                                                                               1,360 - 1,360.00 - -
1175   Glioblastoma ML 33.90                                                                                               34 2.58 33.90 - 87.46
1176   Small Intestine CA ML 5.00                                                                                               5 2.51 5.00 - 12.55
1177   Gall Bladder CA ML 41.00                                                                                               41 4.27 41.00 - 175.07
1178   Tongue CA ML 18.60                                                                                               19 3.03 18.60 - 56.36
1179   Merkel Cell CA ML 7.50                                                                                               8 3.34 7.50 - 25.05
1180   Islets of Langerhans CA ML 10.50                                                                                               11 6.16 10.50 - 64.68
1181   HIV-1 Worldwide Subtype Panel (Lot#50051) ML 1,008.00                                                                                               1,008 - 1,008.00 - -
1185   MGUS ML 60.90                                                                                               61 1.44 60.90 - 87.70
1186   Paraprotien ML 33.20                                                                                               33 1.14 33.20 - 37.85
1188   Gioblastoma ML 3.40                                                                                               3 3.68 3.40 - 12.51
1189   Abdominal CA ML 5.50                                                                                               6 17.90 5.50 - 98.45
1190   Peritoneal CA ML 5.00                                                                                               5 3.29 5.00 - 16.45
1191   Multiple CA (Renal,Breast,Thyroid,Prostate) ML 2.50                                                                                               3 5.01 2.50 - 12.53
1192   Brain Oligodendioglioma ML 2.90                                                                                               3 4.32 2.90 - 12.53
1193   Breast CA (Male) ML 7.00                                                                                               7 4.36 7.00 - 30.52
1194   Lip CA ML 1.80                                                                                               2 6.96 1.80 - 12.53
1199   Pelvic CA ML 7.40                                                                                               7 4.23 7.40 - 31.30
1200   Biliary CA ML 8.10                                                                                               8 7.73 8.10 - 62.61
1201   Fallopian CA ML 4.00                                                                                               4 6.26 4.00 - 25.04
1205   HBV Genotype Panel (Lot# 60011) ML 870.00                                                                                               870 - 870.00 - -
1206   HIV-2 Monospecific Panel (Lot#60021) ML 40.00                                                                                               40 - 40.00 - -
1214   EBV IgM ML 1.00                                                                                               1 - 1.00 - -
1215   Ferritin ML 190.50                                                                                               191 4.05 190.50 - 771.53
1218   CRP ML 161.00   1 6.4 160 6.21                                                                                     - 5.05 161.00 - 1,000.00
1219   Anti-Cardiolipin ML 2.50                                                                                               3 5.00 2.50 - 12.50
1220   Semen ML 32.60                                                                                               33   32.60 - -
1221   Hemoglobin A1c ML 495.00   1 2.77 140.3 2.76 1 3.56 284.9 2.62                                                                             68 4.62 495.00 - 1,453.23
1222   Random Donors ML 3,248.70                               1,479 5.00                                                             1,770 1.70 3,248.70 - 10,402.50
1227   Irritable Bowel Syndrome ML 587.20   1 5.1 48.4 5.06 1 6.42 56.1 6.57             102 6.07 1.00 5.86         33.20 7.53                                             345 11.94 587.20 - 5,613.33
1232   Insulin ML 61.60                                                                                               62 4.17 61.60 - 256.87
1234   Random Hospital Sample ML 383.40                                                                                               383 0.86 383.40 - 329.72
1235   HBsAg(False Positive) ML 3,856.70                                                                                               3,857 0.64 3,856.70 - 2,468.29
1240   CSF ML 90.00                               89 0.51 1.00 0.61                                                         -   90.00 - 46.00
1241   DHEA-S ML 42.50                                               2.60 10.42 1 10.41                                         39 7.49 42.50 - 328.86
1243   Normal Human Serum ML 731.20                                                                                               731 1.25 731.20 - 914.00
1245   Hyperglobulinemia ML 619.60                                                                                               620 2.35 619.60 - 1,456.06
1247   Adenocarcinoma (FFPE) ML 3.00                                                                                               3   3.00 - -
1248   Wilson Disease ML -                                                                                               -   - - -
1250   Whole Blood ML 150.00                                                                                               150   150.00 - -
1254   Elevated IgE ML 29.50                                                                                               30   29.50 - -
1256   Cystic Fibrosis DNA ML 0.10                                                                                               0   0.10 - -
1257   PM/SCL ML 1.20                                                                                               1 - 1.20 - -
1258   HCV-Genotype 6 ML 109.80                                                                                               110 35.12 109.80 - 3,856.18
1259   HBc IgM ML -                               - 7.75                                                             -   - - -
1260   HAV IgM ML -                               - 10.00                                                             -   - - -
1262   WHOLE BLOOD TEMPUS TUBES EA -                                                                                               -   - - -
1263   Factor V Mutation ML 59.30                                                                                               59 9.51 59.30 - 563.94
1264   Pregnancy (Rh-) ML 91.30                               28 8.77 1.00 8.82 25.20 5.55   5.19   5.92   5.98   6.00   4.70   4.68                             38 4.68 91.30 - 565.82
1265   Cadaveric Specimen ML 386.10   1 15.23 385.1 11.49                                                                                     -   386.10 - 4,440.03
1266   Mono IgM ML 25.80                                                                                               26 - 25.80 - -
1267   Dengue ML 1,167.30   1 7.91 18.1 7.85 1 6.45 176.3 6.77             84 7.09 1.00 7.28         511.40 6.44 1 6.58 314 7.13 1 8.33                                 59 9.01 1,167.30 - 8,027.08
1268   HCV GTP (Lot#70021) ML 522.00                                                                                               522 - 522.00 - -
1273   Anti-HBc IgM (pooled) ML -                                                                                               - - - - -
1274   Normal Human Match Sets ML 324.70                                                                                               325 3.75 324.70 - 1,217.63
1275   Stroke ML 6.30   1 238 5.3 238.1                                                                                     - 4.75 6.30 - 1,499.94
1276   Dermamyositis ML -                                                                                               - 65.00 - - -
1277   B2GP1 IgG ML -                                                                                               - - - - -
1278   Fibrillarin ML -                                                                                               - - - - -
1279   PCNA ML -                                                                                               - - - - -
1280   RNA Pol  I/III ML -                                                                                               - - - - -
1281   Polyclonal Gammopathy ML 10.50                                                                                               11   10.50 - -
1286   Hypercholesterolemia ML 48.10                                                                                               48   48.10 - -
1287   Malaria ML 289.00   1 10.07 13.8 10.14 1 7.29 273.2 7.66                                                                             -   289.00 - 2,250.00
                                                                                                                 
                                                                                                                 
    Total   1,292,137.00                                                                                                   Total 1,372,322.33
        -                                                                                               Inventory Asset - Per GL  
                                                                                                            Difference 1,372,322.33

 

 
 

 

Inventory Purchase Receipts

 

Item
Number
Item
number
  Date
Received
QTY
Received
QTY
Sold
Unit
Cost
QTY
Type
TRX
Location
Purchase
Receipt Type
Receipt
Number
Vendor ID Purchase
Order
Number
1 1   5/22/2007 796.1 45 $2.97 On Hand FRTLAUD Variance 0000001 INV VAR INV VAR
2 2   5/22/2007 1,310.00 53.3 $2.96 On Hand FRTLAUD Variance 0000175 INV VAR INV VAR
6 6   5/22/2007 3,539.80 449 $17.61 On Hand FRTLAUD Variance 0000258 INV VAR INV VAR
7 7   5/22/2007 228.2 0 $1.84 On Hand FRTLAUD Variance 0000289 INV VAR INV VAR
8 8   5/22/2007 18,008.20 12,992.50 $1.19 On Hand FRTLAUD Variance 0000325 INV VAR INV VAR
8 8   6/20/2007 899 0 $1.33 On Hand FRTLAUD Receipt RN4662 BIOLOGICALSPECI 4537
8 8   6/20/2007 1 0 $4.33 On Hand FRTLAUD Receipt RN4662 BIOLOGICALSPECI 4537
8 8   6/20/2007 299 0 $1.34 On Hand FRTLAUD Receipt RN4663 BIOLOGICALSPECI 4537
8 8   6/20/2007 1 0 $2.34 On Hand FRTLAUD Receipt RN4663 BIOLOGICALSPECI 4537
8 8   6/25/2007 192 0 $3.75 On Hand FRTLAUD Receipt RN4677 CONTINENTALSERV 4549
8 8   6/26/2007 144 0 $3.75 On Hand FRTLAUD Receipt RN4681 CONTINENTALSERV 4549
8 8   6/27/2007 152 0 $3.75 On Hand FRTLAUD Receipt RN4684 CONTINENTALSERV 4549
8 8   6/28/2007 152 0 $3.75 On Hand FRTLAUD Receipt RN4685 CONTINENTALSERV 4549
8 8   7/9/2007 144 0 $3.75 On Hand FRTLAUD Receipt RN4711 CONTINENTALSERV 4549-1
8 8   7/11/2007 20 0 $3.75 On Hand FRTLAUD Receipt RN4716 CONTINENTALSERV 4549-1
10 10   5/22/2007 24,173.40 317 $0.64 On Hand FRTLAUD Variance 0000002 INV VAR INV VAR
10 10   6/1/2007 41.1 0 $11.88 On Hand FRTLAUD Receipt RN4594 CADEPTOFHEALTHP 4504
10 10   6/1/2007 1 0 $11.73 On Hand FRTLAUD Receipt RN4594 CADEPTOFHEALTHP 4504
10 10   6/1/2007 1,235.10 0 $0.54 On Hand FRTLAUD Receipt RN4596 GULFCOASTREGION 4514
10 10   6/1/2007 1 0 $8.04 On Hand FRTLAUD Receipt RN4596 GULFCOASTREGION 4514
10 10   6/5/2007 1,295.60 0 $0.52 On Hand FRTLAUD Receipt RN4602 GULFCOASTREGION 4514
10 10   6/5/2007 1 0 $1.29 On Hand FRTLAUD Receipt RN4602 GULFCOASTREGION 4514
10 10   6/13/2007 1,131.30 0 $0.59 On Hand FRTLAUD Receipt RN4633 GULFCOASTREGION 4514
10 10   6/13/2007 1 0 $7.53 On Hand FRTLAUD Receipt RN4633 GULFCOASTREGION 4514
10 10   6/14/2007 1,789.30 0 $0.60 On Hand FRTLAUD Receipt RN4639 GULFCOASTREGION 4514
10 10   6/14/2007 1 0 $6.42 On Hand FRTLAUD Receipt RN4639 GULFCOASTREGION 4514
10 10   6/19/2007 2,488.40 0 $0.54 On Hand FRTLAUD Receipt RN4651 GULFCOASTREGION 4514
10 10   6/19/2007 1 0 $6.26 On Hand FRTLAUD Receipt RN4651 GULFCOASTREGION 4514
10 10   7/11/2007 942.4 0 $0.57 On Hand FRTLAUD Receipt RN4713 GULFCOASTREGION 4514-1
10 10   7/11/2007 1 0 $2.83 On Hand FRTLAUD Receipt RN4713 GULFCOASTREGION 4514-1
10 10   7/20/2007 2,412.60 0 $0.55 On Hand FRTLAUD Receipt 4749 GULFCOASTREGION 4448
10 10   7/20/2007 1 0 $23.07 On Hand FRTLAUD Receipt 4749 GULFCOASTREGION 4448
10 10   8/7/2007 1,293.70 0 $0.52 On Hand FRTLAUD Receipt RN4797 GULFCOASTREGION 4448-1
10 10   8/7/2007 1 0 $2.28 On Hand FRTLAUD Receipt RN4797 GULFCOASTREGION 4448-1
10 10   8/14/2007 1,204.20 0 $0.56 On Hand FRTLAUD Receipt RN4811 GULFCOASTREGION 4514
10 10   8/14/2007 1 0 $0.65 On Hand FRTLAUD Receipt RN4811 GULFCOASTREGION 4514
10 10   8/29/2007 149.2 0 $3.33 On Hand FRTLAUD Receipt RN4847 CADEPTOFHEALTHP 4621
10 10   8/29/2007 1 0 $3.16 On Hand FRTLAUD Receipt RN4847 CADEPTOFHEALTHP 4621
11 11   5/22/2007 3,762.80 2,415.40 $0.48 On Hand FRTLAUD Variance 0000062 INV VAR INV VAR
12 12   5/22/2007 2.1 0 $6.80 On Hand FRTLAUD Variance 0000138 INV VAR INV VAR
13 13   5/22/2007 16,762.20 1,401.60 $1.04 On Hand FRTLAUD Variance 0000163 INV VAR INV VAR
13 13   6/8/2007 36.8 0 $6.61 On Hand FRTLAUD Receipt RN4616 CENTERFORRHEUMA 3998
13 13   6/8/2007 1 0 $6.75 On Hand FRTLAUD Receipt RN4616 CENTERFORRHEUMA 3998
13 13   6/13/2007 178.8 0 $6.26 On Hand FRTLAUD Receipt RN4631 TUSCONCLINICALR 3891
13 13   6/13/2007 1 0 $5.71 On Hand FRTLAUD Receipt RN4631 TUSCONCLINICALR 3891
13 13   6/21/2007 80.9 0 $6.11 On Hand FRTLAUD Receipt RN4667 CENTERFORRHEUMA  
13 13   6/21/2007 1 0 $5.70 On Hand FRTLAUD Receipt RN4667 CENTERFORRHEUMA  
13 13   6/25/2007 22 0 $5.43 On Hand FRTLAUD Receipt RN4678 CENTERFORRHEUMA 3998
13 13   6/25/2007 1 0 $5.54 On Hand FRTLAUD Receipt RN4678 CENTERFORRHEUMA 3998
13 13   6/25/2007 463.1 0 $6.46 On Hand FRTLAUD Receipt RN4672 FUNDACIONCARDIO 4491
13 13   6/25/2007 1 0 $8.37 On Hand FRTLAUD Receipt RN4672 FUNDACIONCARDIO 4491
13 13   7/5/2007 502.9 0 $5.95 On Hand FRTLAUD Receipt RN4698 REDCROSSNICARAG 4560
13 13   7/5/2007 1 0 $7.74 On Hand FRTLAUD Receipt RN4698 REDCROSSNICARAG 4560
13 13   7/19/2007 498.7 0 $5.70 On Hand FRTLAUD Receipt RN4744 FUNDACIONCARDIO 4491-1
13 13   7/19/2007 1 0 $7.41 On Hand FRTLAUD Receipt RN4744 FUNDACIONCARDIO 4491-1
13 13   7/20/2007 212.3 0 $7.03 On Hand FRTLAUD Receipt RN4750 DR. CHARLES WEI 4582
13 13   7/20/2007 1 0 $7.53 On Hand FRTLAUD Receipt RN4750 DR. CHARLES WEI 4582
13 13   8/1/2007 97.9 0 $7.58 On Hand FRTLAUD Receipt RN4776 DR. CHARLES WEI 4582-1
13 13   8/1/2007 1 0 $7.92 On Hand FRTLAUD Receipt RN4776 DR. CHARLES WEI 4582-1
13 13   8/9/2007 793.2 0 $0.25 On Hand FRTLAUD Receipt RN4800 REDCROSSNICARAG 4602
13 13   8/9/2007 1 0 $1.70 On Hand FRTLAUD Receipt RN4800 REDCROSSNICARAG 4602
13 13   8/30/2007 391.9 0 $5.73 On Hand FRTLAUD Receipt RN4856 FUNDACIONCARDIO 4492-2
13 13   8/30/2007 1 0 $4.41 On Hand FRTLAUD Receipt RN4856 FUNDACIONCARDIO 4492-2
16 16   5/22/2007 268.8 0 $7.85 On Hand FRTLAUD Variance 0000164 INV VAR INV VAR
19 19   7/6/2007 1.5 1.5 $0.00 On Hand FRTLAUD Receipt RN4708 SLRRESEARCHCORP 4569
26 26   5/22/2007 9.7 2 $2.47 On Hand FRTLAUD Variance 0000182 INV VAR INV VAR
26 26   6/22/2007 2 0 $75.00 On Hand FRTLAUD Receipt RN4647 SLRRESEARCHCORP 4529
27 27   5/22/2007 1,004.80 0 $0.01 On Hand FRTLAUD Variance 0000188 INV VAR INV VAR
29 29   5/22/2007 31,349.30 528 $0.18 On Hand FRTLAUD Variance 0000189 INV VAR INV VAR
30 30   5/22/2007 39.4 33.9 $3.26 On Hand FRTLAUD Variance 0000193 INV VAR INV VAR
30 30   6/20/2007 0.5 0 $0.00 On Hand FRTLAUD Receipt RN4655 SLRRESEARCHCORP 4543
30 30   7/6/2007 0.5 0 $0.00 On Hand FRTLAUD Receipt 4702 SLRRESEARCHCORP 4563
31 31   5/22/2007 0.5 0.5 $0.00 On Hand FRTLAUD Variance 0000195 INV VAR INV VAR
31 31   7/6/2007 2 1.5 $0.00 On Hand FRTLAUD Receipt RN4707 SLRRESEARCHCORP 4568
32 32   6/19/2007 0.5 0.5 $0.00 On Hand FRTLAUD Receipt RN4660 SLRRESEARCHCORP 4547
32 32   7/6/2007 1.5 1.5 $0.00 On Hand FRTLAUD Receipt 4704 SLRRESEARCHCORP 4565
32 32   7/27/2007 100 99.5 $4.25 On Hand FRTLAUD Receipt RN4660-1 SLRRESEARCHCORP 4547
35 35   5/22/2007 59.3 0 $11.87 On Hand FRTLAUD Variance 0000202 INV VAR INV VAR
37 37   5/22/2007 12.9 12 $0.26 On Hand FRTLAUD Variance 0000206 INV VAR INV VAR
37 37   6/22/2007 10 0 $50.00 On Hand FRTLAUD Receipt RN4646 SLRRESEARCHCORP 4528
37 37   7/6/2007 2 0 $0.00 On Hand FRTLAUD Receipt 4705 SLRRESEARCHCORP 4566
38 38   5/22/2007 9,475.50 3.3 $0.78 On Hand FRTLAUD Variance 0000208 INV VAR INV VAR
40 40   5/22/2007 2,333.40 2.8 $0.19 On Hand FRTLAUD Variance 0000211 INV VAR INV VAR
48 48   5/22/2007 75.5 1 $0.00 On Hand FRTLAUD Variance 0000224 INV VAR INV VAR
49 49   7/6/2007 1.5 1.5 $0.00 On Hand FRTLAUD Receipt RN4703 SLRRESEARCHCORP 4564
49 49   9/7/2007 0 5.5 $0.00 On Hand FRTLAUD Override 005782 Sales Entry Sales Entry
63 63   5/22/2007 4,721.20 0 $1.19 On Hand FRTLAUD Variance 0000274 INV VAR INV VAR
63 63   6/1/2007 1,325.10 0 $0.50 On Hand FRTLAUD Receipt RN4595 GULFCOASTREGION 4513
63 63   6/1/2007 1 0 $12.45 On Hand FRTLAUD Receipt RN4595 GULFCOASTREGION 4513
63 63   6/5/2007 1,337.20 0 $0.50 On Hand FRTLAUD Receipt RN4601 GULFCOASTREGION 4513
63 63   6/5/2007 1 0 $6.40 On Hand FRTLAUD Receipt RN4601 GULFCOASTREGION 4513
63 63   6/13/2007 1,239.10 0 $0.54 On Hand FRTLAUD Receipt RN4632 GULFCOASTREGION 4513
63 63   6/13/2007 1 0 $5.89 On Hand FRTLAUD Receipt RN4632 GULFCOASTREGION 4513
63 63   6/14/2007 1,294.00 0 $0.52 On Hand FRTLAUD Receipt RN4641 GULFCOASTREGION 4513
63 63   6/14/2007 1 0 $2.12 On Hand FRTLAUD Receipt RN4641 GULFCOASTREGION 4513
64 64   4/25/2007 2 2 $0.00 On Hand FRTLAUD Receipt RCT0000015 DR. WANG GMBH  
64 64   5/22/2007 27.2 27.2 $8.44 On Hand FRTLAUD Variance 0000281 INV VAR INV VAR
64 64   6/19/2007 1 1 $0.00 On Hand FRTLAUD Receipt RN4659 DR. WANG GMBH 4540
64 64   6/22/2007 790 765.4 $7.75 On Hand FRTLAUD Receipt RN4565 KEYSTONEBIO 4496
64 64   8/13/2007 1 0 $0.00 On Hand FRTLAUD Receipt RN4808 DR. WANG GMBH 4540-1
83 83   5/22/2007 1,106.90 4 $1.34 On Hand FRTLAUD Variance 0000340 INV VAR INV VAR
85 85   5/22/2007 1,054.30 11 $0.60 On Hand FRTLAUD Variance 0000353 INV VAR INV VAR
91 91   5/22/2007 37 0 $6.55 On Hand FRTLAUD Variance 0000396 INV VAR INV VAR
92 92   5/22/2007 1.1 0 $11.39 On Hand FRTLAUD Variance 0000402 INV VAR INV VAR
93 93   5/22/2007 349.1 0 $6.31 On Hand FRTLAUD Variance 0000413 INV VAR INV VAR
93 93   6/8/2007 42.4 0 $5.99 On Hand FRTLAUD Receipt RN4621 LABORATORYCORPO 4242
93 93   6/8/2007 1 0 $6.02 On Hand FRTLAUD Receipt RN4621 LABORATORYCORPO 4242
93 93   6/22/2007 214.5 0 $5.52 On Hand FRTLAUD Receipt RN4670 LABORATORYCORPO 4242
93 93   6/22/2007 1 0 $5.96 On Hand FRTLAUD Receipt RN4670 LABORATORYCORPO 4242
93 93   6/29/2007 11.4 0 $4.84 On Hand FRTLAUD Receipt RN4690 LABORATORYCORPO 4242
93 93   6/29/2007 1 0 $4.82 On Hand FRTLAUD Receipt RN4690 LABORATORYCORPO 4242
93 93   7/12/2007 47.5 0 $5.98 On Hand FRTLAUD Receipt RN4720 LABORATORYCORPO 4242-1
93 93   7/12/2007 1 0 $5.95 On Hand FRTLAUD Receipt RN4720 LABORATORYCORPO 4242-1
93 93   8/10/2007 49.6 0 $5.73 On Hand FRTLAUD Receipt RN4807 LABORATORYCORPO 4242-2
93 93   8/10/2007 1 0 $5.79 On Hand FRTLAUD Receipt RN4807 LABORATORYCORPO 4242-2
101 101   5/22/2007 82 0 $2.29 On Hand FRTLAUD Variance 0000009 INV VAR INV VAR
162 162   5/22/2007 274.6 0 $0.95 On Hand FRTLAUD Variance 0000165 INV VAR INV VAR
171 171   5/22/2007 17,120.60 2,390.30 $0.73 On Hand FRTLAUD Variance 0000166 INV VAR INV VAR
171 171   6/20/2007 899 0 $1.33 On Hand FRTLAUD Receipt RN4664 BIOLOGICALSPECI 4538
171 171   6/20/2007 1 0 $4.33 On Hand FRTLAUD Receipt RN4664 BIOLOGICALSPECI 4538
171 171   7/11/2007 156 0 $3.75 On Hand FRTLAUD Receipt RN4717 CONTINENTALSERV 4550
171 171   7/12/2007 148 0 $3.75 On Hand FRTLAUD Receipt RN4728 CONTINENTALSERV 4550
171 171   7/16/2007 92 0 $3.75 On Hand FRTLAUD Receipt RN4731 CONTINENTALSERV 4550
171 171   7/17/2007 204 0 $3.75 On Hand FRTLAUD Receipt RN4737 CONTINENTALSERV 4550
172 172   5/22/2007 66.7 66.7 $0.71 On Hand FRTLAUD Variance 0000167 INV VAR INV VAR
172 172   7/18/2007 192 192 $3.75 On Hand FRTLAUD Receipt RN4739 CONTINENTALSERV 4551
172 172   7/19/2007 152 152 $3.75 On Hand FRTLAUD Receipt RN4746 CONTINENTALSERV 4551
172 172   7/23/2007 60 60 $3.75 On Hand FRTLAUD Receipt RN4757 CONTINENTALSERV 4551
172 172   7/24/2007 48 48 $3.75 On Hand FRTLAUD Receipt RN4763 CONTINENTALSERV 4551
172 172   7/25/2007 148 81.3 $3.75 On Hand FRTLAUD Receipt RN4765 CONTINENTALSERV 4551
174 174   5/22/2007 83,924.60 1,121.00 $0.28 On Hand FRTLAUD Variance 0000168 INV VAR INV VAR
175 175   5/22/2007 3,743.10 1,620.20 $0.33 On Hand FRTLAUD Variance 0000169 INV VAR INV VAR
175 175   6/20/2007 899 0 $1.33 On Hand FRTLAUD Receipt RN4665 BIOLOGICALSPECI 4539
175 175   6/20/2007 1 0 $4.33 On Hand FRTLAUD Receipt RN4665 BIOLOGICALSPECI 4539
176 176   5/22/2007 32.9 20.8 $10.25 On Hand FRTLAUD Variance 0000170 INV VAR INV VAR
176 176   6/14/2007 650 0 $0.00 On Hand FRTLAUD Receipt RN4643 PLASMASVCSGRP 4536
178 178   5/22/2007 5,474.10 241 $0.93 On Hand FRTLAUD Variance 0000171 INV VAR INV VAR
184 184   5/22/2007 212.8 15 $6.28 On Hand FRTLAUD Variance 0000172 INV VAR INV VAR
197 197   5/22/2007 10,926.70 0 $0.66 On Hand FRTLAUD Variance 0000173 INV VAR INV VAR
199 199   5/22/2007 207,160.60 5,286.80 $0.45 On Hand FRTLAUD Variance 0000174 INV VAR INV VAR
199 199   5/24/2007 3,949.10 0 $0.47 On Hand FRTLAUD Receipt RCT0000013 TENNESSEEBLOODS  
199 199   5/24/2007 1 0 $18.92 On Hand FRTLAUD Receipt RCT0000013 TENNESSEEBLOODS  
225 225   5/22/2007 101.9 5.7 $0.98 On Hand FRTLAUD Variance 0000176 INV VAR INV VAR
226 226   5/22/2007 900.9 9.2 $1.00 On Hand FRTLAUD Variance 0000177 INV VAR INV VAR
227 227   5/22/2007 158 3.9 $1.33 On Hand FRTLAUD Variance 0000178 INV VAR INV VAR
245 245   9/28/2007 0 3 $0.00 On Hand FRTLAUD Override 005824 Sales Entry Sales Entry
247 247   5/22/2007 19.3 2.9 $3.03 On Hand FRTLAUD Variance 0000179 INV VAR INV VAR
252 252   5/22/2007 150.9 28.1 $5.00 On Hand FRTLAUD Variance 0000180 INV VAR INV VAR
253 253   5/22/2007 137.4 14.9 $3.17 On Hand FRTLAUD Variance 0000181 INV VAR INV VAR
261 261   5/22/2007 771.9 3.5 $3.52 On Hand FRTLAUD Variance 0000183 INV VAR INV VAR
262 262   5/18/2007 37.1 0 $5.77 On Hand FRTLAUD Receipt RCT0000009 VIRGINIAMEDICAL  
262 262   5/18/2007 1 0 $5.93 On Hand FRTLAUD Receipt RCT0000009 VIRGINIAMEDICAL  
262 262   5/22/2007 78 0 $6.45 On Hand FRTLAUD Variance 0000184 INV VAR INV VAR
262 262   8/3/2007 11 0 $7.33 On Hand FRTLAUD Receipt RN4781 VIRGINIAMEDICAL 4404
262 262   8/3/2007 1 0 $7.37 On Hand FRTLAUD Receipt RN4781 VIRGINIAMEDICAL 4404
263 263   5/22/2007 185.2 0 $3.80 On Hand FRTLAUD Variance 0000185 INV VAR INV VAR
264 264   5/22/2007 128.5 0 $0.91 On Hand FRTLAUD Variance 0000186 INV VAR INV VAR
266 266   5/22/2007 135.5 0 $2.00 On Hand FRTLAUD Variance 0000187 INV VAR INV VAR
297 297   5/22/2007 55.3 2 $0.00 On Hand FRTLAUD Variance 0000190 INV VAR INV VAR
298 298   5/22/2007 57.9 0 $2.51 On Hand FRTLAUD Variance 0000191 INV VAR INV VAR
299 299   5/22/2007 1 0 $0.00 On Hand FRTLAUD Variance 0000192 INV VAR INV VAR
305 305   5/22/2007 77,378.20 267.2 $0.06 On Hand FRTLAUD Variance 0000194 INV VAR INV VAR
310 310   5/22/2007 16,243.50 0 $0.26 On Hand FRTLAUD Variance 0000196 INV VAR INV VAR
317 317   5/22/2007 108.2 0 $0.55 On Hand FRTLAUD Variance 0000197 INV VAR INV VAR
322 322   5/22/2007 1,106.60 1,106.60 $5.72 On Hand FRTLAUD Variance 0000198 INV VAR INV VAR
322 322   6/22/2007 4,780.00 3,687.70 $10.00 On Hand FRTLAUD Receipt RN4564 KEYSTONEBIO 4495
322 322   8/9/2007 2.9 0 $0.00 On Hand FRTLAUD Receipt RN4799 KEYSTONEBIO 4601
325 325   5/22/2007 3 0 $5.64 On Hand FRTLAUD Variance 0000199 INV VAR INV VAR
333 333   5/22/2007 104.7 0 $0.00 On Hand FRTLAUD Variance 0000200 INV VAR INV VAR
336 336   5/22/2007 677.9 0 $0.58 On Hand FRTLAUD Variance 0000201 INV VAR INV VAR
351 351   5/22/2007 669.8 486.9 $2.35 On Hand FRTLAUD Variance 0000203 INV VAR INV VAR
351 351   7/20/2007 578.4 0 $5.13 On Hand FRTLAUD Receipt RN4754 SERACOLLECTIONS 4585
351 351   7/20/2007 1 0 $2.81 On Hand FRTLAUD Receipt RN4754 SERACOLLECTIONS 4585
351 351   8/1/2007 49 0 $7.03 On Hand FRTLAUD Receipt RN4772 VIRGINIAMEDICAL 4574
351 351   8/20/2007 78.4 0 $6.55 On Hand FRTLAUD Receipt RN4824 VIRGINIAMEDICAL 4574
351 351   8/20/2007 1 0 $6.48 On Hand FRTLAUD Receipt RN4824 VIRGINIAMEDICAL 4574
352 352   5/22/2007 438.4 228.5 $2.20 On Hand FRTLAUD Variance 0000204 INV VAR INV VAR
352 352   7/23/2007 1,320.70 0 $5.11 On Hand FRTLAUD Receipt RN4755 SERACOLLECTIONS 4586
352 352   7/23/2007 1 0 $1.22 On Hand FRTLAUD Receipt RN4755 SERACOLLECTIONS 4586
352 352   8/1/2007 53.6 0 $8.00 On Hand FRTLAUD Receipt RN4773 VIRGINIAMEDICAL 4575
352 352   8/20/2007 76.2 0 $6.57 On Hand FRTLAUD Receipt RN4825 VIRGINIAMEDICAL 4575
352 352   8/20/2007 1 0 $6.37 On Hand FRTLAUD Receipt RN4825 VIRGINIAMEDICAL 4575
353 353   5/22/2007 993.3 239.6 $3.14 On Hand FRTLAUD Variance 0000205 INV VAR INV VAR
353 353   7/23/2007 2,099.80 0 $5.01 On Hand FRTLAUD Receipt RN4756 SERACOLLECTIONS 4587
353 353   7/23/2007 1 0 $10.00 On Hand FRTLAUD Receipt RN4756 SERACOLLECTIONS 4587
353 353   8/3/2007 52.5 0 $7.30 On Hand FRTLAUD Receipt RN4774 VIRGINIAMEDICAL 4576
353 353   8/20/2007 71.3 0 $6.83 On Hand FRTLAUD Receipt RN4823 VIRGINIAMEDICAL 4576
353 353   8/20/2007 1 0 $7.02 On Hand FRTLAUD Receipt RN4823 VIRGINIAMEDICAL 4576
370 370   5/22/2007 3,527.20 0 $0.19 On Hand FRTLAUD Variance 0000207 INV VAR INV VAR
388 388   5/22/2007 50.4 0 $0.03 On Hand FRTLAUD Variance 0000209 INV VAR INV VAR
391 391   5/22/2007 648.2 56.7 $6.19 On Hand FRTLAUD Variance 0000210 INV VAR INV VAR
391 391   6/22/2007 6.9 0 $6.33 On Hand FRTLAUD Receipt RN4668 LABORATORYCORPO 4233
391 391   6/22/2007 1 0 $6.32 On Hand FRTLAUD Receipt RN4668 LABORATORYCORPO 4233
391 391   6/29/2007 1.2 0 $4.55 On Hand FRTLAUD Receipt RN4689 LABORATORYCORPO 4233
391 391   6/29/2007 1 0 $4.54 On Hand FRTLAUD Receipt RN4689 LABORATORYCORPO 4233
391 391   7/12/2007 7.8 0 $6.41 On Hand FRTLAUD Receipt RN4725 LABORATORYCORPO 4233-1
391 391   8/10/2007 9.3 0 $6.80 On Hand FRTLAUD Receipt RN4803 LABORATORYCORPO 4233-2
391 391   8/10/2007 1 0 $6.76 On Hand FRTLAUD Receipt RN4803 LABORATORYCORPO 4233-2
400 400   5/22/2007 377.9 0 $0.21 On Hand FRTLAUD Variance 0000212 INV VAR INV VAR
402 402   5/22/2007 90.7 0 $5.46 On Hand FRTLAUD Variance 0000213 INV VAR INV VAR
410 410   5/22/2007 96.9 0 $28.71 On Hand FRTLAUD Variance 0000214 INV VAR INV VAR
410 410   7/20/2007 25.7 0 $33.71 On Hand FRTLAUD Receipt RN4753 LIVERINSTITUTE 4446
410 410   7/20/2007 1 0 $33.65 On Hand FRTLAUD Receipt RN4753 LIVERINSTITUTE 4446
417 417   5/22/2007 18.2 0 $6.88 On Hand FRTLAUD Variance 0000215 INV VAR INV VAR
418 418   5/22/2007 106.2 0 $6.25 On Hand FRTLAUD Variance 0000216 INV VAR INV VAR
421 421   5/22/2007 21 12 $0.00 On Hand FRTLAUD Variance 0000217 INV VAR INV VAR
429 429   5/22/2007 11.3 0 $0.00 On Hand FRTLAUD Variance 0000218 INV VAR INV VAR
446 446   5/22/2007 66,891.20 1,292.10 $1.72 On Hand FRTLAUD Variance 0000219 INV VAR INV VAR
446 446   5/24/2007 1,414.50 0 $0.44 On Hand FRTLAUD Receipt RCT0000012 TENNESSEEBLOODS  
446 446   5/24/2007 1 0 $2.62 On Hand FRTLAUD Receipt RCT0000012 TENNESSEEBLOODS  
446 446   7/5/2007 11 0 $14.58 On Hand FRTLAUD Receipt RN4700 SOUTHMIAMICLINI 4561
446 446   7/5/2007 1 0 $14.62 On Hand FRTLAUD Receipt RN4700 SOUTHMIAMICLINI 4561
446 446   7/16/2007 23 0 $14.58 On Hand FRTLAUD Receipt RN4733 SOUTHMIAMICLINI 4561
446 446   7/16/2007 1 0 $14.66 On Hand FRTLAUD Receipt RN4733 SOUTHMIAMICLINI 4561
446 446   7/17/2007 23 0 $14.58 On Hand FRTLAUD Receipt RN4738 SOUTHMIAMICLINI 4561
446 446   7/17/2007 1 0 $14.66 On Hand FRTLAUD Receipt RN4738 SOUTHMIAMICLINI 4561
447 447   5/22/2007 1,257.20 0 $1.70 On Hand FRTLAUD Variance 0000220 INV VAR INV VAR
448 448   5/22/2007 1,017.30 94.5 $25.64 On Hand FRTLAUD Variance 0000221 INV VAR INV VAR
456 456   5/22/2007 51 0 $6.01 On Hand FRTLAUD Variance 0000222 INV VAR INV VAR
472 472   5/22/2007 46.8 0 $4.15 On Hand FRTLAUD Variance 0000223 INV VAR INV VAR
501 501   5/22/2007 4.7 0 $5.60 On Hand FRTLAUD Variance 0000225 INV VAR INV VAR
502 502   5/22/2007 22.4 0 $7.63 On Hand FRTLAUD Variance 0000226 INV VAR INV VAR
535 535   5/22/2007 7,868.60 1,488.00 $0.36 On Hand FRTLAUD Variance 0000227 INV VAR INV VAR
535 535   6/15/2007 316.8 0 $0.99 On Hand FRTLAUD Receipt RN4635 TENNESSEEBLOODS 4518
535 535   6/15/2007 1 0 $1.37 On Hand FRTLAUD Receipt RN4635 TENNESSEEBLOODS 4518
535 535   6/15/2007 369.5 0 $0.94 On Hand FRTLAUD Receipt RN4636 TENNESSEEBLOODS 4518
535 535   6/15/2007 1 0 $2.67 On Hand FRTLAUD Receipt RN4636 TENNESSEEBLOODS 4518
535 535   6/22/2007 179 0 $0.39 On Hand FRTLAUD Receipt RN4671 TENNESSEEBLOODS 4518-1
535 535   6/22/2007 1 0 $0.19 On Hand FRTLAUD Receipt RN4671 TENNESSEEBLOODS 4518-1
535 535   6/29/2007 299 0 $1.17 On Hand FRTLAUD Receipt RN4694 TENNESSEEBLOODS 4554
535 535   6/29/2007 1 0 $0.17 On Hand FRTLAUD Receipt RN4694 TENNESSEEBLOODS 4554
535 535   8/2/2007 15 0 $1.17 Returned FRTLAUD Return 000003 Sales Entry Sales Entry
536 536   5/22/2007 89.8 0 $4.38 On Hand FRTLAUD Variance 0000228 INV VAR INV VAR
537 537   5/22/2007 21.3 0 $0.63 On Hand FRTLAUD Variance 0000229 INV VAR INV VAR
538 538   5/22/2007 16.8 0 $0.71 On Hand FRTLAUD Variance 0000230 INV VAR INV VAR
542 542   5/22/2007 6,316.40 0 $0.91 On Hand FRTLAUD Variance 0000231 INV VAR INV VAR
543 543   5/22/2007 3,583.00 1,406.80 $6.99 On Hand FRTLAUD Variance 0000232 INV VAR INV VAR
543 543   6/8/2007 46.9 0 $8.61 On Hand FRTLAUD Receipt RN4617 LABORATORYCORPO 4433
543 543   6/8/2007 1 0 $8.69 On Hand FRTLAUD Receipt RN4617 LABORATORYCORPO 4433
543 543   6/8/2007 75.1 0 $6.57 On Hand FRTLAUD Receipt RN4615 CENTERFORRHEUMA 4443
543 543   6/8/2007 1 0 $6.59 On Hand FRTLAUD Receipt RN4615 CENTERFORRHEUMA 4443
543 543   6/14/2007 41.9 0 $7.87 On Hand FRTLAUD Receipt RN4638 LABORATORYCORPO 4433
543 543   6/14/2007 1 0 $7.75 On Hand FRTLAUD Receipt RN4638 LABORATORYCORPO 4433
543 543   6/21/2007 22.4 0 $5.34 On Hand FRTLAUD Receipt RN4666 CENTERFORRHEUMA 4443
543 543   6/21/2007 1 0 $5.38 On Hand FRTLAUD Receipt RN4666 CENTERFORRHEUMA 4443
543 543   6/25/2007 289.1 0 $6.20 On Hand FRTLAUD Receipt RN4674 FUNDACIONCARDIO 4489
543 543   6/25/2007 1 0 $7.58 On Hand FRTLAUD Receipt RN4674 FUNDACIONCARDIO 4489
543 543   6/25/2007 120 0 $0.00 On Hand FRTLAUD Receipt RN4676 KEYSTONEBIO 4509
543 543   6/27/2007 55.5 0 $8.19 On Hand FRTLAUD Receipt RN4683 LABORATORYCORPO 4433-1
543 543   6/27/2007 1 0 $7.95 On Hand FRTLAUD Receipt RN4683 LABORATORYCORPO 4433-1
543 543   6/29/2007 8 0 $6.94 On Hand FRTLAUD Receipt RN4693 LABORATORYCORPO 4433-1
543 543   6/29/2007 1 0 $6.98 On Hand FRTLAUD Receipt RN4693 LABORATORYCORPO 4433-1
543 543   7/12/2007 7.6 0 $8.72 On Hand FRTLAUD Receipt RN4723 LABORATORYCORPO 4433-2
543 543   7/12/2007 1 0 $8.73 On Hand FRTLAUD Receipt RN4723 LABORATORYCORPO 4433-2
543 543   7/13/2007 73.7 0 $15.06 On Hand FRTLAUD Receipt RN4729 KEYSTONEBIO 4517
543 543   7/13/2007 1 0 $15.08 On Hand FRTLAUD Receipt RN4729 KEYSTONEBIO 4517
543 543   7/19/2007 717 0 $6.06 On Hand FRTLAUD Receipt RN4745 FUNDACIONCARDIO 4489-1
543 543   7/19/2007 1 0 $4.98 On Hand FRTLAUD Receipt RN4745 FUNDACIONCARDIO 4489-1
543 543   7/20/2007 357.4 0 $8.37 On Hand FRTLAUD Receipt RN4751 DR. CHARLES WEI 4583
543 543   7/20/2007 1 0 $8.56 On Hand FRTLAUD Receipt RN4751 DR. CHARLES WEI 4583
543 543   8/1/2007 585.3 0 $7.68 On Hand FRTLAUD Receipt 4775 DR. CHARLES WEI 4583-1
543 543   8/1/2007 1 0 $4.90 On Hand FRTLAUD Receipt 4775 DR. CHARLES WEI 4583-1
543 543   8/13/2007 4.6 0 $8.93 On Hand FRTLAUD Receipt RN4809 LABORATORYCORPO 4433-3
543 543   8/13/2007 1 0 $8.92 On Hand FRTLAUD Receipt RN4809 LABORATORYCORPO 4433-3
543 543   8/30/2007 1,107.50 0 $6.22 On Hand FRTLAUD Receipt RN4857 FUNDACIONCARDIO 4489-2
543 543   8/30/2007 1 0 $11.35 On Hand FRTLAUD Receipt RN4857 FUNDACIONCARDIO 4489-2
544 544   5/22/2007 707.1 0 $39.66 On Hand FRTLAUD Variance 0000233 INV VAR INV VAR
546 546   5/22/2007 15,968.80 146.2 $0.73 On Hand FRTLAUD Variance 0000234 INV VAR INV VAR
547 547   5/22/2007 10,962.40 2 $0.34 On Hand FRTLAUD Variance 0000235 INV VAR INV VAR
548 548   5/22/2007 6.9 0 $0.00 On Hand FRTLAUD Variance 0000236 INV VAR INV VAR
549 549   5/22/2007 29.1 0 $2.48 On Hand FRTLAUD Variance 0000237 INV VAR INV VAR
550 550   5/22/2007 366.7 366.7 $8.25 On Hand FRTLAUD Variance 0000238 INV VAR INV VAR
550 550   6/19/2007 407.8 407.8 $6.12 On Hand FRTLAUD Receipt RN4650 VIRGINIAMEDICAL 4533
550 550   6/19/2007 1 1 $4.26 On Hand FRTLAUD Receipt RN4650 VIRGINIAMEDICAL 4533
550 550   7/12/2007 115.6 84.5 $6.26 On Hand FRTLAUD Receipt RN4721 VIRGINIAMEDICAL 4533-1
550 550   7/12/2007 1 0 $6.34 On Hand FRTLAUD Receipt RN4721 VIRGINIAMEDICAL 4533-1
550 550   7/31/2007 77.4 0 $6.38 On Hand FRTLAUD Receipt RN4771 VIRGINIAMEDICAL 4533
550 550   7/31/2007 1 0 $6.19 On Hand FRTLAUD Receipt RN4771 VIRGINIAMEDICAL 4533
550 550   8/29/2007 149 0 $6.67 On Hand FRTLAUD Receipt RN4846 VIRGINIAMEDICAL 4533-2
550 550   8/29/2007 1 0 $6.17 On Hand FRTLAUD Receipt RN4846 VIRGINIAMEDICAL 4533-2
552 552   5/22/2007 69.8 0 $2.38 On Hand FRTLAUD Variance 0000239 INV VAR INV VAR
554 554   5/22/2007 142.7 3.7 $6.20 On Hand FRTLAUD Variance 0000240 INV VAR INV VAR
555 555   5/22/2007 125,856.30 3,288.40 $0.54 On Hand FRTLAUD Variance 0000241 INV VAR INV VAR
555 555   5/29/2007 4,029.10 0 $0.46 On Hand FRTLAUD Receipt RCT0000011 TENNESSEEBLOODS  
555 555   5/29/2007 1 0 $21.61 On Hand FRTLAUD Receipt RCT0000011 TENNESSEEBLOODS  
555 555   6/8/2007 1,353.00 0 $1.62 On Hand FRTLAUD Receipt RN4624 REDCROSSNICARAG 4521
555 555   6/8/2007 1 0 $8.14 On Hand FRTLAUD Receipt RN4624 REDCROSSNICARAG 4521
555 555   7/11/2007 1,172.30 0 $0.57 On Hand FRTLAUD Receipt RN4714 GULFCOASTREGION 4369
555 555   7/11/2007 1 0 $6.78 On Hand FRTLAUD Receipt RN4714 GULFCOASTREGION 4369
555 555   7/12/2007 633.1 0 $9.46 On Hand FRTLAUD Receipt RN4726 ACCACIASERUMPRO 4559
555 555   7/12/2007 1 0 $10.87 On Hand FRTLAUD Receipt RN4726 ACCACIASERUMPRO 4559
555 555   8/7/2007 2,058.10 0 $0.72 On Hand FRTLAUD Receipt RN4794 REDCROSSNICARAG 4521-1
555 555   8/7/2007 1 0 $18.16 On Hand FRTLAUD Receipt RN4794 REDCROSSNICARAG 4521-1
555 555   8/7/2007 1,300.80 0 $0.51 On Hand FRTLAUD Receipt RN4796 GULFCOASTREGION 4369
555 555   8/7/2007 1 0 $11.59 On Hand FRTLAUD Receipt RN4796 GULFCOASTREGION 4369
555 555   8/14/2007 1,041.50 0 $0.51 On Hand FRTLAUD Receipt RN4810 GULFCOASTREGION 4369
555 555   8/14/2007 1 0 $8.83 On Hand FRTLAUD Receipt RN4810 GULFCOASTREGION 4369
556 556   5/22/2007 40.8 0 $3.18 On Hand FRTLAUD Variance 0000242 INV VAR INV VAR
558 558   5/22/2007 30,589.50 7,107.90 $0.75 On Hand FRTLAUD Variance 0000243 INV VAR INV VAR
558 558   6/13/2007 2,120.80 0 $0.94 On Hand FRTLAUD Receipt RN4623 REDCROSSNICARAG 4519
558 558   6/13/2007 1 0 $6.45 On Hand FRTLAUD Receipt RN4623 REDCROSSNICARAG 4519
558 558   7/5/2007 1,340.40 0 $0.89 On Hand FRTLAUD Receipt 4699 REDCROSSNICARAG 4519
558 558   7/5/2007 1 0 $7.04 On Hand FRTLAUD Receipt 4699 REDCROSSNICARAG 4519
558 558   8/6/2007 1,506.30 0 $0.73 On Hand FRTLAUD Receipt RN4790 REDCROSSNICARAG 4519-1
558 558   8/6/2007 1 0 $0.40 On Hand FRTLAUD Receipt RN4790 REDCROSSNICARAG 4519-1
558 558   8/9/2007 616.3 0 $0.32 On Hand FRTLAUD Receipt RN4801 REDCROSSNICARAG 4603
558 558   8/9/2007 1 0 $2.78 On Hand FRTLAUD Receipt RN4801 REDCROSSNICARAG 4603
558 558   8/30/2007 464.3 0 $6.77 On Hand FRTLAUD Receipt RN4860 FUNDACIONCARDIO 4622
558 558   8/30/2007 1 0 $6.69 On Hand FRTLAUD Receipt RN4860 FUNDACIONCARDIO 4622
562 562   5/22/2007 2,593.10 0 $0.58 On Hand FRTLAUD Variance 0000244 INV VAR INV VAR
563 563   5/22/2007 365.6 0 $0.34 On Hand FRTLAUD Variance 0000245 INV VAR INV VAR
565 565   5/22/2007 5,288.80 109.1 $4.00 On Hand FRTLAUD Variance 0000246 INV VAR INV VAR
567 567   5/22/2007 31.6 0 $0.00 On Hand FRTLAUD Variance 0000247 INV VAR INV VAR
572 572   5/22/2007 6,855.70 0 $0.41 On Hand FRTLAUD Variance 0000248 INV VAR INV VAR
573 573   5/22/2007 3.8 0 $0.00 On Hand FRTLAUD Variance 0000249 INV VAR INV VAR
580 580   5/22/2007 50 27.6 $4.97 On Hand FRTLAUD Variance 0000250 INV VAR INV VAR
580 580   6/12/2007 19 0 $1.88 On Hand FRTLAUD Receipt RN4626 BOCARATONCOMMUN 4526
580 580   6/12/2007 1 0 $1.78 On Hand FRTLAUD Receipt RN4626 BOCARATONCOMMUN 4526
581 581   6/19/2007 10 10 $50.00 On Hand FRTLAUD Receipt RN4648 SLRRESEARCHCORP 4530
582 582   5/22/2007 449.7 94 $8.77 On Hand FRTLAUD Variance 0000251 INV VAR INV VAR
582 582   6/25/2007 89.6 0 $6.62 On Hand FRTLAUD Receipt RN4675 FUNDACIONCARDIO 4493
582 582   6/25/2007 1 0 $6.85 On Hand FRTLAUD Receipt RN4675 FUNDACIONCARDIO 4493
582 582   6/26/2007 155.6 0 $6.70 On Hand FRTLAUD Receipt RN4679 FUNDACIONCARDIO 4552
582 582   6/26/2007 1 0 $7.48 On Hand FRTLAUD Receipt RN4679 FUNDACIONCARDIO 4552
582 582   7/19/2007 160.2 0 $7.44 On Hand FRTLAUD Receipt RN4742 FUNDACIONCARDIO 4552-1
582 582   7/19/2007 1 0 $8.11 On Hand FRTLAUD Receipt RN4742 FUNDACIONCARDIO 4552-1
582 582   8/30/2007 279.4 0 $7.49 On Hand FRTLAUD Receipt RN4853 FUNDACIONCARDIO 4552-2
582 582   8/30/2007 1 0 $7.29 On Hand FRTLAUD Receipt RN4853 FUNDACIONCARDIO 4552-2
584 584   7/6/2007 3 3 $0.00 On Hand FRTLAUD Receipt RN4701 SLRRESEARCHCORP 4562
584 584   8/2/2007 1.1 1.1 $0.00 On Hand FRTLAUD Receipt RN4780 ACCESSBIOLOGICA 4595
586 586   8/23/2007 98.2 98.2 $4.03 On Hand FRTLAUD Receipt RN4819 HEPCALERT 4613
586 586   8/23/2007 1 1 $4.25 On Hand FRTLAUD Receipt RN4819 HEPCALERT 4613
586 586   8/23/2007 153 90.8 $2.60 On Hand FRTLAUD Receipt RN4833 HEPCALERT 4613
586 586   8/23/2007 1 0 $2.20 On Hand FRTLAUD Receipt RN4833 HEPCALERT 4613
587 587   5/22/2007 5 0 $0.00 On Hand FRTLAUD Variance 0000252 INV VAR INV VAR
589 589   5/22/2007 489.4 308.2 $23.75 On Hand FRTLAUD Variance 0000253 INV VAR INV VAR
590 590   5/22/2007 355.3 0 $0.30 On Hand FRTLAUD Variance 0000254 INV VAR INV VAR
592 592   5/22/2007 1,706.30 86.2 $2.88 On Hand FRTLAUD Variance 0000255 INV VAR INV VAR
593 593   5/22/2007 77.2 0 $0.00 On Hand FRTLAUD Variance 0000256 INV VAR INV VAR
594 594   5/22/2007 101.1 0 $6.50 On Hand FRTLAUD Variance 0000257 INV VAR INV VAR
607 607   5/22/2007 19,096.20 905.7 $0.28 On Hand FRTLAUD Variance 0000259 INV VAR INV VAR
609 609   5/22/2007 40.4 0 $0.00 On Hand FRTLAUD Variance 0000260 INV VAR INV VAR
610 610   5/22/2007 94.8 0 $2.77 On Hand FRTLAUD Variance 0000261 INV VAR INV VAR
611 611   5/22/2007 281.8 0 $2.49 On Hand FRTLAUD Variance 0000262 INV VAR INV VAR
612 612   5/22/2007 69.4 0 $1.24 On Hand FRTLAUD Variance 0000263 INV VAR INV VAR
613 613   5/22/2007 609.6 0 $3.88 On Hand FRTLAUD Variance 0000264 INV VAR INV VAR
614 614   5/22/2007 10.8 0 $2.89 On Hand FRTLAUD Variance 0000265 INV VAR INV VAR
615 615   5/22/2007 699.5 0 $3.78 On Hand FRTLAUD Variance 0000266 INV VAR INV VAR
616 616   5/22/2007 108 0 $4.81 On Hand FRTLAUD Variance 0000267 INV VAR INV VAR
620 620   5/22/2007 107.9 0 $0.00 On Hand FRTLAUD Variance 0000268 INV VAR INV VAR
620 620   8/24/2007 32.8 0 $13.31 On Hand FRTLAUD Receipt RN4842 WOHLFEILERPIPER 4619
620 620   8/24/2007 1 0 $13.43 On Hand FRTLAUD Receipt RN4842 WOHLFEILERPIPER 4619
621 621   5/22/2007 30,837.20 207.7 $0.36 On Hand FRTLAUD Variance 0000269 INV VAR INV VAR
623 623   5/21/2007 2,373.20 927.4 $6.19 On Hand FRTLAUD Receipt RCT0000025 KENEMAGOVTHOSPI  
623 623   5/21/2007 1 0 $9.89 On Hand FRTLAUD Receipt RCT0000025 KENEMAGOVTHOSPI  
623 623   5/22/2007 6,132.00 0 $10.33 On Hand FRTLAUD Variance 0000270 INV VAR INV VAR
624 624   5/22/2007 231.3 0 $5.67 On Hand FRTLAUD Variance 0000271 INV VAR INV VAR
627 627   5/22/2007 872.1 0 $1.52 On Hand FRTLAUD Variance 0000272 INV VAR INV VAR
627 627   6/12/2007 1.1 0 $3.64 On Hand FRTLAUD Receipt RN4629 BOCARATONCOMMUN 4523
628 628   5/22/2007 83.9 4.1 $2.96 On Hand FRTLAUD Variance 0000273 INV VAR INV VAR
628 628   6/12/2007 0.5 0 $2.67 On Hand FRTLAUD Receipt 4627 BOCARATONCOMMUN 4525
628 628   6/12/2007 1 0 $2.66 On Hand FRTLAUD Receipt 4627 BOCARATONCOMMUN 4525
631 631   5/22/2007 3,998.80 249.3 $0.56 On Hand FRTLAUD Variance 0000275 INV VAR INV VAR
633 633   5/22/2007 3,019.10 2 $2.93 On Hand FRTLAUD Variance 0000276 INV VAR INV VAR
635 635   5/22/2007 55.1 0 $9.39 On Hand FRTLAUD Variance 0000277 INV VAR INV VAR
637 637   5/22/2007 12.1 6.9 $0.89 On Hand FRTLAUD Variance 0000278 INV VAR INV VAR
637 637   6/8/2007 21.5 0 $8.89 On Hand FRTLAUD Receipt RN4619 LABORATORYCORPO 4381
637 637   6/8/2007 1 0 $8.86 On Hand FRTLAUD Receipt RN4619 LABORATORYCORPO 4381
637 637   6/14/2007 27.3 0 $7.51 On Hand FRTLAUD Receipt RN4637 LABORATORYCORPO 4381
637 637   6/14/2007 1 0 $7.48 On Hand FRTLAUD Receipt RN4637 LABORATORYCORPO 4381
637 637   6/22/2007 41.3 0 $8.27 On Hand FRTLAUD Receipt RN4669 LABORATORYCORPO 4381
637 637   6/22/2007 1 0 $8.45 On Hand FRTLAUD Receipt RN4669 LABORATORYCORPO 4381
637 637   6/29/2007 21.4 0 $8.37 On Hand FRTLAUD Receipt RN4691 LABORATORYCORPO 4381
637 637   6/29/2007 1 0 $8.38 On Hand FRTLAUD Receipt RN4691 LABORATORYCORPO 4381
637 637   7/12/2007 15.4 0 $8.38 On Hand FRTLAUD Receipt 4722 LABORATORYCORPO 4381-1
637 637   7/12/2007 1 0 $8.45 On Hand FRTLAUD Receipt 4722 LABORATORYCORPO 4381-1
637 637   8/10/2007 64 0 $7.88 On Hand FRTLAUD Receipt RN4802 LABORATORYCORPO 4381-2
637 637   8/10/2007 1 0 $8.18 On Hand FRTLAUD Receipt RN4802 LABORATORYCORPO 4381-2
637 637   8/23/2007 12.7 0 $7.30 On Hand FRTLAUD Receipt RN4834 LABORATORYCORPO 4381-2
637 637   8/23/2007 1 0 $7.29 On Hand FRTLAUD Receipt RN4834 LABORATORYCORPO 4381-2
638 638   5/22/2007 147.2 75.5 $0.34 On Hand FRTLAUD Variance 0000279 INV VAR INV VAR
638 638   8/24/2007 22 0 $0.00 On Hand FRTLAUD Receipt RN4838 BIOHEME 4617
639 639   5/22/2007 935.1 0 $2.57 On Hand FRTLAUD Variance 0000280 INV VAR INV VAR
640 640   5/22/2007 8.1 0 $5.95 On Hand FRTLAUD Variance 0000282 INV VAR INV VAR
641 641   5/22/2007 2.9 0 $0.00 On Hand FRTLAUD Variance 0000283 INV VAR INV VAR
643 643   5/22/2007 5,096.40 13 $0.49 On Hand FRTLAUD Variance 0000284 INV VAR INV VAR
659 659   5/22/2007 17.7 0 $6.59 On Hand FRTLAUD Variance 0000285 INV VAR INV VAR
663 663   5/22/2007 9,291.80 2 $0.44 On Hand FRTLAUD Variance 0000286 INV VAR INV VAR
679 679   5/22/2007 25,850.80 371.9 $0.20 On Hand FRTLAUD Variance 0000287 INV VAR INV VAR
683 683   5/22/2007 346.7 0 $0.66 On Hand FRTLAUD Variance 0000288 INV VAR INV VAR
702 702   5/22/2007 781.3 0 $12.53 On Hand FRTLAUD Variance 0000290 INV VAR INV VAR
703 703   5/22/2007 1 0 $5.21 On Hand FRTLAUD Variance 0000291 INV VAR INV VAR
708 708   5/22/2007 13.4 0 $0.10 On Hand FRTLAUD Variance 0000292 INV VAR INV VAR
709 709   5/22/2007 8.8 0 $5.69 On Hand FRTLAUD Variance 0000293 INV VAR INV VAR
714 714   5/22/2007 45 0 $24.56 On Hand FRTLAUD Variance 0000294 INV VAR INV VAR
716 716   5/22/2007 90.9 21.3 $7.92 On Hand FRTLAUD Variance 0000295 INV VAR INV VAR
716 716   5/22/2007 117.3 0 $5.28 On Hand FRTLAUD Receipt RCT0000014 TUSCONCLINICALR  
716 716   5/22/2007 1 0 $5.66 On Hand FRTLAUD Receipt RCT0000014 TUSCONCLINICALR  
718 718   5/22/2007 5.9 0 $6.65 On Hand FRTLAUD Variance 0000296 INV VAR INV VAR
719 719   5/22/2007 19.4 2 $0.36 On Hand FRTLAUD Variance 0000297 INV VAR INV VAR
720 720   5/22/2007 556.8 0 $1.13 On Hand FRTLAUD Variance 0000298 INV VAR INV VAR
721 721   5/22/2007 322.3 0 $1.10 On Hand FRTLAUD Variance 0000299 INV VAR INV VAR
723 723   5/22/2007 2,630.80 289.8 $3.87 On Hand FRTLAUD Variance 0000300 INV VAR INV VAR
724 724   5/22/2007 50,987.90 1,780.30 $0.31 On Hand FRTLAUD Variance 0000301 INV VAR INV VAR
724 724   6/12/2007 1,154.50 0 $0.25 On Hand FRTLAUD Receipt RN4622 REDCROSSNICARAG 4520
724 724   6/12/2007 1 0 $11.37 On Hand FRTLAUD Receipt RN4622 REDCROSSNICARAG 4520
724 724   8/6/2007 1,001.90 0 $0.24 On Hand FRTLAUD Receipt RN4789 REDCROSSNICARAG 4520-1
724 724   8/6/2007 1 0 $9.54 On Hand FRTLAUD Receipt RN4789 REDCROSSNICARAG 4520-1
725 725   5/22/2007 173.8 0 $0.26 On Hand FRTLAUD Variance 0000302 INV VAR INV VAR
731 731   5/22/2007 8.3 0 $2.91 On Hand FRTLAUD Variance 0000303 INV VAR INV VAR
732 732   5/22/2007 1,126.10 0 $3.48 On Hand FRTLAUD Variance 0000304 INV VAR INV VAR
733 733   5/22/2007 130.3 0 $3.93 On Hand FRTLAUD Variance 0000305 INV VAR INV VAR
734 734   5/22/2007 273.2 0 $0.00 On Hand FRTLAUD Variance 0000306 INV VAR INV VAR
737 737   8/16/2007 195.3 180 $4.08 On Hand FRTLAUD Receipt RN4821 HEPCALERT 4612
737 737   8/16/2007 1 0 $3.18 On Hand FRTLAUD Receipt RN4821 HEPCALERT 4612
740 740   5/22/2007 2.4 0 $8.54 On Hand FRTLAUD Variance 0000307 INV VAR INV VAR
742 742   5/22/2007 1.6 0 $6.89 On Hand FRTLAUD Variance 0000308 INV VAR INV VAR
743 743   5/22/2007 199.7 0 $21.56 On Hand FRTLAUD Variance 0000309 INV VAR INV VAR
747 747   5/22/2007 1,314.10 26.8 $0.68 On Hand FRTLAUD Variance 0000310 INV VAR INV VAR
756 756   5/22/2007 2,005.90 91.9 $0.79 On Hand FRTLAUD Variance 0000311 INV VAR INV VAR
762 762   5/22/2007 685.2 0 $4.51 On Hand FRTLAUD Variance 0000312 INV VAR INV VAR
763 763   5/22/2007 688 14.1 $0.00 On Hand FRTLAUD Variance 0000313 INV VAR INV VAR
765 765   5/22/2007 247.6 0 $0.00 On Hand FRTLAUD Variance 0000314 INV VAR INV VAR
777 777   5/22/2007 7 0 $1.73 On Hand FRTLAUD Variance 0000315 INV VAR INV VAR
778 778   5/22/2007 74.2 60 $2.10 On Hand FRTLAUD Variance 0000316 INV VAR INV VAR
782 782   5/22/2007 566.6 0 $3.62 On Hand FRTLAUD Variance 0000317 INV VAR INV VAR
783 783   5/22/2007 207.5 174.3 $6.43 On Hand FRTLAUD Variance 0000318 INV VAR INV VAR
783 783   6/29/2007 60.3 0 $6.12 On Hand FRTLAUD Receipt RN4687 DRMARKLAMET 4484
783 783   6/29/2007 1 0 $5.96 On Hand FRTLAUD Receipt RN4687 DRMARKLAMET 4484
783 783   8/3/2007 28.3 0 $4.27 On Hand FRTLAUD Receipt 4786 DRMARKLAMET 4484-1
783 783   8/3/2007 1 0 $4.16 On Hand FRTLAUD Receipt 4786 DRMARKLAMET 4484-1
783 783   8/17/2007 61.4 0 $6.01 On Hand FRTLAUD Receipt RN4822 DRMARKLAMET 4484-1
783 783   8/17/2007 1 0 $5.99 On Hand FRTLAUD Receipt RN4822 DRMARKLAMET 4484-1
785 785   5/22/2007 1.1 0 $5.04 On Hand FRTLAUD Variance 0000319 INV VAR INV VAR
788 788   5/22/2007 12,520.80 62.4 $1.48 On Hand FRTLAUD Variance 0000320 INV VAR INV VAR
788 788   7/12/2007 1,288.20 0 $0.62 On Hand FRTLAUD Receipt RN4727 BLOODBANKOFCONG 4578
788 788   7/12/2007 1 0 $1.32 On Hand FRTLAUD Receipt RN4727 BLOODBANKOFCONG 4578
791 791   5/22/2007 882.1 65 $0.00 On Hand FRTLAUD Variance 0000321 INV VAR INV VAR
795 795   5/22/2007 8.1 0 $0.00 On Hand FRTLAUD Variance 0000322 INV VAR INV VAR
796 796   5/22/2007 34.2 0 $0.63 On Hand FRTLAUD Variance 0000323 INV VAR INV VAR
797 797   5/22/2007 3,430.50 0 $0.13 On Hand FRTLAUD Variance 0000324 INV VAR INV VAR
800 800   5/22/2007 179.7 0 $0.00 On Hand FRTLAUD Variance 0000326 INV VAR INV VAR
802 802   5/22/2007 6,818.90 3,313.50 $1.33 On Hand FRTLAUD Variance 0000327 INV VAR INV VAR
803 803   5/22/2007 1,208.70 0 $0.00 On Hand FRTLAUD Variance 0000328 INV VAR INV VAR
804 804   5/22/2007 10,330.20 89.2 $1.13 On Hand FRTLAUD Variance 0000329 INV VAR INV VAR
805 805   5/22/2007 136.8 1 $5.14 On Hand FRTLAUD Variance 0000330 INV VAR INV VAR
807 807   5/22/2007 238.3 0 $6.26 On Hand FRTLAUD Variance 0000331 INV VAR INV VAR
815 815   5/22/2007 925 0 $1.32 On Hand FRTLAUD Variance 0000332 INV VAR INV VAR
816 816   5/22/2007 4,608.70 123.3 $0.70 On Hand FRTLAUD Variance 0000333 INV VAR INV VAR
817 817   5/22/2007 293.7 0 $2.63 On Hand FRTLAUD Variance 0000334 INV VAR INV VAR
819 819   5/22/2007 0.8 0 $9.46 On Hand FRTLAUD Variance 0000335 INV VAR INV VAR
823 823   5/22/2007 9.7 0 $3.23 On Hand FRTLAUD Variance 0000336 INV VAR INV VAR
824 824   5/22/2007 34 0 $3.87 On Hand FRTLAUD Variance 0000337 INV VAR INV VAR
827 827   5/22/2007 3,453.70 0 $0.11 On Hand FRTLAUD Variance 0000338 INV VAR INV VAR
828 828   5/22/2007 1,555.30 0 $0.23 On Hand FRTLAUD Variance 0000339 INV VAR INV VAR
831 831   5/22/2007 611.9 30.5 $2.61 On Hand FRTLAUD Variance 0000341 INV VAR INV VAR
832 832   5/22/2007 1,842.00 219.5 $2.29 On Hand FRTLAUD Variance 0000342 INV VAR INV VAR
832 832   5/31/2007 134 0 $8.89 On Hand FRTLAUD Receipt RCT0000010 KEYSTONEBIO  
832 832   5/31/2007 1 0 $8.74 On Hand FRTLAUD Receipt RCT0000010 KEYSTONEBIO  
834 834   5/22/2007 2,148.40 0 $0.00 On Hand FRTLAUD Variance 0000343 INV VAR INV VAR
836 836   5/22/2007 431.7 0 $0.00 On Hand FRTLAUD Variance 0000344 INV VAR INV VAR
838 838   5/22/2007 276.6 30 $2.84 On Hand FRTLAUD Variance 0000345 INV VAR INV VAR
839 839   5/22/2007 348.6 30.2 $5.22 On Hand FRTLAUD Variance 0000346 INV VAR INV VAR
841 841   5/22/2007 44 0 $0.00 On Hand FRTLAUD Variance 0000347 INV VAR INV VAR
843 843   5/22/2007 54.3 50.2 $35.94 On Hand FRTLAUD Variance 0000348 INV VAR INV VAR
844 844   5/22/2007 241.4 0 $3.51 On Hand FRTLAUD Variance 0000349 INV VAR INV VAR
847 847   5/22/2007 81.2 0 $2.56 On Hand FRTLAUD Variance 0000350 INV VAR INV VAR
848 848   5/22/2007 643 0 $1.57 On Hand FRTLAUD Variance 0000351 INV VAR INV VAR
849 849   5/22/2007 535.6 0 $1.19 On Hand FRTLAUD Variance 0000352 INV VAR INV VAR
850 850   5/22/2007 39.2 0 $5.29 On Hand FRTLAUD Variance 0000354 INV VAR INV VAR
850 850   8/2/2007 11 0 $7.33 On Hand FRTLAUD Receipt RN4779 VIRGINIAMEDICAL 4408
850 850   8/2/2007 1 0 $7.37 On Hand FRTLAUD Receipt RN4779 VIRGINIAMEDICAL 4408
851 851   5/22/2007 576.5 0 $0.94 On Hand FRTLAUD Variance 0000355 INV VAR INV VAR
852 852   5/22/2007 1,736.70 4 $1.03 On Hand FRTLAUD Variance 0000356 INV VAR INV VAR
853 853   5/22/2007 2,176.60 412.1 $0.84 On Hand FRTLAUD Variance 0000357 INV VAR INV VAR
855 855   5/22/2007 6,915.70 153.2 $0.28 On Hand FRTLAUD Variance 0000358 INV VAR INV VAR
856 856   5/22/2007 14,803.20 772.6 $0.80 On Hand FRTLAUD Variance 0000359 INV VAR INV VAR
857 857   5/22/2007 3,194.50 0 $0.39 On Hand FRTLAUD Variance 0000360 INV VAR INV VAR
859 859   5/22/2007 8,112.90 811.9 $6.34 On Hand FRTLAUD Variance 0000361 INV VAR INV VAR
859 859   8/22/2007 296.4 0 $8.32 On Hand FRTLAUD Receipt RN4829 SINGCHANMD 4614
859 859   8/22/2007 1 0 $8.95 On Hand FRTLAUD Receipt RN4829 SINGCHANMD 4614
859 859   8/28/2007 26.2 0 $10.11 On Hand FRTLAUD Receipt RN4845 SINGCHANMD 4614
859 859   8/28/2007 1 0 $10.12 On Hand FRTLAUD Receipt RN4845 SINGCHANMD 4614
860 860   5/22/2007 75.3 0 $4.16 On Hand FRTLAUD Variance 0000362 INV VAR INV VAR
861 861   5/22/2007 132.2 4 $0.36 On Hand FRTLAUD Variance 0000363 INV VAR INV VAR
861 861   6/12/2007 1.3 0 $3.08 On Hand FRTLAUD Receipt RN4628 BOCARATONCOMMUN 4524
862 862   5/22/2007 45.1 0 $17.96 On Hand FRTLAUD Variance 0000364 INV VAR INV VAR
865 865   5/22/2007 518.6 54.5 $0.95 On Hand FRTLAUD Variance 0000365 INV VAR INV VAR
866 866   5/22/2007 689.3 0 $4.73 On Hand FRTLAUD Variance 0000366 INV VAR INV VAR
867 867   5/22/2007 38.4 0 $3.02 On Hand FRTLAUD Variance 0000367 INV VAR INV VAR
867 867   6/6/2007 112.4 0 $6.40 On Hand FRTLAUD Receipt RN4611 VIRGINIAMEDICAL 4406
867 867   6/6/2007 1 0 $6.64 On Hand FRTLAUD Receipt RN4611 VIRGINIAMEDICAL 4406
867 867   8/3/2007 89 0 $7.33 On Hand FRTLAUD Receipt RN4783 VIRGINIAMEDICAL 4406-1
867 867   8/3/2007 1 0 $7.63 On Hand FRTLAUD Receipt RN4783 VIRGINIAMEDICAL 4406-1
868 868   5/22/2007 278.2 0 $3.06 On Hand FRTLAUD Variance 0000368 INV VAR INV VAR
869 869   5/22/2007 492.9 0 $2.59 On Hand FRTLAUD Variance 0000369 INV VAR INV VAR
870 870   5/22/2007 3.4 0 $5.76 On Hand FRTLAUD Variance 0000370 INV VAR INV VAR
870 870   6/6/2007 2 0 $7.33 On Hand FRTLAUD Receipt 4610 VIRGINIAMEDICAL 4410
870 870   6/6/2007 1 0 $7.34 On Hand FRTLAUD Receipt 4610 VIRGINIAMEDICAL 4410
874 874   5/22/2007 900.8 0 $2.08 On Hand FRTLAUD Variance 0000371 INV VAR INV VAR
875 875   6/6/2007 4.1 0 $8.63 On Hand FRTLAUD Receipt RN4609 VIRGINIAMEDICAL 4407
875 875   6/6/2007 1 0 $8.62 On Hand FRTLAUD Receipt RN4609 VIRGINIAMEDICAL 4407
876 876   5/18/2007 78.7 0 $5.93 On Hand FRTLAUD Receipt RCT0000024 VIRGINIAMEDICAL  
876 876   5/18/2007 1 0 $6.31 On Hand FRTLAUD Receipt RCT0000024 VIRGINIAMEDICAL  
876 876   5/22/2007 265 0 $6.54 On Hand FRTLAUD Variance 0000372 INV VAR INV VAR
876 876   6/6/2007 69.5 0 $6.71 On Hand FRTLAUD Receipt RN4606 VIRGINIAMEDICAL 4411
876 876   6/6/2007 1 0 $6.65 On Hand FRTLAUD Receipt RN4606 VIRGINIAMEDICAL 4411
877 877   5/22/2007 100.1 0 $9.81 On Hand FRTLAUD Variance 0000373 INV VAR INV VAR
877 877   6/1/2007 29.2 0 $6.56 On Hand FRTLAUD Receipt RN4570 VIRGINIAMEDICAL 4405
877 877   6/1/2007 1 0 $6.45 On Hand FRTLAUD Receipt RN4570 VIRGINIAMEDICAL 4405
877 877   6/6/2007 15 0 $6.60 On Hand FRTLAUD Receipt RN4607 VIRGINIAMEDICAL 4405
877 877   8/3/2007 11 0 $7.33 On Hand FRTLAUD Receipt RN4787 VIRGINIAMEDICAL 4405-1
877 877   8/3/2007 1 0 $7.37 On Hand FRTLAUD Receipt RN4787 VIRGINIAMEDICAL 4405-1
878 878   5/22/2007 2 0 $2.87 On Hand FRTLAUD Variance 0000374 INV VAR INV VAR
879 879   5/22/2007 4 0 $2.87 On Hand FRTLAUD Variance 0000375 INV VAR INV VAR
880 880   5/22/2007 2 0 $2.86 On Hand FRTLAUD Variance 0000376 INV VAR INV VAR
882 882   5/22/2007 94.2 0 $0.73 On Hand FRTLAUD Variance 0000377 INV VAR INV VAR
883 883   5/22/2007 202.8 71 $2.39 On Hand FRTLAUD Variance 0000378 INV VAR INV VAR
885 885   5/22/2007 782.7 0 $0.21 On Hand FRTLAUD Variance 0000379 INV VAR INV VAR
886 886   5/22/2007 759.9 0 $2.33 On Hand FRTLAUD Variance 0000380 INV VAR INV VAR
887 887   5/22/2007 6,142.10 9 $0.34 On Hand FRTLAUD Variance 0000381 INV VAR INV VAR
888 888   5/22/2007 10,317.70 1 $0.26 On Hand FRTLAUD Variance 0000382 INV VAR INV VAR
890 890   5/22/2007 7.2 0 $8.78 On Hand FRTLAUD Variance 0000383 INV VAR INV VAR
895 895   5/22/2007 20.9 0 $1.44 On Hand FRTLAUD Variance 0000384 INV VAR INV VAR
896 896   5/22/2007 24.1 0 $2.13 On Hand FRTLAUD Variance 0000385 INV VAR INV VAR
897 897   5/22/2007 36.9 0 $2.17 On Hand FRTLAUD Variance 0000386 INV VAR INV VAR
898 898   5/22/2007 36.5 0 $1.92 On Hand FRTLAUD Variance 0000387 INV VAR INV VAR
899 899   5/22/2007 2,042.90 0 $2.33 On Hand FRTLAUD Variance 0000388 INV VAR INV VAR
900 900   5/22/2007 67.8 0 $1.90 On Hand FRTLAUD Variance 0000389 INV VAR INV VAR
901 901   5/22/2007 4.7 0 $0.00 On Hand FRTLAUD Variance 0000390 INV VAR INV VAR
903 903   5/22/2007 408.5 0 $2.04 On Hand FRTLAUD Variance 0000391 INV VAR INV VAR
905 905   5/22/2007 823.9 0 $1.52 On Hand FRTLAUD Variance 0000392 INV VAR INV VAR
906 906   5/22/2007 3.7 0 $7.11 On Hand FRTLAUD Variance 0000393 INV VAR INV VAR
907 907   5/22/2007 308.9 240.5 $7.52 On Hand FRTLAUD Variance 0000394 INV VAR INV VAR
907 907   7/20/2007 81.8 0 $6.04 On Hand FRTLAUD Receipt RN4748 DRMARKLAMET 4158
907 907   7/20/2007 1 0 $5.93 On Hand FRTLAUD Receipt RN4748 DRMARKLAMET 4158
907 907   8/3/2007 19.2 0 $6.19 On Hand FRTLAUD Receipt RN4785 DRMARKLAMET 4158-1
907 907   8/3/2007 1 0 $6.15 On Hand FRTLAUD Receipt RN4785 DRMARKLAMET 4158-1
907 907   8/20/2007 58.8 0 $6.27 On Hand FRTLAUD Receipt RN4827 (PO4158-1) DRMARKLAMET 4158-1
907 907   8/20/2007 1 0 $6.32 On Hand FRTLAUD Receipt RN4827 (PO4158-1) DRMARKLAMET 4158-1
908 908   5/22/2007 34.1 0 $2.69 On Hand FRTLAUD Variance 0000395 INV VAR INV VAR
910 910   5/22/2007 40.3 0 $2.35 On Hand FRTLAUD Variance 0000397 INV VAR INV VAR
911 911   5/22/2007 4.8 0 $0.08 On Hand FRTLAUD Variance 0000398 INV VAR INV VAR
916 916   5/22/2007 79.1 0 $3.66 On Hand FRTLAUD Variance 0000399 INV VAR INV VAR
917 917   5/22/2007 169.2 0 $2.24 On Hand FRTLAUD Variance 0000400 INV VAR INV VAR
919 919   5/22/2007 8.9 0 $2.22 On Hand FRTLAUD Variance 0000401 INV VAR INV VAR
920 920   5/22/2007 322.6 0 $2.68 On Hand FRTLAUD Variance 0000403 INV VAR INV VAR
921 921   5/22/2007 454.9 0 $0.55 On Hand FRTLAUD Variance 0000404 INV VAR INV VAR
922 922   5/22/2007 99.6 45.1 $8.08 On Hand FRTLAUD Variance 0000405 INV VAR INV VAR
923 923   5/22/2007 259.3 123.3 $8.62 On Hand FRTLAUD Variance 0000406 INV VAR INV VAR
923 923   6/1/2007 103 0 $5.19 On Hand FRTLAUD Receipt RN4592 SERACOLLECTIONS 4512
923 923   6/1/2007 1 0 $5.43 On Hand FRTLAUD Receipt RN4592 SERACOLLECTIONS 4512
924 924   5/22/2007 126.3 53.6 $9.19 On Hand FRTLAUD Variance 0000407 INV VAR INV VAR
924 924   6/1/2007 414.8 0 $5.19 On Hand FRTLAUD Receipt RN4591 SERACOLLECTIONS 4512
924 924   6/1/2007 1 0 $7.19 On Hand FRTLAUD Receipt RN4591 SERACOLLECTIONS 4512
925 925   5/22/2007 7.8 1.6 $9.59 On Hand FRTLAUD Variance 0000408 INV VAR INV VAR
926 926   5/22/2007 94 0 $43.78 On Hand FRTLAUD Variance 0000409 INV VAR INV VAR
927 927   5/22/2007 2 0 $32.37 On Hand FRTLAUD Variance 0000410 INV VAR INV VAR
928 928   5/22/2007 48 0 $9.83 On Hand FRTLAUD Variance 0000411 INV VAR INV VAR
929 929   5/22/2007 43 0.9 $4.77 On Hand FRTLAUD Variance 0000412 INV VAR INV VAR
930 930   5/22/2007 810.6 0 $1.60 On Hand FRTLAUD Variance 0000414 INV VAR INV VAR
932 932   5/22/2007 66.4 0 $0.00 On Hand FRTLAUD Variance 0000415 INV VAR INV VAR
934 934   5/22/2007 113.2 0 $2.83 On Hand FRTLAUD Variance 0000416 INV VAR INV VAR
935 935   5/22/2007 13.5 5.9 $1.72 On Hand FRTLAUD Variance 0000417 INV VAR INV VAR
936 936   5/22/2007 161.9 73.4 $2.88 On Hand FRTLAUD Variance 0000418 INV VAR INV VAR
936 936   7/20/2007 1,287.80 0 $5.24 On Hand FRTLAUD Receipt RN4752 SERACOLLECTIONS 4584
936 936   7/20/2007 1 0 $1.93 On Hand FRTLAUD Receipt RN4752 SERACOLLECTIONS 4584
937 937   5/22/2007 57.4 0 $0.65 On Hand FRTLAUD Variance 0000419 INV VAR INV VAR
938 938   5/22/2007 2 0 $67.29 On Hand FRTLAUD Variance 0000420 INV VAR INV VAR
939 939   5/22/2007 21.2 0 $3.01 On Hand FRTLAUD Variance 0000421 INV VAR INV VAR
940 940   5/22/2007 760.9 0 $5.56 On Hand FRTLAUD Variance 0000422 INV VAR INV VAR
941 941   5/22/2007 0.8 0.8 $0.00 On Hand FRTLAUD Variance 0000423 INV VAR INV VAR
941 941   8/6/2007 0 5.2 $0.00 On Hand FRTLAUD Override 005697 Sales Entry Sales Entry
943 943   5/22/2007 34.9 0 $1.03 On Hand FRTLAUD Variance 0000424 INV VAR INV VAR
946 946   5/22/2007 1,315.90 0 $9.73 On Hand FRTLAUD Variance 0000425 INV VAR INV VAR
947 947   5/22/2007 160.2 0 $3.48 On Hand FRTLAUD Variance 0000426 INV VAR INV VAR
948 948   5/22/2007 88.2 0 $3.44 On Hand FRTLAUD Variance 0000427 INV VAR INV VAR
949 949   5/22/2007 124.3 0 $3.70 On Hand FRTLAUD Variance 0000428 INV VAR INV VAR
950 950   5/22/2007 751.1 0 $3.77 On Hand FRTLAUD Variance 0000429 INV VAR INV VAR
951 951   5/22/2007 326 67.3 $7.84 On Hand FRTLAUD Variance 0000430 INV VAR INV VAR
952 952   5/22/2007 2,211.90 0 $0.25 On Hand FRTLAUD Variance 0000431 INV VAR INV VAR
956 956   5/22/2007 509.4 0 $5.72 On Hand FRTLAUD Variance 0000432 INV VAR INV VAR
960 960   5/22/2007 725.6 521.9 $2.39 On Hand FRTLAUD Variance 0000433 INV VAR INV VAR
961 961   5/22/2007 822.2 0 $11.97 On Hand FRTLAUD Variance 0000434 INV VAR INV VAR
962 962   5/22/2007 118.8 0 $4.30 On Hand FRTLAUD Variance 0000435 INV VAR INV VAR
965 965   5/22/2007 64 0 $12.76 On Hand FRTLAUD Variance 0000436 INV VAR INV VAR
966 966   5/22/2007 936.6 1 $0.29 On Hand FRTLAUD Variance 0000437 INV VAR INV VAR
967 967   5/22/2007 3,809.20 32.3 $0.33 On Hand FRTLAUD Variance 0000438 INV VAR INV VAR
968 968   5/22/2007 4,293.30 19 $0.21 On Hand FRTLAUD Variance 0000439 INV VAR INV VAR
970 970   5/22/2007 14.6 0 $14.96 On Hand FRTLAUD Variance 0000440 INV VAR INV VAR
971 971   5/22/2007 1,320.00 0 $0.25 On Hand FRTLAUD Variance 0000441 INV VAR INV VAR
973 973   5/22/2007 2,831.20 0 $0.64 On Hand FRTLAUD Variance 0000442 INV VAR INV VAR
974 974   5/22/2007 63 0 $0.00 On Hand FRTLAUD Variance 0000443 INV VAR INV VAR
977 977   5/22/2007 8.4 0 $2.74 On Hand FRTLAUD Variance 0000444 INV VAR INV VAR
978 978   5/22/2007 1,253.90 0 $7.10 On Hand FRTLAUD Variance 0000445 INV VAR INV VAR
984 984   5/22/2007 59 0 $0.00 On Hand FRTLAUD Variance 0000446 INV VAR INV VAR
987 987   5/22/2007 30.2 1.8 $13.93 On Hand FRTLAUD Variance 0000447 INV VAR INV VAR
988 988   5/22/2007 7.1 0 $21.28 On Hand FRTLAUD Variance 0000448 INV VAR INV VAR
989 989   5/22/2007 58.8 0 $15.98 On Hand FRTLAUD Variance 0000449 INV VAR INV VAR
990 990   5/22/2007 572.8 2 $1.59 On Hand FRTLAUD Variance 0000450 INV VAR INV VAR
992 992   5/22/2007 5.5 0 $4.15 On Hand FRTLAUD Variance 0000451 INV VAR INV VAR
993 993   5/22/2007 2.5 0 $5.87 On Hand FRTLAUD Variance 0000452 INV VAR INV VAR
994 994   5/22/2007 253.9 0 $9.62 On Hand FRTLAUD Variance 0000453 INV VAR INV VAR
995 995   5/22/2007 7,573.40 0 $0.55 On Hand FRTLAUD Variance 0000454 INV VAR INV VAR
997 997   5/22/2007 11 0 $14.71 On Hand FRTLAUD Variance 0000455 INV VAR INV VAR
998 998   5/22/2007 13,765.50 342.8 $1.13 On Hand FRTLAUD Variance 0000456 INV VAR INV VAR
1000 1000   5/22/2007 10 0 $5.69 On Hand FRTLAUD Variance 0000003 INV VAR INV VAR
1001 1001   5/22/2007 770 0 $31.32 On Hand FRTLAUD Variance 0000004 INV VAR INV VAR
1002 1002   5/22/2007 20.7 0 $2.77 On Hand FRTLAUD Variance 0000005 INV VAR INV VAR
1003 1003   5/22/2007 2,688.80 0 $0.78 On Hand FRTLAUD Variance 0000006 INV VAR INV VAR
1004 1004   5/22/2007 3,897.30 0 $0.94 On Hand FRTLAUD Variance 0000007 INV VAR INV VAR
1005 1005   5/22/2007 2.6 0 $6.53 On Hand FRTLAUD Variance 0000008 INV VAR INV VAR
1010 1010   5/22/2007 267.9 0 $3.58 On Hand FRTLAUD Variance 0000010 INV VAR INV VAR
1011 1011   5/22/2007 449 0 $4.27 On Hand FRTLAUD Variance 0000011 INV VAR INV VAR
1012 1012   5/22/2007 586.5 25 $1.90 On Hand FRTLAUD Variance 0000012 INV VAR INV VAR
1012 1012   6/4/2007 635.6 0 $8.84 On Hand FRTLAUD Receipt 4599 SERACOLLECTIONS 4515
1012 1012   6/4/2007 1 0 $6.30 On Hand FRTLAUD Receipt 4599 SERACOLLECTIONS 4515
1013 1013   5/22/2007 13.2 0 $0.95 On Hand FRTLAUD Variance 0000013 INV VAR INV VAR
1014 1014   5/22/2007 136.1 4.1 $4.28 On Hand FRTLAUD Variance 0000014 INV VAR INV VAR
1015 1015   5/22/2007 1,901.20 0 $2.29 On Hand FRTLAUD Variance 0000015 INV VAR INV VAR
1016 1016   5/22/2007 2,402.20 0 $2.35 On Hand FRTLAUD Variance 0000016 INV VAR INV VAR
1023 1023   5/22/2007 10.5 0 $2.38 On Hand FRTLAUD Variance 0000017 INV VAR INV VAR
1024 1024   5/22/2007 7,929.30 6 $0.15 On Hand FRTLAUD Variance 0000018 INV VAR INV VAR
1028 1028   5/22/2007 191.5 0 $3.49 On Hand FRTLAUD Variance 0000019 INV VAR INV VAR
1029 1029   5/22/2007 2.9 0 $5.01 On Hand FRTLAUD Variance 0000020 INV VAR INV VAR
1030 1030   5/22/2007 4 0 $5.01 On Hand FRTLAUD Variance 0000021 INV VAR INV VAR
1031 1031   5/22/2007 5.3 0 $3.78 On Hand FRTLAUD Variance 0000022 INV VAR INV VAR
1032 1032   5/22/2007 8.2 0 $4.89 On Hand FRTLAUD Variance 0000023 INV VAR INV VAR
1033 1033   5/22/2007 145.6 0 $2.72 On Hand FRTLAUD Variance 0000024 INV VAR INV VAR
1034 1034   5/22/2007 5.5 0 $7.29 On Hand FRTLAUD Variance 0000025 INV VAR INV VAR
1035 1035   5/22/2007 6.4 0 $2.71 On Hand FRTLAUD Variance 0000026 INV VAR INV VAR
1037 1037   5/22/2007 4.7 0 $4.26 On Hand FRTLAUD Variance 0000027 INV VAR INV VAR
1038 1038   5/22/2007 15.1 0 $3.62 On Hand FRTLAUD Variance 0000028 INV VAR INV VAR
1039 1039   5/22/2007 7 0 $2.14 On Hand FRTLAUD Variance 0000029 INV VAR INV VAR
1040 1040   5/22/2007 5.1 0 $3.28 On Hand FRTLAUD Variance 0000030 INV VAR INV VAR
1041 1041   5/22/2007 3.9 0 $5.14 On Hand FRTLAUD Variance 0000031 INV VAR INV VAR
1043 1043   5/22/2007 1,637.20 0 $3.62 On Hand FRTLAUD Variance 0000032 INV VAR INV VAR
1046 1046   5/22/2007 53.1 1.1 $1.57 On Hand FRTLAUD Variance 0000033 INV VAR INV VAR
1047 1047   5/22/2007 321 0 $2.89 On Hand FRTLAUD Variance 0000034 INV VAR INV VAR
1048 1048   5/22/2007 307.7 0 $2.96 On Hand FRTLAUD Variance 0000035 INV VAR INV VAR
1049 1049   5/22/2007 273.5 0 $2.71 On Hand FRTLAUD Variance 0000036 INV VAR INV VAR
1052 1052   5/22/2007 24 0 $0.00 On Hand FRTLAUD Variance 0000037 INV VAR INV VAR
1054 1054   5/22/2007 10 0 $1.25 On Hand FRTLAUD Variance 0000038 INV VAR INV VAR
1055 1055   5/22/2007 1,757.00 0 $0.99 On Hand FRTLAUD Variance 0000039 INV VAR INV VAR
1056 1056   5/22/2007 1,056.90 0 $0.31 On Hand FRTLAUD Variance 0000040 INV VAR INV VAR
1057 1057   5/22/2007 9.3 0 $0.00 On Hand FRTLAUD Variance 0000041 INV VAR INV VAR
1059 1059   5/22/2007 176.3 0 $3.68 On Hand FRTLAUD Variance 0000042 INV VAR INV VAR
1060 1060   5/22/2007 5,858.60 232.1 $1.33 On Hand FRTLAUD Variance 0000043 INV VAR INV VAR
1062 1062   5/22/2007 45 15 $0.00 On Hand FRTLAUD Variance 0000044 INV VAR INV VAR
1063 1063   5/22/2007 951.4 5 $6.80 On Hand FRTLAUD Variance 0000045 INV VAR INV VAR
1074 1074   5/22/2007 284.6 0 $1.84 On Hand FRTLAUD Variance 0000046 INV VAR INV VAR
1075 1075   5/22/2007 77.1 0 $2.39 On Hand FRTLAUD Variance 0000047 INV VAR INV VAR
1076 1076   5/22/2007 52.2 0 $3.56 On Hand FRTLAUD Variance 0000048 INV VAR INV VAR
1077 1077   5/22/2007 238 0 $4.07 On Hand FRTLAUD Variance 0000049 INV VAR INV VAR
1080 1080   5/22/2007 701.3 482.5 $1.79 On Hand FRTLAUD Variance 0000050 INV VAR INV VAR
1081 1081   5/22/2007 52.2 0 $6.96 On Hand FRTLAUD Variance 0000051 INV VAR INV VAR
1082 1082   5/22/2007 318.7 0 $4.36 On Hand FRTLAUD Variance 0000052 INV VAR INV VAR
1083 1083   5/22/2007 1.2 0 $0.00 On Hand FRTLAUD Variance 0000053 INV VAR INV VAR
1084 1084   5/22/2007 626.9 0 $4.30 On Hand FRTLAUD Variance 0000054 INV VAR INV VAR
1085 1085   5/22/2007 14 0 $11.19 On Hand FRTLAUD Variance 0000055 INV VAR INV VAR
1090 1090   5/22/2007 237.9 0 $2.04 On Hand FRTLAUD Variance 0000056 INV VAR INV VAR
1091 1091   5/22/2007 2 0 $2.51 On Hand FRTLAUD Variance 0000057 INV VAR INV VAR
1091 1091   7/12/2007 131 0 $8.33 On Hand FRTLAUD Receipt RN4724 LABORATORYCORPO 4432
1091 1091   7/12/2007 1 0 $8.77 On Hand FRTLAUD Receipt RN4724 LABORATORYCORPO 4432
1091 1091   8/10/2007 15.6 0 $9.04 On Hand FRTLAUD Receipt RN4805 LABORATORYCORPO 4432-1
1091 1091   8/10/2007 1 0 $8.98 On Hand FRTLAUD Receipt RN4805 LABORATORYCORPO 4432-1
1093 1093   5/22/2007 45 0 $0.00 On Hand FRTLAUD Variance 0000058 INV VAR INV VAR
1094 1094   5/22/2007 85.3 0 $13.21 On Hand FRTLAUD Variance 0000059 INV VAR INV VAR
1097 1097   5/22/2007 780 0 $0.00 On Hand FRTLAUD Variance 0000060 INV VAR INV VAR
1098 1098   5/22/2007 337.8 119 $3.76 On Hand FRTLAUD Variance 0000061 INV VAR INV VAR
1100 1100   5/22/2007 1.6 0 $44.73 On Hand FRTLAUD Variance 0000063 INV VAR INV VAR
1104 1104   5/22/2007 4.4 0 $2.99 On Hand FRTLAUD Variance 0000064 INV VAR INV VAR
1105 1105   5/22/2007 2,605.60 73.1 $4.02 On Hand FRTLAUD Variance 0000065 INV VAR INV VAR
1106 1106   5/22/2007 3,732.00 88.1 $3.75 On Hand FRTLAUD Variance 0000066 INV VAR INV VAR
1107 1107   5/22/2007 268.3 0 $0.70 On Hand FRTLAUD Variance 0000067 INV VAR INV VAR
1108 1108   6/18/2007 1,106.80 294.6 $1.17 On Hand FRTLAUD Receipt RN4645 BLEKINGEINSTITU 4522
1108 1108   6/18/2007 1 0 $5.04 On Hand FRTLAUD Receipt RN4645 BLEKINGEINSTITU 4522
1110 1110   5/22/2007 920 0 $0.00 On Hand FRTLAUD Variance 0000068 INV VAR INV VAR
1111 1111   5/22/2007 49.3 0 $3.31 On Hand FRTLAUD Variance 0000069 INV VAR INV VAR
1112 1112   5/22/2007 20.3 0 $1.24 On Hand FRTLAUD Variance 0000070 INV VAR INV VAR
1113 1113   5/22/2007 6 0 $2.09 On Hand FRTLAUD Variance 0000071 INV VAR INV VAR
1114 1114   5/22/2007 4.4 0 $2.84 On Hand FRTLAUD Variance 0000072 INV VAR INV VAR
1115 1115   5/22/2007 3.5 0 $3.58 On Hand FRTLAUD Variance 0000073 INV VAR INV VAR
1116 1116   5/22/2007 3 0 $4.97 On Hand FRTLAUD Variance 0000074 INV VAR INV VAR
1117 1117   5/22/2007 458.1 208 $1.93 On Hand FRTLAUD Variance 0000075 INV VAR INV VAR
1119 1119   5/22/2007 211.5 0 $0.00 On Hand FRTLAUD Variance 0000076 INV VAR INV VAR
1120 1120   5/22/2007 210 0 $0.00 On Hand FRTLAUD Variance 0000077 INV VAR INV VAR
1123 1123   5/22/2007 959.5 7.9 $1.32 On Hand FRTLAUD Variance 0000078 INV VAR INV VAR
1125 1125   5/22/2007 1,973.40 18.6 $0.23 On Hand FRTLAUD Variance 0000079 INV VAR INV VAR
1126 1126   5/22/2007 22.1 0 $2.78 On Hand FRTLAUD Variance 0000080 INV VAR INV VAR
1127 1127   5/22/2007 102.2 5 $5.81 On Hand FRTLAUD Variance 0000081 INV VAR INV VAR
1128 1128   5/22/2007 28 0 $6.88 On Hand FRTLAUD Variance 0000082 INV VAR INV VAR
1128 1128   6/6/2007 58.4 0 $6.67 On Hand FRTLAUD Receipt RN4608 VIRGINIAMEDICAL 4409
1128 1128   6/6/2007 1 0 $6.47 On Hand FRTLAUD Receipt RN4608 VIRGINIAMEDICAL 4409
1128 1128   8/3/2007 71.4 0 $6.53 On Hand FRTLAUD Receipt RN4782 VIRGINIAMEDICAL 4409-1
1128 1128   8/3/2007 1 0 $6.76 On Hand FRTLAUD Receipt RN4782 VIRGINIAMEDICAL 4409-1
1129 1129   5/22/2007 705.2 0 $3.11 On Hand FRTLAUD Variance 0000083 INV VAR INV VAR
1130 1130   5/22/2007 78.5 0 $46.72 On Hand FRTLAUD Variance 0000084 INV VAR INV VAR
1131 1131   5/22/2007 100.8 0 $4.92 On Hand FRTLAUD Variance 0000085 INV VAR INV VAR
1134 1134   5/22/2007 127.5 7.5 $0.00 On Hand FRTLAUD Variance 0000086 INV VAR INV VAR
1135 1135   5/22/2007 149.6 0 $1.68 On Hand FRTLAUD Variance 0000087 INV VAR INV VAR
1136 1136   5/22/2007 35.5 0 $3.93 On Hand FRTLAUD Variance 0000088 INV VAR INV VAR
1137 1137   5/22/2007 5.7 5.1 $2.99 On Hand FRTLAUD Variance 0000089 INV VAR INV VAR
1138 1138   5/22/2007 48.7 0 $2.64 On Hand FRTLAUD Variance 0000090 INV VAR INV VAR
1139 1139   5/22/2007 62.7 0 $2.79 On Hand FRTLAUD Variance 0000091 INV VAR INV VAR
1140 1140   5/22/2007 284 0 $1.33 On Hand FRTLAUD Variance 0000092 INV VAR INV VAR
1143 1143   5/22/2007 4,565.30 3,014.10 $0.74 On Hand FRTLAUD Variance 0000093 INV VAR INV VAR
1143 1143   5/31/2007 1,483.30 0 $0.97 On Hand FRTLAUD Receipt RCT0000018 LEHIGHVALLEYHOS  
1143 1143   5/31/2007 1 0 $1.20 On Hand FRTLAUD Receipt RCT0000018 LEHIGHVALLEYHOS  
1143 1143   6/1/2007 2,090.50 0 $1.10 On Hand FRTLAUD Receipt RN4509 LEHIGHVALLEYHOS 4456
1143 1143   6/1/2007 1 0 $20.45 On Hand FRTLAUD Receipt RN4509 LEHIGHVALLEYHOS 4456
1143 1143   6/1/2007 928.7 0 $1.98 On Hand FRTLAUD Receipt RN4520 LEHIGHVALLEYHOS 4456
1143 1143   6/1/2007 1 0 $1.17 On Hand FRTLAUD Receipt RN4520 LEHIGHVALLEYHOS 4456
1143 1143   7/10/2007 809.1 0 $3.16 On Hand FRTLAUD Receipt RN4712 LEHIGHVALLEYHOS 4456-1
1143 1143   7/10/2007 1 0 $3.24 On Hand FRTLAUD Receipt RN4712 LEHIGHVALLEYHOS 4456-1
1145 1145   5/22/2007 64.6 0 $2.52 On Hand FRTLAUD Variance 0000094 INV VAR INV VAR
1147 1147   5/22/2007 10 0 $45.72 On Hand FRTLAUD Variance 0000095 INV VAR INV VAR
1148 1148   5/22/2007 545.1 0 $3.61 On Hand FRTLAUD Variance 0000096 INV VAR INV VAR
1149 1149   5/22/2007 175.2 0 $3.21 On Hand FRTLAUD Variance 0000097 INV VAR INV VAR
1150 1150   5/22/2007 6.8 0 $3.68 On Hand FRTLAUD Variance 0000098 INV VAR INV VAR
1151 1151   5/22/2007 36 0 $2.09 On Hand FRTLAUD Variance 0000099 INV VAR INV VAR
1152 1152   5/22/2007 1,678.10 0 $0.11 On Hand FRTLAUD Variance 0000100 INV VAR INV VAR
1153 1153   5/22/2007 0.5 0 $0.00 On Hand FRTLAUD Variance 0000101 INV VAR INV VAR
1154 1154   5/22/2007 0.7 0 $0.00 On Hand FRTLAUD Variance 0000102 INV VAR INV VAR
1155 1155   5/22/2007 4.1 0 $0.00 On Hand FRTLAUD Variance 0000103 INV VAR INV VAR
1156 1156   5/22/2007 17.8 0 $0.00 On Hand FRTLAUD Variance 0000104 INV VAR INV VAR
1157 1157   5/22/2007 3.1 0 $0.00 On Hand FRTLAUD Variance 0000105 INV VAR INV VAR
1158 1158   5/22/2007 19.6 0 $3.19 On Hand FRTLAUD Variance 0000106 INV VAR INV VAR
1159 1159   5/22/2007 3.4 0 $3.68 On Hand FRTLAUD Variance 0000107 INV VAR INV VAR
1160 1160   5/22/2007 56.3 0 $4.22 On Hand FRTLAUD Variance 0000108 INV VAR INV VAR
1161 1161   5/22/2007 2.9 0 $4.32 On Hand FRTLAUD Variance 0000109 INV VAR INV VAR
1162 1162   5/22/2007 13 5.9 $3.42 On Hand FRTLAUD Variance 0000110 INV VAR INV VAR
1162 1162   7/13/2007 5.9 0 $0.00 On Hand FRTLAUD Receipt RN4730 KEYSTONEBIO 4579
1163 1163   5/22/2007 27.9 15.7 $21.17 On Hand FRTLAUD Variance 0000111 INV VAR INV VAR
1164 1164   5/22/2007 10 0 $2.51 On Hand FRTLAUD Variance 0000112 INV VAR INV VAR
1165 1165   5/22/2007 46.8 0 $3.21 On Hand FRTLAUD Variance 0000113 INV VAR INV VAR
1166 1166   5/22/2007 6.6 0 $1.90 On Hand FRTLAUD Variance 0000114 INV VAR INV VAR
1167 1167   5/22/2007 8.9 0 $2.82 On Hand FRTLAUD Variance 0000115 INV VAR INV VAR
1168 1168   5/22/2007 14.6 0 $3.86 On Hand FRTLAUD Variance 0000116 INV VAR INV VAR
1169 1169   5/22/2007 5.6 0 $2.24 On Hand FRTLAUD Variance 0000117 INV VAR INV VAR
1170 1170   5/22/2007 96.4 0 $0.00 On Hand FRTLAUD Variance 0000118 INV VAR INV VAR
1171 1171   5/22/2007 0.6 0 $4.17 On Hand FRTLAUD Variance 0000119 INV VAR INV VAR
1174 1174   5/22/2007 1,360.00 0 $0.00 On Hand FRTLAUD Variance 0000120 INV VAR INV VAR
1175 1175   5/22/2007 33.9 0 $2.58 On Hand FRTLAUD Variance 0000121 INV VAR INV VAR
1176 1176   5/22/2007 5 0 $2.51 On Hand FRTLAUD Variance 0000122 INV VAR INV VAR
1177 1177   5/22/2007 41 0 $4.27 On Hand FRTLAUD Variance 0000123 INV VAR INV VAR
1178 1178   5/22/2007 18.6 0 $3.03 On Hand FRTLAUD Variance 0000124 INV VAR INV VAR
1179 1179   5/22/2007 7.5 0 $3.34 On Hand FRTLAUD Variance 0000125 INV VAR INV VAR
1180 1180   5/22/2007 10.5 0 $6.16 On Hand FRTLAUD Variance 0000126 INV VAR INV VAR
1181 1181   5/22/2007 1,026.00 18 $0.00 On Hand FRTLAUD Variance 0000127 INV VAR INV VAR
1185 1185   5/22/2007 60.9 0 $1.44 On Hand FRTLAUD Variance 0000128 INV VAR INV VAR
1186 1186   5/22/2007 33.2 0 $1.14 On Hand FRTLAUD Variance 0000129 INV VAR INV VAR
1188 1188   5/22/2007 3.4 0 $3.68 On Hand FRTLAUD Variance 0000130 INV VAR INV VAR
1189 1189   5/22/2007 5.5 0 $17.90 On Hand FRTLAUD Variance 0000131 INV VAR INV VAR
1190 1190   5/22/2007 5 0 $3.29 On Hand FRTLAUD Variance 0000132 INV VAR INV VAR
1191 1191   5/22/2007 2.5 0 $5.01 On Hand FRTLAUD Variance 0000133 INV VAR INV VAR
1192 1192   5/22/2007 2.9 0 $4.32 On Hand FRTLAUD Variance 0000134 INV VAR INV VAR
1193 1193   5/22/2007 48.9 0 $4.36 On Hand FRTLAUD Variance 0000135 INV VAR INV VAR
1194 1194   5/22/2007 1.8 0 $6.96 On Hand FRTLAUD Variance 0000136 INV VAR INV VAR
1199 1199   5/22/2007 7.4 0 $4.23 On Hand FRTLAUD Variance 0000137 INV VAR INV VAR
1200 1200   5/22/2007 8.1 0 $7.73 On Hand FRTLAUD Variance 0000139 INV VAR INV VAR
1201 1201   5/22/2007 4 0 $6.26 On Hand FRTLAUD Variance 0000140 INV VAR INV VAR
1205 1205   5/22/2007 870 0 $0.00 On Hand FRTLAUD Variance 0000141 INV VAR INV VAR
1206 1206   5/22/2007 40 0 $0.00 On Hand FRTLAUD Variance 0000142 INV VAR INV VAR
1210 1210   8/15/2007 3.3 3.3 $0.00 On Hand FRTLAUD Receipt RN4814 SATURNBIOMEDICA 4608
1210 1210   8/23/2007 20 20 $0.00 On Hand FRTLAUD Receipt RN4832 SATURNBIOMEDICA 4616
1214 1214   5/22/2007 1 0 $0.00 On Hand FRTLAUD Variance 0000143 INV VAR INV VAR
1215 1215   5/22/2007 190.5 0 $4.05 On Hand FRTLAUD Variance 0000144 INV VAR INV VAR
1218 1218   8/10/2007 160 0 $6.21 On Hand FRTLAUD Receipt RN4806 LABORATORYCORPO 4395
1218 1218   8/10/2007 1 0 $6.40 On Hand FRTLAUD Receipt RN4806 LABORATORYCORPO 4395
1219 1219   5/22/2007 2.5 2.5 $5.00 On Hand FRTLAUD Variance 0000145 INV VAR INV VAR
1219 1219   9/28/2007 0 1.1 $5.00 On Hand FRTLAUD Override 005824 Sales Entry Sales Entry
1221 1221   5/22/2007 67.8 0 $4.62 On Hand FRTLAUD Variance 0000146 INV VAR INV VAR
1221 1221   8/10/2007 284.9 0 $2.62 On Hand FRTLAUD Receipt RN4804 LABORATORYCORPO 4434
1221 1221   8/10/2007 1 0 $3.56 On Hand FRTLAUD Receipt RN4804 LABORATORYCORPO 4434
1221 1221   8/23/2007 140.3 0 $2.76 On Hand FRTLAUD Receipt RN4835 LABORATORYCORPO 4434
1221 1221   8/23/2007 1 0 $2.77 On Hand FRTLAUD Receipt RN4835 LABORATORYCORPO 4434
1222 1222   5/22/2007 1,834.20 1,397.70 $1.70 On Hand FRTLAUD Variance 0000147 INV VAR INV VAR
1222 1222   6/6/2007 15.2 0 $1.54 On Hand FRTLAUD Receipt RN4543 TENNESSEEBLOODS 4455
1222 1222   6/6/2007 1 0 $1.59 On Hand FRTLAUD Receipt RN4543 TENNESSEEBLOODS 4455
1222 1222   7/9/2007 1,000.00 0 $5.00 On Hand FRTLAUD Receipt RN4710 REDCROSSNICARAG 4394
1222 1222   7/16/2007 2,210.00 0 $5.00 On Hand FRTLAUD Receipt RN4732 REDCROSSNICARAG 4394
1222 1222   7/23/2007 1,520.00 0 $5.00 On Hand FRTLAUD Receipt RN4758 REDCROSSNICARAG 4394
1223 1223   9/28/2007 0 3.5 $0.00 On Hand FRTLAUD Override 005824 Sales Entry Sales Entry
1227 1227   5/22/2007 314 0 $11.94 On Hand FRTLAUD Variance 0000148 INV VAR INV VAR
1227 1227   6/29/2007 33.2 0 $7.53 On Hand FRTLAUD Receipt RN4686 DRMARKLAMET 4483
1227 1227   7/20/2007 102 0 $6.07 On Hand FRTLAUD Receipt RN4747 DRMARKLAMET 4483-1
1227 1227   7/20/2007 1 0 $5.86 On Hand FRTLAUD Receipt RN4747 DRMARKLAMET 4483-1
1227 1227   8/3/2007 56.1 0 $6.57 On Hand FRTLAUD Receipt RN4784 DRMARKLAMET 4483-2
1227 1227   8/3/2007 1 0 $6.42 On Hand FRTLAUD Receipt RN4784 DRMARKLAMET 4483-2
1227 1227   8/20/2007 48.4 0 $5.06 On Hand FRTLAUD Receipt RN4826 DRMARKLAMET 4483-2
1227 1227   8/20/2007 1 0 $5.10 On Hand FRTLAUD Receipt RN4826 DRMARKLAMET 4483-2
1232 1232   5/22/2007 61.6 0 $4.17 On Hand FRTLAUD Variance 0000149 INV VAR INV VAR
1234 1234   5/22/2007 383.4 0 $0.86 On Hand FRTLAUD Variance 0000150 INV VAR INV VAR
1235 1235   5/22/2007 3,856.70 0 $0.64 On Hand FRTLAUD Variance 0000151 INV VAR INV VAR
1236 1236   7/6/2007 2.5 2.5 $0.00 On Hand FRTLAUD Receipt RN4706 SLRRESEARCHCORP 4567
1236 1236   9/7/2007 0 103.6 $0.00 On Hand FRTLAUD Override 005782 Sales Entry Sales Entry
1240 1240   5/30/2007 113 113 $0.79 On Hand FRTLAUD Receipt RCT0000023 BOCARATONCOMMUN  
1240 1240   5/30/2007 114 114 $0.73 On Hand FRTLAUD Receipt RCT0000023 BOCARATONCOMMUN  
1240 1240   7/9/2007 89 0 $0.51 On Hand FRTLAUD Receipt RN4709 BOCARATONCOMMUN 4570
1240 1240   7/9/2007 1 0 $0.61 On Hand FRTLAUD Receipt RN4709 BOCARATONCOMMUN 4570
1241 1241   5/22/2007 20.8 0 $7.49 On Hand FRTLAUD Variance 0000152 INV VAR INV VAR
1241 1241   6/29/2007 2.6 0 $10.42 On Hand FRTLAUD Receipt RN4692 LABORATORYCORPO 4243
1241 1241   6/29/2007 1 0 $10.41 On Hand FRTLAUD Receipt RN4692 LABORATORYCORPO 4243
1243 1243   5/22/2007 2,249.40 2,249.40 $1.25 On Hand FRTLAUD Variance 0000153 INV VAR INV VAR
1243 1243   6/27/2007 9 9 $0.00 On Hand FRTLAUD Receipt RN4682 TENNESSEEBLOODS 4555
1243 1243   7/3/2007 180 180 $0.00 On Hand FRTLAUD Receipt 4697 TENNESSEEBLOODS 4556
1243 1243   7/3/2007 1,430.00 803.7 $1.00 On Hand FRTLAUD Receipt RN4682-1 TENNESSEEBLOODS 4555-1
1243 1243   7/19/2007 200 0 $1.00 On Hand FRTLAUD Receipt RN4513 TENNESSEEBLOODS 4453
1243 1243   7/19/2007 50 0 $1.00 On Hand FRTLAUD Receipt RN4513 TENNESSEEBLOODS 4453
1245 1245   5/22/2007 619.6 0 $2.35 On Hand FRTLAUD Variance 0000154 INV VAR INV VAR
1248 1248   5/22/2007 17.2 17.2 $24.56 On Hand FRTLAUD Variance 0000155 INV VAR INV VAR
1250 1250   8/7/2007 0 40 $0.00 On Hand FRTLAUD Override 005727 Sales Entry Sales Entry
1250 1250   9/5/2007 0 70 $0.00 On Hand FRTLAUD Override 005779 Sales Entry Sales Entry
1257 1257   6/19/2007 1.2 0 $0.00 On Hand FRTLAUD Receipt RN4658 SLRRESEARCHCORP 4546
1258 1258   5/22/2007 105.3 1 $35.12 On Hand FRTLAUD Variance 0000156 INV VAR INV VAR
1259 1259   7/3/2007 3.4 3.4 $0.00 On Hand FRTLAUD Receipt RN4695 KEYSTONEBIO 4557
1259 1259   7/3/2007 1,757.00 1,757.00 $7.75 On Hand FRTLAUD Receipt RN4695 KEYSTONEBIO 4557
1259 1259   8/9/2007 2.4 2.4 $0.00 On Hand FRTLAUD Receipt RN4798 KEYSTONEBIO 4600
1260 1260   7/3/2007 8.2 8.2 $0.00 On Hand FRTLAUD Receipt 4696 KEYSTONEBIO 4558
1260 1260   7/3/2007 2,900.00 2,900.00 $10.00 On Hand FRTLAUD Receipt RN4696 KEYSTONEBIO 4558
1263 1263   5/22/2007 59.3 0 $9.51 On Hand FRTLAUD Variance 0000157 INV VAR INV VAR
1264 1264   6/5/2007 25.6 25.6 $4.70 On Hand FRTLAUD Receipt RN4605 DISCOVERYCLINIC 4417
1264 1264   6/5/2007 1 1 $4.68 On Hand FRTLAUD Receipt RN4605 DISCOVERYCLINIC 4417
1264 1264   6/19/2007 19.9 19.9 $5.98 On Hand FRTLAUD Receipt RN4652 DISCOVERYCLINIC 4417
1264 1264   6/19/2007 1 1 $6.00 On Hand FRTLAUD Receipt RN4652 DISCOVERYCLINIC 4417
1264 1264   6/29/2007 41.3 41.3 $5.91 On Hand FRTLAUD Receipt RN4688 DISCOVERYCLINIC 4417
1264 1264   6/29/2007 1 1 $5.92 On Hand FRTLAUD Receipt RN4688 DISCOVERYCLINIC 4417
1264 1264   7/23/2007 134.2 134.2 $5.55 On Hand FRTLAUD Receipt RN4759 DISCOVERYCLINIC 4417
1264 1264   7/23/2007 1 1 $5.19 On Hand FRTLAUD Receipt RN4759 DISCOVERYCLINIC 4417
1264 1264   7/23/2007 0 51.6 $5.55 On Hand FRTLAUD Override 005660 Sales Entry Sales Entry
1264 1264   7/24/2007 27.5 27.5 $8.77 On Hand FRTLAUD Receipt 4764 DISCOVERYCLINIC 4417
1264 1264   7/24/2007 1 1 $8.82 On Hand FRTLAUD Receipt 4764 DISCOVERYCLINIC 4417
1265 1265   5/22/2007 451 451 $44.92 On Hand FRTLAUD Variance 0000158 INV VAR INV VAR
1265 1265   5/31/2007 10.1 10.1 $92.99 On Hand FRTLAUD Receipt RCT0000016 CURELINEINC  
1265 1265   5/31/2007 439.8 439.8 $37.78 On Hand FRTLAUD Receipt RCT0000017 CURELINEINC  
1265 1265   5/31/2007 1 1 $38.76 On Hand FRTLAUD Receipt RCT0000017 CURELINEINC  
1265 1265   7/24/2007 572 572 $31.96 On Hand FRTLAUD Receipt RN4761 CURELINEINC 4498
1265 1265   7/24/2007 1 1 $33.28 On Hand FRTLAUD Receipt RN4761 CURELINEINC 4498
1265 1265   7/24/2007 109 109 $0.00 On Hand FRTLAUD Receipt RN4762 CURELINEINC 4498
1265 1265   8/21/2007 1,012.60 182.7 $11.49 On Hand FRTLAUD Receipt RN4828 CURELINEINC 4625
1265 1265   8/21/2007 1 0 $15.23 On Hand FRTLAUD Receipt RN4828 CURELINEINC 4625
1266 1266   5/22/2007 0.3 0.3 $0.00 On Hand FRTLAUD Variance 0000159 INV VAR INV VAR
1266 1266   6/15/2007 8.5 8.5 $0.00 On Hand FRTLAUD Receipt RN4644 BIOHEME 4534
1266 1266   7/13/2007 200 169.7 $7.00 On Hand FRTLAUD Receipt RN4644-1 BIOHEME 4534-1
1267 1267   5/22/2007 59.5 59.5 $9.01 On Hand FRTLAUD Variance 0000160 INV VAR INV VAR
1267 1267   6/25/2007 314.4 15.2 $7.13 On Hand FRTLAUD Receipt RN4673 FUNDACIONCARDIO 4427
1267 1267   6/25/2007 1 0 $8.33 On Hand FRTLAUD Receipt RN4673 FUNDACIONCARDIO 4427
1267 1267   6/26/2007 511.4 0 $6.44 On Hand FRTLAUD Receipt RN4680 FUNDACIONCARDIO 4553
1267 1267   6/26/2007 1 0 $6.58 On Hand FRTLAUD Receipt RN4680 FUNDACIONCARDIO 4553
1267 1267   7/19/2007 83.6 0 $7.09 On Hand FRTLAUD Receipt RN4741 FUNDACIONCARDIO 4553-1
1267 1267   7/19/2007 1 0 $7.28 On Hand FRTLAUD Receipt RN4741 FUNDACIONCARDIO 4553-1
1267 1267   8/30/2007 176.3 0 $6.77 On Hand FRTLAUD Receipt RN4855 FUNDACIONCARDIO 4553-2
1267 1267   8/30/2007 1 0 $6.45 On Hand FRTLAUD Receipt RN4855 FUNDACIONCARDIO 4553-2
1267 1267   8/30/2007 18.1 0 $7.85 On Hand FRTLAUD Receipt RN4858 FUNDACIONCARDIO 4427-1
1267 1267   8/30/2007 1 0 $7.91 On Hand FRTLAUD Receipt RN4858 FUNDACIONCARDIO 4427-1
1268 1268   5/22/2007 522 0 $0.00 On Hand FRTLAUD Variance 0000161 INV VAR INV VAR
1273 1273   5/22/2007 1.8 0 $0.00 On Hand FRTLAUD Variance 0000162 INV VAR INV VAR
1274 1274   6/4/2007 636.4 636.4 $3.20 On Hand FRTLAUD Receipt RN4580 CONTINENTALSERV 4503
1274 1274   6/4/2007 1 1 $3.52 On Hand FRTLAUD Receipt RN4580 CONTINENTALSERV 4503
1274 1274   6/4/2007 192 192 $3.75 On Hand FRTLAUD Receipt RN4584 CONTINENTALSERV 4503
1274 1274   6/4/2007 383.6 383.6 $3.67 On Hand FRTLAUD Receipt RN4593 CONTINENTALSERV 4503
1274 1274   6/4/2007 336 336 $2.19 On Hand FRTLAUD Receipt RN4593 CONTINENTALSERV 4503
1274 1274   6/5/2007 360 0 $3.75 On Hand FRTLAUD Receipt RN4604-1 CONTINENTALSERV 4503-1
1274 1274   6/6/2007 336 336 $3.75 On Hand FRTLAUD Receipt RN#4600 CONTINENTALSERV 4503
1274 1274   6/8/2007 359 359 $2.42 On Hand FRTLAUD Receipt RN4604 CONTINENTALSERV 4503
1274 1274   6/8/2007 1 1 $1.22 On Hand FRTLAUD Receipt RN4604 CONTINENTALSERV 4503
1274 1274   6/8/2007 256 256 $3.75 On Hand FRTLAUD Receipt RN4613 CONTINENTALSERV 4503
1274 1274   6/8/2007 344 344 $3.75 On Hand FRTLAUD Receipt RN4614 CONTINENTALSERV 4503
1274 1274   6/13/2007 344 344 $3.75 On Hand FRTLAUD Receipt RN4634 CONTINENTALSERV 4503
1274 1274   6/15/2007 328 328 $3.75 On Hand FRTLAUD Receipt RN4625 CONTINENTALSERV 4503
1274 1274   6/15/2007 496 496 $3.75 On Hand FRTLAUD Receipt RN4630 CONTINENTALSERV 4503
1275 1275   8/23/2007 5.3 0 $238.10 On Hand FRTLAUD Receipt RN4837 ACCACIASERUMPRO 4527
1275 1275   8/23/2007 1 0 $238.07 On Hand FRTLAUD Receipt RN4837 ACCACIASERUMPRO 4527
1276 1276   6/22/2007 10 10 $65.00 On Hand FRTLAUD Receipt RN4649 SLRRESEARCHCORP 4531
1277 1277   6/19/2007 1.5 1.5 $0.00 On Hand FRTLAUD Receipt RN4654 SLRRESEARCHCORP 4542
1277 1277   7/27/2007 100 98.5 $4.50 On Hand FRTLAUD Receipt RN4654-1 SLRRESEARCHCORP 4542
1278 1278   6/19/2007 1 0 $0.00 On Hand FRTLAUD Receipt RN4656 SLRRESEARCHCORP 4544
1279 1279   6/19/2007 1 1 $0.00 On Hand FRTLAUD Receipt RN4657 SLRRESEARCHCORP 4545
1279 1279   9/7/2007 0 39.8 $0.00 On Hand FRTLAUD Override 005782 Sales Entry Sales Entry
1280 1280   6/19/2007 1 0 $0.00 On Hand FRTLAUD Receipt RN4661 SLRRESEARCHCORP 4548
1281 1281   8/6/2007 0 30 $0.00 On Hand FRTLAUD Override 005697 Sales Entry Sales Entry
1282 1282   8/7/2007 18 18 $200.00 On Hand FRTLAUD Receipt RN4792 ASTARTEBIOLOGIC 4596
1282 1282   8/7/2007 6 6 $125.00 On Hand FRTLAUD Receipt RN4793 ASTARTEBIOLOGIC 4597
1282 1282   9/26/2007 0 45 $200.00 On Hand FRTLAUD Override 005822 Sales Entry Sales Entry
1283 1283   8/22/2007 5 5 $175.00 On Hand FRTLAUD Receipt RN4830 ANALYTICALBIOLO 4605
1283 1283   8/22/2007 1 1 $175.00 On Hand FRTLAUD Receipt RN4830 ANALYTICALBIOLO 4605
1284 1284   8/16/2007 4 4 $0.00 On Hand FRTLAUD Receipt RN4818 KEYSTONEBIO 4609
1285 1285   8/23/2007 0 125 $0.00 On Hand FRTLAUD Override 005751 Sales Entry Sales Entry
1285 1285   8/27/2007 0 125 $0.00 On Hand FRTLAUD Override 005759 Sales Entry Sales Entry
1287 1287   8/30/2007 273.2 0 $7.66 On Hand FRTLAUD Receipt RN4854 FUNDACIONCARDIO 4623
1287 1287   8/30/2007 1 0 $7.29 On Hand FRTLAUD Receipt RN4854 FUNDACIONCARDIO 4623
1287 1287   8/30/2007 13.8 0 $10.14 On Hand FRTLAUD Receipt RN4859 FUNDACIONCARDIO 4624
1287 1287   8/30/2007 1 0 $10.07 On Hand FRTLAUD Receipt RN4859 FUNDACIONCARDIO 4624
KD-8881676434 #VALUE!   7/9/2007 5 0 $6.50 On Hand FRTLAUD Receipt RCT0000147 LABNETSUPPLYINC PO0006245
C04365 #VALUE!   7/16/2007 1 0 $85.63 On Hand FRTLAUD Receipt RCT0000156 BROWARDPAPERPAC PO0006252
B10650 #VALUE!   7/17/2007 3 0 $113.38 On Hand FRTLAUD Receipt RCT0000158 BROWARDPAPERPAC PO0006252
F04040 #VALUE!   7/17/2007 2 0 $27.31 On Hand FRTLAUD Receipt RCT0000158 BROWARDPAPERPAC PO0006252
C04365 #VALUE!   7/19/2007 1 0 $85.63 On Hand FRTLAUD Receipt RCT0000157 BROWARDPAPERPAC PO0006252
1980-64 #VALUE!   7/23/2007 1 0 $264.00 On Hand FRTLAUD Receipt RCT0000148 ABBOTTDIAGNOSTI PO0006247
1980-64 #VALUE!   7/23/2007 1 0 $264.00 On Hand FRTLAUD Receipt RCT0000149 ABBOTTDIAGNOSTI PO0006247
02-681-141 #VALUE!   7/26/2007 2 0 $275.46 On Hand FRTLAUD Receipt RCT0000150 FISHERSCIENTIFI PO0006251
06-443-19 #VALUE!   7/26/2007 1 0 $210.31 On Hand FRTLAUD Receipt RCT0000150 FISHERSCIENTIFI PO0006251
13-688-367 #VALUE!   7/26/2007 1 0 $58.75 On Hand FRTLAUD Receipt RCT0000150 FISHERSCIENTIFI PO0006251
13-688-368 #VALUE!   7/26/2007 2 0 $33.15 On Hand FRTLAUD Receipt RCT0000150 FISHERSCIENTIFI PO0006251
06-443-19 #VALUE!   8/3/2007 1 0 $210.31 On Hand FRTLAUD Receipt RCT0000195 FISHERSCIENTIFI PO0006257
1980-64 #VALUE!   8/8/2007 2 0 $264.00 On Hand FRTLAUD Receipt RCT0000196 ABBOTTDIAGNOSTI PO0006254
1980-64 #VALUE!   8/31/2007 4 0 $264.00 On Hand FRTLAUD Receipt RCT0000224 ABBOTTDIAGNOSTI PO0006254

 

 
 

 

Item no. Item no. 2 Type Date   Num Name Memo Qty Sales Price Amount
859 859 Credit Memo 07/20/2006   4639 Roche Diagnostics GmbH HBV Match Set (1,306.20) 0.00 0.00
184 184 Invoice 07/03/2006   4588 Adaltis Developement, Inc. Anti-CMV IgM 20.00 25.00 500.00
252 252 Invoice 07/03/2006   4588 Adaltis Developement, Inc. Anti-HSV 1 IgM 20.00 25.00 500.00
253 253 Invoice 07/03/2006   4588 Adaltis Developement, Inc. Anti-HSV 2 IgM 19.60 38.26531 750.00
1125 1125 Invoice 07/03/2006   4588 Adaltis Developement, Inc. TORCH IgM 6.00 50.00 300.00
6 6 Invoice 07/05/2006   4587 Abbott Laboratories Anti-HIV 2 51.10 65.00 3,321.50
8 8 Invoice 07/05/2006   4587 Abbott Laboratories Human Serum 45.00 45.00 2,025.00
172 172 Invoice 07/05/2006   4590 Teragenix Internal Human Plasma (Lithium Heparin) 907.20 0.00 0.00
546 546 Invoice 07/05/2006   4587 Abbott Laboratories Human Plasma 5.00 45.00 225.00
199 199 Invoice 07/06/2006   4593 Teragenix Internal Anti-HCV 0.40 0.00 0.00
802 802 Invoice 07/06/2006   4592 Beckman Coulter-CA Match Patient Set 364.80 1.71327 625.00
199 199 Invoice 07/10/2006   4596 LabCorp Anti-HCV 20.00 50.00 1,000.00
549 549 Invoice 07/10/2006   4595 Bio-Rad France Marnes Myoglobin 304.00 9.62171 2,925.00
550 550 Invoice 07/10/2006   4595 Bio-Rad France Marnes Troponin I 301.10 9.71438 2,925.00
679 679 Invoice 07/10/2006   4597 Biokit, SA HBV - Nicaragua 66.00 0.00 0.00
841 841 Invoice 07/10/2006   4595 Bio-Rad France Marnes CK-MB 302.10 9.68222 2,925.00
174 174 Invoice 07/11/2006   4594 Orgenics Ltd. Human Plasma (Sodium Citrate) 6.00 0.00 0.00
621 621 Invoice 07/11/2006   4594 Orgenics Ltd. RPR 3.10 0.00 0.00
1061 1061 Invoice 07/11/2006   4598 Bio-Rad France Marnes HBV Genotype Panel (HBVGTP-004a) 30.00 210.00 6,300.00
172 172 Invoice 07/12/2006   4600 Siemens Diagnostics-NY (formerly Bayer) Human Plasma (Lithium Heparin) 420.00 16.25 6,825.00
199 199 Invoice 07/12/2006   4599 VA Medical Center Anti-HCV 1.00 150.00 150.00
446 446 Invoice 07/12/2006   4608 Teragenix Internal Anti-HIV 1 10.00 0.00 0.00
8 8 Invoice 07/13/2006   4607 Teragenix Internal Human Serum 0.30 0.00 0.00
172 172 Invoice 07/13/2006   4602 Siemens Diagnostics-NY (formerly Bayer) Human Plasma (Lithium Heparin) 80.00 16.25 1,300.00
298 298 Invoice 07/13/2006   4601 Trinity Biotech-USA H. Pylori (IgG) 871.30 3.25 2,831.73
543 543 Invoice 07/13/2006   4606 Bioreclamation Rheumatoid Factor 2.60 0.00 0.00
724 724 Invoice 07/13/2006   4606 Bioreclamation Syphilis 8.00 0.00 0.00
910 910 Invoice 07/13/2006   4601 Trinity Biotech-USA Mycoplasma IgG 824.00 3.45 2,842.80
29 29 Invoice 07/14/2006   4605 International Bioscience, Inc Anti-HIV 1/2 2.00 0.00 0.00
197 197 Invoice 07/14/2006   4605 International Bioscience, Inc HIVAg 4.00 0.00 0.00
446 446 Invoice 07/14/2006   4605 International Bioscience, Inc Anti-HIV 1 14.00 0.00 0.00
543 543 Invoice 07/14/2006   4604 Orgenics Ltd. Rheumatoid Factor 690.00 2.25 1,552.50
643 643 Invoice 07/14/2006   4605 International Bioscience, Inc HIV-Venezuela 19.50 0.00 0.00
683 683 Invoice 07/14/2006   4605 International Bioscience, Inc HCV-Venezuela 2.00 0.00 0.00
828 828 Invoice 07/14/2006   4605 International Bioscience, Inc HIV NAT+/Ab- 6.00 0.00 0.00
995 995 Invoice 07/14/2006   4605 International Bioscience, Inc HIV and HCV Co-infection 5.80 0.00 0.00
1123 1123 Invoice 07/14/2006   4603 Vital Products HEV 46.40 12.93103 600.00
8 8 Invoice 07/17/2006   4611 Teragenix Internal Human Serum 700.10 0.00 0.00
558 558 Invoice 07/17/2006   4610 Center for Disease Control Chagas 8.00 0.00 0.00
788 788 Invoice 07/17/2006   4609 Siemens Diagnostics-NY (formerly Bayer) HIV-Africa 284.70 0.00 0.00
855 855 Invoice 07/17/2006   4609 Siemens Diagnostics-NY (formerly Bayer) HIV-Cote D'Ivoire 98.60 0.00 0.00
8 8 Invoice 07/18/2006   4618 Teragenix Internal Human Serum 754.40 0.00 0.00
245 245 Invoice 07/18/2006   4614 Pronostics Limited-(formerly Smartbead) Thyroid Peroxidase Antibody (TPO) 160.00 9.00 1,440.00
565 565 Invoice 07/18/2006   4613 Panacea Pharmaceuticals Breast Cancer 35.50 10.56338 375.00
615 615 Invoice 07/18/2006   4613 Panacea Pharmaceuticals Ovarian Cancer 30.00 12.50 375.00
723 723 Invoice 07/18/2006   4613 Panacea Pharmaceuticals Prostate Cancer 33.90 12.53687 425.00
30 30 Invoice 07/19/2006   4616 IBL GmbH dsDNA Antibody 1.60 0.00 0.00
199 199 Invoice 07/19/2006   4612 Center for Disease Control Anti-HCV 40.40 48.26733 1,950.00
199 199 Invoice 07/19/2006   4615 Merck & Co., Inc. Anti-HCV 1.00 500.00 500.00
756 756 Invoice 07/19/2006   4615 Merck & Co., Inc. HCV - Egypt 2.00 500.00 1,000.00
1214 1214 Invoice 07/19/2006   4616 IBL GmbH EBV IgM 6.90 0.00 0.00
174 174 Invoice 07/20/2006   4630 Teragenix Internal Human Plasma (Sodium Citrate) 10.80 0.00 0.00
546 546 Invoice 07/20/2006   4630 Teragenix Internal Human Plasma 9.90 0.00 0.00
2 2 Invoice 07/21/2006   4626 Vital Products TSH 2.00 7.50 15.00
8 8 Invoice 07/21/2006   4623 Dx Laboratories Human Serum 2.10 11.90476 25.00
38 38 Invoice 07/21/2006   4626 Vital Products Thyroglobulin Antibody (TgAb) 21.90 7.53425 165.00
40 40 Invoice 07/21/2006   4626 Vital Products Anti-EBV VCA IgG 1.40 10.71429 15.00
63 63 Invoice 07/21/2006   4623 Dx Laboratories Anti-HBs 6.20 12.09677 75.00
174 174 Invoice 07/21/2006   4626 Vital Products Human Plasma (Sodium Citrate) 69.20 8.88728 615.00
199 199 Invoice 07/21/2006   4623 Dx Laboratories Anti-HCV 8.00 12.50 100.00
199 199 Invoice 07/21/2006   4627 Teragenix Internal Anti-HCV 1.50 0.00 0.00
226 226 Invoice 07/21/2006   4626 Vital Products Anti-HSV 1 IgG 1.20 12.50 15.00
310 310 Invoice 07/21/2006   4626 Vital Products Anti-Mumps IgG 2.00 7.50 15.00
446 446 Invoice 07/21/2006   4625 International Bioscience, Inc Anti-HIV 1 18.00 0.00 0.00
546 546 Invoice 07/21/2006   4626 Vital Products Human Plasma 44.00 7.84091 345.00
555 555 Invoice 07/21/2006   4623 Dx Laboratories HBsAg 16.00 12.50 200.00
558 558 Invoice 07/21/2006   4626 Vital Products Chagas 1.10 13.63636 15.00
802 802 Invoice 07/21/2006   4624 International Bioscience, Inc Match Patient Set 1,143.80 5.11453 5,850.00
1148 1148 Invoice 07/21/2006   4626 Vital Products D-Dimer 37.60 11.96809 450.00
1217 1217 Invoice 07/21/2006   4628 OCD - Europe Beta-HCG (pooled) 157.50 7.50 1,181.25
10 10 Invoice 07/24/2006   4634 Adaltis Developement, Inc. Anti-HTLV I/II 20.60 43.68932 900.00
26 26 Invoice 07/24/2006   4633 Abbott Laboratories Hashimoto's Thyroiditis 4.40 45.00 198.00
174 174 Invoice 07/24/2006   4635 Bio-Rad-Irvine,CA Human Plasma (Sodium Citrate) 11.40 0.00 0.00
199 199 Invoice 07/24/2006   4629 Celera Diagnostics Anti-HCV 12.30 100.00 1,230.00
383 383 Invoice 07/24/2006   4631 Bioreclamation Cerebro Spinal Fluid 474.20 9.00 4,267.80
546 546 Invoice 07/24/2006   4635 Bio-Rad-Irvine,CA Human Plasma 5.70 0.00 0.00
589 589 Invoice 07/24/2006   4629 Celera Diagnostics HCV-Genotype 5a 2.00 100.00 200.00
623 623 Invoice 07/24/2006   4632 Siemens Diagnostics-NY (formerly Bayer) HIV-2 120.20 50.00 6,010.00
633 633 Invoice 07/24/2006   4629 Celera Diagnostics HCV-Genotype 4 1.00 100.00 100.00
640 640 Invoice 07/24/2006   4636 Innovacon, Inc Mononucleosis 3.00 0.00 0.00
683 683 Invoice 07/24/2006   4629 Celera Diagnostics HCV-Venezuela 1.20 100.00 120.00
939 939 Invoice 07/24/2006   4633 Abbott Laboratories Grave's Disease 6.20 45.00 279.00
998 998 Invoice 07/24/2006   4629 Celera Diagnostics HCV-Thailand 1.00 100.00 100.00
1143 1143 Invoice 07/26/2006   4638 Lake Arrowhead Lab Consultants Sepsis 1,009.70 0.99039 1,000.00
8 8 Invoice 07/27/2006   4647 Biotrin Technologies Ltd Human Serum 355.70 5.21507 1,855.00
176 176 Invoice 07/27/2006   4644 Euroimmun AG Anti-Rubella IgM 0.60 0.00 0.00
621 621 Invoice 07/27/2006   4644 Euroimmun AG RPR 364.20 6.50 2,367.30
679 679 Invoice 07/28/2006   4637 Abbott GmbH HBV - Nicaragua 43.10 0.00 0.00
724 724 Invoice 07/28/2006   4646 Abbott GmbH Syphilis 125.40 0.00 0.00
724 724 Invoice 07/28/2006   4648 Omega Diagnostics Syphilis 5.90 0.00 0.00
448 448 Invoice 07/31/2006   4650 Abbott Laboratories Acute HAV 61.70 269.7731 16,645.00
558 558 Invoice 07/31/2006   4643 Center for Disease Control Chagas 343.00 4.95627 1,700.00
565 565 Invoice 07/31/2006   4642 IBT Immunological & Biochemical Breast Cancer 1.00 15.00 15.00
723 723 Invoice 07/31/2006   4642 IBT Immunological & Biochemical Prostate Cancer 1.00 15.00 15.00
816 816 Invoice 07/31/2006   4651 Teragenix Internal HIV Mutation 3.40 0.00 0.00
900 900 Invoice 07/31/2006   4642 IBT Immunological & Biochemical Acute Lymphocytic Leukemia 1.00 15.00 15.00
906 906 Invoice 07/31/2006   4642 IBT Immunological & Biochemical Testicular CA 1.10 13.63636 15.00
916 916 Invoice 07/31/2006   4642 IBT Immunological & Biochemical Acute Myelocytic Leukemia 1.00 15.00 15.00
920 920 Invoice 07/31/2006   4642 IBT Immunological & Biochemical Melanoma 1.00 15.00 15.00
1035 1035 Invoice 07/31/2006   4642 IBT Immunological & Biochemical Bronchial CA 1.00 15.00 15.00
1097 1097 Invoice 07/31/2006   4649 Covance CLS HCV Genotype Panel (HCVGTP-002c) 15.00 63.33333 950.00
1105 1105 Invoice 07/31/2006   4642 IBT Immunological & Biochemical Colon CA 1.00 15.00 15.00
1136 1136 Invoice 07/31/2006   4642 IBT Immunological & Biochemical Uterine Cancer 1.10 13.63636 15.00
1180 1180 Invoice 07/31/2006   4642 IBT Immunological & Biochemical Islets of Langerhans CA 1.00 15.00 15.00
PM-02/SPF-OCD #VALUE! Invoice 07/31/2006   4641 Ortho-Clinical Diagnostics Sample Procurement Fee 2.00 1,500.00 3,000.00
RMS - HIV Positive #VALUE! Invoice 07/31/2006   4402 Roche Diagnostics Corporation-IN HIV Positive Sample Collection 1.00 48,374.75 48,374.75
448 448 Invoice 08/02/2006   4705 Abbott Laboratories Acute HAV 5.50 286.36364 1,575.00
831 831 Invoice 08/02/2006   4652 Abbott Laboratories Monoclonal Gammopathy 5.00 55.00 275.00
832 832 Invoice 08/02/2006   4652 Abbott Laboratories Multiple Myeloma 11.00 55.00 605.00
899 899 Invoice 08/02/2006   4652 Abbott Laboratories Chronic Lymphocytic Leukemia 5.40 55.00 297.00
1015 1015 Invoice 08/02/2006   4652 Abbott Laboratories Non-Hodskins Lymphoma 35.80 55.00 1,969.00
1143 1143 Invoice 08/02/2006   4653 Beckman Coulter-MN Sepsis 20.70 74.87923 1,550.00
1186 1186 Invoice 08/02/2006   4652 Abbott Laboratories Paraprotein 11.60 55.00 638.00
621 621 Invoice 08/03/2006   4655 Plasma Services Group, Inc RPR 151.60 1.50 227.40
1096 1096 Invoice 08/03/2006   4654 Bioreclamation Psoriasis 217.00 26.50 5,750.50
1220 1220 Invoice 08/03/2006   4656 National Forensic Science Technology Ctr Semen 10.00 75.00 750.00
176 176 Invoice 08/04/2006   4658 Labquality OY Anti-Rubella IgM 250.00 9.75 2,437.50
199 199 Invoice 08/04/2006   4658 Labquality OY Anti-HCV 1,680.00 4.00 6,720.00
252 252 Invoice 08/04/2006   4658 Labquality OY Anti-HSV 1 IgM 101.80 7.75 788.95
418 418 Invoice 08/04/2006   4658 Labquality OY Anti - VZV IgM 203.50 7.75002 1,577.13
546 546 Invoice 08/04/2006   4658 Labquality OY Human Plasma 2,535.60 0.38669 980.49
555 555 Invoice 08/04/2006   4658 Labquality OY HBsAg 1,679.70 4.00 6,718.80
703 703 Invoice 08/04/2006   4658 Labquality OY Anti-EBV IgM 1,520.80 5.50 8,364.40
1206 1206 Invoice 08/04/2006   4659 International Bioscience, Inc HIV-2 Monospecific Panel (Lot#60021) 10.00 243.75 2,437.50
29 29 Invoice 08/07/2006   4662 United Biotech, Inc. Anti-HIV 1/2 6.00 0.00 0.00
199 199 Invoice 08/07/2006   4662 United Biotech, Inc. Anti-HCV 4.40 0.00 0.00
446 446 Invoice 08/07/2006   4660 Roche Molecular Systems-NJ Anti-HIV 1 4.10 30.00 123.00
543 543 Invoice 08/07/2006   4663 Abbott GmbH Rheumatoid Factor 13.20 0.00 0.00
555 555 Invoice 08/07/2006   4662 United Biotech, Inc. HBsAg 6.50 0.00 0.00
558 558 Invoice 08/07/2006   4662 United Biotech, Inc. Chagas 15.50 0.00 0.00
572 572 Invoice 08/07/2006   4663 Abbott GmbH HIV-1 Seroconversion Panel 8.00 0.00 0.00
802 802 Invoice 08/07/2006   4661 Beckman Coulter-CA Match Patient Set 346.50 1.80375 625.00
174 174 Invoice 08/08/2006   4666 Teragenix Internal Human Plasma (Sodium Citrate) 182.40 0.00 0.00
227 227 Invoice 08/08/2006   4665 Adaltis Developement, Inc. Anti-HSV 2 IgG 17.50 20.00 350.00
546 546 Invoice 08/08/2006   4666 Teragenix Internal Human Plasma 165.00 0.00 0.00
663 663 Invoice 08/09/2006   4667 Univ of Washington School of Medicine HBV-Venezuela 1.00 244.80 244.80
930 930 Invoice 08/09/2006   4667 Univ of Washington School of Medicine HBV (Genotype G) 1.30 188.30769 244.80
1056 1056 Invoice 08/09/2006   4667 Univ of Washington School of Medicine HBV (Genotype H) 1.10 222.54545 244.80
199 199 Invoice 08/10/2006   4670 John's Hopkins Hospital Anti-HCV 18.00 50.00 900.00
990 990 Invoice 08/10/2006   4668 Zeus Scientific Lyme (European) 2.00 0.00 0.00
1052 1052 Invoice 08/10/2006   4669 Quintiles Laboratories Ltd. HCV Genotype Panel (HCVGTP-004b) 6.00 200.00 1,200.00
1061 1061 Invoice 08/10/2006   4669 Quintiles Laboratories Ltd. HBV Genotype Panel (HBVGTP-004a) 30.00 173.33333 5,200.00
1062 1062 Invoice 08/10/2006   4669 Quintiles Laboratories Ltd. HCV Genotype Panel (HCVGTP-005a) 30.00 98.33333 2,950.00
1093 1093 Invoice 08/10/2006   4669 Quintiles Laboratories Ltd. HCV Genotype Panel (HCVGTP-004c) 15.00 133.33333 2,000.00
8 8 Invoice 08/11/2006   4674 Biotrin Technologies Ltd Human Serum 72.00 5.00 360.00
174 174 Invoice 08/11/2006   4671 Orgenics Ltd. Human Plasma (Sodium Citrate) 659.70 2.00 1,319.40
178 178 Invoice 08/11/2006   4672 Trina Bioreactives AG H. Pylori 545.50 2.75 1,500.13
448 448 Invoice 08/11/2006   4664 Abbott Laboratories Acute HAV 53.50 286.82243 15,345.00
555 555 Invoice 08/11/2006   4673 OctaPharma AB HBsAg 15.80 47.46835 750.00
874 874 Invoice 08/11/2006   4675 Trinity Biotech Plc-Ireland Coumadin 10.00 0.00 0.00
49 49 Invoice 08/14/2006   4677 The Binding Site-UK Jo-1 Antibody 1.60 0.00 0.00
1173 1173 Invoice 08/14/2006   4677 The Binding Site-UK TTG Tissue-Transglutamina 1.60 0.00 0.00
1219 1219 Invoice 08/14/2006   4677 The Binding Site-UK Anti-Cardiolipin 8.00 0.00 0.00
31 31 Invoice 08/15/2006   4683 Zeus Scientific SSA Antibody 2.10 0.00 0.00
724 724 Invoice 08/15/2006   4678 Covance CLS Syphilis 41.40 18.11594 750.00
788 788 Invoice 08/15/2006   4680 Teragenix Internal HIV-Africa 14.60 0.00 0.00
1050 1050 Invoice 08/15/2006   4679 Third Wave Technologies HCV Genotype Panel (HCVGTP-003a) 10.00 0.00 0.00
558 558 Invoice 08/16/2006   4682 Plasma Services Group, Inc Chagas 21.50 0.00 0.00
1222 1222 Invoice 08/16/2006   4685 Abbott Laboratories Random Donors 1,644.00 16.25 26,715.00
543 543 Invoice 08/17/2006   4686 Bioreclamation Rheumatoid Factor 200.00 3.75 750.00
724 724 Invoice 08/17/2006   4686 Bioreclamation Syphilis 230.00 3.75 862.50
802 802 Invoice 08/17/2006   4688 Beckman Coulter-CA Match Patient Set 448.90 1.39229 625.00
1052 1052 Invoice 08/17/2006   4687 Celera Diagnostics HCV Genotype Panel (HCVGTP-004b) 3.00 183.33333 550.00
1093 1093 Invoice 08/17/2006   4687 Celera Diagnostics HCV Genotype Panel (HCVGTP-004c) 7.50 136.00 1,020.00
679 679 Invoice 08/18/2006   4694 Biokit, SA HBV - Nicaragua 424.00 9.00 3,816.00
788 788 Invoice 08/18/2006   4696 Orgenics Ltd. HIV-Africa 12.60 0.00 0.00
802 802 Invoice 08/18/2006   4690 International Bioscience, Inc Match Patient Set 200.00 6.50 1,300.00
802 802 Invoice 08/18/2006   4691 International Bioscience, Inc Match Patient Set 99.00 10.60606 1,050.00
802 802 Invoice 08/18/2006   4692 International Bioscience, Inc Match Patient Set 100.00 9.50 950.00
1218 1218 Invoice 08/18/2006   4693 Innotrac Diagnostics Oy CRP 10.40 24.03846 250.00
8 8 Invoice 08/21/2006   4695 Siemens Diagnostics-NY (formerly Bayer) Human Serum 147.00 6.29252 925.00
174 174 Invoice 08/21/2006   4698 Biokit, SA Human Plasma (Sodium Citrate) 2.80 0.00 0.00
546 546 Invoice 08/21/2006   4698 Biokit, SA Human Plasma 5.40 0.00 0.00
679 679 Invoice 08/21/2006   4698 Biokit, SA HBV - Nicaragua 42.00 0.00 0.00
852 852 Invoice 08/21/2006   4695 Siemens Diagnostics-NY (formerly Bayer) Human Serum (Female) 49.80 6.5261 325.00
26 26 Invoice 08/22/2006   4697 Adaltis Italia S.P.A. Hashimoto's Thyroiditis 1.20 35.00 42.00
939 939 Invoice 08/22/2006   4697 Adaltis Italia S.P.A. Grave's Disease 3.40 35.00 119.00
30 30 Invoice 08/23/2006   4704 IBL GmbH dsDNA Antibody 350.00 6.50 2,275.00
640 640 Invoice 08/23/2006   4702 Innovacon, Inc Mononucleosis 600.00 6.50 3,900.00
640 640 Invoice 08/23/2006   4702 Innovacon, Inc Mononucleosis 1.00 0.00 0.00
788 788 Invoice 08/23/2006   4703 VicTorch Meditek Inc HIV-Africa 5.30 141.50943 750.00
852 852 Invoice 08/23/2006   4703 VicTorch Meditek Inc Human Serum (Female) 5.10 0.00 0.00
1118 1118 Invoice 08/23/2006   4701 Bioreclamation Multiple Sclerosis 500.90 20.00 10,018.00
176 176 Invoice 08/25/2006   4709 Euroimmun AG Anti-Rubella IgM 50.00 10.00 500.00
199 199 Invoice 08/25/2006   4708 International Bioscience, Inc Anti-HCV 18.00 0.00 0.00
261 261 Invoice 08/25/2006   4707 International Bioscience, Inc FREE T4 57.60 23.4375 1,350.00
391 391 Invoice 08/25/2006   4707 International Bioscience, Inc FREE T3 82.60 24.51574 2,025.00
859 859 Invoice 08/28/2006   4711 Novartis Vaccines & Diagnostics HBV Match Set 8.40 83.33333 700.00
874 874 Invoice 08/28/2006   4710 Trinity Biotech Plc-Ireland Coumadin 1,680.00 5.00 8,400.00
1061 1061 Invoice 08/28/2006   4711 Novartis Vaccines & Diagnostics HBV Genotype Panel (HBVGTP-004a) 15.00 210.00 3,150.00
8 8 Invoice 08/31/2006   4714 The Binding Site-UK Human Serum 1.00 0.00 0.00
199 199 Invoice 08/31/2006   4713 Bristol Meyer Squibb Anti-HCV 3.00 110.00 330.00
263 263 Invoice 08/31/2006   4714 The Binding Site-UK Anti-CMV IgG 6.90 0.00 0.00
317 317 Invoice 08/31/2006   4714 The Binding Site-UK Anti-VZV IgG 4.40 0.00 0.00
546 546 Invoice 08/31/2006   4714 The Binding Site-UK Human Plasma 1.90 0.00 0.00
633 633 Invoice 08/31/2006   4713 Bristol Meyer Squibb HCV-Genotype 4 1.70 97.05882 165.00
683 683 Invoice 08/31/2006   4713 Bristol Meyer Squibb HCV-Venezuela 1.20 83.33333 100.00
8 8 Invoice 09/01/2006   4716 Biotrin Technologies Ltd Human Serum 184.20 3.00 552.60
446 446 Invoice 09/01/2006   4715 Roche Interamericana, S.A. Anti-HIV 1 22.20 79.27928 1,760.00
562 562 Invoice 09/01/2006   4715 Roche Interamericana, S.A. HIV-PCR 1.00 160.00 160.00
621 621 Invoice 09/01/2006   4717 Orgenics Ltd. RPR 2.10 0.00 0.00
643 643 Invoice 09/01/2006   4715 Roche Interamericana, S.A. HIV-Venezuela 9.50 117.89474 1,120.00
724 724 Invoice 09/01/2006   4717 Orgenics Ltd. Syphilis 15.20 0.00 0.00
788 788 Invoice 09/01/2006   4715 Roche Interamericana, S.A. HIV-Africa 7.80 82.05128 640.00
807 807 Invoice 09/01/2006   4715 Roche Interamericana, S.A. HIV-1 (Subtype B) 1.00 160.00 160.00
816 816 Invoice 09/01/2006   4715 Roche Interamericana, S.A. HIV Mutation 8.80 109.09091 960.00
855 855 Invoice 09/01/2006   4715 Roche Interamericana, S.A. HIV-Cote D'Ivoire 2.00 80.00 160.00
31 31 Invoice 09/05/2006   4722 Zeus Scientific SSA Antibody 10.80 0.00 0.00
37 37 Invoice 09/05/2006   4722 Zeus Scientific SCL-70 Antibody 18.00 0.00 0.00
171 171 Invoice 09/05/2006   4803 Teragenix Internal Human Plasma(EDTA-K3) 7.30 0.00 0.00
174 174 Invoice 09/05/2006   4721 Trinity Biotech-USA Human Plasma (Sodium Citrate) 3.30 0.00 0.00
199 199 Invoice 09/05/2006   4718 H.D.M. Labs Inc. Anti-HCV Positive Specimen MBID#58032, line item 01-05 3,963.20 1.75 6,935.60
199 199 Invoice 09/05/2006   4719 Walter Reed Army Medical Center Anti-HCV 11.00 68.18182 750.00
319 319 Invoice 09/05/2006   4722 Zeus Scientific Anti-Lyme IgG 8.70 0.00 0.00
546 546 Invoice 09/05/2006   4721 Trinity Biotech-USA Human Plasma 1.00 0.00 0.00
631 631 Invoice 09/05/2006   4721 Trinity Biotech-USA Human Plasma (CPDA) 3.40 0.00 0.00
702 702 Invoice 09/05/2006   4720 Virginia Medical Research, Inc HIV-O 1.30 76.92308 100.00
1125 1125 Invoice 09/05/2006   4721 Trinity Biotech-USA TORCH IgM 4.20 0.00 0.00
640 640 Invoice 09/06/2006   4725 Innovacon, Inc Mononucleosis 900.00 6.50 5,850.00
724 724 Invoice 09/06/2006   4741 Teragenix Internal Syphilis 6.20 0.00 0.00
788 788 Invoice 09/06/2006   4726 Adaltis Developement, Inc. HIV-Africa 4.00 137.50 550.00
788 788 Invoice 09/06/2006   4729 Teragenix Internal HIV-Africa 2.20 0.00 0.00
802 802 Invoice 09/06/2006   4732 Siemens Diagnostics-CA (formerly Bayer) Match Patient Set 270.70 22.57481 6,111.00
948 948 Invoice 09/06/2006   4724 Bioreclamation Scleroderma 10.40 33.65385 350.00
621 621 Invoice 09/07/2006   4728 United Biotech, Inc. RPR 31.20 0.00 0.00
724 724 Invoice 09/07/2006   4727 Teragenix Internal Syphilis 1.50 0.00 0.00
724 724 Invoice 09/07/2006   4728 United Biotech, Inc. Syphilis 20.00 0.00 0.00
724 724 Invoice 09/07/2006   4731 Biological Specialty Corporation, Inc. Syphilis 200.70 0.00 0.00
171 171 Invoice 09/08/2006   4734 Bio-Rad France Marnes Human Plasma(EDTA-K3) -50 Female & Male Specimens, line item 1 226.10 2.21141 500.00
261 261 Invoice 09/08/2006   4735 Abbott Laboratories FREE T4 11.40 35.01754 399.20
543 543 Invoice 09/08/2006   4734 Bio-Rad France Marnes Rheumatoid Factor Samples for Evaluation 22.90 0.00 0.00
555 555 Invoice 09/08/2006   4723 Ortho-Clinical Diagnostics HBsAg 484.60 9.25312 4,484.06
859 859 Invoice 09/08/2006   4723 Ortho-Clinical Diagnostics HBV Match Set 14.00 4.71 65.94
987 987 Invoice 09/08/2006   4733 Pronostics Limited-(formerly Smartbead) Anti-Gliadin IgG Positive Specimens, line item 1 9.20 53.26087 490.00
988 988 Invoice 09/08/2006   4733 Pronostics Limited-(formerly Smartbead) Anti-Gliadin IgA Positive Specimens, line item 2 3.90 71.79487 280.00
1210 1210 Invoice 09/08/2006   4733 Pronostics Limited-(formerly Smartbead) Allergy IgE 6.30 6.34921 40.00
1223 1223 Invoice 09/08/2006   4733 Pronostics Limited-(formerly Smartbead) tTG IgA 1.70 61.76471 105.00
1224 1224 Invoice 09/08/2006   4733 Pronostics Limited-(formerly Smartbead) tTG IgG 0.40 87.50 35.00
1225 1225 Invoice 09/08/2006   4733 Pronostics Limited-(formerly Smartbead) Endomysial IgA 3.10 67.74194 210.00
383 383 Invoice 09/11/2006   4737 Innogenetics Cerebro Spinal Fluid 100.00 22.50 2,250.00
383 383 Invoice 09/11/2006   4738 Innogenetics Cerebro Spinal Fluid 59.90 18.00 1,078.20
621 621 Invoice 09/11/2006   4736 Innogenetics RPR 3.00 12.00 36.00
724 724 Invoice 09/11/2006   4736 Innogenetics Syphilis 12.00 12.00 144.00
724 724 Invoice 09/11/2006   4739 Genesis Diagnostics Ltd Syphilis 17.00 0.00 0.00
802 802 Invoice 09/11/2006   4740 Beckman Coulter-CA Match Patient Set 459.40 1.36047 625.00
621 621 Invoice 09/12/2006   4743 Orgenics Ltd. 1 RPR Positive Specimen MBID# 109821, Line item 2 197.90 4.25 841.08
724 724 Invoice 09/12/2006   4743 Orgenics Ltd. 1 Syphilis Positive Specimen MBID# 115720, Line item 1 123.00 4.25 522.75
832 832 Invoice 09/12/2006   4744 Teragenix Internal Multiple Myeloma 0.50 0.00 0.00
1106 1106 Invoice 09/12/2006   4744 Teragenix Internal Lung Cancer 0.10 0.00 0.00
171 171 Invoice 09/13/2006   4745 Siemens Diagnostics-CA (formerly Bayer) Human Plasma(EDTA-K3) HIV,HCV & HBV Negative Specimens, line item 01 1,125.00 6.00 6,750.00
172 172 Invoice 09/13/2006   4746 Abbott Laboratories 20 x50mL Human Plasma (Lithium Heparin) Line item 1 1,000.00 1.50 1,500.00
831 831 Invoice 09/13/2006   4747 Abbott Laboratories Monoclonal Gammopathy 0.00 55.00 0.00
831 831 Invoice 09/13/2006   4747 Abbott Laboratories Monoclonal Gammopathy 0.00 55.00 0.00
831 831 Invoice 09/13/2006   4763 Abbott Laboratories Monoclonal Gammopathy 4.70 46.80851 220.00
832 832 Invoice 09/13/2006   4747 Abbott Laboratories Multiple Myeloma 0.00 55.00 0.00
832 832 Invoice 09/13/2006   4763 Abbott Laboratories Multiple Myeloma 36.80 50.81522 1,870.00
899 899 Invoice 09/13/2006   4763 Abbott Laboratories Chronic Lymphocytic Leukemia 1.00 55.00 55.00
1015 1015 Invoice 09/13/2006   4747 Abbott Laboratories Non-Hodskins Lymphoma 0.00 55.00 0.00
1015 1015 Invoice 09/13/2006   4763 Abbott Laboratories Non-Hodskins Lymphoma 2.00 55.00 110.00
1106 1106 Invoice 09/13/2006   4763 Abbott Laboratories Lung Cancer 1.00 55.00 55.00
1186 1186 Invoice 09/13/2006   4747 Abbott Laboratories Paraprotein 0.00 55.00 0.00
1186 1186 Invoice 09/13/2006   4763 Abbott Laboratories Paraprotein 1.00 55.00 55.00
1186 1186 Invoice 09/13/2006   4802 Teragenix Internal Paraprotein 0.30 0.00 0.00
1143 1143 Invoice 09/14/2006   4749 Beckman Coulter-MN Sepsis 22.50 67.11111 1,510.00
1228 1228 Invoice 09/14/2006   4750 Genentech Inc. Breast CA (FFT) 10.00 625.00 6,250.00
1229 1229 Invoice 09/14/2006   4750 Genentech Inc. Liver CA (FFT) 4.00 625.00 2,500.00
1230 1230 Invoice 09/14/2006   4750 Genentech Inc. Lung CA (FFT) 18.00 625.00 11,250.00
10 10 Invoice 09/15/2006   4752 International Bioscience, Inc Anti-HTLV I/II 80.90 27.81211 2,250.00
199 199 Invoice 09/15/2006   4753 International Bioscience, Inc Anti-HCV 3.20 40.625 130.00
683 683 Invoice 09/15/2006   4753 International Bioscience, Inc HCV-Venezuela 1.20 62.50 75.00
724 724 Invoice 09/15/2006   4751 Omega Diagnostics Syphilis 170.00 9.50588 1,616.00
887 887 Invoice 09/15/2006   4754 International Bioscience, Inc HCV Seroconversion Panel 11.00 0.00 0.00
998 998 Invoice 09/15/2006   4753 International Bioscience, Inc HCV-Thailand 1.00 40.00 40.00
10 10 Invoice 09/18/2006   4757 Adaltis Developement, Inc. Anti-HTLV II Positive Specimens, line item 01 94.40 28.60169 2,700.00
30 30 Invoice 09/18/2006   4759 Dr. Fooke Laboratorien GmbH dsDNA Antibody 1.90 0.00 0.00
37 37 Invoice 09/18/2006   4759 Dr. Fooke Laboratorien GmbH SCL-70 Antibody 8.80 0.00 0.00
724 724 Invoice 09/18/2006   4761 Orgenics Ltd. 1 Syphilis Positive Specimen MBID# 115699, Line item 1 204.80 4.25 870.40
802 802 Invoice 09/18/2006   4758 Adaltis Developement, Inc. 25 Match Patient Sets 756.20 4.1325 3,125.00
832 832 Invoice 09/18/2006   4762 Abbott Laboratories Multiple Myeloma 10.80 41.66667 450.00
910 910 Invoice 09/18/2006   4760 Savyon Diagnostics Mycoplasma IgG 6.90 0.00 0.00
911 911 Invoice 09/18/2006   4760 Savyon Diagnostics Mycoplasma IgM 3.50 0.00 0.00
1061 1061 Invoice 09/18/2006   4756 Sacred Heart Medical Center HBV Genotype Panel (HBVGTP-004a), line item 1 15.00 173.33333 2,600.00
1210 1210 Invoice 09/18/2006   4759 Dr. Fooke Laboratorien GmbH Allergy IgE 19.40 0.00 0.00
1226 1226 Invoice 09/18/2006   4759 Dr. Fooke Laboratorien GmbH ANA (Nucleolar) 6.70 0.00 0.00
621 621 Invoice 09/19/2006   4766 Teragenix Internal RPR 0.60 0.00 0.00
8 8 Invoice 09/20/2006   4808 Teragenix Internal Human Serum 4.30 0.00 0.00
29 29 Invoice 09/20/2006   4808 Teragenix Internal Anti-HIV 1/2 15.00 0.00 0.00
31 31 Invoice 09/20/2006   4765 Zeus Scientific 1 SSA Antibody Positive Specimen MBID#117042, line item 1 442.00 5.50 2,431.00
175 175 Invoice 09/20/2006   4808 Teragenix Internal Human Plasma (Sodium Heparin) 12.90 0.00 0.00
199 199 Invoice 09/20/2006   4808 Teragenix Internal Anti-HCV 13.80 0.00 0.00
546 546 Invoice 09/20/2006   4808 Teragenix Internal Human Plasma 135.40 0.00 0.00
555 555 Invoice 09/20/2006   4808 Teragenix Internal HBsAg 14.60 0.00 0.00
615 615 Invoice 09/20/2006   4764 Abbott Laboratories Ovarian Cancer 273.00 25.00103 6,825.28
621 621 Invoice 09/20/2006   4808 Teragenix Internal RPR 2.30 0.00 0.00
797 797 Invoice 09/20/2006   4825 IRL-2 Icteric 30.00 0.00 0.00
855 855 Invoice 09/20/2006   4808 Teragenix Internal HIV-Cote D'Ivoire 212.20 0.00 0.00
8 8 Invoice 09/21/2006   4769 Abbott Laboratories Human Serum 659.00 1.2519 825.00
8 8 Invoice 09/21/2006   4792 Teragenix Internal Human Serum 4.50 0.00 0.00
13 13 Invoice 09/21/2006   4768 Bioreclamation SLE 38.70 28.50 1,102.95
802 802 Invoice 09/21/2006   4767 Siemens Diagnostics-CA (formerly Bayer) Match Patient Set 166.50 15.72973 2,619.00
175 175 Invoice 09/22/2006   4782 Teragenix Internal Human Plasma (Sodium Heparin) 2.20 0.00 0.00
317 317 Invoice 09/22/2006   4772 The Binding Site-UK Anti-VZV IgG 1,858.00 4.75 8,825.50
543 543 Invoice 09/22/2006   4771 International Bioscience, Inc Rheumatoid Factor 8.90 0.00 0.00
579 579 Invoice 09/22/2006   4780 Phadia GmbH Anti-Cardiolipin IgG 6.30 0.00 0.00
635 635 Invoice 09/22/2006   4770 International Bioscience, Inc Albumin 60.00 12.50 750.00
724 724 Invoice 09/22/2006   4774 Innogenetics 11 x 1mL Syphilis IgM Positive Specimen, line item 010-020,040-120 11.00 5.00 55.00
1219 1219 Invoice 09/22/2006   4773 The Binding Site-UK Anti-Cardiolipin 1,544.00 4.85 7,488.40
1233 1233 Invoice 09/22/2006   4780 Phadia GmbH B2GP IgM 1.10 0.00 0.00
8 8 Invoice 09/25/2006   4775 Gen-Probe, Inc. Human Serum 2,068.50 8.46024 17,500.01
8 8 Invoice 09/25/2006   4776 Siemens Diagnostics-CA (formerly Bayer) Human Serum 468.75 6.00 2,812.50
10 10 Invoice 09/25/2006   4781 California Department of Health Anti-HTLV I/II 14.00 0.00 0.00
10 10 Invoice 09/25/2006   4784 Abbott GmbH Anti-HTLV I/II 11.60 0.00 0.00
40 40 Invoice 09/25/2006   4775 Gen-Probe, Inc. Anti-EBV VCA IgG 105.70 11.82592 1,250.00
174 174 Invoice 09/25/2006   4775 Gen-Probe, Inc. Human Plasma (Sodium Citrate) 616.60 12.16348 7,500.00
175 175 Invoice 09/25/2006   4775 Gen-Probe, Inc. Human Plasma (Sodium Heparin) 300.00 12.50 3,750.00
199 199 Invoice 09/25/2006   4777 LabCorp Anti-HCV 20.60 36.40777 750.00
305 305 Invoice 09/25/2006   4784 Abbott GmbH Anti-HBc Total 9.90 0.00 0.00
448 448 Invoice 09/25/2006   4800 Abbott Laboratories Acute HAV 44.50 172.02247 7,655.00
546 546 Invoice 09/25/2006   4775 Gen-Probe, Inc. Human Plasma 610.80 12.27898 7,500.00
546 546 Invoice 09/25/2006   4776 Siemens Diagnostics-CA (formerly Bayer) Human Plasma 468.75 6.00 2,812.50
558 558 Invoice 09/25/2006   4779 BBI Chagas 64.00 0.00 0.00
998 998 Invoice 09/25/2006   4783 Innogenetics HCV-Thailand 160.00 0.00 0.00
1116 1116 Invoice 09/25/2006   4778 Miraculins 16 Gastrointestinal CA Specimens, line item 01 100.20 13.47305 1,350.00
1127 1127 Invoice 09/25/2006   4775 Gen-Probe, Inc. HGV 300.80 12.46676 3,750.00
29 29 Invoice 09/26/2006   4786 Gen-Probe, Inc. Anti-HIV 1/2 405.80 12.32134 5,000.00
174 174 Invoice 09/26/2006   4786 Gen-Probe, Inc. Human Plasma (Sodium Citrate) 105.90 11.80359 1,250.00
199 199 Invoice 09/26/2006   4786 Gen-Probe, Inc. Anti-HCV 1,129.90 11.06293 12,500.00
446 446 Invoice 09/26/2006   4786 Gen-Probe, Inc. Anti-HIV 1 131.70 9.49127 1,250.00
555 555 Invoice 09/26/2006   4786 Gen-Probe, Inc. HBsAg 785.40 11.14082 8,750.00
643 643 Invoice 09/26/2006   4786 Gen-Probe, Inc. HIV-Venezuela 305.40 8.18599 2,500.00
716 716 Invoice 09/26/2006   4788 Bioreclamation Rheumatoid Arthritis 47.50 25.00 1,187.50
855 855 Invoice 09/26/2006   4786 Gen-Probe, Inc. HIV-Cote D'Ivoire 244.90 10.20825 2,500.00
995 995 Invoice 09/26/2006   4786 Gen-Probe, Inc. HIV and HCV Co-infection 303.50 12.35585 3,750.00
1220 1220 Invoice 09/26/2006   4789 National Forensic Science Technology Ctr Semen 20.00 75.00 1,500.00
13 13 Invoice 09/27/2006   4791 Gen-Probe, Inc. SLE 1,000.00 12.50 12,500.00
199 199 Invoice 09/27/2006   4785 LabCorp Anti-HCV 50.00 45.00 2,250.00
542 542 Invoice 09/27/2006   4790 Gen-Probe, Inc. HBV Vaccinated 1,000.00 12.50 12,500.00
543 543 Invoice 09/27/2006   4790 Gen-Probe, Inc. Rheumatoid Factor 1,000.00 12.50 12,500.00
546 546 Invoice 09/27/2006   4790 Gen-Probe, Inc. Human Plasma 817.20 12.23691 10,000.00
592 592 Invoice 09/27/2006   4791 Gen-Probe, Inc. ANA 1,000.00 12.50 12,500.00
797 797 Invoice 09/27/2006   4791 Gen-Probe, Inc. Icteric 1,028.40 12.1548 12,500.00
832 832 Invoice 09/27/2006   4791 Gen-Probe, Inc. Multiple Myeloma 1,000.00 12.50 12,500.00
865 865 Invoice 09/27/2006   4790 Gen-Probe, Inc. Flu Vaccine Recipient 1,058.10 11.81363 12,500.00
1125 1125 Invoice 09/27/2006   4790 Gen-Probe, Inc. TORCH IgM 301.70 8.28638 2,500.00
8 8 Invoice 09/28/2006   4794 Abbott Laboratories Human Serum 212.80 2.70677 576.00
10 10 Invoice 09/28/2006   4795 Gen-Probe, Inc. Anti-HTLV I/II 1,979.00 12.00101 23,750.00
10 10 Invoice 09/28/2006   4801 Teragenix Internal Anti-HTLV I/II 24.50 0.00 0.00
383 383 Invoice 09/28/2006   4799 Wash Univ of St. Louis 10 x 1mL Cerebro Spinal Fluid Positive Specimens, line item 1 10.00 25.00 250.00
555 555 Invoice 09/28/2006   4797 Abbott Laboratories HBsAg 17.10 41.81287 715.00
621 621 Invoice 09/28/2006   4795 Gen-Probe, Inc. RPR 2,624.70 7.61992 20,000.00
724 724 Invoice 09/28/2006   4795 Gen-Probe, Inc. Syphilis 504.40 9.91277 5,000.00
831 831 Invoice 09/28/2006   4796 Abbott Laboratories Monoclonal Gammopathy 1.00 45.00 45.00
832 832 Invoice 09/28/2006   4796 Abbott Laboratories Multiple Myeloma 12.00 45.00 540.00
852 852 Invoice 09/28/2006   4794 Abbott Laboratories Human Serum (Female) 208.00 3.00 624.00
896 896 Invoice 09/28/2006   4794 Abbott Laboratories Renal Insufficiency 5.30 51.88679 275.00
922 922 Invoice 09/28/2006   4794 Abbott Laboratories Chronic Heart Failure - Class I 12.40 53.22581 660.00
923 923 Invoice 09/28/2006   4794 Abbott Laboratories Chronic Heart Failure - Class II 9.20 53.80435 495.00
924 924 Invoice 09/28/2006   4794 Abbott Laboratories Chronic Heart Failure - Class III 9.00 48.88889 440.00
1138 1138 Invoice 09/28/2006   4794 Abbott Laboratories Renal Cancer 17.70 49.71751 880.00
199 199 Invoice 09/29/2006   4806 International Bioscience, Inc Anti-HCV 46.20 58.44156 2,700.00
446 446 Invoice 09/29/2006   4798 Talecris Biotherapeutics, Inc 1 Anti-HIV 1 Positive Specimen MBID#26070, line item 1 5.20 20.00 104.00
543 543 Invoice 09/29/2006   4807 Bio-Rad France Marnes Rheumatoid Factor 117.00 3.2906 385.00
555 555 Invoice 09/29/2006   4798 Talecris Biotherapeutics, Inc 1 HBsAg Specimen MBID#96289, line item 2 5.00 20.00 100.00
555 555 Invoice 09/29/2006   4806 International Bioscience, Inc HBsAg 10.40 64.90385 675.00
683 683 Invoice 09/29/2006   4806 International Bioscience, Inc HCV-Venezuela 14.60 46.23288 675.00
723 723 Invoice 09/29/2006   4815 Teragenix Internal Prostate Cancer 16.50 0.00 0.00
859 859 Invoice 09/29/2006   4806 International Bioscience, Inc HBV Match Set 22.60 59.73451 1,350.00
967 967 Invoice 09/29/2006   4806 International Bioscience, Inc HBV - Indonesia 31.30 64.69649 2,025.00
968 968 Invoice 09/29/2006   4806 International Bioscience, Inc HCV - Indonesia 10.00 67.50 675.00
199 199 Invoice 10/02/2006   4811 Abbott Laboratories Anti-HCV 414.40 10.85907 4,500.00
199 199 Invoice 10/02/2006   4814 Teragenix Internal Anti-HCV 0.40 0.00 0.00
171 171 Invoice 10/03/2006   4812 Roche Diagnostics Corporation-IN Human Plasma(EDTA-K3) 526.20 3.08818 1,625.00
199 199 Invoice 10/03/2006   4813 Novartis Vaccines & Diagnostics Anti-HCV 31.40 11.46497 360.00
562 562 Invoice 10/03/2006   4812 Roche Diagnostics Corporation-IN HIV-PCR 41.70 43.16547 1,800.00
623 623 Invoice 10/03/2006   4943 HemaCare BioScience HIV-2 17.00 0.00 0.00
816 816 Invoice 10/03/2006   4812 Roche Diagnostics Corporation-IN HIV Mutation 88.80 40.54054 3,600.00
10 10 Invoice 10/04/2006   4818 Ortho-Clinical Diagnostics Anti-HTLV I/II 13.30 0.00 0.00
174 174 Invoice 10/04/2006   4819 Innovacon, Inc Human Plasma (Sodium Citrate) 9.30 0.00 0.00
546 546 Invoice 10/04/2006   4819 Innovacon, Inc Human Plasma 3.00 0.00 0.00
565 565 Invoice 10/04/2006   4820 Virginia Medical Research, Inc Breast Cancer 152.60 8.00 1,220.80
615 615 Invoice 10/04/2006   4820 Virginia Medical Research, Inc Ovarian Cancer 94.60 10.00 946.00
628 628 Invoice 10/04/2006   4820 Virginia Medical Research, Inc CA-125 45.40 10.00 454.00
724 724 Invoice 10/04/2006   4819 Innovacon, Inc Syphilis 8.90 0.00 0.00
802 802 Invoice 10/04/2006   4817 Beckman Coulter-CA Match Patient Set 351.00 1.78063 625.00
907 907 Invoice 10/04/2006   4820 Virginia Medical Research, Inc Crohn's Disease 20.80 28.84615 600.00
1049 1049 Invoice 10/04/2006   4820 Virginia Medical Research, Inc Kidney CA 4.90 8.00 39.20
1190 1190 Invoice 10/04/2006   4820 Virginia Medical Research, Inc Peritoneal CA 7.50 10.00 75.00
877 877 Invoice 10/05/2006   4816 Siemens Diagnostics-Walpole (Bayer) Gentamycin 68.90 20.3193 1,400.00
446 446 Invoice 10/06/2006   4824 Keystone Biologicals Anti-HIV 1 4.00 0.00 0.00
555 555 Invoice 10/06/2006   4823 International Bioscience, Inc HBsAg (20 x 5mL Anti-HB Core Positive Specimens), line item 2 105.50 6.63507 700.00
883 883 Invoice 10/06/2006   4822 International Bioscience, Inc 20 x 5mL Multiple Transfusion Specimens, line item 1 104.60 6.69216 700.00
887 887 Invoice 10/06/2006   4821 International Bioscience, Inc HCV Seroconversion Panel 1,277.50 3.99217 5,100.00
8 8 Invoice 10/09/2006   4826 Panacea Pharmaceuticals Human Serum 490.00 10.00 4,900.00
199 199 Invoice 10/09/2006   4830 Siemens Diagnostics-Walpole (Bayer) Anti-HCV 149.30 9.84595 1,470.00
723 723 Invoice 10/09/2006   4827 Panacea Pharmaceuticals Prostate Cancer 159.00 14.77358 2,349.00
831 831 Invoice 10/09/2006   4828 Abbott Laboratories Monoclonal Gammopathy 122.30 35.54374 4,347.00
832 832 Invoice 10/09/2006   4828 Abbott Laboratories Multiple Myeloma 126.10 34.47264 4,347.00
1143 1143 Invoice 10/09/2006   4829 Bioreclamation Sepsis 12.50 80.00 1,000.00
1143 1143 Invoice 10/09/2006   4832 Lake Arrowhead Lab Consultants Sepsis 1,005.00 2.36318 2,375.00
1234 1234 Invoice 10/09/2006   4831 Abbott Laboratories Random Hospital Samples 1,188.00 5.05051 6,000.01
8 8 Invoice 10/10/2006   4839 Siemens Diagnostics-NY (formerly Bayer) Human Serum 34.60 12.00 415.20
8 8 Invoice 10/10/2006   4840 Teragenix Internal Human Serum 0.70 0.00 0.00
10 10 Invoice 10/10/2006   4835 Adaltis Developement, Inc. Anti-HTLV I/II 1.00 0.00 0.00
543 543 Invoice 10/10/2006   4838 Scipac LTD Rheumatoid Factor 12.00 10.41667 125.00
543 543 Invoice 10/10/2006   4953 HemaCare BioScience Rheumatoid Factor 12.00 0.00 0.00
555 555 Invoice 10/10/2006   4834 Siemens Diagnostics-Walpole (Bayer) HBsAg 109.20 45.00 4,914.00
839 839 Invoice 10/10/2006   4838 Scipac LTD Elevated IgM 11.50 13.04348 150.00
839 839 Invoice 10/10/2006   4953 HemaCare BioScience Elevated IgM 12.30 0.00 0.00
852 852 Invoice 10/10/2006   4839 Siemens Diagnostics-NY (formerly Bayer) Human Serum (Female) 3.80 12.00 45.60
855 855 Invoice 10/10/2006   4841 Ortho-Clinical Diagnostics HIV-Cote D'Ivoire 3.00 0.00 0.00
882 882 Invoice 10/10/2006   4838 Scipac LTD Elevated IgA 13.70 9.12409 125.00
882 882 Invoice 10/10/2006   4953 HemaCare BioScience Elevated IgA 14.20 0.00 0.00
960 960 Invoice 10/10/2006   4836 MARDX Diagnostics, Inc. Lyme (European) IgM 10.00 0.00 0.00
1240 1240 Invoice 10/10/2006   4845 Innogenetics 9 CSF Positive Specimens, line item 010 48.60 18.00 874.80
85 85 Invoice 10/11/2006   4955 HemaCare BioScience Syphilis - Primary Stage 0.10 0.00 0.00
568 568 Invoice 10/11/2006   4955 HemaCare BioScience Syphilis-Late (untreated) 0.10 0.00 0.00
832 832 Invoice 10/11/2006   4955 HemaCare BioScience Multiple Myeloma 0.20 0.00 0.00
171 171 Invoice 10/12/2006   4893 HemaCare BioScience Human Plasma(EDTA-K3) 11.70 0.00 0.00
546 546 Invoice 10/12/2006   4894 Trina Bioreactives AG Human Plasma 5.40 0.00 0.00
555 555 Invoice 10/12/2006   4894 Trina Bioreactives AG HBsAg 2.00 0.00 0.00
558 558 Invoice 10/12/2006   4842 BioMedical Resource Chagas 1,328.20 6.43917 8,552.51
960 960 Invoice 10/12/2006   4894 Trina Bioreactives AG Lyme (European) IgM 10.00 0.00 0.00
1125 1125 Invoice 10/12/2006   4894 Trina Bioreactives AG TORCH IgM 2.00 0.00 0.00
1220 1220 Invoice 10/12/2006   4844 National Forensic Science Technology Ctr Semen samples - with sperm ( can be frozen), Line Item 1 30.00 50.00 1,500.00
29 29 Invoice 10/13/2006   4884 Bio-Rad France Marnes Anti-HIV 1/2 2.00 0.00 0.00
30 30 Invoice 10/13/2006   4892 The Binding Site-UK dsDNA Antibody 0.90 0.00 0.00
31 31 Invoice 10/13/2006   4892 The Binding Site-UK SSA Antibody 1.40 0.00 0.00
49 49 Invoice 10/13/2006   4892 The Binding Site-UK Jo-1 Antibody 1.30 0.00 0.00
197 197 Invoice 10/13/2006   4884 Bio-Rad France Marnes HIVAg 2.00 0.00 0.00
199 199 Invoice 10/13/2006   4891 International Bioscience, Inc Anti-HCV 3.00 0.00 0.00
264 264 Invoice 10/13/2006   4884 Bio-Rad France Marnes HBeAg 0.90 0.00 0.00
446 446 Invoice 10/13/2006   4884 Bio-Rad France Marnes Anti-HIV 1 17.70 0.00 0.00
562 562 Invoice 10/13/2006   4884 Bio-Rad France Marnes HIV-PCR 18.00 0.00 0.00
575 575 Invoice 10/13/2006   4897 Human GmbH Mitochondrial Antibody 1.50 0.00 0.00
578 578 Invoice 10/13/2006   4892 The Binding Site-UK Anti-Cardiolipin IgM 1.40 0.00 0.00
643 643 Invoice 10/13/2006   4884 Bio-Rad France Marnes HIV-Venezuela 17.00 0.00 0.00
788 788 Invoice 10/13/2006   4884 Bio-Rad France Marnes HIV-Africa 2.00 0.00 0.00
816 816 Invoice 10/13/2006   4884 Bio-Rad France Marnes HIV Mutation 4.40 0.00 0.00
855 855 Invoice 10/13/2006   4884 Bio-Rad France Marnes HIV-Cote D'Ivoire 12.00 0.00 0.00
987 987 Invoice 10/13/2006   4892 The Binding Site-UK Anti-Gliadin IgG 0.50 0.00 0.00
988 988 Invoice 10/13/2006   4892 The Binding Site-UK Anti-Gliadin IgA 0.50 0.00 0.00
1060 1060 Invoice 10/13/2006   4884 Bio-Rad France Marnes HIV-Thailand 14.00 0.00 0.00
1223 1223 Invoice 10/13/2006   4892 The Binding Site-UK tTG IgA 0.50 0.00 0.00
1233 1233 Invoice 10/13/2006   4892 The Binding Site-UK B2GP IgM 1.60 0.00 0.00
1236 1236 Invoice 10/13/2006   4892 The Binding Site-UK Sm/RNP 1.90 0.00 0.00
1237 1237 Invoice 10/13/2006   4897 Human GmbH LKM 0.70 0.00 0.00
1238 1238 Invoice 10/13/2006   4897 Human GmbH Lamin B 0.10 0.00 0.00
1239 1239 Invoice 10/13/2006   4897 Human GmbH SP 100 0.30 0.00 0.00
10 10 Invoice 10/16/2006   4849 Ortho-Clinical Diagnostics Anti-HTLV I/II, Line item 1 & 2 323.00 24.7678 8,000.00
10 10 Invoice 10/16/2006   4885 Abbott GmbH Anti-HTLV I/II 18.00 0.00 0.00
10 10 Invoice 10/16/2006   4889 Trina Bioreactives AG Anti-HTLV I/II 4.00 0.00 0.00
85 85 Invoice 10/16/2006   4847 Bio-Rad-Hercules,CA Syphilis - Primary Stage 15.80 12.1519 192.00
171 171 Invoice 10/16/2006   4843 Roche Diagnostics Corporation-IN Human Plasma(EDTA-K3) MBID#61283 120.00 3.25 390.00
171 171 Invoice 10/16/2006   4843 Roche Diagnostics Corporation-IN Human Plasma(EDTA-K3) @ no charge 5.00 0.00 0.00
171 171 Invoice 10/16/2006   4954 HemaCare BioScience Human Plasma(EDTA-K3) 68.50 0.00 0.00
174 174 Invoice 10/16/2006   4889 Trina Bioreactives AG Human Plasma (Sodium Citrate) 2.00 0.00 0.00
199 199 Invoice 10/16/2006   4847 Bio-Rad-Hercules,CA Anti-HCV 34.30 13.11953 450.00
446 446 Invoice 10/16/2006   4887 Roche Interamericana, S.A. Anti-HIV 1 23.80 0.00 0.00
562 562 Invoice 10/16/2006   4887 Roche Interamericana, S.A. HIV-PCR 1.00 0.00 0.00
567 567 Invoice 10/16/2006   4847 Bio-Rad-Hercules,CA Syphilis-Secondary (untreated) 11.30 11.68142 132.00
568 568 Invoice 10/16/2006   4847 Bio-Rad-Hercules,CA Syphilis-Late (untreated) 18.60 10.96774 204.00
631 631 Invoice 10/16/2006   4889 Trina Bioreactives AG Human Plasma (CPDA) 3.00 0.00 0.00
643 643 Invoice 10/16/2006   4887 Roche Interamericana, S.A. HIV-Venezuela 9.70 0.00 0.00
724 724 Invoice 10/16/2006   4889 Trina Bioreactives AG Syphilis 2.00 0.00 0.00
788 788 Invoice 10/16/2006   4887 Roche Interamericana, S.A. HIV-Africa 8.00 0.00 0.00
807 807 Invoice 10/16/2006   4887 Roche Interamericana, S.A. HIV-1 (Subtype B) 1.00 0.00 0.00
816 816 Invoice 10/16/2006   4887 Roche Interamericana, S.A. HIV Mutation 9.70 0.00 0.00
832 832 Invoice 10/16/2006   4847 Bio-Rad-Hercules,CA Multiple Myeloma 65.90 9.55994 630.00
855 855 Invoice 10/16/2006   4887 Roche Interamericana, S.A. HIV-Cote D'Ivoire 2.00 0.00 0.00
907 907 Invoice 10/16/2006   4846 Virginia Medical Research, Inc 20 Crohn's Disease Positive Specimens, line item 01 40.90 24.4499 1,000.00
1050 1050 Invoice 10/16/2006   4848 OraSure Technologies, Inc. HCV Genotype Panel (HCVGTP-003a), Line item 1 10.00 225.00 2,250.00
1125 1125 Invoice 10/16/2006   4889 Trina Bioreactives AG TORCH IgM 2.00 0.00 0.00
10 10 Invoice 10/17/2006   4851 Adaltis Developement, Inc. Anti-HTLV I/II 91.10 19.75851 1,800.00
446 446 Invoice 10/18/2006   4854 Keystone Biologicals Anti-HIV 1 1,425.80 1.00 1,425.80
555 555 Invoice 10/18/2006   4852 Roche Molecular Systems-NJ HBsAg 38.80 73.45361 2,850.00
565 565 Invoice 10/18/2006   4855 Diagnostic Products Corporation Breast Cancer 54.70 22.85192 1,250.00
859 859 Invoice 10/18/2006   4852 Roche Molecular Systems-NJ HBV Match Set 82.60 77.14891 6,372.50
960 960 Invoice 10/18/2006   4853 Trinity Biotech-USA Lyme (European) IgM 252.40 6.7393 1,701.00
336 336 Invoice 10/19/2006   4895 Omega Diagnostics Anti-Dengue IgG 10.00 0.00 0.00
6 6 Invoice 10/20/2006   4856 Bio-Rad France Marnes Anti-HIV 2, Line item 1 thru 4 41.10 79.0146 3,247.50
8 8 Invoice 10/20/2006   4850 Biotrin Technologies Ltd Human Serum 1,568.60 3.50 5,490.10
30 30 Invoice 10/20/2006   4870 Dr. Fooke Laboratorien GmbH dsDNA Antibody 20.00 10.00 200.00
37 37 Invoice 10/20/2006   4870 Dr. Fooke Laboratorien GmbH SCL-70 Antibody 20.00 10.00 200.00
175 175 Invoice 10/20/2006   4896 Biomerieux SA-France Human Plasma (Sodium Heparin) 2.00 0.00 0.00
555 555 Invoice 10/20/2006   4896 Biomerieux SA-France HBsAg 16.00 0.00 0.00
555 555 Invoice 10/20/2006   5082 HemaCare BioScience HBsAg 2.00 0.00 0.00
679 679 Invoice 10/20/2006   4896 Biomerieux SA-France HBV - Nicaragua 40.00 0.00 0.00
702 702 Invoice 10/20/2006   4856 Bio-Rad France Marnes HIV-O, Line item 5 10.00 100.00 1,000.00
1210 1210 Invoice 10/20/2006   4870 Dr. Fooke Laboratorien GmbH Allergy IgE 838.00 3.73658 3,131.25
199 199 Invoice 10/23/2006   4858 Roche Molecular Systems-NJ Anti-HCV 35.20 24.85795 875.00
446 446 Invoice 10/23/2006   4858 Roche Molecular Systems-NJ Anti-HIV 1 20.80 24.03846 500.00
502 502 Invoice 10/23/2006   4857 Siemens Diagnostics-Walpole (Bayer) CA 19 - 9, Line item 2 49.30 15.21298 750.00
550 550 Invoice 10/23/2006   4857 Siemens Diagnostics-Walpole (Bayer) Troponin I, Line item 1 150.00 15.00 2,250.00
565 565 Invoice 10/23/2006   4956 HemaCare BioScience Breast Cancer 1.20 0.00 0.00
788 788 Invoice 10/23/2006   4947 HemaCare BioScience HIV-Africa 1.00 0.00 0.00
816 816 Invoice 10/23/2006   4858 Roche Molecular Systems-NJ HIV Mutation 21.10 24.88152 525.00
855 855 Invoice 10/23/2006   4859 Adaltis Developement, Inc. HIV-Cote D'Ivoire 4.00 43.75 175.00
861 861 Invoice 10/23/2006   4956 HemaCare BioScience CA 15-3 9.10 0.00 0.00
10 10 Invoice 10/24/2006   4945 Abbott GmbH Anti-HTLV I/II 12.00 0.00 0.00
336 336 Invoice 10/24/2006   4890 Bio Heme Anti-Dengue IgG 10.00 0.00 0.00
565 565 Invoice 10/24/2006   4876 Siemens Diagnostics-NY (formerly Bayer) Breast Cancer 83.60 14.14474 1,182.50
617 617 Invoice 10/24/2006   4861 Celera Diagnostics Whole Blood-EDTA (K3) 35.00 14.28571 500.00
861 861 Invoice 10/24/2006   4876 Siemens Diagnostics-NY (formerly Bayer) CA 15-3 133.00 13.64662 1,815.00
867 867 Invoice 10/24/2006   4863 Siemens Diagnostics-Walpole (Bayer) Carbamazepine 23.00 21.30435 490.00
1240 1240 Invoice 10/24/2006   4860 Bioreclamation CSF 79.70 9.00 717.30
8 8 Invoice 10/25/2006   4864 Panacea Pharmaceuticals Human Serum 116.00 10.00 1,160.00
10 10 Invoice 10/26/2006   4886 HemaCare BioScience Anti-HTLV I/II 12.00 0.00 0.00
555 555 Invoice 10/27/2006   4872 Trina Bioreactives AG 1 HBsAg Specimen MBID#61068 606.10 1.50 909.15
555 555 Invoice 10/27/2006   4874 International Bioscience, Inc 1 HBsAg Positive Specimen MBID#61659, line item 1 51.10 9.78474 500.00
863 863 Invoice 10/27/2006   4873 International Bioscience, Inc 10 x 2mL Dialysis Specimens, line item 1 19.90 25.12563 500.00
1174 1174 Invoice 10/27/2006   4875 International Bioscience, Inc 1 HBc IgM Panel (Lot#50011), line item 2 20.00 25.00 500.00
1231 1231 Invoice 10/27/2006   4871 Euro-Diagnostica AB B2GP IgA 25.50 58.82353 1,500.00
171 171 Invoice 10/30/2006   4878 Innogenetics Human Plasma(EDTA-K3) 31.10 0.00 0.00
802 802 Invoice 10/30/2006   4881 Beckman Coulter-CA Match Patient Set 454.90 1.37393 625.00
1093 1093 Invoice 10/30/2006   4869 ARUP Labs 2 HCV Genotype Panels (HCVGTP-004c), line item 001 15.00 166.66667 2,500.00
1123 1123 Invoice 10/30/2006   4879 Novartis Vaccines & Diagnostics HEV 2.00 27.50 55.00
1143 1143 Invoice 10/30/2006   4880 Lake Arrowhead Lab Consultants Sepsis 0.00 0.00 0.00
6 6 Invoice 10/31/2006   4951 HemaCare BioScience Anti-HIV 2 1.00 0.00 0.00
38 38 Invoice 10/31/2006   4951 HemaCare BioScience Thyroglobulin Antibody (TgAb) 3.30 0.00 0.00
63 63 Invoice 10/31/2006   4951 HemaCare BioScience Anti-HBs 82.80 0.00 0.00
199 199 Invoice 10/31/2006   4883 Novartis Vaccines & Diagnostics 1 x 830mL Anti-HCV Positive Specimen, line item 1 830.10 3.47548 2,885.00
305 305 Invoice 10/31/2006   4951 HemaCare BioScience Anti-HBc Total 0.80 0.00 0.00
336 336 Invoice 10/31/2006   4949 HemaCare BioScience Anti-Dengue IgG 0.50 0.00 0.00
446 446 Invoice 10/31/2006   4951 HemaCare BioScience Anti-HIV 1 0.50 0.00 0.00
763 763 Invoice 10/31/2006   4951 HemaCare BioScience HBV-Senegal 3.10 0.00 0.00
831 831 Invoice 10/31/2006   4888 Abbott Laboratories Monoclonal Gammopathy 12.80 37.91328 485.29
832 832 Invoice 10/31/2006   4888 Abbott Laboratories Multiple Myeloma 11.90 40.78067 485.29
899 899 Invoice 10/31/2006   4888 Abbott Laboratories Chronic Lymphocytic Leukemia 14.10 34.41773 485.29
907 907 Invoice 10/31/2006   4952 HemaCare BioScience Crohn's Disease 2.60 0.00 0.00
1012 1012 Invoice 10/31/2006   4888 Abbott Laboratories Anemia 10.00 48.529 485.29
1015 1015 Invoice 10/31/2006   4888 Abbott Laboratories Non-Hodskins Lymphoma 24.20 56.15041 1,358.84
1243 1243 Invoice 10/31/2006   4882 Abbott Laboratories Normal Human Serum 2,173.60 0.80512 1,750.01
336 336 Invoice 11/01/2006   4900 InBios International, Inc. Anti-Dengue IgG 10.00 10.00 100.00
558 558 Invoice 11/01/2006   4900 InBios International, Inc. Chagas 24.00 10.00 240.00
802 802 Invoice 11/01/2006   4899 National Forensic Science Technology Ctr 10 Match Patient Set (Whole Blood,Serum/Saliva Swab), line item 1 91.00 38.46154 3,500.00
940 940 Invoice 11/01/2006   4950 HemaCare BioScience Diabetes 4.10 0.00 0.00
13 13 Invoice 11/02/2006   4901 Bioreclamation 5 SLE Positive Specimens, line item 01 57.80 27.50 1,589.50
543 543 Invoice 11/02/2006   4902 Siemens Diagnostics-Walpole (Bayer) 25 x 2mL Rheumatoid Factor Positive Specimens, line item 01 52.10 15.35509 800.00
907 907 Invoice 11/02/2006   4898 Bioreclamation 38 Crohn's Disease Positive Specimens, line item 1 486.97 27.70 13,489.07
579 579 Invoice 11/03/2006   4904 Phadia GmbH Anti-Cardiolipin IgG 280.00 6.25 1,750.00
1210 1210 Invoice 11/03/2006   4903 Dr. Fooke Laboratorien GmbH 1 x 838mL Allergy IgE Specimen MBID#117898, line item 1 838.00 3.50 2,933.00
199 199 Invoice 11/06/2006   4909 Research Think Tank Anti-HCV 15.40 9.74026 150.00
336 336 Invoice 11/06/2006   4948 HemaCare BioScience Anti-Dengue IgG 3.10 0.00 0.00
558 558 Invoice 11/06/2006   4944 BBI Chagas 15.00 0.00 0.00
683 683 Invoice 11/06/2006   4909 Research Think Tank HCV-Venezuela 5.10 9.80392 50.00
940 940 Invoice 11/06/2006   4908 Virginia Medical Research, Inc 12 x 1mL Diabetes Specimens per e-mail request 12.00 30.00 360.00
6 6 Invoice 11/07/2006   4905 Institut Virion\Serion GmbH Anti-HIV 2 4.00 75.00 300.00
6 6 Invoice 11/07/2006   4906 Institut Virion\Serion GmbH Anti-HIV 2 214.30 15.00 3,214.50
8 8 Invoice 11/07/2006   4907 Institut Virion\Serion GmbH Human Serum 1.00 0.00 0.00
10 10 Invoice 11/07/2006   4906 Institut Virion\Serion GmbH Anti-HTLV I/II 85.20 2.50 213.00
29 29 Invoice 11/07/2006   4906 Institut Virion\Serion GmbH Anti-HIV 1/2 121.90 1.25004 152.38
38 38 Invoice 11/07/2006   4905 Institut Virion\Serion GmbH Thyroglobulin Antibody (TgAb) 5.50 10.90909 60.00
38 38 Invoice 11/07/2006   4906 Institut Virion\Serion GmbH Thyroglobulin Antibody (TgAb) 8.00 1.25 10.00
63 63 Invoice 11/07/2006   4905 Institut Virion\Serion GmbH Anti-HBs 1.00 10.00 10.00
64 64 Invoice 11/07/2006   4906 Institut Virion\Serion GmbH Anti-HBc IgM 2.00 1.25 2.50
85 85 Invoice 11/07/2006   4906 Institut Virion\Serion GmbH Syphilis - Primary Stage 57.60 1.25 72.00
227 227 Invoice 11/07/2006   4906 Institut Virion\Serion GmbH Anti-HSV 2 IgG 20.30 1.25025 25.38
264 264 Invoice 11/07/2006   4907 Institut Virion\Serion GmbH HBeAg 2.80 0.00 0.00
305 305 Invoice 11/07/2006   4905 Institut Virion\Serion GmbH Anti-HBc Total 1.00 10.00 10.00
336 336 Invoice 11/07/2006   4910 Biological Specialty Corporation, Inc. Anti-Dengue IgG 60.00 0.00 0.00
446 446 Invoice 11/07/2006   4905 Institut Virion\Serion GmbH Anti-HIV 1 0.90 11.11111 10.00
446 446 Invoice 11/07/2006   4906 Institut Virion\Serion GmbH Anti-HIV 1 284.70 1.25002 355.88
446 446 Invoice 11/07/2006   4907 Institut Virion\Serion GmbH Anti-HIV 1 1.80 0.00 0.00
542 542 Invoice 11/07/2006   4906 Institut Virion\Serion GmbH HBV Vaccinated 23.90 1.25021 29.88
546 546 Invoice 11/07/2006   4907 Institut Virion\Serion GmbH Human Plasma 3.20 0.00 0.00
555 555 Invoice 11/07/2006   4946 HemaCare BioScience HBsAg 69.00 0.00 0.00
558 558 Invoice 11/07/2006   4906 Institut Virion\Serion GmbH Chagas 90.90 1.55424 141.28
558 558 Invoice 11/07/2006   4911 Access Bio Chagas 128.80 0.00 0.00
567 567 Invoice 11/07/2006   4906 Institut Virion\Serion GmbH Syphilis-Secondary (untreated) 6.30 1.25079 7.88
568 568 Invoice 11/07/2006   4906 Institut Virion\Serion GmbH Syphilis-Late (untreated) 4.70 1.25106 5.88
643 643 Invoice 11/07/2006   4905 Institut Virion\Serion GmbH HIV-Venezuela 1.00 50.00 50.00
643 643 Invoice 11/07/2006   4906 Institut Virion\Serion GmbH HIV-Venezuela 177.60 1.50 266.40
663 663 Invoice 11/07/2006   4905 Institut Virion\Serion GmbH HBV-Venezuela 1.20 41.66667 50.00
663 663 Invoice 11/07/2006   4906 Institut Virion\Serion GmbH HBV-Venezuela 331.30 1.75002 579.78
663 663 Invoice 11/07/2006   4907 Institut Virion\Serion GmbH HBV-Venezuela 4.50 0.00 0.00
712 712 Invoice 11/07/2006   4906 Institut Virion\Serion GmbH HIV-Senegal 3.90 1.50 5.85
725 725 Invoice 11/07/2006   4906 Institut Virion\Serion GmbH HBsAg-Senegal 10.20 1.75 17.85
739 739 Invoice 11/07/2006   4906 Institut Virion\Serion GmbH HIV-1 (Subtype A) 28.60 15.00 429.00
740 740 Invoice 11/07/2006   4906 Institut Virion\Serion GmbH HIV-1 (Subtype G) 26.60 15.00 399.00
747 747 Invoice 11/07/2006   4906 Institut Virion\Serion GmbH HIV-Nigeria 14.60 1.50 21.90
763 763 Invoice 11/07/2006   4905 Institut Virion\Serion GmbH HBV-Senegal 1.00 50.00 50.00
763 763 Invoice 11/07/2006   4906 Institut Virion\Serion GmbH HBV-Senegal 159.50 1.74959 279.06
763 763 Invoice 11/07/2006   4907 Institut Virion\Serion GmbH HBV-Senegal 3.70 0.00 0.00
816 816 Invoice 11/07/2006   4906 Institut Virion\Serion GmbH HIV Mutation 235.40 1.50438 354.13
960 960 Invoice 11/07/2006   4911 Access Bio Lyme (European) IgM 10.00 0.00 0.00
1242 1242 Invoice 11/07/2006   4907 Institut Virion\Serion GmbH Anti-Aspergillus 2.60 0.00 0.00
1244 1244 Invoice 11/07/2006   4907 Institut Virion\Serion GmbH Bordetella Pertusis 6.50 0.00 0.00
724 724 Invoice 11/08/2006   4913 Keystone Biologicals Syphilis 83.00 0.00 0.00
543 543 Invoice 11/09/2006   4914 Bioreclamation Rheumatoid Factor 157.40 27.50 4,328.50
702 702 Invoice 11/09/2006   4915 Ortho-Clinical Diagnostics HIV-O 12.00 250.00 3,000.00
716 716 Invoice 11/09/2006   4914 Bioreclamation Rheumatoid Arthritis 148.50 27.50 4,083.75
802 802 Invoice 11/09/2006   5007 National Forensic Science Technology Ctr 10 Match Patient Sets (Blood & Semen), line item 2 90.00 27.77778 2,500.00
197 197 Invoice 11/10/2006   4918 Bio-Rad France Marnes HIVAg 102.00 3.79608 387.20
199 199 Invoice 11/10/2006   4927 AcroMetrix Europe BV Anti-HCV 11.20 0.00 0.00
643 643 Invoice 11/10/2006   4918 Bio-Rad France Marnes HIV-Venezuela 51.00 4.00 204.00
816 816 Invoice 11/10/2006   4918 Bio-Rad France Marnes HIV Mutation 51.80 4.00 207.20
855 855 Invoice 11/10/2006   4919 Roche Diagnostics GmbH HIV-Cote D'Ivoire 1.90 197.36842 375.00
1060 1060 Invoice 11/10/2006   4918 Bio-Rad France Marnes HIV-Thailand 100.80 3.98413 401.60
38 38 Invoice 11/13/2006   4926 IMMCO Diagnostics, Inc. Thyroglobulin Antibody (TgAb) 20.00 0.00 0.00
174 174 Invoice 11/13/2006   4934 HemaCare BioScience Human Plasma (Sodium Citrate) 0.60 0.00 0.00
336 336 Invoice 11/13/2006   4922 Bio Heme Anti-Dengue IgG 160.60 6.50 1,043.90
555 555 Invoice 11/13/2006   4921 Biomerieux SA-France HBsAg 800.10 10.00 8,001.00
615 615 Invoice 11/13/2006   4932 HemaCare BioScience Ovarian Cancer 1.40 0.00 0.00
628 628 Invoice 11/13/2006   4932 HemaCare BioScience CA-125 0.10 0.00 0.00
631 631 Invoice 11/13/2006   4934 HemaCare BioScience Human Plasma (CPDA) 0.10 0.00 0.00
702 702 Invoice 11/13/2006   4916 Roche Molecular Systems-NJ 4 x 2mL HIV-O Positive Specimen MBID#60736, line item 0020 8.00 200.00 1,600.00
723 723 Invoice 11/13/2006   4930 HemaCare BioScience Prostate Cancer 3.80 0.00 0.00
723 723 Invoice 11/13/2006   4933 HemaCare BioScience Prostate Cancer 36.00 0.00 0.00
807 807 Invoice 11/13/2006   4916 Roche Molecular Systems-NJ 4 x 2mL HIV-1 (Subtype B) Positive Specimen MBID#60735, line item 0010 8.00 125.00 1,000.00
1033 1033 Invoice 11/13/2006   4932 HemaCare BioScience Endometrial CA 0.10 0.00 0.00
1125 1125 Invoice 11/13/2006   4931 HemaCare BioScience TORCH IgM 2.30 0.00 0.00
64 64 Invoice 11/14/2006   4928 Abbott GmbH Anti-HBc IgM 0.90 0.00 0.00
174 174 Invoice 11/14/2006   4929 Bioreclamation Human Plasma (Sodium Citrate) 3.00 0.00 0.00
555 555 Invoice 11/14/2006   4928 Abbott GmbH HBsAg 20.00 0.00 0.00
631 631 Invoice 11/14/2006   4929 Bioreclamation Human Plasma (CPDA) 1.00 0.00 0.00
8 8 Invoice 11/15/2006   4924 DPC-Siemens Human Serum 2.00 0.00 0.00
174 174 Invoice 11/15/2006   4923 Gen-Probe, Inc. Human Plasma (Sodium Citrate) 243.10 10.28383 2,500.00
546 546 Invoice 11/15/2006   4923 Gen-Probe, Inc. Human Plasma 41.60 12.01923 500.00
621 621 Invoice 11/15/2006   4923 Gen-Probe, Inc. RPR 42.20 11.84834 500.00
723 723 Invoice 11/15/2006   4935 HemaCare BioScience Prostate Cancer 182.70 0.00 0.00
802 802 Invoice 11/15/2006   4920 Biomerieux SA-France Match Patient Set 1.00 0.00 0.00
816 816 Invoice 11/15/2006   4925 HemaCare BioScience HIV Mutation 3.90 0.00 0.00
884 884 Invoice 11/15/2006   4960 HemaCare BioScience Kidney Disorder 46.40 0.00 0.00
1105 1105 Invoice 11/15/2006   4942 HemaCare BioScience Colon CA 0.60 0.00 0.00
1125 1125 Invoice 11/15/2006   4923 Gen-Probe, Inc. TORCH IgM 120.00 12.50 1,500.00
1245 1245 Invoice 11/15/2006   4923 Gen-Probe, Inc. Hyperglobulinemia 446.60 13.43484 6,000.00
8 8 Invoice 11/16/2006   4936 Panacea Pharmaceuticals Human Serum 72.00 23.33333 1,680.00
558 558 Invoice 11/16/2006   4939 BBI 1 Chagas Positive Specimen MBID#121515 172.30 6.50 1,119.95
723 723 Invoice 11/16/2006   4937 Panacea Pharmaceuticals Prostate Cancer 182.70 24.74001 4,520.00
783 783 Invoice 11/16/2006   4940 Virginia Medical Research, Inc Ulcerative Colitis 54.20 19.37269 1,050.00
1105 1105 Invoice 11/16/2006   4938 Onconome Inc. 15 Colon CA Positive Specimens (see PO for Lot# shipped) 30.20 22.50 679.50
1143 1143 Invoice 11/16/2006   4941 Bioreclamation 1 x 5mL Sepsis Positive Specimen, line item 01 5.00 80.00 400.00
49 49 Invoice 11/17/2006   4957 The Binding Site-UK Jo-1 Antibody 650.70 6.23794 4,059.03
64 64 Invoice 11/17/2006   4959 Trina Bioreactives AG Anti-HBc IgM 3.00 0.00 0.00
336 336 Invoice 11/17/2006   4958 Omega Diagnostics 1 x 50mL Anti-Dengue IgG Positive Specimen, line item 1 50.00 12.50 625.00
615 615 Invoice 11/17/2006   4961 HemaCare Corporation Ovarian Cancer 48.80 35.16393 1,716.00
628 628 Invoice 11/17/2006   4961 HemaCare Corporation CA-125 31.70 31.98738 1,014.00
1033 1033 Invoice 11/17/2006   4961 HemaCare Corporation Endometrial CA 2.00 39.00 78.00
10 10 Invoice 11/20/2006   4962 Adaltis Developement, Inc. Anti-HTLV I/II 275.90 20.80464 5,740.00
448 448 Invoice 11/20/2006   4965 Siemens Diagnostics-NY (formerly Bayer) 30 Acute HAV Positive Specimens, line item 01 59.40 75.00 4,455.00
555 555 Invoice 11/20/2006   4965 Siemens Diagnostics-NY (formerly Bayer) 3 HBc IgM Positive Specimens, line item 02 14.30 45.00 643.50
562 562 Invoice 11/20/2006   4966 Roche Diagnostics Corporation-IN HIV-PCR 2.00 0.00 0.00
724 724 Invoice 11/20/2006   4964 Keystone Biologicals 23 RPR Positive Specimens, line item 1 4,429.70 1.25 5,537.13
1143 1143 Invoice 11/20/2006   4963 Lake Arrowhead Lab Consultants Sepsis 990.80 2.73678 2,711.60
13 13 Invoice 11/21/2006   4970 HemaCare BioScience SLE 8.90 0.00 0.00
175 175 Invoice 11/21/2006   4971 Bioreclamation Human Plasma (Sodium Heparin) 2.00 0.00 0.00
615 615 Invoice 11/21/2006   4967 Siemens Diagnostics-NY (formerly Bayer) Ovarian Cancer 85.80 18.26923 1,567.50
628 628 Invoice 11/21/2006   4967 Siemens Diagnostics-NY (formerly Bayer) CA-125 55.60 19.28957 1,072.50
1029 1029 Invoice 11/21/2006   4967 Siemens Diagnostics-NY (formerly Bayer) Lung/Ovarian CA 1.10 25.00 27.50
1033 1033 Invoice 11/21/2006   4967 Siemens Diagnostics-NY (formerly Bayer) Endometrial CA 1.10 25.00 27.50
1050 1050 Invoice 11/21/2006   4968 Center for Disease Control HCV Genotype Panel (HCVGTP-003a), line item 1 10.00 200.00 2,000.00
1052 1052 Invoice 11/21/2006   4969 Center for Disease Control HCV Genotype Panel (HCVGTP-004b), line item 2 3.00 250.00 750.00
1093 1093 Invoice 11/21/2006   4969 Center for Disease Control HCV Genotype Panel (HCVGTP-004c), line item 1 7.50 153.33333 1,150.00
1190 1190 Invoice 11/21/2006   4967 Siemens Diagnostics-NY (formerly Bayer) Peritoneal CA 2.70 10.18519 27.50
1201 1201 Invoice 11/21/2006   4967 Siemens Diagnostics-NY (formerly Bayer) Fallopian CA 1.00 27.50 27.50
199 199 Invoice 11/27/2006   4974 Roche Molecular Systems-NJ Anti-HCV 3,813.30 10.00 38,133.00
446 446 Invoice 11/27/2006   4974 Roche Molecular Systems-NJ Anti-HIV 1 1,222.00 10.00 12,220.00
547 547 Invoice 11/27/2006   4974 Roche Molecular Systems-NJ HCV-PCR 20.40 10.00 204.00
555 555 Invoice 11/27/2006   4975 Roche Molecular Systems-NJ 98 HBsAg Specimens, line item 0030 1,850.90 20.00 37,018.00
558 558 Invoice 11/27/2006   4978 AcroMetrix Europe BV 3 Chagas Positive Specimens, line item 1 26.40 14.20455 375.00
816 816 Invoice 11/27/2006   4974 Roche Molecular Systems-NJ HIV Mutation 57.40 10.00 574.00
816 816 Invoice 11/27/2006   4977 New York State Dept of Health HIV Mutation 8.00 450.00 3,600.00
991 991 Invoice 11/27/2006   4976 Roche Molecular Systems-NJ HBV Genotype Panel (HBVGTP-003a) 30.00 133.00 3,990.00
1050 1050 Invoice 11/27/2006   4976 Roche Molecular Systems-NJ HCV Genotype Panel (HCVGTP-003a) 20.00 150.00 3,000.00
1050 1050 Invoice 11/27/2006   4977 New York State Dept of Health HCV Genotype Panel (HCVGTP-003a) 10.00 202.50 2,025.00
1052 1052 Invoice 11/27/2006   4976 Roche Molecular Systems-NJ HCV Genotype Panel (HCVGTP-004b) 3.00 166.66667 500.00
1061 1061 Invoice 11/27/2006   4976 Roche Molecular Systems-NJ HBV Genotype Panel (HBVGTP-004a) 30.00 143.33333 4,300.00
1062 1062 Invoice 11/27/2006   4976 Roche Molecular Systems-NJ HCV Genotype Panel (HCVGTP-005a) 15.00 63.66667 955.00
1062 1062 Invoice 11/27/2006   4977 New York State Dept of Health HCV Genotype Panel (HCVGTP-005a) 15.00 117.00 1,755.00
1093 1093 Invoice 11/27/2006   4976 Roche Molecular Systems-NJ HCV Genotype Panel (HCVGTP-004c) 7.50 110.00 825.00
1093 1093 Invoice 11/27/2006   4977 New York State Dept of Health HCV Genotype Panel (HCVGTP-004c) 7.50 150.00 1,125.00
1097 1097 Invoice 11/27/2006   4976 Roche Molecular Systems-NJ HCV Genotype Panel (HCVGTP-002c) 15.00 43.33333 650.00
1181 1181 Invoice 11/27/2006   4976 Roche Molecular Systems-NJ HIV-1 Worldwide Subtype Panel (Lot#50051) 54.00 319.44444 17,250.00
1205 1205 Invoice 11/27/2006   4976 Roche Molecular Systems-NJ HBV Genotype Panel (Lot#60011) 60.00 163.33333 9,800.00
1206 1206 Invoice 11/27/2006   4976 Roche Molecular Systems-NJ HIV-2 Monospecific Panel (Lot#60021) 30.00 225.00 6,750.00
174 174 Invoice 11/28/2006   4980 Ciphergen Biosystems, Inc. Human Plasma (Sodium Citrate) 11.50 0.00 0.00
247 247 Invoice 11/28/2006   4981 Biokit, SA Anti-Toxoplasmosis IgM 3.00 0.00 0.00
555 555 Invoice 11/28/2006   4981 Biokit, SA HBsAg 48.00 0.00 0.00
863 863 Invoice 11/28/2006   4979 Ciphergen Biosystems, Inc. 10 Dialysis Specimens, line item 01 29.40 20.40816 600.00
13 13 Invoice 11/29/2006   4986 Bioreclamation 7 SLE Positive Specimens, line item 01 57.80 25.00 1,445.00
93 93 Invoice 11/29/2006   4990 Abbott Laboratories Total T3 192.60 11.94185 2,300.00
199 199 Invoice 11/29/2006   4982 Siemens Diagnostics-Walpole (Bayer) Anti-HCV 3.20 140.625 450.00
199 199 Invoice 11/29/2006   4999 HemaCare BioScience Anti-HCV 44.70 0.00 0.00
391 391 Invoice 11/29/2006   4990 Abbott Laboratories FREE T3 129.60 14.66049 1,900.00
391 391 Invoice 11/29/2006   4991 Abbott Laboratories FREE T3 762.10 8.43065 6,425.00
543 543 Invoice 11/29/2006   4989 Abbott Laboratories 173 x 1mL Rheumatoid Factor Positive Specimens, line item 01 249.40 31.21492 7,785.00
555 555 Invoice 11/29/2006   4987 Talecris Biotherapeutics, Inc 1 HBsAg Specimen, line item 1 9.50 20.00 190.00
589 589 Invoice 11/29/2006   4983 Siemens Diagnostics-Walpole (Bayer) HCV Genotype Panel (remainder), line item 001 0.00 50.00 0.00
589 589 Invoice 11/29/2006   4982 Siemens Diagnostics-Walpole (Bayer) HCV-Genotype 5a 1.00 200.00 200.00
702 702 Invoice 11/29/2006   4984 Roche Molecular Systems-NJ HIV-O 5.00 200.00 1,000.00
756 756 Invoice 11/29/2006   4982 Siemens Diagnostics-Walpole (Bayer) HCV - Egypt 1.00 200.00 200.00
807 807 Invoice 11/29/2006   4984 Roche Molecular Systems-NJ HIV-1 (Subtype B) 10.00 125.00 1,250.00
968 968 Invoice 11/29/2006   4982 Siemens Diagnostics-Walpole (Bayer) HCV - Indonesia 2.00 200.00 400.00
998 998 Invoice 11/29/2006   4982 Siemens Diagnostics-Walpole (Bayer) HCV-Thailand 2.00 150.00 300.00
1062 1062 Invoice 11/29/2006   4985 ARUP Labs 1 HCV Genotype Panel (HCVGTP-005a) MBID#74762, line item 001 15.00 98.33333 1,475.00
1093 1093 Invoice 11/29/2006   4982 Siemens Diagnostics-Walpole (Bayer) HCV Genotype Panel (HCVGTP-004c) 7.50 133.33333 1,000.00
1241 1241 Invoice 11/29/2006   4990 Abbott Laboratories DHEA-S 257.10 9.6266 2,475.00
10 10 Invoice 11/30/2006   4993 Abbott Laboratories Anti-HTLV I/II 203.30 18.44565 3,750.00
546 546 Invoice 11/30/2006   4992 Abbott Laboratories 4 EBV Positive Specimens, line item 01 813.70 9.46295 7,700.00
1240 1240 Invoice 11/30/2006   4994 Bioreclamation 24 CSF Positive Specimens, line item 01 77.40 12.00 928.80
199 199 Invoice 12/01/2006   5004 International Bioscience, Inc Anti-HCV 8.00 0.00 0.00
543 543 Invoice 12/01/2006   4998 International Bioscience, Inc 1 x 50mL Rheumatoid Factor Positive Specimen MBID#118862, line item 2 50.00 18.50 925.00
638 638 Invoice 12/01/2006   4996 Human GmbH 72 x 1mL EBV IgG Panel, line item 01 72.00 17.36111 1,250.00
863 863 Invoice 12/01/2006   4997 International Bioscience, Inc 100 x 1mL Dialysis Specimens, line item 1 200.00 23.75 4,750.00
1234 1234 Invoice 12/01/2006   4995 International Bioscience, Inc 250 Random Hospital Samples, line item 1 971.40 12.00 11,656.80
631 631 Invoice 12/04/2006   5003 Bioreclamation 1 Human Plasma (CPDA) Specimen MBID#84304, line item 1 190.60 4.81637 918.00
805 805 Invoice 12/04/2006   5010 HemaCare BioScience Pancreatic CA 4.10 0.00 0.00
855 855 Invoice 12/04/2006   5000 Roche Molecular Systems-NJ HIV-Cote D'Ivoire 153.80 170.6762 26,250.00
1247 1247 Invoice 12/04/2006   5002 Genentech Inc. 3 Adenocarcinoma (FFPE) Positive Specimens, per e-mail request 3.00 750.00 2,250.00
1249 1249 Invoice 12/04/2006   5005 Southern Blood Services Monoclonal IgM 2.90 0.00 0.00
8 8 Invoice 12/05/2006   5009 Siemens Diagnostics-NY (formerly Bayer) Human Serum 157.50 7.93651 1,250.00
10 10 Invoice 12/05/2006   5008 Roche Diagnostics Corporation-IN Anti-HTLV I/II 104.00 16.82692 1,750.00
13 13 Invoice 12/05/2006   5008 Roche Diagnostics Corporation-IN SLE 15.00 13.33333 200.00
199 199 Invoice 12/05/2006   5008 Roche Diagnostics Corporation-IN Anti-HCV 105.40 11.85958 1,250.00
543 543 Invoice 12/05/2006   5008 Roche Diagnostics Corporation-IN Rheumatoid Factor 29.80 10.06711 300.00
555 555 Invoice 12/05/2006   5008 Roche Diagnostics Corporation-IN HBsAg 107.00 11.68224 1,250.00
592 592 Invoice 12/05/2006   5008 Roche Diagnostics Corporation-IN ANA 48.60 10.28807 500.00
816 816 Invoice 12/05/2006   5001 Roche Diagnostics Corporation-IN HIV Mutation 71.70 48.10321 3,449.00
448 448 Invoice 12/06/2006   5012 Roche Diagnostics Corporation-IN 70 Acute HAV Positive Specimens MBID#'s 121185-121254, line item 00010 148.70 269.33423 40,050.00
702 702 Invoice 12/06/2006   5013 Roche Molecular Systems-NJ 1 x 10mL HIV-O Positive Specimen MBID#60735, line item 0010 10.00 125.00 1,250.00
807 807 Invoice 12/06/2006   5013 Roche Molecular Systems-NJ 1 x 10mL HIV-1 (Subtype B) Positive Specimen MBID#60736, line item 0020 10.00 200.00 2,000.00
816 816 Invoice 12/06/2006   5006 Roche Diagnostics Corporation-IN 2 HIV-1 EDTA Positive Specimen MBID#58388, line item 001 102.40 34.16992 3,499.00
1062 1062 Invoice 12/06/2006   5096 HemaCare BioScience HCV Genotype Panel (HCVGTP-005a) 15.00 0.00 0.00
1105 1105 Invoice 12/06/2006   5016 HemaCare BioScience Colon CA 2.10 0.00 0.00
1106 1106 Invoice 12/06/2006   5016 HemaCare BioScience Lung Cancer 0.50 0.00 0.00
565 565 Invoice 12/07/2006   5017 Virginia Medical Research, Inc 200 x 1mL CA-15-3 Positive Specimens, line item 2 200.00 18.00 3,600.00
565 565 Invoice 12/07/2006   5019 Virginia Medical Research, Inc Breast Cancer 6.80 15.88235 108.00
610 610 Invoice 12/07/2006   5019 Virginia Medical Research, Inc Colon Cancer-Active 2.10 17.14286 36.00
611 611 Invoice 12/07/2006   5019 Virginia Medical Research, Inc Lung Cancer-Active 2.00 18.00 36.00
615 615 Invoice 12/07/2006   5018 Virginia Medical Research, Inc Ovarian Cancer 70.30 17.15505 1,206.00
615 615 Invoice 12/07/2006   5019 Virginia Medical Research, Inc Ovarian Cancer 1.00 18.00 18.00
627 627 Invoice 12/07/2006   5019 Virginia Medical Research, Inc CEA 10.20 12.35294 126.00
628 628 Invoice 12/07/2006   5018 Virginia Medical Research, Inc CA-125 31.00 18.00 558.00
802 802 Invoice 12/07/2006   5014 Beckman Coulter-CA Match Patient Set 472.10 1.32387 625.00
805 805 Invoice 12/07/2006   5019 Virginia Medical Research, Inc Pancreatic CA 1.50 12.00 18.00
805 805 Invoice 12/07/2006   5020 Virginia Medical Research, Inc Pancreatic CA 28.20 15.31915 432.00
832 832 Invoice 12/07/2006   5019 Virginia Medical Research, Inc Multiple Myeloma 1.10 16.36364 18.00
1011 1011 Invoice 12/07/2006   5019 Virginia Medical Research, Inc Rectal CA 1.00 18.00 18.00
1014 1014 Invoice 12/07/2006   5019 Virginia Medical Research, Inc Colorectal CA 2.20 16.36364 36.00
1033 1033 Invoice 12/07/2006   5018 Virginia Medical Research, Inc Endometrial CA 2.00 18.00 36.00
1105 1105 Invoice 12/07/2006   5019 Virginia Medical Research, Inc Colon CA 19.60 17.44898 342.00
1106 1106 Invoice 12/07/2006   5019 Virginia Medical Research, Inc Lung Cancer 9.80 14.69388 144.00
19 19 Invoice 12/08/2006   5022 The Binding Site-UK SSB Antibody 2.00 0.00 0.00
30 30 Invoice 12/08/2006   5022 The Binding Site-UK dsDNA Antibody 0.70 0.00 0.00
31 31 Invoice 12/08/2006   5022 The Binding Site-UK SSA Antibody 2.00 0.00 0.00
32 32 Invoice 12/08/2006   5022 The Binding Site-UK RNP Antibody 3.10 0.00 0.00
575 575 Invoice 12/08/2006   5015 Human GmbH 1 x 10mL Mitochondrial Antibody Positive Specimen MBID#120743, line item 01 10.30 24.27184 250.00
575 575 Invoice 12/08/2006   5021 Orgentec Diagnostica GmbH Mitochondrial Antibody 1.40 0.00 0.00
577 577 Invoice 12/08/2006   5022 The Binding Site-UK Anti-Cardiolipin IgA 1.50 0.00 0.00
578 578 Invoice 12/08/2006   5022 The Binding Site-UK Anti-Cardiolipin IgM 2.00 0.00 0.00
707 707 Invoice 12/08/2006   5021 Orgentec Diagnostica GmbH Smooth Muscle Antibody 1.20 0.00 0.00
1233 1233 Invoice 12/08/2006   5022 The Binding Site-UK B2GP IgM 2.00 0.00 0.00
1236 1236 Invoice 12/08/2006   5022 The Binding Site-UK Sm/RNP 2.80 0.00 0.00
1237 1237 Invoice 12/08/2006   5021 Orgentec Diagnostica GmbH LKM 1.20 0.00 0.00
8 8 Invoice 12/11/2006   5066 TeraLab Human Serum 1,734.40 0.00 0.00
64 64 Invoice 12/11/2006   5023 Abbott GmbH Anti-HBc IgM 822.00 12.00 9,864.00
64 64 Invoice 12/11/2006   5024 Abbott GmbH Anti-HBc IgM 5.60 0.00 0.00
446 446 Invoice 12/11/2006   5025 Roche Molecular Systems-NJ Anti-HIV 1 112.00 43.75 4,900.00
543 543 Invoice 12/11/2006   5027 BBI Rheumatoid Factor 2.10 0.00 0.00
555 555 Invoice 12/11/2006   5023 Abbott GmbH HBsAg 410.60 8.50 3,490.10
555 555 Invoice 12/11/2006   5024 Abbott GmbH HBsAg 9.00 0.00 0.00
555 555 Invoice 12/11/2006   5063 HemaCare BioScience HBsAg 96.50 0.00 0.00
816 816 Invoice 12/11/2006   5028 HemaCare BioScience HIV Mutation 5.90 0.00 0.00
1243 1243 Invoice 12/11/2006   5066 TeraLab Normal Human Serum 14.00 0.00 0.00
8 8 Invoice 12/12/2006   5026 Institut Virion\Serion GmbH Human Serum 99.90 3.50 349.65
8 8 Invoice 12/12/2006   5030 OCD - Europe Human Serum 14.00 4.68 65.52
13 13 Invoice 12/12/2006   5030 OCD - Europe SLE 35.80 4.67989 167.54
184 184 Invoice 12/12/2006   5030 OCD - Europe Anti-CMV IgM 6.00 4.68 28.08
199 199 Invoice 12/12/2006   5030 OCD - Europe Anti-HCV 19.00 4.68 88.92
263 263 Invoice 12/12/2006   5030 OCD - Europe Anti-CMV IgG 6.00 4.68 28.08
448 448 Invoice 12/12/2006   5030 OCD - Europe Acute HAV 17.10 4.68012 80.03
543 543 Invoice 12/12/2006   5035 Keystone Biologicals Rheumatoid Factor 261.40 0.00 0.00
543 543 Invoice 12/12/2006   5043 HemaCare BioScience Rheumatoid Factor 0.10 0.00 0.00
543 543 Invoice 12/12/2006   5030 OCD - Europe Rheumatoid Factor 15.00 3.868 58.02
546 546 Invoice 12/12/2006   5026 Institut Virion\Serion GmbH Human Plasma 90.40 3.50 316.40
554 554 Invoice 12/12/2006   5030 OCD - Europe Diagnostic Specimens 1.80 4.67778 8.42
637 637 Invoice 12/12/2006   5030 OCD - Europe CMV 0.90 4.67778 4.21
638 638 Invoice 12/12/2006   5030 OCD - Europe EBV 6.20 4.68387 29.04
716 716 Invoice 12/12/2006   5030 OCD - Europe Rheumatoid Arthritis 2.00 4.68 9.36
814 814 Invoice 12/12/2006   5029 Paul-Erlich Institute HBV Genotype Panel 0.00 0.00 0.00
940 940 Invoice 12/12/2006   5031 Bioreclamation Diabetes 79.50 37.73585 3,000.00
1120 1120 Invoice 12/12/2006   5029 Paul-Erlich Institute HBVSCP-003a 37.50 208.00 7,800.00
1205 1205 Invoice 12/12/2006   5029 Paul-Erlich Institute HBV Genotype Panel (Lot#60011) 150.00 105.00 15,750.00
1242 1242 Invoice 12/12/2006   5026 Institut Virion\Serion GmbH Anti-Aspergillus 200.00 5.00 1,000.00
1243 1243 Invoice 12/12/2006   5069 OCD - Europe Normal Human Serum 3,827.30 2.22089 8,500.01
1243 1243 Invoice 12/12/2006   5030 OCD - Europe Normal Human Serum 785.20 2.29791 1,804.32
8 8 Invoice 12/13/2006   5032 Siemens Diagnostics-NY (formerly Bayer) Human Serum 308.40 8.10636 2,500.00
261 261 Invoice 12/13/2006   5033 DPC-Siemens FREE T4 30.00 11.66667 350.00
261 261 Invoice 12/13/2006   5034 DPC-Siemens FREE T4 62.80 15.32643 962.50
558 558 Invoice 12/13/2006   5042 HemaCare BioScience Chagas 33.00 0.00 0.00
448 448 Invoice 12/14/2006   5036 Abbott Laboratories Acute HAV 35.00 192.85714 6,750.00
558 558 Invoice 12/14/2006   5044 BBI Chagas 134.40 0.00 0.00
1251 1251 Invoice 12/14/2006   5040 Fisher Scientific/Chiron Blood Testing 5 Leucocyte Filters preserved with RNA Later, line item 01 5.00 195.00 975.00
63 63 Invoice 12/15/2006   5039 Orgenics Ltd. Anti-HBs 10.00 112.50 1,125.00
543 543 Invoice 12/15/2006   5038 Orgenics Ltd. 1 Rheumatoid Factor Positive Specimen, line item 1 600.00 2.25 1,350.00
724 724 Invoice 12/15/2006   5037 Trina Bioreactives AG 1 Syphilis Positive Specimen MBID#115692, as per e-mail 233.80 2.75 642.95
802 802 Invoice 12/15/2006   5041 International Bioscience, Inc Match Patient Set 26.00 17.30769 450.00
264 264 Invoice 12/18/2006   5052 OCD - Europe HBeAg 832.70 4.87571 4,060.00
322 322 Invoice 12/18/2006   5045 Abbott GmbH Anti-HAV IgM 1.00 0.00 0.00
555 555 Invoice 12/18/2006   5048 HemaCare BioScience HBsAg 0.70 0.00 0.00
707 707 Invoice 12/18/2006   5051 Roche Diagnostics GmbH Smooth Muscle Antibody 40.00 87.50 3,500.00
1252 1252 Invoice 12/18/2006   5052 OCD - Europe Anti-HBe 935.80 4.33853 4,060.00
13 13 Invoice 12/19/2006   5049 Bioreclamation SLE 410.10 21.94587 9,000.00
199 199 Invoice 12/19/2006   5056 HemaCare BioScience Anti-HCV 3.30 0.00 0.00
410 410 Invoice 12/19/2006   5053-PAID Roche Diagnostics Corporation-IN Acute HBV 45.30 210.2649 9,525.00
546 546 Invoice 12/19/2006   5047 Abbott GmbH Human Plasma Units (563,776mL), line item 01 563,776.00 0.12 67,653.12
1093 1093 Invoice 12/19/2006   5050 Celera Diagnostics HCV Genotype Panel (HCVGTP-004c) 7.50 166.66667 1,250.00
174 174 Invoice 12/20/2006   5062 HemaCare BioScience Human Plasma (Sodium Citrate) 25.20 0.00 0.00
199 199 Invoice 12/20/2006   5055 Gilead Sciences, Inc. Anti-HCV 36.10 64.81994 2,340.00
546 546 Invoice 12/20/2006   5062 HemaCare BioScience Human Plasma 2.40 0.00 0.00
621 621 Invoice 12/20/2006   5062 HemaCare BioScience RPR 3.30 0.00 0.00
1125 1125 Invoice 12/20/2006   5062 HemaCare BioScience TORCH IgM 2.30 0.00 0.00
317 317 Invoice 12/21/2006   5058 Abbott Laboratories Anti-VZV IgG 106.10 28.27521 3,000.00
171 171 Invoice 12/22/2006   5061 International Bioscience, Inc Human Plasma(EDTA-K3) 1.00 0.00 0.00
199 199 Invoice 12/22/2006   5061 International Bioscience, Inc Anti-HCV 5.20 0.00 0.00
555 555 Invoice 12/22/2006   5059 International Bioscience, Inc HBsAg 43.70 50.34325 2,200.00
814 814 Invoice 12/22/2006   5060 International Bioscience, Inc 1 HBV Genotype G Positive Specimen MBID#42974, line item 1 1.00 250.00 250.00
859 859 Invoice 12/22/2006   5059 International Bioscience, Inc HBV Match Set 12.00 45.83333 550.00
305 305 Invoice 12/26/2006   5064 Bio-Rad-Hercules,CA Anti-HBc Total 40.00 12.50 500.00
565 565 Invoice 12/26/2006   5065 HemaCare Corporation Breast Cancer 1.40 12.50 17.50
615 615 Invoice 12/26/2006   5065 HemaCare Corporation Ovarian Cancer 1.00 17.50 17.50
723 723 Invoice 12/26/2006   5065 HemaCare Corporation Prostate Cancer 1.00 17.50 17.50
920 920 Invoice 12/26/2006   5065 HemaCare Corporation Melanoma 1.10 15.90909 17.50
1105 1105 Invoice 12/26/2006   5065 HemaCare Corporation Colon CA 1.00 17.50 17.50
2 2 Invoice 12/28/2006   5071 Siemens Diagnostics-Walpole (Bayer) TSH 9.10 26.92308 245.00
10 10 Invoice 12/28/2006   5074 HemaCare BioScience Anti-HTLV I/II 50.00 0.00 0.00
13 13 Invoice 12/28/2006   5068 HemaCare BioScience SLE 16.00 0.00 0.00
261 261 Invoice 12/28/2006   5072 Siemens Diagnostics-Walpole (Bayer) FREE T4 7.90 17.72152 140.00
554 554 Invoice 12/28/2006   5071 Siemens Diagnostics-Walpole (Bayer) Diagnostic Specimens 2.50 28.00 70.00
961 961 Invoice 12/28/2006   5073 Rhode Island Hospital Parvo B-19 DNA+ 2.00 50.00 100.00
64 64 Invoice 01/02/2007   5078 Abbott GmbH 2 Anti-HBc IgM Positive Specimens MBID#'s 121629/124508, line item 1 1,705.00 12.00 20,460.00
587 587 Invoice 01/02/2007   5080 Merck & Co., Inc. 10 HCV-Genotype 3a Positive Specimens, line item 1 10.00 200.00 2,000.00
737 737 Invoice 01/02/2007   5081 Merck & Co., Inc. 20 HCV-Genotype 1 Positive Specimens, line item 1 20.00 200.00 4,000.00
998 998 Invoice 01/02/2007   5079 Abbott Laboratories HCV-Thailand 94.70 75.00 7,102.50
1205 1205 Invoice 01/02/2007   5077 AJ Roboscreen GmbH HBV Genotype Panel (Lot#60011) 15.00 210.00 3,150.00
199 199 Invoice 01/03/2007   5086 Siemens Diagnostics-CA (formerly Bayer) Anti-HCV 368.20 24.29794 8,946.50
543 543 Invoice 01/03/2007   5083 Siemens Diagnostics-Walpole (Bayer) Rheumatoid Factor 44.80 32.8125 1,470.00
592 592 Invoice 01/03/2007   5083 Siemens Diagnostics-Walpole (Bayer) ANA 50.40 31.25 1,575.00
802 802 Invoice 01/03/2007   5084 Beckman Coulter-CA Match Patient Set 389.00 1.60668 625.00
6 6 Invoice 01/05/2007   5088 Institut Virion\Serion GmbH Anti-HIV 2 231.80 55.00 12,749.00
19 19 Invoice 01/05/2007   5095 Orgentec Diagnostica GmbH SSB Antibody 1.50 0.00 0.00
30 30 Invoice 01/05/2007   5095 Orgentec Diagnostica GmbH dsDNA Antibody 1.00 0.00 0.00
31 31 Invoice 01/05/2007   5090 The Binding Site-UK SSA Antibody 756.10 10.00 7,561.00
31 31 Invoice 01/05/2007   5095 Orgentec Diagnostica GmbH SSA Antibody 1.50 0.00 0.00
32 32 Invoice 01/05/2007   5095 Orgentec Diagnostica GmbH RNP Antibody 1.50 0.00 0.00
37 37 Invoice 01/05/2007   5095 Orgentec Diagnostica GmbH SCL-70 Antibody 1.50 0.00 0.00
49 49 Invoice 01/05/2007   5095 Orgentec Diagnostica GmbH Jo-1 Antibody 1.00 0.00 0.00
171 171 Invoice 01/05/2007   5087 Trinity Biotech Plc-Ireland Human Plasma(EDTA-K3) 9,775.00 1.82007 17,791.18
264 264 Invoice 01/05/2007   5088 Institut Virion\Serion GmbH HBeAg 212.40 10.00 2,124.00
305 305 Invoice 01/05/2007   5088 Institut Virion\Serion GmbH Anti-HBc Total 262.70 5.00 1,313.50
446 446 Invoice 01/05/2007   5088 Institut Virion\Serion GmbH Anti-HIV 1 111.90 5.00 559.50
543 543 Invoice 01/05/2007   5094 Bio-Rad France Marnes Rheumatoid Factor 35.40 2.9661 105.00
577 577 Invoice 01/05/2007   5095 Orgentec Diagnostica GmbH Anti-Cardiolipin IgA 1.00 0.00 0.00
578 578 Invoice 01/05/2007   5095 Orgentec Diagnostica GmbH Anti-Cardiolipin IgM 1.50 0.00 0.00
583 583 Invoice 01/05/2007   5095 Orgentec Diagnostica GmbH Histone Antibody 2.00 0.00 0.00
584 584 Invoice 01/05/2007   5095 Orgentec Diagnostica GmbH Centromere Antibody 1.00 0.00 0.00
709 709 Invoice 01/05/2007   5095 Orgentec Diagnostica GmbH p-ANCA 0.50 0.00 0.00
710 710 Invoice 01/05/2007   5095 Orgentec Diagnostica GmbH B2GP1 1.50 0.00 0.00
802 802 Invoice 01/05/2007   5089 International Bioscience, Inc Match Patient Set 750.00 8.33333 6,250.00
1233 1233 Invoice 01/05/2007   5091 The Binding Site-UK B2GP IgM 252.60 9.89707 2,500.00
1236 1236 Invoice 01/05/2007   5095 Orgentec Diagnostica GmbH Sm/RNP 2.00 0.00 0.00
555 555 Invoice 01/08/2007   5110 HemaCare BioScience HBsAg 82.50 0.00 0.00
862 862 Invoice 01/08/2007   5116 HemaCare BioScience Autoimmune 54.80 0.00 0.00
863 863 Invoice 01/08/2007   5093 Roche Diagnostics Corporation-IN Dialysis 57.30 22.68761 1,300.00
1004 1004 Invoice 01/08/2007   5110 HemaCare BioScience HBV/HCV SCP 24.00 0.00 0.00
1024 1024 Invoice 01/08/2007   5110 HemaCare BioScience HBV NAT Seroconversion 12.00 0.00 0.00
1220 1220 Invoice 01/08/2007   5092 National Forensic Science Technology Ctr 20 x 1mL Semen Specimens, line item 1 20.00 150.00 3,000.00
10 10 Invoice 01/09/2007   5098 Abbott Laboratories Anti-HTLV I/II 273.00 13.73626 3,750.00
174 174 Invoice 01/09/2007   5113 HemaCare BioScience Human Plasma (Sodium Citrate) 0.50 0.00 0.00
546 546 Invoice 01/09/2007   5104 HemaCare BioScience Human Plasma 10.00 0.00 0.00
546 546 Invoice 01/09/2007   5105 HemaCare BioScience Human Plasma 1,870.30 0.00 0.00
13 13 Invoice 01/10/2007   5145 TeraLab SLE 3.80 0.00 0.00
174 174 Invoice 01/10/2007   5111 HemaCare BioScience Human Plasma (Sodium Citrate) 57.20 0.00 0.00
446 446 Invoice 01/10/2007   5112 HemaCare BioScience Anti-HIV 1 419.90 0.00 0.00
6 6 Invoice 01/11/2007   5102 H.D.M. Labs Inc. Anti-HIV 2 48.30 67.28778 3,250.00
10 10 Invoice 01/11/2007   5102 H.D.M. Labs Inc. Anti-HTLV I/II 51.20 15.625 800.00
10 10 Invoice 01/11/2007   5115 HemaCare BioScience Anti-HTLV I/II 0.30 0.00 0.00
225 225 Invoice 01/11/2007   5102 H.D.M. Labs Inc. Anti-Toxoplasmosis IgG 58.30 6.00343 350.00
336 336 Invoice 01/11/2007   5102 H.D.M. Labs Inc. Anti-Dengue IgG 20.90 15.311 320.00
859 859 Invoice 01/11/2007   5100 Novartis Vaccines & Diagnostics HBV Match Set 13.40 52.23881 700.00
859 859 Invoice 01/11/2007   5109 Sacred Heart Medical Center HBV Match Set 2.00 0.00 0.00
1061 1061 Invoice 01/11/2007   5100 Novartis Vaccines & Diagnostics HBV Genotype Panel (HBVGTP-004a) 15.00 210.00 3,150.00
63 63 Invoice 01/12/2007   5107 Baxter AG Anti-HBs 112.80 4.43262 500.00
171 171 Invoice 01/12/2007   5106 Innogenetics Human Plasma(EDTA-K3) 3,286.80 2.99726 9,851.39
171 171 Invoice 01/12/2007   5108 International Bioscience, Inc Human Plasma(EDTA-K3) 262.20 5.25 1,376.55
940 940 Invoice 01/12/2007   5103 American Lab Products d/b/a ALPCO D 1 Diabetes Type 1 Positive Specimen, line item 1 11.70 45.00 526.50
10 10 Invoice 01/15/2007   5117 Adaltis Developement, Inc. Anti-HTLV I/II 29.10 30.92784 900.00
10 10 Invoice 01/15/2007   5119 Ortho-Clinical Diagnostics Anti-HTLV I/II 230.70 0.00 0.00
446 446 Invoice 01/15/2007   5122 HemaCare BioScience Anti-HIV 1 138.60 0.00 0.00
578 578 Invoice 01/15/2007   5120 The Binding Site-UK Anti-Cardiolipin IgM 0.80 0.00 0.00
623 623 Invoice 01/15/2007   5118 Roche Molecular Systems-NJ HIV-2 1,722.30 0.00 0.00
788 788 Invoice 01/15/2007   5114 HemaCare BioScience HIV-Africa 1.40 0.00 0.00
1173 1173 Invoice 01/15/2007   5120 The Binding Site-UK TTG Tissue-Transglutamina 1.30 0.00 0.00
8 8 Invoice 01/17/2007   5123 Panacea Pharmaceuticals Human Serum 97.50 10.05128 980.00
546 546 Invoice 01/17/2007   5121 Roche Diagnostics GmbH Human Plasma 4,460.00 11.34753 50,609.98
565 565 Invoice 01/17/2007   5125 Virginia Medical Research, Inc Breast Cancer 5.00 22.00 110.00
611 611 Invoice 01/17/2007   5125 Virginia Medical Research, Inc Lung Cancer-Active 4.00 22.00 88.00
628 628 Invoice 01/17/2007   5125 Virginia Medical Research, Inc CA-125 5.40 20.37037 110.00
805 805 Invoice 01/17/2007   5125 Virginia Medical Research, Inc Pancreatic CA 1.90 23.15789 44.00
817 817 Invoice 01/17/2007   5125 Virginia Medical Research, Inc Stomach CA 1.00 22.00 22.00
1220 1220 Invoice 01/17/2007   5124 National Forensic Science Technology Ctr Semen 27.00 83.33333 2,250.00
13 13 Invoice 01/19/2007   5133 International Bioscience, Inc SLE 2.00 0.00 0.00
615 615 Invoice 01/19/2007   5131 International Bioscience, Inc Ovarian Cancer 12.50 66.00 825.00
628 628 Invoice 01/19/2007   5131 International Bioscience, Inc CA-125 1.00 75.00 75.00
862 862 Invoice 01/19/2007   5132 Pronostics Limited-(formerly Smartbead) Autoimmune 24.10 20.74689 500.00
1033 1033 Invoice 01/19/2007   5131 International Bioscience, Inc Endometrial CA 1.00 75.00 75.00
543 543 Invoice 01/22/2007   5136 Abbott Laboratories Rheumatoid Factor 59.10 20.55838 1,215.00
816 816 Invoice 01/22/2007   5137 Celera Diagnostics HIV Mutation 4.00 0.00 0.00
832 832 Invoice 01/22/2007   5135 Abbott Laboratories Multiple Myeloma 37.90 35.62005 1,350.00
542 542 Invoice 01/23/2007   5138 Abbott Laboratories HBV Vaccinated 71.20 42.34551 3,015.00
543 543 Invoice 01/23/2007   5140 Dx Laboratories Rheumatoid Factor 3.30 22.72727 75.00
546 546 Invoice 01/23/2007   5141 Biotecx Laboratories, Inc. Human Plasma 3.10 0.00 0.00
621 621 Invoice 01/23/2007   5140 Dx Laboratories RPR 1.00 25.00 25.00
724 724 Invoice 01/23/2007   5141 Biotecx Laboratories, Inc. Syphilis 16.90 0.00 0.00
724 724 Invoice 01/23/2007   5140 Dx Laboratories Syphilis 4.00 25.00 100.00
1220 1220 Invoice 01/23/2007   5139 National Forensic Science Technology Ctr 5 Semen Frozen Specimens, line item 1 5.00 150.00 750.00
13 13 Invoice 01/25/2007   5144 HemaCare BioScience SLE 2.20 0.00 0.00
13 13 Invoice 01/26/2007   5146 TeraLab SLE 0.70 0.00 0.00
709 709 Invoice 01/26/2007   5143 Orgentec Diagnostica GmbH p-ANCA 252.70 6.92521 1,750.00
1060 1060 Invoice 01/26/2007   5153 HemaCare BioScience HIV-Thailand 0.70 0.00 0.00
13 13 Invoice 01/29/2007   5151 Cortex Biochem, Inc. SLE 6.00 0.00 0.00
13 13 Invoice 01/29/2007   5152 Zeus Scientific SLE 10.90 0.00 0.00
546 546 Invoice 01/29/2007   5155 HemaCare BioScience Human Plasma 97.70 0.00 0.00
565 565 Invoice 01/29/2007   5148 Virginia Medical Research, Inc Breast Cancer 45.40 14.6696 666.00
565 565 Invoice 01/29/2007   5149 Virginia Medical Research, Inc Breast Cancer 1.00 18.00 18.00
565 565 Invoice 01/29/2007   5176 HemaCare BioScience Breast Cancer 8.60 0.00 0.00
589 589 Invoice 01/29/2007   5154 HemaCare BioScience HCV-Genotype 5a 0.70 0.00 0.00
610 610 Invoice 01/29/2007   5149 Virginia Medical Research, Inc Colon Cancer-Active 3.20 16.875 54.00
611 611 Invoice 01/29/2007   5149 Virginia Medical Research, Inc Lung Cancer-Active 3.10 17.41935 54.00
621 621 Invoice 01/29/2007   5151 Cortex Biochem, Inc. RPR 8.00 0.00 0.00
627 627 Invoice 01/29/2007   5149 Virginia Medical Research, Inc CEA 64.40 9.2236 594.00
631 631 Invoice 01/29/2007   5151 Cortex Biochem, Inc. Human Plasma (CPDA) 2.10 0.00 0.00
724 724 Invoice 01/29/2007   5150 Biotecx Laboratories, Inc. Syphilis 179.40 2.75 493.35
724 724 Invoice 01/29/2007   5151 Cortex Biochem, Inc. Syphilis 14.20 0.00 0.00
832 832 Invoice 01/29/2007   5148 Virginia Medical Research, Inc Multiple Myeloma 1.00 18.00 18.00
861 861 Invoice 01/29/2007   5148 Virginia Medical Research, Inc CA 15-3 47.30 17.12474 810.00
861 861 Invoice 01/29/2007   5176 HemaCare BioScience CA 15-3 32.20 0.00 0.00
1125 1125 Invoice 01/29/2007   5151 Cortex Biochem, Inc. TORCH IgM 7.20 0.00 0.00
1220 1220 Invoice 01/29/2007   5147 National Forensic Science Technology Ctr Semen 10.00 150.00 1,500.00
6 6 Invoice 01/30/2007   5156 Roche Molecular Systems-NJ Anti-HIV 2 1,140.10 53.13569 60,580.00
8 8 Invoice 01/30/2007   5160 Bio-Rad-Hercules,CA Human Serum 7.80 9.61538 75.00
13 13 Invoice 01/30/2007   5160 Bio-Rad-Hercules,CA SLE 16.00 3.75 60.00
13 13 Invoice 01/30/2007   5161 Bioreclamation SLE 122.80 24.42997 3,000.00
174 174 Invoice 01/30/2007   5160 Bio-Rad-Hercules,CA Human Plasma (Sodium Citrate) 1.00 15.00 15.00
226 226 Invoice 01/30/2007   5160 Bio-Rad-Hercules,CA Anti-HSV 1 IgG 16.30 12.26994 200.00
322 322 Invoice 01/30/2007   5157 Abbott GmbH 1 Anti-HAV IgM Positive Specimen MBID#124596, line item 1 880.00 17.50 15,400.00
446 446 Invoice 01/30/2007   5158 Thompson Health Care Anti-HIV 1 10.90 13.76147 150.00
446 446 Invoice 01/30/2007   5160 Bio-Rad-Hercules,CA Anti-HIV 1 10.00 20.00 200.00
546 546 Invoice 01/30/2007   5160 Bio-Rad-Hercules,CA Human Plasma 7.40 8.10811 60.00
621 621 Invoice 01/30/2007   5169 HemaCare BioScience RPR 6.70 0.00 0.00
724 724 Invoice 01/30/2007   5162 Biomerieux-Brazil 1 Syphilis Positive Specimen, line item 1 3,305.20 2.665 8,808.36
724 724 Invoice 01/30/2007   5169 HemaCare BioScience Syphilis 12.30 0.00 0.00
802 802 Invoice 01/30/2007   5159 Beckman Coulter-CA Match Patient Set 373.60 1.67291 625.00
1220 1220 Invoice 01/30/2007   5163 National Forensic Science Technology Ctr 10 Fresh Semen Specimens, line item 2 10.00 150.00 1,500.00
6 6 Invoice 01/31/2007   5164 Roche Molecular Systems-NJ Anti-HIV 2 967.10 99.59942 96,322.60
8 8 Invoice 01/31/2007   5167 Genentech Inc. Human Serum 328.60 1.50 492.90
317 317 Invoice 01/31/2007   5165 Abbott Laboratories Anti-VZV IgG 48.10 13.06798 628.57
589 589 Invoice 01/31/2007   5168 BBI 6 x 1mL HCV-Genotype 5a Positive Specimens, line item 1 6.00 95.00 570.00
592 592 Invoice 01/31/2007   5165 Abbott Laboratories ANA 106.30 40.20969 4,274.29
621 621 Invoice 01/31/2007   5165 Abbott Laboratories RPR 3.00 20.95333 62.86
724 724 Invoice 01/31/2007   5165 Abbott Laboratories Syphilis 15.00 25.14267 377.14
831 831 Invoice 01/31/2007   5165 Abbott Laboratories Monoclonal Gammopathy 39.10 16.07596 628.57
832 832 Invoice 01/31/2007   5165 Abbott Laboratories Multiple Myeloma 24.70 17.81377 440.00
855 855 Invoice 01/31/2007   5171 Boca Biolistics, LLC HIV-Cote D'Ivoire 251.20 14.92834 3,750.00
1015 1015 Invoice 01/31/2007   5165 Abbott Laboratories Non-Hodskins Lymphoma 11.20 16.83661 188.57
1234 1234 Invoice 01/31/2007   5166 Abbott Laboratories Random Hospital Samples 423.80 6.99387 2,964.00
550 550 Invoice 02/01/2007   5172 Siemens Diagnostics-Walpole (Bayer) Troponin I 74.10 18.21862 1,350.00
1254 1254 Invoice 02/01/2007   5172 Siemens Diagnostics-Walpole (Bayer) Elevated IgE 29.50 15.25424 450.00
199 199 Invoice 02/02/2007   5175 International Bioscience, Inc Anti-HCV 26.00 7.69231 200.00
546 546 Invoice 02/02/2007   5174 Roche Diagnostics GmbH Human Plasma 7,991.01 2.42648 19,390.03
1255 1255 Invoice 02/02/2007   5173 Baxter AG Anti-HBs (Negative) 100.00 0.00 0.00
199 199 Invoice 02/05/2007   5181 LabCorp 1 x 30mL Anti-HCV Positive Specimen MBID#46000, line item 1 31.00 36.29032 1,125.00
543 543 Invoice 02/05/2007   5177 BBI 3 x 1000mL Rheumatoid Factor Positive Specimen, line item 01 3,000.00 8.75 26,250.00
543 543 Invoice 02/05/2007   5191 HemaCare BioScience Rheumatoid Factor 0.50 0.00 0.00
554 554 Invoice 02/05/2007   5180 Siemens Diagnostics-NY (formerly Bayer) Diagnostic Specimens 57.10 17.07531 975.00
558 558 Invoice 02/05/2007   5178 BBI Chagas 1,060.90 5.99491 6,360.00
831 831 Invoice 02/05/2007   5179 Siemens Diagnostics-NY (formerly Bayer) Monoclonal Gammopathy 13.40 28.73134 385.00
831 831 Invoice 02/05/2007   5192 HemaCare BioScience Monoclonal Gammopathy 5.90 0.00 0.00
832 832 Invoice 02/05/2007   5179 Siemens Diagnostics-NY (formerly Bayer) Multiple Myeloma 1.10 31.81818 35.00
855 855 Invoice 02/05/2007   5188 VicTorch Meditek Inc HIV-Cote D'Ivoire 5.20 0.00 0.00
866 866 Invoice 02/05/2007   5180 Siemens Diagnostics-NY (formerly Bayer) Vancomycin 16.30 16.87117 275.00
1128 1128 Invoice 02/05/2007   5180 Siemens Diagnostics-NY (formerly Bayer) Phenytoin 77.50 16.12903 1,250.00
1256 1256 Invoice 02/05/2007   5189 Vital Products Cystic Fibrosis DNA 0.10 7,250.00 725.00
446 446 Invoice 02/06/2007   5182 Bio-Rad-Hercules,CA Anti-HIV 1 396.60 9.45537 3,750.00
543 543 Invoice 02/06/2007   5183 Bio-Rad-Hercules,CA Rheumatoid Factor 167.00 11.0479 1,845.00
555 555 Invoice 02/06/2007   5190 HemaCare BioScience HBsAg 1.00 0.00 0.00
627 627 Invoice 02/06/2007   5193 HemaCare BioScience CEA 51.50 0.00 0.00
716 716 Invoice 02/06/2007   5183 Bio-Rad-Hercules,CA Rheumatoid Arthritis 3.00 15.00 45.00
788 788 Invoice 02/06/2007   5184 New York State Dept of Health HIV-Africa 2.00 125.00 250.00
966 966 Invoice 02/06/2007   5184 New York State Dept of Health HIV - Indonesia 2.00 125.00 250.00
1033 1033 Invoice 02/06/2007   5193 HemaCare BioScience Endometrial CA 0.30 0.00 0.00
1050 1050 Invoice 02/06/2007   5185 Walter Reed Army Medical Center HCV Genotype Panel (HCVGTP-003a) 10.00 225.00 2,250.00
1060 1060 Invoice 02/06/2007   5184 New York State Dept of Health HIV-Thailand 15.70 127.38854 2,000.00
1105 1105 Invoice 02/06/2007   5193 HemaCare BioScience Colon CA 6.30 0.00 0.00
1106 1106 Invoice 02/06/2007   5193 HemaCare BioScience Lung Cancer 6.80 0.00 0.00
353 353 Invoice 02/07/2007   5187-PAID Virginia Medical Research, Inc Pregnancy - 3rd Trimester 15.10 18.27815 276.00
565 565 Invoice 02/07/2007   5187-PAID Virginia Medical Research, Inc Breast Cancer 4.10 17.56098 72.00
615 615 Invoice 02/07/2007   5187-PAID Virginia Medical Research, Inc Ovarian Cancer 1.00 18.00 18.00
627 627 Invoice 02/07/2007   5187-PAID Virginia Medical Research, Inc CEA 144.70 17.29095 2,502.00
1011 1011 Invoice 02/07/2007   5187-PAID Virginia Medical Research, Inc Rectal CA 3.00 12.00 36.00
1033 1033 Invoice 02/07/2007   5187-PAID Virginia Medical Research, Inc Endometrial CA 1.00 18.00 18.00
1105 1105 Invoice 02/07/2007   5187-PAID Virginia Medical Research, Inc Colon CA 36.50 16.76712 612.00
1106 1106 Invoice 02/07/2007   5187-PAID Virginia Medical Research, Inc Lung Cancer 21.10 16.20853 342.00
1143 1143 Invoice 02/07/2007   5186 Lake Arrowhead Lab Consultants Sepsis 1,480.00 2.70534 4,003.90
8 8 Invoice 02/08/2007   5254 HemaCare BioScience Human Serum 0.60 0.00 0.00
171 171 Invoice 02/08/2007   5254 HemaCare BioScience Human Plasma(EDTA-K3) 3.20 0.00 0.00
174 174 Invoice 02/08/2007   5254 HemaCare BioScience Human Plasma (Sodium Citrate) 269.10 0.00 0.00
446 446 Invoice 02/08/2007   5254 HemaCare BioScience Anti-HIV 1 0.30 0.00 0.00
546 546 Invoice 02/08/2007   5254 HemaCare BioScience Human Plasma 19.40 0.00 0.00
631 631 Invoice 02/08/2007   5254 HemaCare BioScience Human Plasma (CPDA) 4.20 0.00 0.00
1243 1243 Invoice 02/08/2007   5240 HemaCare BioScience Normal Human Serum 0.40 0.00 0.00
199 199 Invoice 02/09/2007   5211 HemaCare BioScience Anti-HCV 87.50 0.00 0.00
8 8 Invoice 02/12/2007   5203 HemaCare BioScience Human Serum 0.40 0.00 0.00
8 8 Invoice 02/12/2007   5205 HemaCare BioScience Human Serum 8.90 0.00 0.00
10 10 Invoice 02/12/2007   5197 Adaltis Developement, Inc. Anti-HTLV I/II 2.00 0.00 0.00
10 10 Invoice 02/12/2007   5204 HemaCare BioScience Anti-HTLV I/II 3.40 0.00 0.00
13 13 Invoice 02/12/2007   5194 Bio-Rad-Hercules,CA SLE 25.10 10.00 251.00
543 543 Invoice 02/12/2007   5195 Siemens Diagnostics-NY (formerly Bayer) 2 Rheumatoid Factor Positive Specimens, line item 01 2.30 43.47826 100.00
816 816 Invoice 02/12/2007   5198 HemaCare BioScience HIV Mutation 2.10 0.00 0.00
1009 1009 Invoice 02/12/2007   5196 Bioreclamation 25 x 1mL Hodskins Lymphoma Positive Specimens, line item 01 25.60 29.29688 750.00
1009 1009 Invoice 02/12/2007   5212 HemaCare BioScience Hodskins Lymphoma 21.70 0.00 0.00
10 10 Invoice 02/13/2007   5199 Adaltis Developement, Inc. Anti-HTLV I/II 150.30 29.64072 4,455.00
13 13 Invoice 02/13/2007   5202 Bioreclamation SLE 99.10 26.4884 2,625.00
550 550 Invoice 02/13/2007   5200 Siemens Diagnostics-Walpole (Bayer) Troponin I 217.50 17.24138 3,750.00
555 555 Invoice 02/13/2007   5201 Siemens Diagnostics-NY (formerly Bayer) HBsAg 19.30 45.00 868.50
8 8 Invoice 02/14/2007   5207 INOVA Diagnostics, Inc. Human Serum 62.00 1.18984 73.77
171 171 Invoice 02/14/2007   5207 INOVA Diagnostics, Inc. Human Plasma(EDTA-K3) 42.00 2.09643 88.05
174 174 Invoice 02/14/2007   5207 INOVA Diagnostics, Inc. Human Plasma (Sodium Citrate) 227.10 1.28899 292.73
175 175 Invoice 02/14/2007   5207 INOVA Diagnostics, Inc. Human Plasma (Sodium Heparin) 12.00 1.19 14.28
317 317 Invoice 02/14/2007   5217 HemaCare BioScience Anti-VZV IgG 3.90 0.00 0.00
421 421 Invoice 02/14/2007   5210 Genentech Inc. Hepatocellular Carcinoma 40.00 468.75 18,750.00
446 446 Invoice 02/14/2007   5208 Bio-Rad-Hercules,CA Anti-HIV 1 123.90 12.10654 1,500.00
546 546 Invoice 02/14/2007   5207 INOVA Diagnostics, Inc. Human Plasma 72.40 1.21616 88.05
631 631 Invoice 02/14/2007   5207 INOVA Diagnostics, Inc. Human Plasma (CPDA) 34.40 1.79855 61.87
978 978 Invoice 02/14/2007   5209 HemaCare BioScience HBV 14.60 0.00 0.00
1234 1234 Invoice 02/14/2007   5206 Abbott Laboratories Random Hospital Samples 60.30 7.9602 480.00
8 8 Invoice 02/15/2007   5216 HemaCare BioScience Human Serum 0.40 0.00 0.00
10 10 Invoice 02/15/2007   5220 HemaCare BioScience Anti-HTLV I/II 17.30 0.00 0.00
383 383 Invoice 02/15/2007   5215 Bioreclamation 60 Cerebro Spinal Fluid Positive Specimens, line item 01 198.40 11.50 2,281.60
543 543 Invoice 02/15/2007   5214 Keystone Biologicals 44 Rheumatoid Factor Positive Specimens, line item 01 134.40 10.00 1,344.00
8 8 Invoice 02/16/2007   5239 HemaCare BioScience Human Serum 0.10 0.00 0.00
10 10 Invoice 02/16/2007   5219 Innogenetics Anti-HTLV I/II 5.30 0.00 0.00
10 10 Invoice 02/16/2007   5229 HemaCare BioScience Anti-HTLV I/II 4.20 0.00 0.00
802 802 Invoice 02/16/2007   5218 International Bioscience, Inc Match Patient Set 686.20 5.02769 3,450.00
960 960 Invoice 02/16/2007   5238 HemaCare BioScience Lyme (European) IgM 2.00 0.00 0.00
8 8 Invoice 02/19/2007   5223 Abbott Laboratories Human Serum 33.10 28.83837 954.55
10 10 Invoice 02/19/2007   5228 Adaltis Developement, Inc. Anti-HTLV I/II 2.00 0.00 0.00
10 10 Invoice 02/19/2007   5221 Abbott Laboratories Anti-HTLV I/II 584.20 19.2571 11,250.00
199 199 Invoice 02/19/2007   5225-PAID Virginia Medical Research, Inc Anti-HCV 7.70 41.06753 316.22
351 351 Invoice 02/19/2007   5225-PAID Virginia Medical Research, Inc Pregnancy - 1st Trimester 30.00 19.76367 592.91
410 410 Invoice 02/19/2007   5237-PAID Abbott Laboratories Acute HBV 31.10 153.78167 4,782.61
448 448 Invoice 02/19/2007   5237-PAID Abbott Laboratories Acute HAV 50.40 232.4879 11,717.39
543 543 Invoice 02/19/2007   5225-PAID Virginia Medical Research, Inc Rheumatoid Factor 7.20 38.42917 276.69
555 555 Invoice 02/19/2007   5225-PAID Virginia Medical Research, Inc HBsAg 33.30 7.12132 237.14
565 565 Invoice 02/19/2007   5222 Bioreclamation 16 x 7mL Breast Cancer Positive Specimens, line item 01 117.70 25.00 2,942.50
565 565 Invoice 02/19/2007   5225-PAID Virginia Medical Research, Inc Breast Cancer 33.20 17.85873 592.91
615 615 Invoice 02/19/2007   5227 Virginia Medical Research, Inc Ovarian Cancer 107.10 17.92717 1,920.00
716 716 Invoice 02/19/2007   5225-PAID Virginia Medical Research, Inc Rheumatoid Arthritis 15.60 20.27051 316.22
1009 1009 Invoice 02/19/2007   5226-PAID Virginia Medical Research, Inc 27 Hodskins Lymphoma Positive Specimens, line item 01 109.10 22.50 2,454.75
1105 1105 Invoice 02/19/2007   5225-PAID Virginia Medical Research, Inc Colon CA 40.10 14.78579 592.91
1243 1243 Invoice 02/19/2007   5223 Abbott Laboratories Normal Human Serum 5.60 17.04464 95.45
1258 1258 Invoice 02/19/2007   5224 Abbott Laboratories HCV-Genotype 6 35.80 257.14525 9,205.80
10 10 Invoice 02/20/2007   5231 Boca Biolistics, LLC Anti-HTLV I/II 15.10 0.00 0.00
262 262 Invoice 02/20/2007   5232 Siemens Diagnostics-NY (formerly Bayer) Tobramycin 16.80 16.07143 270.00
554 554 Invoice 02/20/2007   5232 Siemens Diagnostics-NY (formerly Bayer) Diagnostic Specimens 3.30 13.63636 45.00
716 716 Invoice 02/20/2007   5233 HemaCare BioScience Rheumatoid Arthritis 0.30 0.00 0.00
850 850 Invoice 02/20/2007   5232 Siemens Diagnostics-NY (formerly Bayer) Cortisol 16.00 19.6875 315.00
867 867 Invoice 02/20/2007   5232 Siemens Diagnostics-NY (formerly Bayer) Carbamazepine 105.60 11.93182 1,260.00
870 870 Invoice 02/20/2007   5232 Siemens Diagnostics-NY (formerly Bayer) Theophylline 4.00 22.50 90.00
875 875 Invoice 02/20/2007   5232 Siemens Diagnostics-NY (formerly Bayer) Phenobarbital 16.80 14.73214 247.50
876 876 Invoice 02/20/2007   5232 Siemens Diagnostics-NY (formerly Bayer) Valproic Acid 52.74 11.51877 607.50
877 877 Invoice 02/20/2007   5232 Siemens Diagnostics-NY (formerly Bayer) Gentamycin 14.50 17.06897 247.50
960 960 Invoice 02/20/2007   5230 Trina Bioreactives AG 1 Lyme (European) IgM Positive Specimen MBID#120851, line item 01 294.10 5.25 1,544.03
1128 1128 Invoice 02/20/2007   5232 Siemens Diagnostics-NY (formerly Bayer) Phenytoin 20.90 13.99522 292.50
8 8 Invoice 02/21/2007   5235 Abbott Laboratories Human Serum 16.60 24.09639 400.00
199 199 Invoice 02/21/2007   5261 HemaCare BioScience Anti-HCV 3.30 0.00 0.00
317 317 Invoice 02/21/2007   5235 Abbott Laboratories Anti-VZV IgG 48.80 32.78689 1,600.00
556 556 Invoice 02/21/2007   5234 Vital Products Cardiac Specimen 3.10 32.25806 100.00
589 589 Invoice 02/21/2007   5261 HemaCare BioScience HCV-Genotype 5a 0.30 0.00 0.00
731 731 Invoice 02/21/2007   5234 Vital Products Cardiac Serial Panel 1.50 40.00 60.00
756 756 Invoice 02/21/2007   5261 HemaCare BioScience HCV - Egypt 1.10 0.00 0.00
968 968 Invoice 02/21/2007   5261 HemaCare BioScience HCV - Indonesia 1.10 0.00 0.00
1171 1171 Invoice 02/21/2007   5234 Vital Products Acute MI 1.30 30.76923 40.00
175 175 Invoice 02/22/2007   5242 HemaCare BioScience Human Plasma (Sodium Heparin) 2.70 0.00 0.00
446 446 Invoice 02/22/2007   5243 HemaCare BioScience Anti-HIV 1 0.10 0.00 0.00
555 555 Invoice 02/22/2007   5242 HemaCare BioScience HBsAg 15.30 0.00 0.00
1234 1234 Invoice 02/22/2007   5241 Abbott Laboratories Random Hospital Samples 20.10 7.76119 156.00
1259 1259 Invoice 02/22/2007   5249 Abbott GmbH HBc IgM 1.50 0.00 0.00
1260 1260 Invoice 02/22/2007   5249 Abbott GmbH HAV IgM 1.20 0.00 0.00
10 10 Invoice 02/23/2007   5251 International Bioscience, Inc Anti-HTLV I/II 1.00 0.00 0.00
13 13 Invoice 02/23/2007   5272 HemaCare BioScience SLE 7.60 0.00 0.00
199 199 Invoice 02/23/2007   5251 International Bioscience, Inc Anti-HCV 14.10 0.00 0.00
199 199 Invoice 02/23/2007   5252 HemaCare BioScience Anti-HCV 1.20 0.00 0.00
446 446 Invoice 02/23/2007   5244 Roche Diagnostics GmbH Anti-HIV 1 1,590.80 40.07418 63,750.01
555 555 Invoice 02/23/2007   5253 HemaCare BioScience HBsAg 0.70 0.00 0.00
1210 1210 Invoice 02/23/2007   5250 Dr. Fooke Laboratorien GmbH Allergy IgE 42.10 0.00 0.00
1257 1257 Invoice 02/23/2007   5250 Dr. Fooke Laboratorien GmbH PM/SCL 0.40 0.00 0.00
174 174 Invoice 02/26/2007   5247 Bio-Rad France Marnes Human Plasma (Sodium Citrate) 5.90 0.00 0.00
175 175 Invoice 02/26/2007   5247 Bio-Rad France Marnes Human Plasma (Sodium Heparin) 1.00 0.00 0.00
555 555 Invoice 02/26/2007   5247 Bio-Rad France Marnes HBsAg 42.30 0.00 0.00
807 807 Invoice 02/26/2007   5246 Oregon Medical Laboratories 1 x 1mL HIV-1 (Subtype B) Positive Specimen MBID#60735, line item 1 1.00 150.00 150.00
816 816 Invoice 02/26/2007   5248 HemaCare BioScience HIV Mutation 0.90 0.00 0.00
998 998 Invoice 02/26/2007   5245 Abbott GmbH 3 x 2mL HCV-Genotype 6 Positive Specimens, line item 1 6.00 175.00 1,050.00
8 8 Invoice 02/27/2007   5264 HemaCare BioScience Human Serum 0.20 0.00 0.00
93 93 Invoice 02/27/2007   5259 Siemens Diagnostics-Walpole (Bayer) Total T3 27.30 25.27473 690.00
199 199 Invoice 02/27/2007   5257 Virco BVBA Anti-HCV 2.20 175.00 385.00
199 199 Invoice 02/27/2007   5260 HemaCare BioScience Anti-HCV 0.80 0.00 0.00
589 589 Invoice 02/27/2007   5257 Virco BVBA HCV-Genotype 5a 6.00 250.00 1,500.00
589 589 Invoice 02/27/2007   5268 Boca Biolistics, LLC HCV-Genotype 5a 621.10 12.88037 8,000.00
590 590 Invoice 02/27/2007   5257 Virco BVBA HCV-Genotype 6a 1.10 175.00 192.50
683 683 Invoice 02/27/2007   5257 Virco BVBA HCV-Venezuela 4.40 175.00 770.00
802 802 Invoice 02/27/2007   5255 Beckman Coulter-CA Match Patient Set 374.90 1.66711 625.00
851 851 Invoice 02/27/2007   5264 HemaCare BioScience Human Serum (Male) 0.10 0.00 0.00
852 852 Invoice 02/27/2007   5264 HemaCare BioScience Human Serum (Female) 0.40 0.00 0.00
998 998 Invoice 02/27/2007   5257 Virco BVBA HCV-Thailand 19.10 175.00 3,342.50
998 998 Invoice 02/27/2007   5260 HemaCare BioScience HCV-Thailand 0.30 0.00 0.00
1137 1137 Invoice 02/27/2007   5262 HemaCare BioScience Liver Cancer 0.40 0.00 0.00
1240 1240 Invoice 02/27/2007   5258 Wash Univ of St. Louis CSF 11.00 22.72727 250.00
1240 1240 Invoice 02/27/2007   5263 HemaCare BioScience CSF 1.00 0.00 0.00
1015 1015 Invoice 02/28/2007   5265 Bioreclamation Non-Hodskins Lymphoma 44.60 24.66368 1,100.00
1015 1015 Invoice 02/28/2007   5267 HemaCare BioScience Non-Hodskins Lymphoma 37.50 0.00 0.00
1240 1240 Invoice 02/28/2007   5266 Bioreclamation 20 CSF Positive Specimens, line item 01 78.00 11.50 897.00
8 8 Invoice 03/02/2007   5270 HemaCare BioScience Human Serum 8.50 0.00 0.00
29 29 Invoice 03/02/2007   5256-VOID Productos Roche Q.F.S.A Anti-HIV 1/2 5.20 30.76923 160.00
446 446 Invoice 03/02/2007   5256-VOID Productos Roche Q.F.S.A Anti-HIV 1 52.40 31.10687 1,630.00
502 502 Invoice 03/02/2007   5269 International Bioscience, Inc CA 19 - 9 26.90 41.82156 1,125.00
562 562 Invoice 03/02/2007   5256-VOID Productos Roche Q.F.S.A HIV-PCR 3.00 31.66667 95.00
565 565 Invoice 03/02/2007   5269 International Bioscience, Inc Breast Cancer 42.60 21.12676 900.00
643 643 Invoice 03/02/2007   5256-VOID Productos Roche Q.F.S.A HIV-Venezuela 21.00 31.90476 670.00
747 747 Invoice 03/02/2007   5256-VOID Productos Roche Q.F.S.A HIV-Nigeria 5.20 30.76923 160.00
788 788 Invoice 03/02/2007   5256-VOID Productos Roche Q.F.S.A HIV-Africa 20.00 32.00 640.00
805 805 Invoice 03/02/2007   5269 International Bioscience, Inc Pancreatic CA 10.10 37.12871 375.00
807 807 Invoice 03/02/2007   5256-VOID Productos Roche Q.F.S.A HIV-1 (Subtype B) 3.00 31.66667 95.00
816 816 Invoice 03/02/2007   5256-VOID Productos Roche Q.F.S.A HIV Mutation 15.90 29.87421 475.00
855 855 Invoice 03/02/2007   5256-VOID Productos Roche Q.F.S.A HIV-Cote D'Ivoire 10.50 30.47619 320.00
919 919 Invoice 03/02/2007   5269 International Bioscience, Inc Liver Cancer - Secondary 3.40 44.11765 150.00
1049 1049 Invoice 03/02/2007   5269 International Bioscience, Inc Kidney CA 11.70 46.15385 540.00
1105 1105 Invoice 03/02/2007   5269 International Bioscience, Inc Colon CA 81.00 22.22222 1,800.00
1137 1137 Invoice 03/02/2007   5269 International Bioscience, Inc Liver Cancer 5.00 30.00 150.00
8 8 Invoice 03/05/2007   5273 HemaCare BioScience Human Serum 0.70 0.00 0.00
8 8 Invoice 03/05/2007   5274 Bio-Rad France Marnes Human Serum 1.50 0.00 0.00
8 8 Invoice 03/05/2007   5277 DRG International Inc. Human Serum 1,148.10 4.35502 5,000.00
174 174 Invoice 03/05/2007   5274 Bio-Rad France Marnes Human Plasma (Sodium Citrate) 0.50 0.00 0.00
1062 1062 Invoice 03/05/2007   5271 Roche Diagnostics GmbH HCV Genotype Panel (HCVGTP-005a) 60.00 117.00 7,020.00
1125 1125 Invoice 03/05/2007   5273 HemaCare BioScience TORCH IgM 1.20 0.00 0.00
1125 1125 Invoice 03/05/2007   5274 Bio-Rad France Marnes TORCH IgM 1.00 0.00 0.00
13 13 Invoice 03/06/2007   5318 HemaCare BioScience SLE 176.40 0.00 0.00
13 13 Invoice 03/07/2007   5280 Bio-Rad-Irvine,CA SLE 2.00 0.00 0.00
199 199 Invoice 03/07/2007   5279 Center for Disease Control Anti-HCV 1.00 250.00 250.00
199 199 Invoice 03/07/2007   5281 BioMedical Resource Anti-HCV 1.00 0.00 0.00
199 199 Invoice 03/07/2007   5278 Merck & Co., Inc. Anti-HCV 17.00 175.00 2,975.00
589 589 Invoice 03/07/2007   5279 Center for Disease Control HCV-Genotype 5a 6.00 250.00 1,500.00
589 589 Invoice 03/07/2007   5282 HemaCare BioScience HCV-Genotype 5a 1.30 0.00 0.00
968 968 Invoice 03/07/2007   5278 Merck & Co., Inc. HCV - Indonesia 11.00 175.00 1,925.00
998 998 Invoice 03/07/2007   5278 Merck & Co., Inc. HCV-Thailand 11.00 175.00 1,925.00
1222 1222 Invoice 03/07/2007   5283-PAID Abbott Laboratories Random Donors 2,250.00 13.00 29,250.00
8 8 Invoice 03/08/2007   5302 HemaCare BioScience Human Serum 0.40 0.00 0.00
13 13 Invoice 03/08/2007   5347 HemaCare BioScience SLE 285.70 0.00 0.00
543 543 Invoice 03/08/2007   5289 International Bioscience, Inc Rheumatoid Factor 33.10 18.96707 627.81
716 716 Invoice 03/08/2007   5289 International Bioscience, Inc Rheumatoid Arthritis 14.00 18.96 265.44
1137 1137 Invoice 03/08/2007   5290 International Bioscience, Inc 1 x 2mL Liver Cancer Positive Specimen, line item 2A 2.00 37.50 75.00
543 543 Invoice 03/09/2007   5284 Bio-Rad France Marnes Rheumatoid Factor 158.70 25.00 3,967.50
8 8 Invoice 03/12/2007   5291-PAID INOVA Diagnostics, Inc. 1 x 232.6mL Human Serum Specimen MBID#46953, line item 1 232.60 1.50 348.90
446 446 Invoice 03/12/2007   5285 Roche Diagnostics GmbH Anti-HIV 1 962.10 39.75678 38,250.00
546 546 Invoice 03/12/2007   5291-PAID INOVA Diagnostics, Inc. Human Plasma 196.50 1.50 294.75
802 802 Invoice 03/12/2007   5288 Beckman Coulter-CA Match Patient Set 328.70 1.90143 625.00
1123 1123 Invoice 03/12/2007   5286 Innovacon, Inc HEV 5.20 33.65385 175.00
1123 1123 Invoice 03/12/2007   5301 HemaCare BioScience HEV 0.50 0.00 0.00
1220 1220 Invoice 03/12/2007   5287 National Forensic Science Technology Ctr 20 Semen Specimens, line item 1 20.00 150.00 3,000.00
8 8 Invoice 03/13/2007   5293 Vital Products Human Serum 14.20 9.85915 140.00
10 10 Invoice 03/13/2007   5295 Adaltis Developement, Inc. Anti-HTLV I/II 1.00 0.00 0.00
199 199 Invoice 03/13/2007   5297 Boca Biolistics, LLC Anti-HCV 8.20 0.00 0.00
543 543 Invoice 03/13/2007   5294 Bioreclamation Rheumatoid Factor 44.80 25.11161 1,125.00
558 558 Invoice 03/13/2007   5296 Boca Biolistics, LLC Chagas 999.50 1.997 1,996.00
716 716 Invoice 03/13/2007   5294 Bioreclamation Rheumatoid Arthritis 29.50 25.42373 750.00
1222 1222 Invoice 03/13/2007   5292-PAID Abbott Laboratories Random Donors 1,995.00 13.00 25,935.00
446 446 Invoice 03/15/2007   5300 TeraLab Anti-HIV 1 3.00 0.00 0.00
765 765 Invoice 03/16/2007   5299 Dade Behring Marburg, GmbH 38 HBV-China Positive Specimens, line item 00010 81.90 10.00 819.00
1205 1205 Invoice 03/16/2007   5298 Dade Behring Marburg, GmbH 1 HBV Genotype Panel (Lot#60011), line item 00010 15.00 236.66667 3,550.00
8 8 Invoice 03/19/2007   5306 Siemens Diagnostics-NY (formerly Bayer) Human Serum 15.60 14.10256 220.00
247 247 Invoice 03/19/2007   5305 Siemens Diagnostics-NY (formerly Bayer) Anti-Toxoplasmosis IgM 249.60 13.55168 3,382.50
550 550 Invoice 03/19/2007   5303 Siemens Diagnostics-NY (formerly Bayer) Troponin I 305.10 14.74926 4,500.00
550 550 Invoice 03/19/2007   5304 Siemens Diagnostics-NY (formerly Bayer) Troponin I 77.20 15.44689 1,192.50
679 679 Invoice 03/19/2007   5307 Beckman Coulter-CA HBV - Nicaragua 57.10 5.51664 315.00
13 13 Invoice 03/20/2007   5309 Abbott GmbH SLE 21.30 35.21127 750.00
832 832 Invoice 03/20/2007   5310 Bio-Rad-Hercules,CA Multiple Myeloma 9.60 32.8125 315.00
832 832 Invoice 03/20/2007   5311 Abbott Laboratories 2 Total IgG Positive Replacement Samples, line item 07 10.20 0.00 0.00
13 13 Invoice 03/21/2007   5317 HemaCare BioScience SLE 2.00 0.00 0.00
171 171 Invoice 03/21/2007   5315 HemaCare BioScience Human Plasma(EDTA-K3) 3.90 0.00 0.00
171 171 Invoice 03/21/2007   5349 HemaCare BioScience Human Plasma(EDTA-K3) 250.00 0.00 0.00
199 199 Invoice 03/21/2007   5313 Roche Molecular Systems-NJ Anti-HCV 11.00 56.81818 625.00
546 546 Invoice 03/21/2007   5314 INOVA Diagnostics, Inc. Human Plasma 291.50 1.50 437.25
555 555 Invoice 03/21/2007   5316 HemaCare BioScience HBsAg 0.40 0.00 0.00
800 800 Invoice 03/21/2007   5315 HemaCare BioScience Hemoglobin 0.30 0.00 0.00
856 856 Invoice 03/21/2007   5316 HemaCare BioScience HBV-Cote D'Ivoire 0.60 0.00 0.00
859 859 Invoice 03/21/2007   5316 HemaCare BioScience HBV Match Set 0.60 0.00 0.00
930 930 Invoice 03/21/2007   5316 HemaCare BioScience HBV (Genotype G) 0.50 0.00 0.00
1222 1222 Invoice 03/21/2007   5312-PAID Abbott Laboratories Random Donors 2,007.00 13.01943 26,130.00
8 8 Invoice 03/22/2007   5362 TeraLab Human Serum 1.50 0.00 0.00
13 13 Invoice 03/22/2007   5319 Bioreclamation SLE 73.00 25.68493 1,875.00
592 592 Invoice 03/22/2007   5362 TeraLab ANA 1.50 0.00 0.00
716 716 Invoice 03/22/2007   5362 TeraLab Rheumatoid Arthritis 3.20 0.00 0.00
1264 1264 Invoice 03/22/2007   5456 Sequenom Pregnancy (Rh-) 26.00 0.00 0.00
13 13 Invoice 03/23/2007   5331 Human GmbH SLE 31.20 20.19231 630.00
174 174 Invoice 03/23/2007   5323 HemaCare BioScience Human Plasma (Sodium Citrate) 3.90 0.00 0.00
175 175 Invoice 03/23/2007   5323 HemaCare BioScience Human Plasma (Sodium Heparin) 107.90 0.00 0.00
199 199 Invoice 03/23/2007   5322 Tibotec BVBA Anti-HCV 39.60 70.00 2,772.00
546 546 Invoice 03/23/2007   5323 HemaCare BioScience Human Plasma 5.10 0.00 0.00
555 555 Invoice 03/23/2007   5320 Bio-Rad France Marnes HBsAg 1,647.80 5.00 8,239.00
998 998 Invoice 03/23/2007   5322 Tibotec BVBA HCV-Thailand 4.00 70.00 280.00
1181 1181 Invoice 03/23/2007   5321 Bio-Rad France Marnes 1 HIV-1 Worldwide Subtype Panel (Lot#50051), line item 1 18.00 444.44444 8,000.00
8 8 Invoice 03/26/2007   5326 INOVA Diagnostics, Inc. Human Serum 200.80 1.49402 300.00
171 171 Invoice 03/26/2007   5324 Roche Molecular Systems-NJ Human Plasma(EDTA-K3) 7.30 11.9863 87.50
174 174 Invoice 03/26/2007   5326 INOVA Diagnostics, Inc. Human Plasma (Sodium Citrate) 200.30 1.49775 300.00
175 175 Invoice 03/26/2007   5326 INOVA Diagnostics, Inc. Human Plasma (Sodium Heparin) 100.30 1.49551 150.00
199 199 Invoice 03/26/2007   5328 Center for Disease Control Anti-HCV 2.00 150.00 300.00
546 546 Invoice 03/26/2007   5326 INOVA Diagnostics, Inc. Human Plasma 201.10 1.4918 300.00
555 555 Invoice 03/26/2007   5325-PAID John's Hopkins Hospital HBsAg 2.10 185.71429 390.00
631 631 Invoice 03/26/2007   5326 INOVA Diagnostics, Inc. Human Plasma (CPDA) 200.20 1.4985 300.00
663 663 Invoice 03/26/2007   5325-PAID John's Hopkins Hospital HBV-Venezuela 1.00 195.00 195.00
756 756 Invoice 03/26/2007   5328 Center for Disease Control HCV - Egypt 3.00 150.00 450.00
756 756 Invoice 03/26/2007   5330 HemaCare BioScience HCV - Egypt 2.20 0.00 0.00
800 800 Invoice 03/26/2007   5324 Roche Molecular Systems-NJ Hemoglobin 5.00 12.50 62.50
856 856 Invoice 03/26/2007   5325-PAID John's Hopkins Hospital HBV-Cote D'Ivoire 1.00 195.00 195.00
859 859 Invoice 03/26/2007   5325-PAID John's Hopkins Hospital HBV Match Set 1.10 177.27273 195.00
930 930 Invoice 03/26/2007   5325-PAID John's Hopkins Hospital HBV (Genotype G) 1.00 195.00 195.00
967 967 Invoice 03/26/2007   5325-PAID John's Hopkins Hospital HBV - Indonesia 1.00 195.00 195.00
968 968 Invoice 03/26/2007   5328 Center for Disease Control HCV - Indonesia 6.10 147.54098 900.00
1046 1046 Invoice 03/26/2007   5327-PAID Abbott Laboratories Preeclampsia (3rd Trimester) 3.20 42.1875 135.00
1163 1163 Invoice 03/26/2007   5327-PAID Abbott Laboratories Preeclampsia 37.20 43.54839 1,620.00
1259 1259 Invoice 03/26/2007   5329 Abbott GmbH 2 Anti-HBc IgM Positive Specimens MBID#'s 129113/129114, line item 1 1,558.80 12.00 18,705.60
844 844 Invoice 03/27/2007   5351 HemaCare BioScience HCV Patient-Match Set 1.10 0.00 0.00
1222 1222 Invoice 03/27/2007   5332-PAID Abbott Laboratories 240 x 5mL Random Donors Specimens, line item 01 1,240.00 12.58065 15,600.01
1222 1222 Invoice 03/27/2007   5333-PAID Abbott Laboratories 152 x 5mL Random Donors Specimens, line item 01 763.90 12.93363 9,880.00
1264 1264 Invoice 03/27/2007   5457 Sequenom Pregnancy (Rh-) 13.50 0.00 0.00
1265 1265 Invoice 03/27/2007   5335 Roche Molecular Systems-NJ Cadaveric Specimen 57.00 103.07018 5,875.00
8 8 Invoice 03/28/2007   5342 HemaCare BioScience Human Serum 0.50 0.00 0.00
174 174 Invoice 03/28/2007   5342 HemaCare BioScience Human Plasma (Sodium Citrate) 0.30 0.00 0.00
843 843 Invoice 03/28/2007   5337 Abbott Laboratories Non-Viral Liver Disease 43.50 51.72414 2,250.00
995 995 Invoice 03/28/2007   5342 HemaCare BioScience HIV and HCV Co-infection 4.30 0.00 0.00
1050 1050 Invoice 03/28/2007   5336 OraSure Technologies, Inc. 1 HCV Genotype Panel (HCVGTP-003a), line item 0010 10.00 225.00 2,250.00
174 174 Invoice 03/29/2007   5341 MP Biomedicals Asia Pacific Pte Ltd. Human Plasma (Sodium Citrate) 21.20 0.00 0.00
621 621 Invoice 03/29/2007   5341 MP Biomedicals Asia Pacific Pte Ltd. RPR 1.00 0.00 0.00
716 716 Invoice 03/29/2007   5339 Bioreclamation 2 Rheumatoid Arthritis Positive Specimens, line item 1 26.70 28.08989 750.00
1240 1240 Invoice 03/29/2007   5338 Bioreclamation 17 CSF Positive Specimens, line item 01 72.80 11.50 837.20
13 13 Invoice 03/30/2007   5334 The Binding Site-UK SLE 2.00 0.00 0.00
13 13 Invoice 03/30/2007   5350 HemaCare BioScience SLE 0.60 0.00 0.00
199 199 Invoice 03/30/2007   5340 International Bioscience, Inc Anti-HCV 373.60 12.50 4,670.00
199 199 Invoice 04/02/2007   5345 Roche Molecular Systems-NJ Anti-HCV 5.10 0.00 0.00
199 199 Invoice 04/02/2007   5346 HemaCare BioScience Anti-HCV 0.20 0.00 0.00
555 555 Invoice 04/02/2007   5343 Vital Products 4 HBCore IgM Positive Specimens, line item 01 8.00 12.50 100.00
624 624 Invoice 04/02/2007   5348 HemaCare BioScience HCV-Genotype 2a/2c 0.40 0.00 0.00
756 756 Invoice 04/02/2007   5345 Roche Molecular Systems-NJ HCV - Egypt 3.70 0.00 0.00
998 998 Invoice 04/02/2007   5345 Roche Molecular Systems-NJ HCV-Thailand 2.00 0.00 0.00
10 10 Invoice 04/03/2007   5352-PAID Adaltis Developement, Inc. 23 Anti-HTLV I/II Positive Specimens, line item 2.000 28.90 47.75087 1,380.00
10 10 Invoice 04/03/2007   5353-PAID Adaltis Developement, Inc. 105 Anti-HTLV I/II Positive Specimens, line item 1.000 166.40 37.86058 6,300.00
199 199 Invoice 04/03/2007   5354 Roche Molecular Systems-NJ 1 x 7mL Anti-HCV Viral Positive Specimen, line item 0010 7.00 62.50 437.50
802 802 Invoice 04/03/2007   5344-PAID Beckman Coulter-CA Match Patient Set 372.30 1.67875 625.00
446 446 Invoice 04/04/2007   5360 HemaCare BioScience Anti-HIV 1 0.50 0.00 0.00
535 535 Invoice 04/04/2007   5360 HemaCare BioScience Hemolyzed 0.10 0.00 0.00
995 995 Invoice 04/04/2007   5356 OraSure Technologies, Inc. HIV and HCV Co-infection 40.70 12.89926 525.00
1052 1052 Invoice 04/04/2007   5356 OraSure Technologies, Inc. HCV Genotype Panel (HCVGTP-004b) 3.00 250.00 750.00
1062 1062 Invoice 04/04/2007   5356 OraSure Technologies, Inc. HCV Genotype Panel (HCVGTP-005a) 15.00 130.00 1,950.00
1093 1093 Invoice 04/04/2007   5356 OraSure Technologies, Inc. HCV Genotype Panel (HCVGTP-004c) 7.50 166.66667 1,250.00
1097 1097 Invoice 04/04/2007   5356 OraSure Technologies, Inc. HCV Genotype Panel (HCVGTP-002c) 15.00 63.33333 950.00
1220 1220 Invoice 04/04/2007   5361 HemaCare BioScience Semen 5.00 0.00 0.00
1222 1222 Invoice 04/04/2007   5355 Abbott Laboratories 399 x 5mL Random Donors Specimens, line item 01 1,995.00 13.00 25,935.00
558 558 Invoice 04/05/2007   5359 BBI Chagas 15.10 0.00 0.00
724 724 Invoice 04/05/2007   5359 BBI Syphilis 82.90 0.00 0.00
831 831 Invoice 04/05/2007   5358 Abbott Laboratories 1 x 4mL Monoclonal Gammopathy Replacement Specimen MBID#75475, line item 06 4.00 0.00 0.00
998 998 Invoice 04/05/2007   5357 Roche Molecular Systems-NJ HCV-Thailand 2.00 0.00 0.00
547 547 Invoice 04/06/2007   5363 International Bioscience, Inc HCV-PCR 70.00 0.00 0.00
8 8 Invoice 04/09/2007   5366 Bio-Rad France Marnes Human Serum 71.00 35.00 2,485.00
29 29 Invoice 04/09/2007   5419 Boca Biolistics, LLC Anti-HIV 1/2 614.50 1.75001 1,075.38
40 40 Invoice 04/09/2007   5368 Trinity Biotech-USA Anti-EBV VCA IgG 3.60 0.00 0.00
174 174 Invoice 04/09/2007   5368 Trinity Biotech-USA Human Plasma (Sodium Citrate) 1.00 0.00 0.00
174 174 Invoice 04/09/2007   5369 HemaCare BioScience Human Plasma (Sodium Citrate) 5.00 0.00 0.00
184 184 Invoice 04/09/2007   5366 Bio-Rad France Marnes Anti-CMV IgM 58.20 35.00 2,037.00
446 446 Invoice 04/09/2007   5419 Boca Biolistics, LLC Anti-HIV 1 196.20 1.75 343.35
543 543 Invoice 04/09/2007   5369 HemaCare BioScience Rheumatoid Factor 0.10 0.00 0.00
546 546 Invoice 04/09/2007   5368 Trinity Biotech-USA Human Plasma 1.00 0.00 0.00
716 716 Invoice 04/09/2007   5369 HemaCare BioScience Rheumatoid Arthritis 0.40 0.00 0.00
788 788 Invoice 04/09/2007   5419 Boca Biolistics, LLC HIV-Africa 725.60 1.75 1,269.80
849 849 Invoice 04/09/2007   5367 Siemens Diagnostics-Walpole (Bayer) 18 Prolactin Positive Specimens (>50 ng/mL), line item 001 32.50 19.38462 630.00
990 990 Invoice 04/09/2007   5368 Trinity Biotech-USA Lyme (European) 2.00 0.00 0.00
1210 1210 Invoice 04/09/2007   5364 Dr. Fooke Laboratorien GmbH Allergy IgE 1,677.00 3.75 6,288.75
1222 1222 Invoice 04/09/2007   5365-PAID Abbott Laboratories 175 x 5mL Random Donors Specimens, line item 01 875.00 13.00 11,375.00
1264 1264 Invoice 04/10/2007   5458 Sequenom Pregnancy (Rh-) 38.50 0.00 0.00
174 174 Invoice 04/11/2007   5371-PAID Bio-Rad-Hercules,CA Human Plasma (Sodium Citrate) 110.70 22.45935 2,486.25
227 227 Invoice 04/11/2007   5371-PAID Bio-Rad-Hercules,CA Anti-HSV 2 IgG 8.40 17.50 147.00
410 410 Invoice 04/11/2007   5370-PAID Abbott Laboratories Acute HBV 15.60 96.15385 1,500.00
446 446 Invoice 04/11/2007   5372 Siemens Diagnostics-NY (formerly Bayer) Anti-HIV 1 70.00 0.00 0.00
448 448 Invoice 04/11/2007   5370-PAID Abbott Laboratories Acute HAV 3.70 202.7027 750.00
543 543 Invoice 04/11/2007   5371-PAID Bio-Rad-Hercules,CA Rheumatoid Factor 7.50 32.66667 245.00
546 546 Invoice 04/11/2007   5371-PAID Bio-Rad-Hercules,CA Human Plasma 2.00 22.50 45.00
716 716 Invoice 04/11/2007   5371-PAID Bio-Rad-Hercules,CA Rheumatoid Arthritis 13.20 26.51515 350.00
788 788 Invoice 04/11/2007   5372 Siemens Diagnostics-NY (formerly Bayer) HIV-Africa 100.00 0.00 0.00
966 966 Invoice 04/11/2007   5372 Siemens Diagnostics-NY (formerly Bayer) HIV - Indonesia 6.00 0.00 0.00
1060 1060 Invoice 04/11/2007   5372 Siemens Diagnostics-NY (formerly Bayer) HIV-Thailand 40.00 0.00 0.00
550 550 Invoice 04/12/2007   5373 Siemens Diagnostics-NY (formerly Bayer) Troponin I 126.90 16.31206 2,070.00
922 922 Invoice 04/12/2007   5374 HemaCare BioScience Chronic Heart Failure - Class I 2.60 0.00 0.00
171 171 Invoice 04/13/2007   5406 HemaCare BioScience Human Plasma(EDTA-K3) 150.20 0.00 0.00
998 998 Invoice 04/13/2007   5406 HemaCare BioScience HCV-Thailand 7.20 0.00 0.00
8 8 Invoice 04/16/2007   5382 HemaCare BioScience Human Serum 40.00 0.00 0.00
10 10 Invoice 04/16/2007   5377-PAID Abbott GmbH Anti-HTLV I/II 172.20 45.73171 7,875.00
10 10 Invoice 04/16/2007   5380 Adaltis Developement, Inc. Anti-HTLV I/II 27.20 0.00 0.00
174 174 Invoice 04/16/2007   5381 Siemens Diagnostics-CA (formerly Bayer) Human Plasma (Sodium Citrate) 7.40 0.00 0.00
199 199 Invoice 04/16/2007   5378 Abbott GmbH Anti-HCV 2.00 0.00 0.00
199 199 Invoice 04/16/2007   5383 HemaCare BioScience Anti-HCV 0.20 0.00 0.00
446 446 Invoice 04/16/2007   5375 Roche Diagnostics GmbH Anti-HIV 1 230.90 25.98528 6,000.00
446 446 Invoice 04/16/2007   5376 Roche Diagnostics GmbH Anti-HIV 1 55.60 53.95683 3,000.00
547 547 Invoice 04/16/2007   5378 Abbott GmbH HCV-PCR 10.00 0.00 0.00
1259 1259 Invoice 04/16/2007   5379 Abbott GmbH HBc IgM 3.10 0.00 0.00
1260 1260 Invoice 04/16/2007   5379 Abbott GmbH HAV IgM 0.70 0.00 0.00
1222 1222 Invoice 04/17/2007   5389 Abbott Laboratories Random Donors 1,870.00 13.00 24,310.00
1265 1265 Invoice 04/17/2007   5390 Roche Molecular Systems-NJ Cadaveric Specimen 115.40 132.36568 15,275.00
174 174 Invoice 04/18/2007   5393 Siemens Diagnostics-CA (formerly Bayer) Human Plasma (Sodium Citrate) 2.00 0.00 0.00
199 199 Invoice 04/18/2007   5448 HemaCare BioScience Anti-HCV 2.60 0.00 0.00
555 555 Invoice 04/18/2007   5395 HemaCare BioScience HBsAg 0.80 0.00 0.00
855 855 Invoice 04/18/2007   5394 HemaCare BioScience HIV-Cote D'Ivoire 0.20 0.00 0.00
968 968 Invoice 04/18/2007   5448 HemaCare BioScience HCV - Indonesia 4.10 0.00 0.00
1143 1143 Invoice 04/18/2007   5396-PAID Lake Arrowhead Lab Consultants Sepsis 2,019.80 2.71562 5,485.01
1234 1234 Invoice 04/18/2007   5391-PAID Abbott Laboratories Random Hospital Samples 295.70 7.10179 2,100.00
1234 1234 Invoice 04/18/2007   5392-PAID Abbott Laboratories Random Hospital Samples 235.90 8.90208 2,100.00
13 13 Invoice 04/19/2007   5400-PAID Bioreclamation SLE 42.80 25.36285 1,085.53
199 199 Invoice 04/19/2007   5403 HemaCare BioScience Anti-HCV 0.70 0.00 0.00
410 410 Invoice 04/19/2007   5398-PAID Abbott Laboratories 6 Acute HBV Reactive Specimens, line item 01 13.80 163.04348 2,250.00
448 448 Invoice 04/19/2007   5397-PAID Abbott Laboratories Acute HAV 36.60 235.65574 8,625.00
543 543 Invoice 04/19/2007   5400-PAID Bioreclamation Rheumatoid Factor 100.00 26.6447 2,664.47
922 922 Invoice 04/19/2007   5399-PAID Abbott Laboratories Chronic Heart Failure - Class I 11.20 53.98571 604.64
923 923 Invoice 04/19/2007   5399-PAID Abbott Laboratories Chronic Heart Failure - Class II 12.10 38.43967 465.12
924 924 Invoice 04/19/2007   5399-PAID Abbott Laboratories Chronic Heart Failure - Class III 11.40 40.80 465.12
960 960 Invoice 04/19/2007   5404 BBI Lyme (European) IgM 6.00 0.00 0.00
1098 1098 Invoice 04/19/2007   5399-PAID Abbott Laboratories BNP 11.90 39.08571 465.12
174 174 Invoice 04/20/2007   5401 International Bioscience, Inc 5 HCV Negative Specimens, line item 1B 50.87 19.65795 1,000.00
199 199 Invoice 04/20/2007   5401 International Bioscience, Inc 6 Anti-HCV Positive Specimens, line item 1A 48.80 73.77049 3,600.00
621 621 Invoice 04/20/2007   5405 Genzyme Virotech, GmbH RPR 19.00 0.00 0.00
724 724 Invoice 04/20/2007   5405 Genzyme Virotech, GmbH Syphilis 88.10 0.00 0.00
1243 1243 Invoice 04/20/2007   5402-PAID MP Biomedicals Asia Pacific Pte Ltd. 500 x 5mL Normal Human Serum Specimens, line item 1 2,501.00 2.39904 6,000.00
1 1 Invoice 04/23/2007   5408-PAID Bio-Rad-Hercules,CA PSA 3.20 14.0625 45.00
8 8 Invoice 04/23/2007   5408-PAID Bio-Rad-Hercules,CA Human Serum 64.50 13.48837 870.00
8 8 Invoice 04/23/2007   5411 HemaCare BioScience Human Serum 5.80 0.00 0.00
8 8 Invoice 04/23/2007   5414 Zeus Scientific Human Serum 1.00 0.00 0.00
199 199 Invoice 04/23/2007   5407 Merck & Co., Inc. Anti-HCV 72.60 75.00 5,445.00
199 199 Invoice 04/23/2007   5412 Roche Molecular Systems-NJ Anti-HCV 7.80 0.00 0.00
225 225 Invoice 04/23/2007   5408-PAID Bio-Rad-Hercules,CA Anti-Toxoplasmosis IgG 14.00 15.00 210.00
543 543 Invoice 04/23/2007   5410-PAID Bio-Rad-Hercules,CA Rheumatoid Factor 23.70 30.00 711.00
555 555 Invoice 04/23/2007   5409-PAID Beckman Coulter-MN HBsAg 4.00 7.50 30.00
631 631 Invoice 04/23/2007   5414 Zeus Scientific Human Plasma (CPDA) 5.40 0.00 0.00
679 679 Invoice 04/23/2007   5409-PAID Beckman Coulter-MN HBV - Nicaragua 93.00 5.80645 540.00
716 716 Invoice 04/23/2007   5410-PAID Bio-Rad-Hercules,CA Rheumatoid Arthritis 16.80 30.00 504.00
961 961 Invoice 04/23/2007   5413 Roche Molecular Systems-NJ Parvo B-19 DNA+ 2.00 0.00 0.00
968 968 Invoice 04/23/2007   5407 Merck & Co., Inc. HCV - Indonesia 72.60 75.00 5,445.00
998 998 Invoice 04/23/2007   5412 Roche Molecular Systems-NJ HCV-Thailand 12.00 0.00 0.00
1125 1125 Invoice 04/23/2007   5414 Zeus Scientific TORCH IgM 12.30 0.00 0.00
446 446 Invoice 04/24/2007   5427 HemaCare BioScience Anti-HIV 1 1.20 0.00 0.00
546 546 Invoice 04/24/2007   5416-PAID Siemens Diagnostics-CA (formerly Bayer) Human Plasma 2,514.60 4.97097 12,500.00
558 558 Invoice 04/24/2007   5417 BBI 10 Chagas Positive Specimens, line item 1 1,863.20 6.00 11,179.20
1243 1243 Invoice 04/24/2007   5418-PAID Siemens Diagnostics-NY (formerly Bayer) 46 Fresh Normal Human Serum Specimens, line item 01 138.00 10.00 1,380.00
1264 1264 Invoice 04/24/2007   5459 Sequenom Pregnancy (Rh-) 78.00 0.00 0.00
1272 1272 Invoice 04/24/2007   5415 Zeptometrix Tuberculosis 400.00 0.00 0.00
802 802 Invoice 04/25/2007   5420-PAID Applied Biosystems Match Patient Set 1,100.00 1.81818 2,000.00
1243 1243 Invoice 04/25/2007   5421-PAID Siemens Diagnostics-NY (formerly Bayer) Normal Human Serum 204.00 7.50 1,530.00
592 592 Invoice 04/26/2007   5447 HemaCare BioScience ANA 8.80 0.00 0.00
1243 1243 Invoice 04/26/2007   5426-PAID Siemens Diagnostics-NY (formerly Bayer) 53 Fresh Normal Human Serum Specimens, line item 01 212.00 7.50 1,590.00
174 174 Invoice 04/27/2007   5435 Dr. Fooke Laboratorien GmbH Human Plasma (Sodium Citrate) 7.20 0.00 0.00
446 446 Invoice 04/27/2007   5425-PAID Institut Virion\Serion GmbH 10 x 1mL Anti-HIV 1 Positive Specimens, line item 1 10.90 32.11009 350.00
8 8 Invoice 04/30/2007   5438 HemaCare BioScience Human Serum 1.90 0.00 0.00
10 10 Invoice 04/30/2007   5423-PAID Adaltis Developement, Inc. 128 Anti-HTLV I/II Positive Specimens, line item 1.000 176.10 43.61158 7,680.00
29 29 Invoice 04/30/2007   5431-PAID Siemens Diagnostics-Walpole (Bayer) 1 x 2mL Anti-HIV Positive Specimen MBID#55350, line item 001 2.00 175.00 350.00
29 29 Invoice 04/30/2007   5439 HemaCare BioScience Anti-HIV 1/2 0.40 0.00 0.00
174 174 Invoice 04/30/2007   5430-PAID Trinity Biotech-USA 1 Human Plasma IgG Positive Specimen MBID#33762, line item 2 765.90 3.00 2,297.70
322 322 Invoice 04/30/2007   5434-PAID ViroMed Laboratories Anti-HAV IgM 3.00 25.00 75.00
448 448 Invoice 04/30/2007   5434-PAID ViroMed Laboratories Acute HAV 47.00 19.68085 925.00
546 546 Invoice 04/30/2007   5430-PAID Trinity Biotech-USA 1 Human Plasma IgG Positive Specimen MBID#24826, line item 1 696.00 3.00 2,088.00
555 555 Invoice 04/30/2007   5434-PAID ViroMed Laboratories HBsAg 7.00 25.00 175.00
555 555 Invoice 04/30/2007   5436 Beckman Coulter-MN 2 x 2mL HBsAg MBID#116342 4.00 0.00 0.00
679 679 Invoice 04/30/2007   5436 Beckman Coulter-MN 2 x 2mL HBV - Nicaragua MBID#100805 4.00 0.00 0.00
855 855 Invoice 04/30/2007   5431-PAID Siemens Diagnostics-Walpole (Bayer) HIV-Cote D'Ivoire 2.00 175.00 350.00
855 855 Invoice 04/30/2007   5439 HemaCare BioScience HIV-Cote D'Ivoire 0.10 0.00 0.00
1062 1062 Invoice 04/30/2007   5424-PAID St. John Medical Center HCV Genotype Panel (HCVGTP-005a) 15.00 98.33333 1,475.00
1093 1093 Invoice 04/30/2007   5424-PAID St. John Medical Center HCV Genotype Panel (HCVGTP-004c) 7.50 100.00 750.00
1097 1097 Invoice 04/30/2007   5424-PAID St. John Medical Center HCV Genotype Panel (HCVGTP-002c) 15.00 66.66667 1,000.00
1143 1143 Invoice 04/30/2007   5433-PAID Lake Arrowhead Lab Consultants Sepsis 881.90 3.00159 2,647.10
1243 1243 Invoice 04/30/2007   5429-PAID Siemens Diagnostics-NY (formerly Bayer) 50 Fresh Normal Human Serum Specimens, line item 01 198.90 7.54148 1,500.00
1267 1267 Invoice 04/30/2007   5437 HemaCare BioScience Dengue 2.00 0.00 0.00
1269 1269 Invoice 04/30/2007   5432 Roche Molecular Systems-NJ 30 x 6mL HCV Genotype Panels (Lot#70011), line item 0010 186.00 177.41935 33,000.00
1 1 Invoice 05/01/2007   5444-PAID DRG International Inc. PSA 15.10 6.68411 100.93
8 8 Invoice 05/01/2007   5444-PAID DRG International Inc. Human Serum 235.30 11.15257 2,624.20
178 178 Invoice 05/01/2007   5444-PAID DRG International Inc. H. Pylori 77.50 6.51161 504.65
199 199 Invoice 05/01/2007   5446 HemaCare BioScience Anti-HCV 396.00 0.00 0.00
446 446 Invoice 05/01/2007   5444-PAID DRG International Inc. Anti-HIV 1 92.70 9.25469 857.91
535 535 Invoice 05/01/2007   5444-PAID DRG International Inc. Hemolyzed 15.40 6.5539 100.93
592 592 Invoice 05/01/2007   5442-PAID Pronostics Limited-(formerly Smartbead) 48 x .5-1mL ANA Positive Specimens, line item 1 48.00 20.00 960.00
724 724 Invoice 05/01/2007   5444-PAID DRG International Inc. Syphilis 62.20 8.92492 555.13
1243 1243 Invoice 05/01/2007   5445-PAID Siemens Diagnostics-NY (formerly Bayer) 50 Fresh Normal Human Serum Specimens, line item 01 210.20 7.13606 1,500.00
1267 1267 Invoice 05/01/2007   5443-PAID H.D.M. Labs Inc. 6 x 5mL Anti-Dengue IgG Positive Specimens, line item 5 30.70 15.63518 480.00
1243 1243 Invoice 05/02/2007   5449-PAID Siemens Diagnostics-NY (formerly Bayer) 41 Fresh Normal Human Serum Specimens, line item 01 164.00 7.50 1,230.00
1243 1243 Invoice 05/02/2007   5455 HemaCare BioScience Normal Human Serum 200.00 0.00 0.00
1265 1265 Invoice 05/02/2007   5450-PAID Roche Molecular Systems-NJ 30 Cadaveric Specimens, line item 0010 317.40 111.0586 35,250.00
6 6 Invoice 05/03/2007   5454 California Department of Health Anti-HIV 2 15.00 0.00 0.00
6 6 Invoice 05/03/2007   5495 HemaCare BioScience Anti-HIV 2 12.30 0.00 0.00
816 816 Invoice 05/03/2007   5453 Beckman Coulter-MN HIV Mutation 7.00 0.00 0.00
1222 1222 Invoice 05/03/2007   5452 HemaCare BioScience Random Donors 231.00 0.00 0.00
1243 1243 Invoice 05/03/2007   5451-PAID Siemens Diagnostics-NY (formerly Bayer) 9 Fresh Normal Human Serum Specimens, line item 01 41.00 6.58537 270.00
8 8 Invoice 05/04/2007   5467 Labquality OY Human Serum 2.00 0.00 0.00
29 29 Invoice 05/04/2007   5467 Labquality OY Anti-HIV 1/2 3.00 0.00 0.00
171 171 Invoice 05/04/2007   5467 Labquality OY Human Plasma(EDTA-K3) 1.00 0.00 0.00
174 174 Invoice 05/04/2007   5467 Labquality OY Human Plasma (Sodium Citrate) 4.70 0.00 0.00
175 175 Invoice 05/04/2007   5467 Labquality OY Human Plasma (Sodium Heparin) 2.00 0.00 0.00
199 199 Invoice 05/04/2007   5467 Labquality OY Anti-HCV 10.00 0.00 0.00
446 446 Invoice 05/04/2007   5467 Labquality OY Anti-HIV 1 4.00 0.00 0.00
546 546 Invoice 05/04/2007   5467 Labquality OY Human Plasma 5.20 0.00 0.00
547 547 Invoice 05/04/2007   5465 International Bioscience, Inc 1 Anti-HCV Positive Specimen MBID#133298, line item 1 249.00 8.50 2,116.50
555 555 Invoice 05/04/2007   5466 International Bioscience, Inc HBsAg 125.40 8.45295 1,060.00
555 555 Invoice 05/04/2007   5467 Labquality OY HBsAg 4.90 0.00 0.00
631 631 Invoice 05/04/2007   5467 Labquality OY Human Plasma (CPDA) 6.00 0.00 0.00
679 679 Invoice 05/04/2007   5466 International Bioscience, Inc HBV - Nicaragua 70.90 8.3921 595.00
724 724 Invoice 05/04/2007   5467 Labquality OY Syphilis 15.20 0.00 0.00
888 888 Invoice 05/04/2007   5467 Labquality OY HBsAg Seroconversion Panel 1.00 0.00 0.00
995 995 Invoice 05/04/2007   5467 Labquality OY HIV and HCV Co-infection 4.00 0.00 0.00
1024 1024 Invoice 05/04/2007   5467 Labquality OY HBV NAT Seroconversion 2.00 0.00 0.00
1061 1061 Invoice 05/04/2007   5464 International Bioscience, Inc HBV Genotype Panel (HBVGTP-004a), line item 1 15.00 210.00 3,150.00
1125 1125 Invoice 05/04/2007   5467 Labquality OY TORCH IgM 5.30 0.00 0.00
1264 1264 Invoice 05/04/2007   5460 Sequenom Pregnancy (Rh-) 78.00 0.00 0.00
171 171 Invoice 05/07/2007   5461 Roche Molecular Systems-NJ 2 Human Plasma(EDTA-K3) with elevated Triglyceride MBID#62546, line item 00010 10.50 11.90476 125.00
421 421 Invoice 05/07/2007   5463-PAID Genentech Inc. 5 Hepatocellular Carcinoma Match Sets 15.00 625.00 9,375.00
448 448 Invoice 05/07/2007   5468-PAID Abbott Laboratories 19 x 1mL Acute HAV Positive Specimens, line item 01 20.80 342.54808 7,125.00
800 800 Invoice 05/07/2007   5461 Roche Molecular Systems-NJ Hemoglobin 10.10 12.37624 125.00
802 802 Invoice 05/07/2007   5462-PAID Beckman Coulter-CA 5 Match Patient Sets (Serum/Urine), line item 01 330.80 1.88936 625.00
174 174 Invoice 05/08/2007   5473-PAID Dr. Fooke Laboratorien GmbH Human Plasma (Sodium Citrate) 1,666.80 0.65 1,083.42
199 199 Invoice 05/08/2007   5469 Boca Biolistics, LLC 1 Anti-HCV RNA Type 2 Positive Specimen MBID#45990, line item 1 396.00 1.86869 740.00
1080 1080 Invoice 05/08/2007   5472 Abbott GmbH HCV (NS5 single band) 6.00 0.00 0.00
1251 1251 Invoice 05/08/2007   5470-PAID Novartis Institute 5 Leucocyte Filter Specimens, line item 1 5.00 195.00 975.00
1259 1259 Invoice 05/08/2007   5471-PAID Abbott GmbH 3 Anti-HBc IgM Positive Specimens, line item 1 2,472.00 12.00 29,664.00
29 29 Invoice 05/09/2007   5474-PAID Argos Therapeutics Anti-HIV 1/2 15.60 72.11538 1,125.00
446 446 Invoice 05/09/2007   5474-PAID Argos Therapeutics Anti-HIV 1 58.30 30.44597 1,775.00
643 643 Invoice 05/09/2007   5474-PAID Argos Therapeutics HIV-Venezuela 5.10 44.11765 225.00
788 788 Invoice 05/09/2007   5474-PAID Argos Therapeutics HIV-Africa 27.90 122.75986 3,425.00
816 816 Invoice 05/09/2007   5475-PAID Beckman Coulter-MN 1 x 25mL HIV Positive Specimen MBID#65408, line item 1 25.60 29.29688 750.00
816 816 Invoice 05/09/2007   5476 Roche Molecular Systems-NJ 1 x 17mL HIV-1 Positive Specimen, line item 00010 17.00 40.00 680.00
855 855 Invoice 05/09/2007   5474-PAID Argos Therapeutics HIV-Cote D'Ivoire 5.20 72.11538 375.00
1060 1060 Invoice 05/09/2007   5474-PAID Argos Therapeutics HIV-Thailand 10.40 43.26923 450.00
1264 1264 Invoice 05/09/2007   5497 Sequenom Pregnancy (Rh-) 58.70 0.00 0.00
6 6 Invoice 05/11/2007   5481 Roche Diagnostics GmbH Anti-HIV 2 146.20 0.00 0.00
13 13 Invoice 05/11/2007   5480-PAID Roche Diagnostics GmbH SLE 109.00 52.76697 5,751.60
543 543 Invoice 05/11/2007   5480-PAID Roche Diagnostics GmbH Rheumatoid Factor 72.20 55.76343 4,026.12
592 592 Invoice 05/11/2007   5480-PAID Roche Diagnostics GmbH ANA 102.70 56.00389 5,751.60
716 716 Invoice 05/11/2007   5480-PAID Roche Diagnostics GmbH Rheumatoid Arthritis 31.60 54.6038 1,725.48
1181 1181 Invoice 05/11/2007   5478-PAID Qiagen GmbH HIV-1 Worldwide Subtype Panel (Lot#50051) 18.00 444.44444 8,000.00
1243 1243 Invoice 05/11/2007   5479-PAID Allvivo Vascular Normal Human Serum 3,720.00 1.45161 5,399.99
1268 1268 Invoice 05/11/2007   5478-PAID Qiagen GmbH HCV-GTP Panel (Lot#70021) 6.00 175.00 1,050.00
174 174 Invoice 05/14/2007   5482-PAID INOVA Diagnostics, Inc. Human Plasma (Sodium Citrate) 1,682.20 1.49893 2,521.50
174 174 Invoice 05/14/2007   5485-PAID MP Biomedicals Asia Pacific Pte Ltd. 7 Human Plasma (Sodium Citrate) Specimens, line item 1 5,121.60 0.35 1,792.56
446 446 Invoice 05/14/2007   5488 Roche Molecular Systems-NJ Anti-HIV 1 9.40 0.00 0.00
550 550 Invoice 05/14/2007   5484-PAID Siemens Diagnostics-Walpole (Bayer) Troponin I 176.60 14.14213 2,497.50
555 555 Invoice 05/14/2007   5483 Dade Behring Marburg, GmbH HBsAg 9.30 0.00 0.00
679 679 Invoice 05/14/2007   5483 Dade Behring Marburg, GmbH HBV - Nicaragua 5.00 0.00 0.00
816 816 Invoice 05/14/2007   5488 Roche Molecular Systems-NJ HIV Mutation 1.30 0.00 0.00
856 856 Invoice 05/14/2007   5483 Dade Behring Marburg, GmbH HBV-Cote D'Ivoire 4.00 0.00 0.00
888 888 Invoice 05/14/2007   5483 Dade Behring Marburg, GmbH HBsAg Seroconversion Panel 2.00 0.00 0.00
1024 1024 Invoice 05/14/2007   5483 Dade Behring Marburg, GmbH HBV NAT Seroconversion 2.00 0.00 0.00
1262 1262 Invoice 05/14/2007   5489-PAID Applied Biosystems 20 Tubes for Whole Blood-Tempus Collection from 10 different normal donors, shipped directly fro... 10.00 187.50 1,875.00
10 10 Invoice 05/15/2007   5486-PAID Abbott Laboratories Anti-HTLV I/II 30.50 20.65574 630.00
13 13 Invoice 05/15/2007   5486-PAID Abbott Laboratories SLE 38.60 34.97409 1,350.00
550 550 Invoice 05/15/2007   5487-PAID Siemens Diagnostics-NY (formerly Bayer) Troponin I 139.80 16.09442 2,250.00
1262 1262 Invoice 05/15/2007   5477-PAID Metrika, Inc. Whole Blood Heparin Samples (10 Donors/2 Tubes Each), line item 1 10.00 225.00 2,250.00
8 8 Invoice 05/16/2007   5494 Plasma Services Group, Inc Human Serum 204.30 0.00 0.00
13 13 Invoice 05/16/2007   5494 Plasma Services Group, Inc SLE 13.40 0.00 0.00
446 446 Invoice 05/16/2007   5492-PAID Roche Molecular Systems-NJ Anti-HIV 1 199.10 45.26369 9,012.00
631 631 Invoice 05/16/2007   5494 Plasma Services Group, Inc Human Plasma (CPDA) 587.50 0.00 0.00
724 724 Invoice 05/16/2007   5494 Plasma Services Group, Inc Syphilis 16.80 0.00 0.00
816 816 Invoice 05/16/2007   5492-PAID Roche Molecular Systems-NJ HIV Mutation 36.30 45.61983 1,656.00
1080 1080 Invoice 05/16/2007   5496 HemaCare BioScience HCV (NS5 single band) 12.90 0.00 0.00
1125 1125 Invoice 05/16/2007   5494 Plasma Services Group, Inc TORCH IgM 1,078.50 0.00 0.00
1265 1265 Invoice 05/16/2007   5493-PAID Roche Molecular Systems-NJ Cadaveric Specimen 251.50 121.47117 30,550.00
 
 

Schedule B-5 HemaCare Bioscience, Inc.

Accounts Receivable

Detail Historical Aged Trial Balance

11/9/2007

 

Customer ID Customer Name Document Number Type Date   Amount     Current 31 - 60 Days 61 - 90 Days 91 - 120 Days 120 and Over Balance
ABBOTTGMBH Abbott GmbH & Ko 5903 SLS 10/30/2007 24,275.00   24,275.00         24,275.00
ABBOTTGMBH Abbott GmbH & Ko 5904 SLS 10/30/2007 2,205.78   2,205.78         2,205.78
ABBOTTGMBH Abbott GmbH & Ko 5906 SLS 10/30/2007 14,926.00   14,926.00         14,926.00
ABBOTTGMBH Total         41,406.78   41,406.78 - - - - 41,406.78
ABBOTTLABORATOR Abbott Laboratories 5355 SLS 4/4/2007 25,980.00           25,980.00 25,980.00
ABBOTTLABORATOR Abbott Laboratories 5698 SLS 8/8/2007 260.00         260.00   260.00
ABBOTTLABORATOR Abbott Laboratories 5760 SLS 8/27/2007 3,890.00       3,890.00     3,890.00
ABBOTTLABORATOR Abbott Laboratories 5833 SLS 10/2/2007 785.00     785.00       785.00
ABBOTTLABORATOR Abbott Laboratories 5834 SLS 10/2/2007 2,485.00     2,485.00       2,485.00
ABBOTTLABORATOR Abbott Laboratories 5851 SLS 10/8/2007 900.00     900.00       900.00
ABBOTTLABORATOR Abbott Laboratories 5867 SLS 10/15/2007 6,335.00   6,335.00         6,335.00
ABBOTTLABORATOR Abbott Laboratories 5868 SLS 10/15/2007 6,635.00   6,635.00         6,635.00
ABBOTTLABORATOR Abbott Laboratories 5875 SLS 10/18/2007 2,235.00   2,235.00         2,235.00
ABBOTTLABORATOR Abbott Laboratories 5902 SLS 10/30/2007 1,280.00   1,280.00         1,280.00
ABBOTTLABORATOR Total         50,785.00   16,485.00 4,170.00 3,890.00 260.00 25,980.00 50,785.00
BECKMANCOULTERC Beckman Coulter-CA 5853 SLS 10/8/2007 660.00     660.00       660.00
BECKMANCOULTERC Total         660.00   - 660.00 - - - 660.00
BECKMANCOULTERM Beckman Coulter-MN 5856 SLS 10/8/2007 917.50     917.50       917.50
BECKMANCOULTERM Total         917.50   - 917.50 - - - 917.50
BIORADHERCULESC Bio-Rad-Hercules,CA 5814 SLS 9/20/2007 135.00     135.00       135.00
BIORADHERCULESC Bio-Rad-Hercules,CA 5895 SLS 10/29/2007 730.00   730.00         730.00
BIORADHERCULESC Total         865.00   730.00 135.00 - - - 865.00
BIORECLAMATION Bioreclamation 5866 SLS 10/15/2007 1,015.00   1,015.00         1,015.00
BIORECLAMATION Bioreclamation 5874 SLS 10/17/2007 1,330.00   1,330.00         1,330.00
BIORECLAMATION Bioreclamation 5890 SLS 10/25/2007 953.85   953.85         953.85
BIORECLAMATION Total         3,298.85   3,298.85 - - - - 3,298.85
BIORESOURCETECH BioResource Technology, Inc. 5797 SLS 9/13/2007 3,003.25     3,003.25       3,003.25
BIORESOURCETECH Total         3,003.25   - 3,003.25 - - - 3,003.25
BOCABIOLISTICSL Boca Biolistics, LLC 5844 SLS 10/5/2007 462.50     462.50       462.50
BOCABIOLISTICSL Total         462.50   - 462.50 - - - 462.50
CELERADIAGNOSTI Celera Diagnostics 5857 SLS 10/9/2007 385.00     385.00       385.00
CELERADIAGNOSTI Celera Diagnostics 5880 SLS 10/23/2007 1,088.00   1,088.00         1,088.00
CELERADIAGNOSTI Celera Diagnostics 5888 SLS 10/24/2007 131.00   131.00         131.00
CELERADIAGNOSTI Celera Diagnostics 5889 SLS 10/25/2007 422.50   422.50         422.50
CELERADIAGNOSTI Celera Diagnostics 5899 SLS 10/30/2007 179.00   179.00         179.00
CELERADIAGNOSTI Celera Diagnostics 5908 SLS 10/31/2007 386.00   386.00         386.00
CELERADIAGNOSTI Celera Diagnostics 5913 SLS 11/1/2007 68.00   68.00         68.00
CELERADIAGNOSTI Total         2,659.50   2,274.50 385.00 - - - 2,659.50
CHEMBIODIAGNOST Chembio Diagnostic Systems 5861 SLS 10/11/2007 2,840.00   2,840.00         2,840.00
CHEMBIODIAGNOST Total         2,840.00   2,840.00 - - - - 2,840.00
DADEBEHRINGMARB Dade Behring Marburg, GmbH 5631 SLS 7/23/2007 3,019.00         3,019.00   3,019.00
DADEBEHRINGMARB Total         3,019.00   - - - 3,019.00 - 3,019.00
DRFOOKELABORATO Dr. Fooke Laboratorien GmbH 5876 SLS 10/19/2007 5,558.00   5,558.00         5,558.00
DRFOOKELABORATO Total         5,558.00   5,558.00 - - - - 5,558.00
DXLABORATORIES Dx Laboratories 5587 SLS 6/29/2007 320.00           320.00 320.00
DXLABORATORIES Total         320.00   - - - - 320.00 320.00
FISHERSCIENTIFI Fisher Scientific/Chiron Blood Testing 5894 SLS 10/29/2007 2,310.00   2,310.00         2,310.00
FISHERSCIENTIFI Total         2,310.00   2,310.00 - - - - 2,310.00
FUTUREDIAGNOSTI Future Diagnostics BV 5850 SLS 10/5/2007 3,215.00     3,215.00       3,215.00
FUTUREDIAGNOSTI Future Diagnostics BV 5877 SLS 10/19/2007 93.00   93.00         93.00
FUTUREDIAGNOSTI Total         3,308.00   93.00 3,215.00 - - - 3,308.00
INBIOSINTERNATI InBios International, Inc. 5911 SLS 10/31/2007 1,041.95   1,041.95         1,041.95
INBIOSINTERNATI Total         1,041.95   1,041.95 - - - - 1,041.95
INNOGENETICS Innogenetics CREDT0000001 CR 4/4/2007 (235.00)           (235.00) (235.00)
INNOGENETICS Total         (235.00)   - - - - (235.00) (235.00)
LAKEARROWHEADLA Lake Arrowhead Lab Consultants 5802 SLS 9/17/2007 1,952.20     1,952.20       1,952.20
LAKEARROWHEADLA Lake Arrowhead Lab Consultants 5807 SLS 9/18/2007 7,447.51     7,447.51       7,447.51
LAKEARROWHEADLA Total         9,399.71   - 9,399.71 - - - 9,399.71
MILLENNIUMBIOTE Millenium Biotechnology, Inc 5872 SLS 10/17/2007 240.00   240.00         240.00
MILLENNIUMBIOTE Total         240.00   240.00 - - - - 240.00
NEWLINKSGENETIC New Link Genetics Corporation 5878 SLS 10/4/2007 430.46     430.46       430.46
NEWLINKSGENETIC Total         430.46   - 430.46 - - - 430.46
NYPRESBYTERIAN NEW YORK PRESBYTERIAN HOSPITAL 5780 SLS 9/4/2007 850.00       850.00     850.00
NYPRESBYTERIAN Total         850.00   - - 850.00 - - 850.00
OCDEUROPE OCD - Europe 5785 SLS 9/7/2007 2,120.00       2,120.00     2,120.00
OCDEUROPE OCD - Europe 5864 SLS 10/12/2007 1,005.00   1,005.00         1,005.00
OCDEUROPE Total         3,125.00   1,005.00 - 2,120.00 - - 3,125.00
OMEGADIAGNOSTIC Omega Diagnostics CREDT0000002 CR 1/25/2007 (725.00)           (725.00) (725.00)
OMEGADIAGNOSTIC Total         (725.00)   - - - - (725.00) (725.00)
ORASURETECHNOLO OraSure Technologies, Inc. 5901 SLS 10/30/2007 735.00   735.00         735.00
ORASURETECHNOLO Total         735.00   735.00 - - - - 735.00
ORGENICSLTD Orgenics Ltd. 5645 SLS 7/27/2007 573.25         573.25   573.25
ORGENICSLTD Total         573.25   - - - 573.25 - 573.25
ORTHOCLINICALDI Ortho-Clinical Diagnostics 5511 SLS 6/5/2007 1,075.00           1,075.00 1,075.00
ORTHOCLINICALDI Ortho-Clinical Diagnostics 5827 SLS 9/28/2007 1,200.00     1,200.00       1,200.00
ORTHOCLINICALDI Total         2,275.00   - 1,200.00 - - 1,075.00 2,275.00
PANACEAPHARMACE Panacea Pharmaceuticals 5503 SLS 5/24/2007 1,015.00           1,015.00 1,015.00
PANACEAPHARMACE Panacea Pharmaceuticals 5554 SLS 6/25/2007 2,035.00           2,035.00 2,035.00
PANACEAPHARMACE Panacea Pharmaceuticals 5737 SLS 8/21/2007 4,080.00       4,080.00     4,080.00
PANACEAPHARMACE Total         7,130.00   - - 4,080.00 - 3,050.00 7,130.00
ROCHEDIAGCORP Roche Diagnostics Corporation-IN 5640 SLS 7/27/2007 9,215.00         9,215.00   9,215.00
ROCHEDIAGCORP Total         9,215.00   - - - 9,215.00 - 9,215.00
ROCHEMOLECULARS Roche Molecular Systems, Inc. 5499 SLS 5/23/2007 3,370.00           3,370.00 3,370.00
ROCHEMOLECULARS Roche Molecular Systems, Inc. 5525 SLS 5/30/2007 336.50           336.50 336.50
ROCHEMOLECULARS Roche Molecular Systems, Inc. 5815 SLS 9/25/2007 24,775.00     24,775.00       24,775.00
ROCHEMOLECULARS Roche Molecular Systems, Inc. PYMNT0000177 PMT 10/4/2007 (336.50)     (336.50)       (336.50)
ROCHEMOLECULARS Total         28,145.00   - 24,438.50 - - 3,706.50 28,145.00
SEQUENOM Sequenom 5832 SLS 9/28/2007 77,468.00     77,468.00       77,468.00
SEQUENOM Total         77,468.00   - 77,468.00 - - - 77,468.00
SIEMENSDIAGBER Siemens Medical Solutions Diagnostics 5786 SLS 8/29/2007 7,234.98       7,234.98     7,234.98
SIEMENSDIAGBER Siemens Medical Solutions Diagnostics 5794 SLS 9/12/2007 3,863.25     3,863.25       3,863.25
SIEMENSDIAGBER Siemens Medical Solutions Diagnostics 5900 SLS 10/31/2007 65,150.00   65,150.00         65,150.00
SIEMENSDIAGBER Total         76,248.23   65,150.00 3,863.25 7,234.98 - - 76,248.23
SIEMENSDIAGNY Siemens Medical Solutions Diagnostics 5553 SLS 5/22/2007 2,400.00           2,400.00 2,400.00
SIEMENSDIAGNY Siemens Medical Solutions Diagnostics 5581 SLS 6/28/2007 27,765.00           27,765.00 27,765.00
SIEMENSDIAGNY Siemens Medical Solutions Diagnostics 5582 SLS 6/28/2007 20,160.00           20,160.00 20,160.00
SIEMENSDIAGNY Siemens Medical Solutions Diagnostics 5666 SLS 8/2/2007 1,180.00         1,180.00   1,180.00
SIEMENSDIAGNY Siemens Medical Solutions Diagnostics 5667 SLS 8/2/2007 14,100.00         14,100.00   14,100.00
SIEMENSDIAGNY Siemens Medical Solutions Diagnostics 5668 SLS 8/2/2007 412.50         412.50   412.50
SIEMENSDIAGNY Siemens Medical Solutions Diagnostics 5689 SLS 8/7/2007 687.50         687.50   687.50
SIEMENSDIAGNY Siemens Medical Solutions Diagnostics 5703 SLS 8/13/2007 2,660.00       2,660.00     2,660.00
SIEMENSDIAGNY Siemens Medical Solutions Diagnostics 5801 SLS 9/17/2007 2,235.00     2,235.00       2,235.00
SIEMENSDIAGNY Siemens Medical Solutions Diagnostics 5816 SLS 9/25/2007 7,060.00     7,060.00       7,060.00
SIEMENSDIAGNY Siemens Medical Solutions Diagnostics 5817 SLS 9/25/2007 4,100.00     4,100.00       4,100.00
SIEMENSDIAGNY Siemens Medical Solutions Diagnostics 5818 SLS 9/25/2007 6,700.00     6,700.00       6,700.00
SIEMENSDIAGNY Siemens Medical Solutions Diagnostics 5819 SLS 9/25/2007 3,680.00     3,680.00       3,680.00
SIEMENSDIAGNY Siemens Medical Solutions Diagnostics PYMNT0000150 PMT 9/24/2007 (485.00)     (485.00)       (485.00)
SIEMENSDIAGNY Total         92,655.00   - 23,290.00 2,660.00 16,380.00 50,325.00 92,655.00
SIEMENSDIAGWALP Siemens Medical Solutions Diagnostics 5803 SLS 9/18/2007 2,285.00     2,285.00       2,285.00
SIEMENSDIAGWALP Siemens Medical Solutions Diagnostics 5805 SLS 9/18/2007 875.00     875.00       875.00
SIEMENSDIAGWALP Siemens Medical Solutions Diagnostics 5811 SLS 9/21/2007 1,080.00     1,080.00       1,080.00
SIEMENSDIAGWALP Siemens Medical Solutions Diagnostics 5898 SLS 10/30/2007 813.00   813.00         813.00
SIEMENSDIAGWALP Total         5,053.00   813.00 4,240.00 - - - 5,053.00
SIEMENSUK SIEMENS MEDICAL SOLUTIONS DIAG. LTD PYMNT0000165 PMT 10/1/2007 (0.01)     (0.01)       (0.01)
SIEMENSUK Total         (0.01)   - (0.01) - - - (0.01)
THEBINDINGSITEU The Binding Site-UK 5892 SLS 10/26/2007 6,905.00   6,905.00         6,905.00
THEBINDINGSITEU Total         6,905.00   6,905.00 - - - - 6,905.00
THEGOODWORKS THE GOOD WORKS COMPANY 5776 SLS 8/29/2007 390.00       390.00     390.00
THEGOODWORKS Total         390.00   - - 390.00 - - 390.00
TRINABIOREACTIV Trina Bioreactives AG 5855 SLS 10/8/2007 2,540.00     2,540.00       2,540.00
TRINABIOREACTIV Total         2,540.00   - 2,540.00 - - - 2,540.00
VIRGINIAMEDICAL Virginia Medical Research, Inc 5762 SLS 8/28/2007 1,715.00       1,715.00     1,715.00
VIRGINIAMEDICAL Virginia Medical Research, Inc 5769 SLS 8/30/2007 735.00       735.00     735.00
VIRGINIAMEDICAL Total         2,450.00   - - 2,450.00 - - 2,450.00
VIROMEDLABORATO ViroMed Laboratories 5870 SLS 10/17/2007 2,535.00   2,535.00         2,535.00
VIROMEDLABORATO Total         2,535.00   2,535.00 - - - - 2,535.00
VITALPRODUCTS Vital Products 5854 SLS 10/8/2007 1,100.00     1,100.00       1,100.00
VITALPRODUCTS Total         1,100.00   - 1,100.00 - - - 1,100.00
Grand Total         450,957.97   153,421.08 160,918.16 23,674.98 29,447.25 83,496.50 450,957.97

 

 
 

 

 

   
               
               
Accounts Receivable Reserve - Hemabio        
9/30/2007        
Customer ID # 00000 Reason   Amount        
Abbott GmBH   Old Invoices   $            21.00        
Abbott Lab   Old Invoices   $      25,980.00 a      
Fujirebio Diagnostics   Old Invoices   $                 -   c      
Ortho-Clinical Diagnostics   Old Invoices   $       3,040.00 d      
Panacea Pharmaceuticals   Old Invoices   $       1,015.00 e      
Roche Molecular Systems   Old Invoices   $       3,370.00 b      
               
               
        Unadjusted   684,337.61 < =Per GL
General Miscellaneous     0.25% of 650911.61   $       1,627.28 GL Adjustment (33,426.00) < =100% Provision
Total:       $      35,053.28      35,053.28             -      
            650,911.61 < =Bal.= GL-Provision
               
               
Total Reserve Required:       $      35,053.28      35,053.28      -      
               
GL Balance       $      35,053.28        
               
Adjustment:       $                 -          
               
               
      $     684,337.61 < =Total AR Balance per GL    
      5.12% < =Total Provision %    
               
Accounts subsequently paid up to 10/22/2007          
               
Abbott Lab   Old Invoices 50,325.00        
Payments   10/3/07 (24,345.00)        
      25,980.00 a      
               
Roche Molecular Systems   Old Invoices 10,246.10        
Payments   10/10/07 (6,539.60)        
    10/4/07 (336.50)        
      3,370.00 b      
               
Fujirebio Diagnostics   Old Invoices 20,150.00        
payments   10/15/07 (20,150.00)        
      - c      
               
Ortho-Clinical Diagnostics   Old Invoices 4,240.00        
payments   10/15/07 (1,200.00)        
      3,040.00 d      
               
Panacea Pharmaceuticals   Old Invoices 3,065.00        
payments   10/15/07 (2,050.00)        
      1,015.00 e      
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
Notes: As per Bob on 1/16/2007          
1 100% allowance for accounts that are over 90-days past due      
2 HC general provision reduced to 0.25%        
3 Coral general provision reduced to 0.5%        

 

EX-10.5 6 ex10-5.htm

Exhibit 10.5

SETTLEMENT AGREEMENT AND MUTUAL GENERAL RELEASE

This Settlement Agreement and Mutual General Release ("Agreement") is entered as of August 26, 2008 between HEMACARE CORPORATION (“HemaCare”) on the one hand and JOSEPH MAURO (“Mauro”) and VALENTIN ADIA (“Adia”) on the other hand, with reference to the following:

RECITALS

WHEREAS, in or around August 2006, HemaCare on the one hand and Mauro and Adia on the other hand, entered a Stock Purchase Agreement, which the parties amended in or around November, 2006 (“SPA”);

WHEREAS, pursuant to the SPA, HemaCare purchased all of Mauro’s and Adia’s issued and outstanding stock of Teragenix Corporation, a Florida corporation (“Teragenix”) which, after the transaction, became known as HemaCare BioScience, Inc. (“HemaCare BioScience”);

WHEREAS, as consideration for the purchase of the Teragenix stock, HemaCare, among other things, transferred to Mauro and Adia, 376,000 shares of HemaCare common stock.  Mauro and Adia currently have in their possession 248,000 shares of HemaCare common stock (“HemaCare Stock”).  HemaCare also delivered to Mauro and Adia promissory notes in the amount of $200,000 (“Promissory Notes”) (copies of the Promissory Notes are attached hereto as Exhibit “A”);

WHEREAS, disputes have arisen in connection with the SPA and the Promissory Notes;

WHEREAS, HemaCare filed a lawsuit against Mauro and Adia in the Los Angeles County Superior Court, bearing Case No. LC082173 (the “Lawsuit”), alleging causes of action against Mauro and Adia for fraudulent inducement, fraud and breach of contract;

WHEREAS, Mauro and Adia have alleged that HemaCare owes Mauro and Adia $200,000, plus interest, based on the amounts of the Promissory Notes;

WHEREAS, this Agreement is a compromise of the claims and liabilities alleged between the parties to this Agreement and shall not be construed as an admission of liability or wrongdoing by the parties or by any of the individuals or entities released in this Agreement; and

WHEREAS, the parties desire to fully and finally settle and resolve all disputes and differences which exist or may exist between them.

In consideration of the Recitals and covenants below, the parties agree as follows:

AGREEMENT

1.           No Admission of Liability.  The parties mutually acknowledge and agree that (i) the settlement, (ii) the delivery of this Agreement, (iii) the consideration provided for in this Agreement, and (iv) everything contained or omitted from this Agreement, shall not be interpreted or construed as an admission of liability.  Rather, this Agreement represents the settlement of disputed claims and the parties expressly deny any liability.

 
 

 

2.           Consideration.  As consideration for this Agreement, the receipt and sufficiency of which are hereby acknowledged, Mauro and Adia shall, simultaneously, with the execution of this Agreement: (i)  cancel the Promissory Notes and waive all payments, interest or other rights associated with the Promissory Notes; (ii) pay to HemaCare the following:  (a)  Mauro shall pay to HemaCare the amount of Twenty-Seven Thousand, Six-Hundred and Twenty-One Dollars and 88/100 ($27,621.88); and (b) Adia shall pay to HemaCare the amount of Twenty-Two Thousand, Three Hundred Seventy-Eight and 12/100 ($22,378.12); (iii) transfer to HemaCare all right, title and interest in and to the HemaCare Stock;

3.           Dismissal of the Lawsuit.  After receipt of this Agreement fully executed by Mauro and Adia and after Mauro and Adia provide to HemaCare all the consideration specified in paragraph 2 above, HemaCare agrees to dismiss the Lawsuit with prejudice and serve on Mauro and Adia a conformed copy of the dismissal.

4.           Releases by Mauro and Adia.  Effective on signing this Agreement, and with the exception of the obligations stated in this Agreement, Mauro and Adia, for themselves and for each of their respective representatives, heirs, agents, successors and assigns (collectively “Mauro and Adia Releasors”), irrevocably release and forever discharge HemaCare and each of its employees, affiliates, predecessors, successors, subsidiaries, agents, servants, officers, directors, principals, owners, stockholders, representatives, insurers, investors, members, attorneys, experts, parent and related companies, joint venturers, assigns and any and all of their associated, affiliated or related persons or entities of any type or nature whatsoever, whether current or former (collectively “Mauro’s and Adia’s Releasees”), of and from any and all claims, demands, damages, debts, liabilities, accounts, reckonings, obligations, costs, expenses, liens, actions and causes of action of every kind and nature whatsoever whether now known or unknown, suspected or unsuspected which the Mauro and Adia Releasors now have, own, or hold, or at any time heretofore ever had, owned or held, or could, shall or may hereafter have, own or hold including any claim under any rule, statute, regulation or local law (“Mauro’s and Adia’s Released Claims”).  Mauro and Adia acknowledge and agree that the term Mauro’s and Adia’s Released Claims includes, but is not limited to claims in connection with the Promissory Notes, the HemaCare Stock, the SPA, as well as any claim for contract (oral, written, implied in fact or implied in law) or tort, including alter ego or agency claims, or claims for interference, defamation, wrongful termination, infliction of emotional distress, discrimination, retaliation, fraud, misrepresentation, and any claim, lien, liability, matter, cause, fact, thing, act or omission whatsoever occurring or existing at any time to and including the date of this Agreement.

5.           Releases by HemaCare.  Effective on signing this Agreement, and with the exception of the obligations stated in this Agreement, HemaCare irrevocably releases and forever discharges Mauro and Adia of and from any and all claims, demands, damages, debts, liabilities, accounts, reckonings, obligations, costs, expenses, liens, actions and causes of action of every kind and nature whatsoever whether now known or unknown, suspected or unsuspected which HemaCare now has, owns, or holds, or at any time heretofore ever had, owned or held, or could, shall or may hereafter have, own or hold including any claim under any rule, statute, regulation or local law (“HemaCare’s Released Claims”).  HemaCare acknowledges and agrees that the term HemaCare’s Released Claims includes, but is not limited to claims alleged in the Lawsuit as well as any claim for contract (oral, written, implied in fact or implied in law) or tort, including claims for interference, fraud, misrepresentation, and any claim, lien, liability, matter, cause, fact, thing, act or omission whatsoever occurring or existing at any time to and including the date of this Agreement.

2
 

 

6.           Scope.  It is the parties’ intention in giving and accepting the consideration in this Agreement, and in executing this Agreement that this Agreement shall be a full and final release of all claims.  The parties acknowledge familiarity with Section 1542 of the Civil Code of the State of California which provides:

A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.

7.           Waiver and Acknowledgment.  The parties waive any right or benefit each has or may have under Section 1542, or under any similar law of similar effect in any jurisdiction, including under Florida law, to the full extent each may lawfully waive all such rights and benefits pertaining to the subject matter of this Agreement.  The parties acknowledge they may hereafter discover facts in addition to or different from those they now know or believe to be true with respect to the subject matter of this Agreement, and that it is their intention to fully and forever settle and release all disputes and differences, known or unknown, suspected or unsuspected, which do now exist, may exist or heretofore have existed and that in furtherance of such intention the releases herein given shall be and remain in effect as full and complete general releases, notwithstanding the discovery or existence of any such additional or different facts.

8.           No Assignment.  The parties warrant and represent that neither they, nor anyone on their behalf, previously assigned or transferred or purported to assign or transfer to any person or entity not a party to this Agreement any claims released in this Agreement, or any part or portion thereof.  Specifically, Mauro and Adia warrant and represent that each of them is the sole owner of all rights, title and interests in and to the Promissory Notes and that their cancellation of the Promissory Notes eliminates all obligations in connection with the Promissory Notes.  Mauro and Adia further warrant and represent that each of them is the sole owner of all rights, title and interest in and to the HemaCare stock which they are hereby transferring to HemaCare.  Mauro and Adia further warrant and represent that they alone have full and complete authority to cancel the Promissory Notes and that no other individual or entity has any interest in the Promissory Notes or needs to provide consent in order to cancel the Promissory Notes.  Mauro and Adia acknowledge, however, that HemaCare BioScience filed an Assignment for the Benefit of Creditors, pursuant to Florida Statutes Section 727 et al. (“Assignee”).  Mauro and Adia agree that nothing in this Agreement is intended to cause a release of their claims filed with the Assignee or of any claims the Assignee may have against Mauro and Adia.  The parties acknowledge and agree that these warranties and representations are essential and material terms of this Agreement without which none of the consideration received in connection herewith would have been made or delivered.  The foregoing warranties and representations shall survive the delivery of this Agreement, and the parties shall each indemnify and hold the other harmless from any claims, demands or actions which have been assigned or transferred, or purported to have been assigned or transferred, in violation of the foregoing representation and warranty, including all damages, attorneys’ fees and costs if there is a breach or purported breach of these representations and warranties.

9.           Representations and Warranties.  The parties represent and warrant that the following statements are true, correct and complete and the parties shall indemnify and hold the other harmless from and against any claim arising out of any breach or claimed breach of these representations and warranties:

3
 

 

a.           Agreement Explained.  The parties had the opportunity to obtain a complete explanation from legal counsel of their own choosing as to the meaning and legal effect of each term in this Agreement.  The parties entered into this Agreement with full knowledge as to the meanings and effects of this Agreement.

b.           No Actions or Proceedings.   Other than the Lawsuit there is no pending or threatened suit, proceeding or compliance review before any court, governmental agency, or arbitrator with respect to Mauro’s and Adia’s Released Claims or with respect to HemaCare’s Released Claims.  The parties agree to immediately dismiss with prejudice any such suit, proceeding or compliance review and provide proof of such dismissal immediately to the parties’ counsel.

c.           Actions By Third Parties.  The parties agree not to benefit from any lawsuit, administrative proceeding or compliance review brought by any other person or agency against any of the individuals and entities released in this Agreement, to the fullest extent of law.

10.        Notice.  Any notice or other communication under this Agreement must be in writing and shall be effective upon delivery by hand or three (3) business days after deposit in the United States mail, postage prepaid, certified or registered, and addressed to the parties at the corresponding addresses below.  The parties shall be obligated to notify each other in writing of any change in address.  Notice of change of address shall be effective only when done in accordance with this Section.

  HemaCare’s Notice Address:
  Attention Sue Bendavid
  Lewitt, Hackman, Shapiro, Marshall & Harlan
  16633 Ventura Blvd.
  Suite 1100
  Encino, CA 91436
   
  Mauro’s Notice Address:
  12590 Little Palm Lane
  Boca Raton, FL  33428
   
  Adia’s Notice Address:
  11001 Sunset Ridge Circle
  Boynton Beach, FL  33473

11.        General Provisions.

a.           Law.  This Agreement shall be interpreted, enforced and governed under California law.

b.           Severability.  The provisions of this Agreement shall be severable.  If any provision is held by an arbitrator or a court of competent jurisdiction to be unenforceable, in whole or in part, the remainder shall remain in effect and the stricken provision shall be replaced, to the extent possible, with an enforceable provision as similar in tenor as legally possible.

4
 

 

c.           Counterparts.  This Agreement may be signed by facsimile and in one or more counterparts, each of which shall be deemed an original instrument and together shall constitute the entire Agreement.

d.           Entire Agreement.  This is the entire Agreement of the parties relating to the transactions set forth herein, and all prior understandings, representations and statements, oral, written or implied, concerning this transaction are superseded by this Agreement.  No amendments will be valid unless written and signed by both parties.  The parties acknowledge they are not executing this Agreement in reliance on any oral promise, representation or warranty not contained herein.

e.           Binding on Heirs.  This Agreement shall inure to the benefit of and be binding upon the heirs, executors, administrators and legal successors of the parties hereto.

f.           Negotiated Agreement.  This Agreement is the result of negotiations between the parties.  Any ambiguity shall not be construed against either side on the basis of such side having drafted or prepared the language of any provision.

g.           Payments of Costs, Expenses, and Fees.  All costs and expenses incurred in negotiating this Agreement and in connection with the Lawsuit shall be borne by each party by themselves.  If any claim, controversy, dispute or legal action is brought in connection with the terms or conditions of this Agreement or for the enforcement of this Agreement, the prevailing party shall be entitled to recover reasonable attorneys' fees and costs incurred, in addition to any other relief to which they may be entitled, whether or not suit or arbitration is filed and whether or not any such suit or arbitration proceeds to judgment.

h.           Understood Agreement/Independent Counsel.  The parties acknowledge they read and understood this Agreement, in its entirety, and are voluntarily entering into this Agreement of their own free will, without duress or undue influence by any non-party or by any party to this Agreement.  The parties, and each of them, acknowledge, represent and warrant that they were represented by independent legal counsel of their own choice throughout all negotiations preceding and occurring in connection with the negotiation and execution of this Agreement.

Joseph Mauro HemaCare Corporation
     
/s/ Joseph Mauro   /s/   Julian Steffenhagen
  By: Julian Steffenhagen
  Its: Interim Chief Executive Officer
     

Valentin Adia

 

/s/ Valentin Adia

 

5
 

EXHIBIT A

 

PROMISSORY NOTES

 

 

THIS SUBORDINATED SECURED NON-NEGOTIABLE PROMISSORY NOTE (THIS “NOTE”) HAS NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR UNDER ANY U.S. STATE SECURITIES LAWS.  NEITHER THIS NOTE NOR ANY INTEREST OR PARTICIPATION HEREIN MAY BE REOFFERED, SOLD, ASSIGNED, TRANSFERRED, PLEDGED, ENCUMBERED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF SUCH REGISTRATION WITHOUT AN OPINION OF COUNSEL FOR THE PAYEE, REASONABLY ACCEPTABLE TO THE MAKER, STATING THAT SUCH SALE, TRANSFER OR ASSIGNMENT IS EXEMPT FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND QUALIFICATION REQUIREMENTS UNDER APPLICABLE U.S. STATE SECURITIES LAWS.  THIS NOTE MUST BE SURRENDERED TO THE MAKER AS A CONDITION PRECEDENT TO THE TRANSFER OF ANY INTEREST IN THIS NOTE.

SUBORDINATED SECURED NON-NEGOTIABLE PROMISSORY NOTE

$46,200   August 29, 2006

 

FOR VALUE RECEIVED, HemaCare Corporation. a California corporation (“Maker”), promises to pay to Valentin Adia, an individual resident in the State of Florida (“Payee”), in lawful money of the United States of America, the principal sum of Forty-Six Thousand Two Hundred Dollars ($46,200), together with interest in arrears on the unpaid principal balance at an annual rate equal to 5.0%, in the manner provided below.  Interest shall be calculated on the basis of a year of 365 or 366 days, as applicable, and charged for the actual number of days elapsed.

This Note has been executed and delivered pursuant to that certain Stock Purchase Agreement, dated August 29, 2006, by and among Maker, Payee and Joseph Mauro (the “Agreement”).

1. Payments.

1.1 Principal and Interest.  The principal amount of this Note shall be due and payable in four (4) equal consecutive annual installments of Eleven Thousand Five Hundred Fifty Dollars ($11,550) commencing on August 29, 2007, and continuing on August 29 of each year thereafter until paid in full.  Interest on the unpaid principal balance of this Note shall be due and payable annually, together with each payment of principal.

1.2 Manner of Payment.  All payments of principal and interest on this Note shall be made by wire transfer of immediately available funds to an account designated by Payee in writing.  If any payment of principal or interest on this Note is due on a day which is not a Business Day, such payment shall be due on the next succeeding Business Day and such extension of time shall be taken into account in calculating the amount of interest payable under this Note.  “Business Day” means any day other than a Saturday, Sunday or legal holiday in the State of California.

1.3 Prepayment.  Subject to Section 3(c) below, Maker may, without premium or penalty, at any time and from time to time, prepay all or any portion of the outstanding principal balance due under this Note, provided that each such prepayment is accompanied by accrued interest on the amount of principal prepaid calculated to the date of such prepayment.  Any partial prepayments shall be applied to installments of principal in inverse order of their maturity.

 
 

 

1.4 Right of Set-Off.  Maker shall have the right to withhold and set-off against any amount due and payable hereunder any amount to which it may be entitled under Section 6.4 or Section 10 of the Agreement or otherwise under the Agreement or any Buyer Closing Document (as defined in the Agreement) or Sellers’ Closing Document (as defined in the Agreement) in accordance with the terms of Section 10.7 of the Agreement.  The exercise of such right to withhold and set-off by Maker in good faith, whether or not ultimately determined to be justified, will not constitute an Event of Default (as defined below).

2. Defaults.

2.1 Events of Default.  The occurrence of any one or more of the following events with respect to Maker shall constitute an event of default hereunder (“Event of Default”):

(a) If Maker shall fail to pay when due any payment of principal or interest on this Note and such failure continues for fifteen (15) days after Payee notifies Maker thereof in writing; provided, however, that the exercise by Maker in good faith of its right of set-off pursuant to Section 1.4 above, whether or not ultimately determined to be justified, shall not constitute an Event of Default.

(b) If, pursuant to or within the meaning of the United States Bankruptcy Code or any other federal or state law relating to insolvency or relief of debtors (a “Bankruptcy Law”), Maker shall (i) commence a voluntary case or proceeding; (ii) consent to the entry of an order for relief against it in an involuntary case; (iii) consent to the appointment of a trustee, receiver, assignee, liquidator or similar official; or (iv) make an assignment for the benefit of its creditors.

(c) If a court of competent jurisdiction enters an order or decree under any Bankruptcy Law that (i) is for relief against Maker in an involuntary case, (ii) appoints a trustee, receiver, assignee, liquidator or similar official for Maker or substantially all of Maker’s properties, or (iii) orders the liquidation of Maker, and in each case the order or decree is not dismissed within 120 days.

2.2 Notice By Maker.  Maker shall notify Payee in writing within five days after the occurrence of any Event of Default of which Maker acquires knowledge.

2.3 Remedies.  Upon the occurrence of an Event of Default hereunder (unless all existing Events of Default have been cured or waived by Payee), Payee may, at its option, (i) by written notice to Maker, declare the entire unpaid principal balance of this Note, together with all accrued and unpaid interest thereon, immediately due and payable regardless of any prior forbearance, and (ii) exercise any and all rights and remedies available to it under applicable law, including, without limitation, the right to collect from Maker all sums due under this Note.  Maker shall pay all reasonable costs and expenses incurred by or on behalf of Payee in connection with Payee’s exercise of any or all of its rights and remedies under this Note, including, without limitation, reasonable attorneys’ fees.

3. Subordination to Senior Debt.  Payee, by acceptance of this Note, agrees that the payment of the principal and interest of this Note is subordinated to the Senior Debt to the extent and as provided below and undertakes, as a condition to the right to receive any payments hereunder, to execute such subordination agreements as may be requested by the Senior Lenders (as defined below) from time to time.

2
 

 

(a) As used herein, the term “Senior Debt” shall mean any and all indebtedness of Maker and all of its subsidiaries (collectively, the “Company”) owed to Senior Lenders together with (i) all complete or partial refinancings of such indebtedness, (ii) any amendments, restatements, extensions, modifications, renewals or substitutions with respect to the foregoing, (iii) interest, reasonable attorney fees, other fees and other sums payable in respect thereof, and (iv) any interest accruing thereon after the commencement of a case or proceeding under a Bankruptcy Law, without regard to whether or not such interest is an allowed claim in such proceeding.  The term “Senior Lenders” shall mean any institutional lender or lenders providing one or more senior secured credit facilities to the Company.  Senior Debt shall be considered to be outstanding whenever any loan or loan commitment remains outstanding under a loan agreement entered into with a Senior Lender.

(b) Except as specifically permitted in Section 3(c) below, Payee, by acceptance of this Note, agrees that Payee will not ask, demand, sue for, accept, or receive payment from Maker, by set-off or in any other manner, either in whole or in part, of any of the principal of or interest accrued on the indebtedness evidenced by this Note (the “Subordinated Indebtedness”).

(c) Maker shall pay or cause to be paid to Payee the Subordinated Indebtedness in accordance with the schedule set forth in Section 1.1 above, except that Maker shall not be required or permitted to make any payment on the Subordinated Indebtedness if an event of default exists with respect to the Senior Debt until such time as such event of default has been cured or waived by the Senior Lender.  Maker may make prepayments of this Note only upon receipt of written consent thereto from the Senior Lender.

4. Security.  This Note is secured by a security interest granted pursuant to that certain Security Agreement of even date herewith between Teragenix Corporation, as debtor, and Payee, as secured party.

5. Miscellaneous.

5.1 Waiver.  The rights and remedies of Payee under this Note shall be cumulative and not alternative.  No waiver by Payee of any right or remedy under this Note shall be effective unless in a writing signed by Payee.  Neither the failure nor any delay in exercising any right, power or privilege under this Note will operate as a waiver of such right, power or privilege and no single or partial exercise of any such right, power or privilege by Payee will preclude any other or further exercise of such right, power or privilege or the exercise of any other right, power or privilege.  To the maximum extent permitted by applicable law, (a) no claim or right of Payee arising out of this Note can be discharged by Payee, in whole or in part, by a waiver or renunciation of the claim or right unless in a writing, signed by Payee; (b) no waiver that may be given by Payee will be applicable except in the specific instance for which it is given; and (c) no notice to or demand on Maker will be deemed to be a waiver of any obligation of Maker or of the right of Payee to take further action without notice or demand as provided in this Note.  Maker hereby waives presentment, demand, protest and notice of dishonor and protest.

5.2 Notices.  Any notice required or permitted to be given hereunder shall be given in accordance with Section 11.4 of the Agreement.

3
 

 

5.3 Severability.  If any provision in this Note is held invalid or unenforceable by any court of competent jurisdiction, the other provisions of this Note will remain in full force and effect.  Any provision of this Note held invalid or unenforceable only in part or degree will remain in full force and effect to the extent not held invalid or unenforceable.

5.4 Governing Law.  This Note will be governed by the laws of the State of California without regard to conflicts of laws principles.

5.5 Parties In Interest.  This Note shall bind Maker and its successors and assigns.  This Note shall not be assigned or transferred by Payee without the express prior written consent of Maker, except by will or by operation of law.

5.6 Section Headings, Construction.  The headings of Sections in this Note are provided for convenience only and will not affect its construction or interpretation.  All references to “Section” or “Sections” refer to the corresponding Section or Sections of this Note unless otherwise specified.  All words used in this Note will be construed to be of such gender or number as the circumstances require.  Unless otherwise expressly provided, the words “hereof” and “hereunder” and similar references refer to this Note in its entirety and not to any specific section or subsection hereof.

 

[SIGNATURE PAGE FOLLOWS]

 

4
 

 

IN WITNESS WHEREOF, Maker has executed and delivered this Note as of the date first stated above.

  HEMACARE CORPORATION
   
   
  By: /s/ Judi Irving 
   
   
  Title: President & CEO 

S-1
 

THIS SUBORDINATED SECURED NON-NEGOTIABLE PROMISSORY NOTE (THIS “NOTE”) HAS NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR UNDER ANY U.S. STATE SECURITIES LAWS.  NEITHER THIS NOTE NOR ANY INTEREST OR PARTICIPATION HEREIN MAY BE REOFFERED, SOLD, ASSIGNED, TRANSFERRED, PLEDGED, ENCUMBERED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF SUCH REGISTRATION WITHOUT AN OPINION OF COUNSEL FOR THE PAYEE, REASONABLY ACCEPTABLE TO THE MAKER, STATING THAT SUCH SALE, TRANSFER OR ASSIGNMENT IS EXEMPT FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND QUALIFICATION REQUIREMENTS UNDER APPLICABLE U.S. STATE SECURITIES LAWS.  THIS NOTE MUST BE SURRENDERED TO THE MAKER AS A CONDITION PRECEDENT TO THE TRANSFER OF ANY INTEREST IN THIS NOTE.

SUBORDINATED SECURED NON-NEGOTIABLE PROMISSORY NOTE

$153,800   August 29, 2006

 

FOR VALUE RECEIVED, HemaCare Corporation. a California corporation (“Maker”), promises to pay to Joseph Mauro, an individual resident in the State of Florida (“Payee”), in lawful money of the United States of America, the principal sum of One Hundred Fifty-Three Thousand Eight Hundred Dollars ($153,800), together with interest in arrears on the unpaid principal balance at an annual rate equal to 5.0%, in the manner provided below.  Interest shall be calculated on the basis of a year of 365 or 366 days, as applicable, and charged for the actual number of days elapsed.

This Note has been executed and delivered pursuant to that certain Stock Purchase Agreement, dated August 29, 2006, by and among Maker, Payee and Valentin Adia (the “Agreement”).

1. Payments.

1.1 Principal and Interest.  The principal amount of this Note shall be due and payable in four (4) equal consecutive annual installments of Thirty Eight Thousand Four Hundred Fifty Dollars ($38,450) commencing on August 29, 2007, and continuing on August 29 of each year thereafter until paid in full.  Interest on the unpaid principal balance of this Note shall be due and payable annually, together with each payment of principal.

1.2 Manner of Payment.  All payments of principal and interest on this Note shall be made by wire transfer of immediately available funds to an account designated by Payee in writing.  If any payment of principal or interest on this Note is due on a day which is not a Business Day, such payment shall be due on the next succeeding Business Day and such extension of time shall be taken into account in calculating the amount of interest payable under this Note.  “Business Day” means any day other than a Saturday, Sunday or legal holiday in the State of California.

1.3 Prepayment.  Subject to Section 3(c) below, Maker may, without premium or penalty, at any time and from time to time, prepay all or any portion of the outstanding principal balance due under this Note, provided that each such prepayment is accompanied by accrued interest on the amount of principal prepaid calculated to the date of such prepayment.  Any partial prepayments shall be applied to installments of principal in inverse order of their maturity.

 
 

 

2. Defaults.

2.1 Events of Default.  The occurrence of any one or more of the following events with respect to Maker shall constitute an event of default hereunder (“Event of Default”):

(a) If Maker shall fail to pay when due any payment of principal or interest on this Note and such failure continues for fifteen (15) days after Payee notifies Maker thereof in writing; provided, however, that the exercise by Maker in good faith of its right of set-off pursuant to Section 1.4 above, whether or not ultimately determined to be justified, shall not constitute an Event of Default;

(b) If, pursuant to or within the meaning of the United States Bankruptcy Code or any other federal or state law relating to insolvency or relief of debtors (a “Bankruptcy Law”), Maker shall (i) commence a voluntary case or proceeding; (ii) consent to the entry of an order for relief against it in an involuntary case; (iii) consent to the appointment of a trustee, receiver, assignee, liquidator or similar official; or (iv) make an assignment for the benefit of its creditors;

(c) If a court of competent jurisdiction enters an order or decree under any Bankruptcy Law that (i) is for relief against Maker in an involuntary case, (ii) appoints a trustee, receiver, assignee, liquidator or similar official for Maker or substantially all of Maker’s properties, or (iii) orders the liquidation of Maker, and in each case the order or decree is not dismissed within 120 days;

(d) If Maker Defaults under its Senior Debt.  For purposes of this Section 2.1(d), the term “Default” shall have the meaning as such term is defined in any of Maker’s Senior Debt documents; or

(e) A final, non-appealable judgment which exceeds $1,000,000 shall be rendered against the Maker and within sixty (60) days after entry thereof, such judgment is not discharged or execution thereof stayed pending appeal, or within sixty (60) days after the expiration of such stay, such judgment is not discharged (unless such judgment relates to Payee).

2.2 Notice By Maker.  Maker shall notify Payee in writing within five days after the occurrence of any Event of Default of which Maker acquires knowledge.

2.3 Remedies.  Upon the occurrence of an Event of Default hereunder (unless all existing Events of Default have been cured or waived by Payee), Payee may, at its option, (i) by written notice to Maker, declare the entire unpaid principal balance of this Note, together with all accrued and unpaid interest thereon, immediately due and payable regardless of any prior forbearance, and (ii) exercise any and all rights and remedies available to it under applicable law, including, without limitation, the right to collect from Maker all sums due under this Note.  Upon the occurrence of any Event of Default, interest on the unpaid balance shall thereafter accrue at an annual rate of 12% per annum.  Maker shall pay all reasonable costs and expenses incurred by or on behalf of Payee in connection with Payee’s exercise of any or all of its rights and remedies under this Note, including, without limitation, reasonable attorneys’ fees.

3. Subordination to Senior Debt.  Payee, by acceptance of this Note, agrees that the payment of the principal and interest of this Note is subordinated to the Senior Debt to the extent and as provided below and undertakes, as a condition to the right to receive any payments hereunder, to execute such subordination agreements as may be requested by the Senior Lenders (as defined below) from time to time.

2
 

(a) As used herein, the term “Senior Debt” shall mean any and all indebtedness of Maker and all of its subsidiaries (collectively, the “Company”) owed to Senior Lenders together with (i) all complete or partial refinancings of such indebtedness, (ii) any amendments, restatements, extensions, modifications, renewals or substitutions with respect to the foregoing, (iii) interest, reasonable attorney fees, other fees and other sums payable in respect thereof, and (iv) any interest accruing thereon after the commencement of a case or proceeding under a Bankruptcy Law, without regard to whether or not such interest is an allowed claim in such proceeding.  The term “Senior Lenders” shall mean any institutional lender or lenders providing one or more senior secured credit facilities to the Company.  Senior Debt shall be considered to be outstanding whenever any loan or loan commitment remains outstanding under a loan agreement entered into with a Senior Lender.

(b) Except as specifically permitted in Section 3(c) below, Payee, by acceptance of this Note, agrees that Payee will not ask, demand, sue for, accept, or receive payment from Maker, by set-off or in any other manner, either in whole or in part, of any of the principal of or interest accrued on the indebtedness evidenced by this Note (the “Subordinated Indebtedness”).

(c) Maker shall pay or cause to be paid to Payee the Subordinated Indebtedness in accordance with the schedule set forth in Section 1.1 above, except that Maker shall not be required or permitted to make any payment on the Subordinated Indebtedness if an event of default exists with respect to the Senior Debt until such time as such event of default has been cured or waived by the Senior Lender.  Maker may make prepayments of this Note only upon receipt of written consent thereto from the Senior Lender.

4. Security.  This Note is secured by a security interest granted pursuant to that certain Security Agreement of even date herewith between Teragenix Corporation, as debtor, and Payee, as secured party.

5. Miscellaneous.

5.1 Waiver.  The rights and remedies of Payee under this Note shall be cumulative and not alternative.  No waiver by Payee of any right or remedy under this Note shall be effective unless in a writing signed by Payee.  Neither the failure nor any delay in exercising any right, power or privilege under this Note will operate as a waiver of such right, power or privilege and no single or partial exercise of any such right, power or privilege by Payee will preclude any other or further exercise of such right, power or privilege or the exercise of any other right, power or privilege.  To the maximum extent permitted by applicable law, (a) no claim or right of Payee arising out of this Note can be discharged by Payee, in whole or in part, by a waiver or renunciation of the claim or right unless in a writing, signed by Payee; (b) no waiver that may be given by Payee will be applicable except in the specific instance for which it is given; and (c) no notice to or demand on Maker will be deemed to be a waiver of any obligation of Maker or of the right of Payee to take further action without notice or demand as provided in this Note.  Maker hereby waives presentment, demand, protest and notice of dishonor and protest.

5.2 Notices.  Any notice required or permitted to be given hereunder shall be given in accordance with Section 11.4 of the Agreement.

3
 

5.3 Severability.  If any provision in this Note is held invalid or unenforceable by any court of competent jurisdiction, the other provisions of this Note will remain in full force and effect.  Any provision of this Note held invalid or unenforceable only in part or degree will remain in full force and effect to the extent not held invalid or unenforceable.

5.4 Governing Law.  This Note will be governed by the laws of the State of California without regard to conflicts of laws principles.

5.5 Parties In Interest.  This Note shall bind Maker and its successors and assigns.  This Note shall not be assigned or transferred by Payee without the express prior written consent of Maker, except by will or by operation of law.

5.6 Section Headings, Construction.  The headings of Sections in this Note are provided for convenience only and will not affect its construction or interpretation.  All references to “Section” or “Sections” refer to the corresponding Section or Sections of this Note unless otherwise specified.  All words used in this Note will be construed to be of such gender or number as the circumstances require.  Unless otherwise expressly provided, the words “hereof” and “hereunder” and similar references refer to this Note in its entirety and not to any specific section or subsection hereof.

[SIGNATURE PAGE FOLLOWS]

4
 

IN WITNESS WHEREOF, Maker has executed and delivered this Note as of the date first stated above.

 

  HEMACARE CORPORATION
   
   
  By: /s/ Judi Irving 
   
   
  Title: President & CEO 

 

 

S-1

EX-10.6 7 ex10-6.htm

Exhibit 10.6

 

January 15, 2011

 

 

 

Hemacare Corporation

Coral Blood Services, Inc.

15350 Sherman Way

Suite 350

Van Nuys, CA 91406

 

Dear Lisa Bacerra:

 

Wells Fargo Bank, National Association ("Bank"), has made certain credit accommodations available to Hemacare Corporation, a California corporation, and Coral Blood Services, Inc., a California corporation (collectively, “Borrowers” and each, a “Borrower”) pursuant to the Credit Agreement dated as of December 4, 2009 (the “Credit Agreement”). Except as otherwise defined herein, all capitalized terms herein shall have the meanings given in the Credit Agreement.

 

The following Events of Default exist under the Credit Agreement (the “Existing Events of Default”):

 

(i) Borrowers failed to maintain their Tangible Net Worth as required by Section 4.9(a) of the Credit Agreement for the fiscal quarter ended September 30, 2010. For the fiscal quarter ended September 30, 2010 their Tangible Net Worth was to be not less than $5,090,000, but instead was $4,846,000.

 

(ii) Borrowers failed to maintain their net income after taxes as required by Section 4.9(c) of the Credit Agreement for the rolling 2 quarter period ended September 30, 2010. For such period their net income after taxes was to be not less than $200,000, but instead was ($396,000).

 

(iii) Prior to September 30, 2010, Borrowers incurred indebtedness for borrowings in violation of Section 5.2 without the prior written consent of Bank. Borrower incurred indebtedness of $97,900.

 

As of the date of this letter, there are no outstanding advances under the Line of Credit, but there is an outstanding Letter of Credit in the amount of $660,150 (the “Prior Issued Letter of Credit”).

 

Borrowers have asked Bank to waive the Existing Events of Default and continue to make advances to Borrowers and issue Letters of Credit for the account of Borrowers under the Line of Credit until the scheduled maturity date thereof. Bank is willing to waive the Existing Events of Default and continue to extend credit to Borrowers under the Credit Agreement until the scheduled maturity date, subject to the following terms and conditions. Accordingly, this letter will confirm the following agreement between Bank and Borrowers:

 
 

 

Hemacare Corporation

Coral Blood Services, Inc.

January 15, 2011

Page 2

 

1. Bank hereby waives the Existing Events of Default, subject to the terms and conditions herein. This waiver applies only to the Existing Events of Default for the prior periods indicated above.

 

2. Section 1.1(b) shall be deleted hereby and replaced by the following:

 

(b) Limitation on Borrowings. Outstanding borrowings under the Line of Credit, including outstanding advances and Letters of Credit, to a maximum of the principal amount set forth above, shall not at any time exceed the amount of cash collateral in a segregated, blocked deposit account maintained by Hemacare Corporation and Coral Blood Services, Inc., or either of them, with Bank, in which Bank has been granted a security interest of first priority to secure all present and future indebtedness of Borrower to Bank pursuant to such security agreement as Bank may require (the “Pledged Account”).”

 

3. Section 1.4 is hereby amended by adding the following at the end of the first paragraph thereunder:

 

“The foregoing collateral shall include, without limitation, the Pledged Account and all other deposit accounts of Borrower with Bank.”

 

4. Borrowers hereby acknowledge that as a result of the foregoing requirement for cash collateral, if Borrowers have not already done so, then concurrently with the execution and delivery of this letter by Borrowers to Bank, Borrowers will (a) execute and deliver to Bank such security agreement as Bank may require in connection therewith, and (b) open the Pledged Account and deposit funds therein in an amount sufficient to cover all outstanding borrowings under the Line of Credit (including without limitation the Prior Issued Letter of Credit). Borrowers hereby further acknowledge that they are jointly and severally liable for all such outstanding borrowings, including without limitation the Prior Issued Letter of Credit.

 

 

5. Section 4.3(d) is hereby modified to delete the part thereof that would require a monthly borrowing base certificate, an aged listing of accounts receivable and accounts payable and a reconciliation of accounts.

 

6. Section 4.9 is hereby deleted.

 

7. Concurrently with the execution and delivery by Borrowers to Bank of this letter, Borrowers shall pay to Bank a restructure fee of $4,000.

 

8. Borrowers acknowledge that Bank has not committed to extend the maturity date of the Line of Credit beyond its scheduled maturity date of December 1, 2011.

 
 

Hemacare Corporation

Coral Blood Services, Inc.

January 15, 2011

Page 3

 

 

9. It is a condition precedent to the waiver granted hereunder and the effectiveness hereof that all of the following conditions be satisfied on or before December 15, 2010, or such later date as may be approved by Bank:

 

(a) Borrowers execute this letter or a copy hereof in the spaces indicated below and deliver same to Bank.

 

(b) Borrowers pay to Bank the restructure fee described above.

 

(c) Borrowers fund the Pledged Account to cover outstanding borrowings under the Line of Credit as described above.

 

10. Except as expressly provided herein, all terms and provisions of the Credit Agreement, the Line of Credit Note and the other Loan Documents shall continue in full force and effect, without waiver or modification. This letter shall be deemed one of the Loan Documents entered into in connection with the Credit Agreement.

 

11. This letter constitutes the entire agreement between Bank and Borrowers with respect to the waiver and other agreements herein; and supersedes all prior negotiations, discussions and correspondence concerning the subject matter hereof.

 

12. The agreements set forth herein are entered into for the sole protection and benefit of Bank and Borrowers, and their respective permitted successors and assigns, and no other person or entity shall be a third party beneficiary of the agreements herein.

 

 

 
 

Hemacare Corporation

Coral Blood Services, Inc.

January 15, 2011

Page 4

 

 

Please arrange to have this letter or a copy hereof executed and returned to the Bank in accordance with the foregoing. This letter may be executed in counterparts, each of which shall be deemed an original, and all of which when taken together shall be deemed one agreement.

 

  Sincerely,
   
  WELLS FARGO BANK,
  NATIONAL ASSOCIATION
     
  By: /s/ Seth Evenson
    Seth Evenson, Relationship Manager

 

 

Acknowledged and agreed to by the undersigned Borrowers:

 

      WELLS FARGO BANK,
HEMACARE CORPORATION   NATIONAL ASSOCIATION
         
By: /s/ Peter van der Wal   By: /s/ Seth Evenson
  Peter van der Wal, Chief Executive Officer     Seth Evenson, Relationship Manager
         
By: /s/ Lisa Bacerra      
  Lisa Bacerra, Chief Financial Officer      
         
CORAL BLOOD SERVICES, INC.  
         
By: /s/ Peter van der Wal      
  Peter van der Wal, Chief Executive Officer      
         
By: /s/ Lisa Bacerra      
  Lisa Bacerra, Chief Financial Officer      

 

EX-10.7 8 ex10-7.htm

Exhibit 10.7

 

FIRST MODIFICATION TO PROMISSORY NOTE

 

 

This modification to PROMISSORY NOTE (this “Modification”) is entered into as of January 15, 2011, by and between HEMACARE CORPORATION and CORAL BLOOD SERVICES, INC. (“Borrower”), and Wells Fargo Bank, National Association (“Bank”).

 

RECITALS

 

WHEREAS, Borrower is currently indebted to Bank pursuant to the terms and conditions of that certain Revolving Line of Credit Note in the maximum principal amount of $5,000,000.00, executed by Borrower and payable to the order of Bank, dated as of December 4, 2009 (the "Note"), which Note is subject to the terms and conditions of a loan agreement between Borrower and Bank dated as of December 4, 2009, as amended from time to time (the "Loan Agreement").

 

WHEREAS, Bank and Borrower have agreed to certain changes in the terms and conditions set forth in the Note, and have agreed to modify the Note to reflect said changes.

 

NOW, THEREFORE, for valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree that the Note shall be modified as follows:

 

1. Section 2.2 is hereby deleted in its entirety, and the following substituted therefore:

 

“2.2. Advances. Advances hereunder, to the total amount of the principal sum available hereunder, may be made by the holder at the oral or written request of (a) Lisa Bacerra or Pete van der Wal, any one acting alone, who are authorized to request advances and direct the disposition of any advances until written notice of the revocation of such authority is received by the holder at the office designated above, or (b) any person, with respect to advances deposited to the credit of any deposit account of Borrower, which advances, when so deposited, shall be the conclusively presumed to have been made to or for the benefit of Borrower regardless of the fact that persons other than those authorized to request advances may have authority to draw against such account. The holder shall have no obligation to determine whether any person requesting an advance is or has been authorized by Borrower."

 

2. The effective date of the changes set forth herein shall be January 15, 2011.

 

3. Except as expressly set forth herein, all terms and conditions of the Note remain in full force and effect, without waiver or modification. All terms defined in the Note or the Loan Agreement shall have the same meaning when used in this Modification. This Modification and the Note shall be read together, as one document.

 

4. Borrower certifies that as of the date of this Modification, after giving effect to the waivers by Bank of the Events of Default that exist on the date hereof provided concurrently herewith, there exists no Event of Default under the Note, nor any condition, act or event which with the giving of notice or the passage of time or both would constitute any such Event of Default.

 
 

IN WITNESS WHEREOF, the parties hereto have caused this Modification to be executed as of the day and year first written above.

 

 

      WELLS FARGO BANK,
HEMACARE CORPORATION   NATIONAL ASSOCIATION
         
By: /s/ Peter van der Wal   By: /s/ Seth Evenson
  Peter van der Wal, Chief Executive Officer     Seth Evenson, Relationship Manager
         
By: /s/ Lisa Bacerra      
  Lisa Bacerra, Chief Financial Officer      
         
         
CORAL BLOOD SERVICES, INC.  
         
By: /s/ Peter van der Wal      
  Peter van der Wal, Chief Executive Officer      
         
By: /s/ Lisa Bacerra      
  Lisa Bacerra, Chief Financial Officer      

 

 

 

2

EX-10.8 9 ex10-8.htm

Exhibit 10.8

SECURITY AGREEMENT:
SPECIFIC RIGHTS TO PAYMENT

1. GRANT OF SECURITY INTEREST. For valuable consideration, the undersigned HemaCare Corporation, or any of them ("Debtor"), hereby grants and transfers to WELLS FARGO BANK, NATIONAL ASSOCIATION ("Bank") a security interest in the following accounts, deposit accounts, chattel paper (whether electronic or tangible), instruments, promissory notes, documents, general intangibles, payment intangibles, software, letter of credit rights, health-care insurance receivables and other rights to payment (collectively called "Collateral"):

Certificate of Deposit number 5321120262 maintained with or issued by Bank, all funds now or hereafter deposited therein or evidenced thereby, all interest now or hereafter earned thereon, and all renewals and replacements thereof, whether or not any such renewal or replacement is evidenced by a certificate of deposit

and all renewals thereof, including all securities, guaranties, warranties, indemnity agreements, insurance policies, supporting obligations and other agreements pertaining to the same or the property described therein, together with whatever is receivable or received when any of the Collateral or proceeds thereof are sold, collected, exchanged or otherwise disposed of, whether such disposition is voluntary or involuntary, including without limitation, all rights to payment, including returned premiums, with respect to any insurance relating to any of the foregoing, and all rights to payment with respect to any claim or cause of action affecting or relating to any of the foregoing (hereinafter called "Proceeds").

2. OBLIGATIONS SECURED. The obligations secured hereby are the payment and performance of: (a) all present and future Indebtedness of Debtor to Bank; (b) all obligations of Debtor and rights of Bank under this Agreement; and (c) all present and future obligations of Debtor to Bank of other kinds. The word "Indebtedness" is used herein in its most comprehensive sense and includes any and all advances, debts, obligations and liabilities of Debtor, or any of them, heretofore, now or hereafter made, incurred or created, whether voluntary or involuntary and however arising, whether due or not due, absolute or contingent, liquidated or unliquidated, determined or undetermined, including under any swap, derivative, foreign exchange, hedge, deposit, treasury management or other similar transaction or arrangement, and whether Debtor may be liable individually or jointly with others, or whether recovery upon such Indebtedness may be or hereafter becomes unenforceable.

3. TERMINATION. This Agreement will terminate upon the performance of all obligations of Debtor to Bank, including without limitation, the payment of all Indebtedness of Debtor to Bank, and the termination of all commitments of Bank to extend credit to Debtor, existing at the time Bank receives written notice from Debtor of the termination of this Agreement.

4. OBLIGATIONS OF BANK. Bank has no obligation to make any loans hereunder. Any money received by Bank in respect of the Collateral may be deposited, at Bank's option, into a non-interest bearing account over which Debtor shall have no control, and the same shall, for all purposes, be deemed Collateral hereunder.

 
 

5. REPRESENTATIONS AND WARRANTIES. Debtor represents and warrants to Bank that: (a) Debtor's legal name is exactly as set forth on the first page of this Agreement, and all of Debtor's organizational documents or agreements delivered to Bank are complete and accurate in every respect; (b) Debtor is the owner and has possession or control of the Collateral and Proceeds; (c) Debtor has the exclusive right to grant a security interest in the Collateral and Proceeds; (d) all Collateral and Proceeds are genuine, free from liens, adverse claims, setoffs, default, prepayment, defenses and conditions precedent of any kind or character, except the lien created hereby or as otherwise agreed to by Bank, or as heretofore disclosed by Debtor to Bank, in writing; (e) all statements contained herein and, where applicable, in the Collateral are true and complete in all material respects; (f) no financing statement covering any of the Collateral or Proceeds, and naming any secured party other than Bank, is on file in any public office; (g) all persons appearing to be obligated on Collateral and Proceeds have authority and capacity to contract and are bound as they appear to be; (h) all property subject to chattel paper has been properly registered and filed in compliance with la w and to perfect the interest of Debtor in such property; and (i) all Collateral and Proceeds comply with all applicable laws concerning form, content and manner of preparation and execution, including where applicable Federal Reserve Regulation Z and any State consumer credit laws.

6. COVENANTS OF DEBTOR.

(a) Debtor agrees in general: (i) to pay Indebtedness secured hereby when due; (ii) to indemnify Bank against all losses, claims, demands, liabilities and expenses of every kind caused by property subject hereto; (iii) to permit Bank to exercise its powers; (iv) to execute and deliver such documents as Bank deems necessary to create, perfect and continue the security interests contemplated hereby; (v) not to change its name, and as applicable, its chief executive office, its principal residence or the jurisdiction in which it is organized and/or registered without giving Bank prior written notice thereof; (vi) not to change the places where Debtor keeps any Collateral or Debtor's records concerning the Collateral and Proceeds without giving Bank prior written notice of the address to which Debtor is moving same; and (vii) to cooperate with Bank in perfecting all security interests granted herein and in obtaining such agreements from third parties as Bank deems necessary, proper or convenient in connection with the preservation, perfection or enforcement of any of its rights hereunder.

(b) Debtor agrees with regard to the Collateral and Proceeds, unless Bank agrees otherwise in writing: (i) that Bank is authorized to file financing statements in the name of Debtor to perfect Bank's security interest in Collateral and Proceeds; (ii) where applicable, to insure the Collateral with Bank named as loss payee, in form, substance and amounts, under agreement s, against risks and liabilities, and with insurance companies satisfactory to Bank; (iii) not to permit any lien on the Collateral or Proceeds, except in favor of Bank; (iv) not to sell, hypothecate or otherwise dispose of, nor permit the transfer by operation of law of, any of the Collateral or Proceeds or any interest therein, nor withdraw any funds from any deposit account pledged to Bank hereunder; (v) to keep, in accordance with generally accepted accounting principles, complete and accurate records regarding all Collateral and Proceeds, and to permit Bank to inspect the same and make copies thereof at any reasonable time; (iv) if requested by Bank, to receive and use reasonable diligence to collect Proceeds, in trust and as the property of Bank, and to immediately endorse as appropriate and deliver such Proceeds to Bank daily in the exact form in which they are received together with a collection report in form satisfactory to Bank; (vii) not to commingle Collateral or Proceeds, or collections thereunder, with other property; (viii) in the event Bank elects to receive payments of Collateral and Proceeds hereunder, to pay all expenses incurred by Bank in connection therewith, including expenses of accounting, correspondence, collection efforts, reporting to account or contract debtors, filing, recording, record keeping and expenses incidental there to; and (ix) to provide any service and do any other acts which may be necessary to keep all Collateral and Proceeds free and clear of all defenses, rights of offset and counterclaims.

2
 

7. POWERS OF BANK. Debtor appoints Bank its true attorney in fact to perform any of the following powers, which are coupled with an interest, are irrevocable until termination of this Agreement and may be exercised from time to time by Bank's officers and employees , or any of them, whether or not Debtor is in default: (a) to perform any obligation of Debtor hereunder in Debtor's name or otherwise; (b) to give notice to account debtors or others of Bank's rights in the Collateral and Proceeds, to enforce or forebear from enforcing the same and make extension or modification agreements with respect thereto; (c) to release persons liable on Collateral or Proceeds and to give receipts and acquaintances and compromise disputes in connection therewith; (d) to release or substitute security; (e) to resort to security in any order; (f) to prepare, execute, file, record or deliver notes, assignments, schedules, designation statements, financing statements, continuation statements, termination statements, statements of assignment, applications for registration or like papers to perfect, preserve or release Bank's interest in the Collateral and Proceeds; (g) to receive, open and read mail addressed to Debtor; (h) to take cash, instruments for the payment of money and other property to which Bank is entitled; (i) to verify facts concerning the Collateral and Proceeds by inquiry of obligors thereon, or otherwise, in its own name or a fictitious name; (j) to endorse, collect, deliver and receive payment under instruments for the payment of money constituting or relating to Proceeds; (k) to prepare, adjust, execute, deliver and receive payment under insurance claims, and to collect and receive payment of and endorse any instrument in payment of loss or returned premi ums or any other insurance refund or return, and to apply such amounts received by Bank, at Bank's sole option, toward repayment of the Indebtedness; (l) to exercise all rights, powers and remedies which Debtor would have, but for this Agreement, with respect to all Collateral and Proceeds subject hereto; (m) to make withdrawals from and to close deposit accounts or other accounts with any financial institution, wherever located, into which Proceeds may have bee n deposited, and to apply funds so withdrawn to payment of the Indebtedness; (n) to preserve or release the interest evidenced by chattel paper to which Bank is entitled hereunder and to endorse and deliver any evidence of title incidental thereto; and (o) to do all acts and things and execute all documents in the name of Debtor or otherwise, deemed by Bank as necessary, proper and convenient in connection with the preservation, perfection or enforcement of its rights hereunder.

8. PAYMENT OF PREMIUMS, TAXES, CHARGES, LIENS AND ASSESSMENTS. Debtor agrees to pay, prior to delinquency, all insurance premiums, taxes, charges, liens and assessments against the Collateral and Proceeds, and upon the failure of Debtor to do so, Bank at its option may pay any of them and shall be the sole judge of the legality or validity thereof and the amount necessary to discharge the same. Any such payments made by Bank shall be obligations of Debtor to Bank, due and payable immediately upon demand, together with interest at a rate determined in accordance with the provisions of this Agreement, and shall be secured by the Collateral and Proceeds, subject to all terms and conditions of this Agreement.

3
 

9. EVENTS OF DEFAULT. The occurrence of any of the following shall constitute an "Event of Default" under this Agreement: (a) any default in the payment or performance o f any obligation, or any defined event of default, under (i) any contract or instrument evidencing any Indebtedness, or (ii) any other agreement between Debtor and Bank, including without limitation any loan agreement, relating to or executed in connection with any Indebtedness; (b) any representation or warranty made by Debtor herein shall prove to be incorrect, false or misleading in any material respect when made; (c) Debtor shall fail to observe or perform any obligation or agreement contained herein; (d) any impairment of the rights of Bank in any Collateral or Proceeds, or any attachment or like levy on any property of Debtor; and (e) Bank, in good faith, believes any or all of the Collateral and/or Proceeds to be in danger of misuse, dissipation, commingling, loss, theft, damage or destruction, or otherwise in jeopardy or unsatisfactory in character or value.

10. REMEDIES. Upon the occurrence of any Event of Default, Bank shall have the right to declare immediately due and payable all or any Indebtedness secured hereby and to terminate any commitments to make loans or otherwise extend credit to Debtor. Bank shall have all other rights, powers, privileges and remedies granted to a secured party upon default under the California Uniform Commercial Code or otherwise provided by law, including without limitation, the right (a) to contact all persons obligated to Debtor on any Collateral or Proceeds and to instruct such persons to deliver all Collateral and/or Proceeds directly to Bank, and (b) to sell, lease, license or otherwise dispose of any or all Collateral. All rights, powers, privileges and remedies of Bank shall be cumulative. No delay, failure or discontinuance of Bank in exercising any right, power, privilege or remedy hereunder shall affect or operate as a waiver of such right, power, privilege or remedy; nor shall any single or partial exercise of any such right, power, privilege or remedy preclude, waive or otherwise affect any other or further exercise thereof or the exercise of any other right, power, privilege or remedy. Any waiver, permit, consent or approval of any kind by Bank of any default hereunder, or any such waiver of an y provisions or conditions hereof, must be in writing and shall be effective only to the extent set forth in writing. It is agreed that public or private sales or other dispositions, for cash or on credit, to a wholesaler or retailer or investor, or user of property of the types subject to this Agreement, or public auctions, are all commercially reasonable since differences in the pr ices generally realized in the different kinds of dispositions are ordinarily offset by the differences in the costs and credit risks of such dispositions. While an Event of Default exists: (a) Debtor will deliver to Bank from time to time, as requested by Bank, current lists of all Collateral and Proceeds; (b) Debtor will not dispose of any Collateral or Proceeds except on terms app roved by Bank; (c) Bank may, at any time and at Bank's sole option, liquidate any time deposits pledged to Bank hereunder and apply the Proceeds thereof to payment of the Indebtedness, whether or not said time deposits have matured and notwithstanding the fact that such liquidation may give rise to penalties for early withdrawal of funds; and (d) at Bank's request, Debtor will assemble and deliver all Collateral and Proceeds, and books and records pertaining thereto, to Bank at a reasonably convenient place designated by Bank. Debtor further agrees that Bank shall have no obligation to process or prepare any Collateral for sale or other disposition.

4
 

11. DISPOSITION OF COLLATERAL AND PROCEEDS; TRANSFER OF INDEBTEDNESS. In disposing of Collateral hereunder, Bank may disclaim all warranties of title, possession, quiet enjoyment and the like. Any proceeds of any disposition of any Collateral or Proceeds, or any part thereof, may be applied by Bank to the payment of expense s incurred by Bank in connection with the foregoing, including reasonable attorneys' fees, and t he balance of such proceeds may be applied by Bank toward the payment of the Indebtedness in such order of application as Bank may from time to time elect. Upon the transfer of all or any part of the Indebtedness, Bank may transfer all or any part of the Collateral or Proceeds and shall be fully discharged thereafter from all liability and responsibility with respect to any of th e foregoing so transferred, and the transferee shall be vested with all rights and powers of Bank hereunder with respect to any of the foregoing so transferred; but with respect to any Collateral or Proceeds not so transferred Bank shall retain all rights, powers, privileges and remedies herein given.

12. STATUTE OF LIMITATIONS. Until all Indebtedness shall have been paid in ful l and all commitments by Bank to extend credit to Debtor have been terminated, the power of sale or other disposition and all other rights, powers, privileges and remedies granted to Bank hereunder shall continue to exist and may be exercised by Bank at any time and from time to time irrespective of the fact that the Indebtedness or any part thereof may have become barred by any statute of limitations, or that the personal liability of Debtor may have ceased, unless such liability shall have ceased due to the payment in full of all Indebtedness secured hereunder.

13. MISCELLANEOUS. When there is more than one Debtor named herein: (a) the word "Debtor" shall mean all or any one or more of them as the context requires; (b) the obligations of each Debtor hereunder are joint and several; and (c) until all Indebtedness shall have been paid in full, no Debtor shall have any right of subrogation or contribution, and each Debtor hereby waives any benefit of or right to participate in any of the Collateral or Proceeds o r any other security now or hereafter held by Bank. Debtor hereby waives any right to require Bank to (i) proceed against Debtor or any other person, (ii) marshal assets or proceed against or exhaust any security from Debtor or any other person, (iii) perform any obligation of Debtor with respect to any Collateral or Proceeds, and (d) make any presentment or demand, or give any notice of nonpayment or nonperformance, protest, notice of protest or notice of dishonor hereunder or in connection with any Collateral or Proceeds. Debtor further waives any right to direct the application of payments or security for any Indebtedness of Debtor or indebtedness of customers of Debtor.

14. NOTICES. All notices, requests and demands required under this Agreement must be in writing, addressed to Bank at the address specified in any other loan documents entered into between Debtor and Bank and to Debtor at the address of its chief executive office (or principal residence, if applicable) specified below or to such other address as any part y may designate by written notice to each other party, an d shall be deemed to have been given or made as follows: (a) if personally delivered, upon delivery; (b) if sent by mail, upon the earlier of the date of receipt or three (3) days after deposit in the U.S. mail, first class and postage prepaid; and (c) if sent by telecopy, upon receipt.

5
 

15. COSTS, EXPENSES AND ATTORNEYS' FEES. Debtor shall pay to Bank immediately upon demand the full amount of all payments, advances, charges, costs and expenses, including reasonable attorneys' fees (to include outside counsel fees and all allocated costs of Bank's in-house counsel), expended or incurred by Bank in connection with (a) the perfection and preservation of the Collateral or Bank's interest therein, and (b) the realization, enforcement and exercise of any right, power, privilege or remedy conferred by this Agreement, whether incurred at the trial or appellate level, in an arbitration proceeding or otherwise, and including any of the foregoing incurred in connection with any bankruptcy proceeding (including without limitation, any adversary proceeding, contested matter or motion brought by Bank or any other person) relating to Debtor or in any way affecting any of the Collateral or Bank's ability to exercise any of its rights or remedies with respect thereto. All of the foregoing shall be paid by Debtor with interest from the date of demand until paid in full at a rate per annum equal to the greater of ten percent (10%) or Bank’s Prime Rate in effect from time to time.

16. SUCCESSORS; ASSIGNS; AMENDMENT. This Agreement shall be binding upon and inure to the benefit of the heirs, executors, administrators, legal representatives, successors and assigns of the parties, and may be amended or modified only in writing signed by Bank and Debtor.

17. OBLIGATIONS OF MARRIED PERSONS. Any married person who signs this Agreement as Debtor hereby expressly agrees that recourse may be had against his or her separate property for all his or her Indebtedness to Bank secured by the Collateral and Proceeds under this Agreement.

18. SEVERABILITY OF PROVISIONS. If any provision of this Agreement shall be held to be prohibited by or invalid under applicable law, such provision shall be ineffective on ly to the extent of such prohibition or invalidity, without invalidating the remainder of such provision or any remaining provisions of this Agreement.

19. GOVERNING LAW. This Agreement shall be governed by and construed in accordance with the laws of the State of California.

Debtor warrants that Debtor is an organization registered under the laws of California.

Debtor warrants that its chief executive office (or principal residence, if applicable) is located at the following address: 15350 Sherman Way, Suite #350, Van Nuys, CA 91406.

IN WITNESS WHEREOF, this Agreement has been duly executed as of January 15, 2011.

HemaCare Corporation
   
By: /s/ Pete van der Wal
  Pete van der Wal, Chief Executive Officer
   
By: /s/ Lisa Bacerra
  Lisa Bacerra, Chief Financial Officer

  

6
 

ADDENDUM TO SECURITY AGREEMENT SPECIFIC RIGHTS TO PAYMENT

 

THIS ADDENDUM is attached to and made a part of that certain Security Agreement Specific Rights to Payment dated January 15, 2011 (the “Security Agreement”), executed by HEMACARE CORPORATION, a California corporation ("Debtor") for the benefit of WELLS FARGO BANK, NATIONAL ASSOCIATION ("Bank").

 

The Security Agreement is amended as follows:

 

1. In Section 7, in the third line, the words “whether or not Debtor is in default” are hereby deleted and replaced by the words “if Debtor is in default”.

 

2. The following is hereby added at the end of Section 7:

 

“Notwithstanding the foregoing, Bank may exercise the powers to act described in the following above-listed subdivisions of this Section 7 regardless of whether Debtor is in default: (b) as it relates to giving notice of Bank’s rights in the Collateral and Proceeds; (f) as it relates to items (other than notes) to perfect, preserve or release Bank’s interest in the Collateral and Proceeds; (i); and (o) to the extent it relates to the preservation or perfection of Bank’s rights hereunder.”

 

IN WITNESS WHEREOF, this Addendum has been executed as of the same date as the Security Agreement.

 

 

HEMACARE CORPORATION
   
By: /s/ Peter van der Wal
  Peter van der Wal, Chief Executive Officer
   
By: /s/ Lisa Bacerra
  Lisa Bacerra, Chief Financial Officer

 

 

  Accepted by:
   
  WELLS FARGO BANK, NATIONAL ASSOCIATION
   
  By: /s/ Seth Evenson
    Seth Evenson, Relationship Manager

 

GRAPHIC 10 hemacare.jpg GRAPHIC begin 644 hemacare.jpg M_]C_X``02D9)1@`!`@$`2`!(``#_X0U%17AI9@``34T`*@````@`!P$2``,` M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q M``(````<````<@$R``(````4````CH=I``0````!````I````-``"OR````G M$``*_(```"<0061O8F4@4&AO=&]S:&]P($-3,B!7:6YD;W=S`#(P,3$Z,#$Z M,C$@,3(Z,3,Z,C4``````Z`!``,````!``$``*`"``0````!```!=Z`#``0` M```!````9@`````````&`0,``P````$`!@```1H`!0````$```$>`1L`!0`` M``$```$F`2@``P````$``@```@$`!`````$```$N`@(`!`````$```P/```` M`````$@````!````2`````'_V/_@`!!*1DE&``$"``!(`$@``/_M``Q!9&]B M95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\, M#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P, M#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P, M#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`+`"@`P$B``(1`0,1`?_=``0` M"O_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$``04!`0$!`0$` M`````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$% M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F M]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B M$P4R@9$4H;%"(\%2T?`S)&+A7U5F9VAI:FML;6YO8G-T=7 M9W>'EZ>WQ__:``P#`0`"$0,1`#\`]$ZWU:OI>$ZV0LZ[GQIN'^B9]* MU&Z9U&GJ6$S+IT#I#V]Q#?LS?3&XM'T[?5VZ_\` M$^I_UM6/J)ZOKYNPEV/(W^[;.*O1\OU^;C;LN M5@.4&6_7I*^E2]/`]1GYV/T_%?E9+MM;.PU+B?HUL'YSWJGT#K(ZKBDV!K,J MHQ?4W@3/IO9,_HWM_P"GO63]>_4]+`U+:/5>'P8&_P!-WI;C_5]99GU1-G_. M!HI>2ST'F\;MPV3[.9_PNS:E/F9QYJ.(#T:1/CQ_I_X*8@26;B_6 M3ZO9ES:,3J>)?<_1E5=U;GN_J,:_W8C4]7Z3 M?AOSJI:';&;?Y27">Q4W$EEU?6GZM76-JJZKAOL>=K M&"^LDD\-:-ZS\GJ?7^H=?S>D]'MQL2KIE=!R;LBM]KW/R`^UC:F,LIKV,J9^ M>G#'+6_30L\2+>D27-7XWU[Q:++ZNI8.6^MKGMILQ7L#H&[9OJR'/6@SZR=* MJP,/*ZGDT].MS**[QCY%K6/;ZC6NV;;"QSO3<[9]%(P/0B7]U5NJDJ&-U_H> M77;9C=0QKF8[#9>ZNYCA6PG^D M_FJV/]-:_P!+^MV;4\&; M[IQ"7IOBX/`_I.3]0>JYO6;LSH'5;;,W$=C^NRRYQ?96YKV,AMS]S_=ZOJ5> MH[]'Z'L7:_5SIN/@]/#JWLOMO]]N0SA\$[-O\BO]S^NL/J6%@?5/IK<+HM9J MOZB\B[):YG!+G@(PHUP\7]:7RZ?UD8L&;[I*7%Z;XN']Z,/F MD]BN*R.A=(ZW]>>IT]3H-[:<3%?6-]E<$FW=_,/KW?FKM5B=0Z[D8O4CAAM% M36BHL=D.>TWFUWI^GB-JKM]]7_7?^+9_.J;WQA!E9'%Z+&E?I?\`ST/5H98QF2ZS_@_\(O0NM=1MZ=A?:*JQ82]E;G.)#*P\[3D7;&O?Z57Y MZCT7J5O4<>ZRQK!Z-SJ6VU$FNT-#3Z]! MH\724?TN+]Y7LRX/<`'#=6\EDYU>=;@XU_UFQ.J..7C64XV)AL?;ZC+66M>Q MU658[&:UK'^O?_@Z/470?4ZJEN#FVUL:Q]W4[Z'[ZC/-PGCD0#42`177^[",?WEQY><9B)JY`R&NE1^; M7_!:/U=HQZ^O?62RIC6.?ETAY:`V?U:FS6/^%NML_KV+`^L5]>'U/ZP/&/5; M78[I/VA]U9MII!=D;L[)HJV.N;0VJKV?\7O_`$:[;'OS#@"_*QQ5E;"Y^,QW MJ>X3#&V`#Z:S>@]?R.IY!JMJK#33ZQ=2YSO2<7^G]BR=[&?K3/SO_/2>.9C& M8L']8(@#;Y>'_O$>Q(QD158SZC<>KROUAZR^WH.?4[ZR=-ZL+:+&_8F8TO?[ M7.W5_9\G)LKLHV^O7:^GTJGU[[O3K_2*YT[K/3^@?6/JF3UJXXM/5YEHJH=5D1;6Q[?T=CF_P`Y[UM=;Z_E]-SW4T4565-IKNM<]Q:??88Q`1,8R/N>D:B>O^*HX)W(&A[8XCY/'=3ZB+U8LZ+U-OVG$I-4>VA_P!GML%V33=QZM;*W^I5_A/YQB[;#Z=B7?5RKIH8 M&8MV(*2U@`ACZ]CML@M_._=16VYSW$D%OI"LLV#Z/N]15N MM=8NZ?=136*:VW-L<$_H^W(?XW^#P_ MO*AAG(Q`UXP9#^[&[_Z#R..'=`ZMU#!=UFGHKBZEN/;FXK;#?CU48^-CV-SG M68U=GI;'UOI;_-6^I_I%H]%NKSOK51D#K%?6,C'Q;J[+,/%%=;:WNK+*\K-K MOM9_.5[\:C_COH+I?VA:[HAZEZ6RPXOV@4/D0[T_6]*QT;OI>WZ"H])Z_EYN M=1B7XK<<68OV@G<7`ZL]-]#HVNH?79_7KL_1(SYR-B)'JR1$1I'^[^YQ?\Y4 M>7F1*0V@3Q:_N^#_`/_1ZWZX](ML'[6IL]/TW>K'IP=^[C;'NW M3^:G5,#E_O1/%^MVX/Z_[U_W&[*7,?=:,?U>AX[CQ<'Z,:^=QOK3T>SJ6$RS M'G[3B.-E;1^>TC;;5K[=SF_0_P"$69]3>DN-AZO<26[37B@P)!/Z6[:&M_XJ MO_KBZU0J]+TV^EM]./;MB(\H2G'E_O429?K*^2MY?H:HA+F/NL@(_J]?78L8 M_P!,5\WS,TDDE<::DDDDE*22224I))))2DDDDE*22224I))))2DDDDE/_]G_ M[1(B4&AO=&]S:&]P(#,N,``X0DE-!"4``````!`````````````````````` M.$))30/M```````0`$@````!``$`2`````$``3A"24T$)@``````#@`````` M```````_@```.$))300-```````$````>#A"24T$&0``````!````!XX0DE- M`_,```````D```````````$`.$))300*```````!```X0DE-)Q````````H` M`0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&```````!`"]F9@`! M`*&9F@`&```````!`#(````!`%H````&```````!`#4````!`"T````&```` M```!.$))30/X``````!P``#_____________________________`^@````` M_____________________________P/H`````/______________________ M______\#Z`````#_____________________________`^@``#A"24T$```` M`````@`!.$))300"```````$`````#A"24T$,````````@$!.$))300M```` M```&``$````".$))300(```````0`````0```D````)``````#A"24T$'@`` M````!``````X0DE-!!H``````TD````&``````````````!F```!=P````H` M50!N`'0`:0!T`&P`90!D`"T`,0````$``````````````````````````0`` M```````````!=P```&8``````````````````````0`````````````````` M```````0`````0```````&YU;&P````"````!F)O=6YD'1)D%L:6=N96YU;0````]%4VQI8V5(;W)Z06QI9VX````'9&5F875L M=`````EV97)T06QI9VYE;G5M````#T53;&EC959E7!E96YU;0```!%%4VQI8V5"1T-O;&]R5'EP90`` M``!.;VYE````"71O<$]U='-E=&QO;F<`````````"FQE9G1/=71S971L;VYG M``````````QB;W1T;VU/=71S971L;VYG``````````MR:6=H=$]U='-E=&QO M;F<``````#A"24T$*```````#`````$_\````````#A"24T$%```````!``` M``(X0DE-!`P`````#"L````!````H````"P```'@``!2@```#`\`&``!_]C_ MX``02D9)1@`!`@``2`!(``#_[0`,061O8F5?0TT``?_N``Y!9&]B90!D@``` M``'_VP"$``P("`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43$Q@1#`P,#`P,$0P, M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-$`X.$!0.#@X4%`X. M#@X4$0P,#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P, M#/_``!$(`"P`H`,!(@`"$0$#$0'_W0`$``K_Q`$_```!!0$!`0$!`0`````` M```#``$"!`4&!P@)"@L!``$%`0$!`0$!``````````$``@,$!08'"`D*"Q`` M`00!`P($`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B M,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8G ME*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0`"`@$" M!`0#!`4&!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*" MDD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25 MQ-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@`,`P$``A$#$0`_ M`/1.M]6KZ7A.MD'(>"W'K.NY\:;A_HF?2M1NF=1IZEA,RZ=`Z0]G):]IVV5N M_JN7)?72?VS7O<0W[,WTQN+1].WU=NO_`!/J?];5CZB>KZ^;L)=CR-_NW#U- MSHY_.]+Z7_6_Y"I#F9GFSBKT?+]?FXV[+E8#E!EOUZ2OI4O3P/49^=C]/Q7Y M62[;6SL-2XGZ-;!^<]ZI]`ZR.JXI-@:S*J,7U-X$SZ;V3/Z-[?\`I[UD_7OU M/2P-2VCU7A\&!O\`3=Z6X_U?669]439_S@:*7DL]!YO&[<-D^SF?\+LVI3YF M<>:CB`]&D3X\?Z?^"F'*PERLLM^NC,>'!Z>'_">]226+B=4S+OK5U#I;RTXF M+C46U@-]V^TV;]SY_P"#5X1)OP%M%VDDES_0?K'7;T4]1ZSE48P^TWT"U[FU M,BNVRJIDV.V[]E:0B2"1TH?XRGH$EFXOUD^KV9/I_FO;M2X975'[%6Z:2S;/K+]7:JZ[ M;.J8;:[@34XWUPX`ECG5^_W[7MV(U/5^DWX;\ZG-HLPZI]3(;:PUMCZ7J6AV MQFW^4EPGL5-Q)9=7UI^K5UC:JNJX;['G:Q@OK))/#6C>L_)ZGU_J'7\WI/1[ M<;$JZ970\6BR M^KJ6#EOK:Y[:;,5[`Z!NV;ZLASUH,^LG2JL##RNIY-/3K\5Y^?C M8KW`.:RZUC'$'\X,>X.VJ>#U;I74MW[/S*,OTXW^A8VS;/&_TW.VI<)JZ-=U M/__0]#Z_T_'SNF7"XMK=2QUM5SN*W-!.]W/Z/_2_\&N.^O74,WZO8'3^B]*M M?C59#+;;\JOVV6%I9N;7/H?HM]BK]'Q\'ZR=,LZ+UBKU/L9+L6YKB+&M)?6W9:-NU]/\` M-_N65;/4K>H,',X(\[4H7*N'B_K=FU/!F^Z<0EZ;XN#P/Z3D_4'JN;UF[,Z! MU6VS-Q'8_KLLN<7V5N:]C(;<_<_W>KZE7J._1^A[%VOUJ6UY3NE6?S-C39CZR&N;_.L&@]MC?TG^?_`*1'FN9P2YX" M,*-F^+A_>C#YI/8KBLCH72.M_7GJ=/4Z#>VG$Q7 MUC?97!)MW?S#Z]WYJ[58G4.NY&+U(X8;14UHJ+'9#GM-YM=Z?IXC:J[??5_U MW_BV?SJF]\80961Q>BQI7Z7_`'+!#%+(:B+K5J_^-U]3N?L!T_X?(_\`2ZY/ M`VXF'T;-9D-Z=BXMW4Z6YMN.G87VBJL6$O96YSB0RL/.TY%VQKW^E5^>H]%ZE;U''NLL:P>C5[,N#W`!PW5O)9.= M7G6X.-?]9L3JCCEXUE.-B8;'V^HRUEK7L=5E6.QFM:Q_KW_X.CU%T'U.JI;@ MYMM;&L?=U'.=8YH@N(R+F-W'\[;6UK$/#^L699U)F-9CU,HNR+J&VAQ;K43K MO]S;+G_Z#;7_`,';8K_6.HYF';B4X=3;;7G&8B:N0,AKI4?FU_P6C]7:,>OKWUDLJ8UCGY=(>6@ M-G]6ILUC_A;K;/Z]BP/K%?7A]3^L#QCU6UV.Z3]H?=6;::079&[.R:*MCKFT M-JJ]G_%[_P!&NVQ[\PX`ORL<596PN?C,=ZGN$PQM@`^FLWH/7\CJ>0:K:JPT MT^L74N<[TG%_I_8LG>QGZTS\[_STGCF8QF+!_6"(`V^7A_[Q'L2,9$56,^HW M'J\K]8>LOMZ#GU.^LG3>K"VBQOV)F-+W^USMU?V?)R;*[*-OKUVOI]*I]>^[ MTZ_TBN=.ZST_H'UCZID]:N.+3U7'P+,.Y[7N9:*J'59$6UL>W]'8YO\`.>]; M76^OY?3<]U-%%5E3::[K7/<6GWV''][P'-JK;[?TVVS8M;.SZ<'!LS+C+&-D M!NNXGZ%=?[SK'>QB(YO&1.%:1_G-H:>F7[G#_DU'!,"!_?\`D_2_E\SB6_XQ M?JS=K*W+%?US)_;-C\O(Q/JQFV8>(Y]V70ZRR\O9ZM M]-5E]^/571AW/^S[/YSU?4]3Z"ZSHG5K.HU6LR:Q1F8[@VZD;H`FVMQ_2I8VVQPW[BQY>UC&M=[?4;L]Z;'F,0$3&, MC[GI&HGK_BJ."=R!H>V.(^3QW4^HG+NS)ZGB]6+.B]3;]IQ*35'MH?\`9[;! M=DTW<>K6RM_J5?X3^<8NVP^G8EWU,&0_NQN_^@\CCAW0. MK=0P7=9IZ*XNI;CVYN*VPWX]5&/C8]C_&H_X[Z"Z7]H6NZ(>I>E MLL.+]H%#Y$.]/UO2L=&[Z7M^@J/2>OY>;G48E^*W'%F+]H)W%P.K/3?0Z-KJ M'UV?UZ[/T2,^M^N/2+ M;!^UJ7']#6&9%<`_HVE]@N9[?\'ZC_5_X+_BE8^J71GX6*[,R)^T9>H8X`;* MY<^L;6_X2S=ZEBWK/3]-WJQZ<'?NXVQ[MT_FIU3`Y?[T3Q?K=N#^O^]?]QNR MES'W6C']7H>.X\7!^C&OG<;ZT]'LZEA,LQY^TXCC96T?GM(VVU:^WKW$ENTUXH,"03^ENVAK?^*K_ZXNM4*O2]-OI;?3CV[8B/*$IQ MY?[U$F7ZRODK>7Z&J(2YC[K("/ZO7UV+&/\`3%?-\S-)))7&FI))))2DDDDE M*22224I))))2DDDDE*22224I))))3__9`#A"24T$(0``````50````$!```` M#P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`G)E4WI.5&-Z:V,Y M9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM M<'1K/2(S+C$N,2TQ,3(B/@H@("`\"UN&%P.DUE=&%D871A1&%T93XR,#$Q+3`Q+3(Q5#$R M.C$S.C(U+3`U.C`P/"]X87`Z365T861A=&%$871E/@H@("`@("`\+W)D9CI$ M97-C&UL;G,Z>&%P34T](FAT='`Z+R]N&%P+S$N,"]M;2\B"B`@("`@("`@("`@('AM;&YS.G-T4F5F/2)H='1P M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O&%P34TZ1&]C=6UE;G1)1#X*("`@("`@ M("`@/'AA<$U-.DEN&%P34TZ26YS=&%N8V5)1#X*("`@("`@("`@/'AA M<$U-.D1E&EF/2)H='1P M.B\O;G,N861O8F4N8V]M+V5X:68O,2XP+R(^"B`@("`@("`@(#QE>&EF.E!I M>&5L6$1I;65N&EF.E!I>&5L641I M;65N&EF.D-O M;&]R4W!A8V4^"B`@("`@("`@(#QE>&EF.DYA=&EV941I9V5S=#XS-C@V-"PT M,#DV,"PT,#DV,2PS-S$R,2PS-S$R,BPT,#DV,BPT,#DV,RPS-S4Q,"PT,#DV M-"PS-C@V-RPS-C@V."PS,S0S-"PS,S0S-RPS-#@U,"PS-#@U,BPS-#@U-2PS M-#@U-BPS-S,W-RPS-S,W."PS-S,W.2PS-S,X,"PS-S,X,2PS-S,X,BPS-S,X M,RPS-S,X-"PS-S,X-2PS-S,X-BPS-S,Y-BPT,30X,RPT,30X-"PT,30X-BPT M,30X-RPT,30X."PT,30Y,BPT,30Y,RPT,30Y-2PT,3&UL;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H M;W1O'!A8VME="!E;F0] M(G0``9&5S8P`````````2D!\@'Z`@,"#`(4`AT")@(O M`C@"00)+`E0"70)G`G$">@*$`HX"F`*B`JP"M@+!`LL"U0+@`NL"]0,``PL# M%@,A`RT#.`-#`T\#6@-F`W(#?@.*`Y8#H@.N`[H#QP/3`^`#[`/Y!`8$$P0@ M!"T$.P1(!%4$8P1Q!'X$C`2:!*@$M@3$!-,$X03P!/X%#044%]@8&!A8&)P8W!D@&609J!GL&C`:=!J\&P`;1 M!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E!_@("P@?"#((1@A:"&X( M@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)N@G/">4)^PH1"B<*/0I4 M"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X`+F`NP"\@+X0OY#!(,*@Q##%P, M=0R.#*<,P`S9#/,-#0TF#4`-6@UT#8X-J0W##=X-^`X3#BX.20YD#G\.FPZV M#M(.[@\)#R4/00]>#WH/E@^S#\\/[!`)$"800Q!A$'X0FQ"Y$-<0]1$3$3$1 M3Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3(Q-#$V,3@Q.D$\43Y10& M%"<4211J%(L4K13.%/`5$A4T%585>!6;%;T5X!8#%B86219L%H\6LA;6%OH7 M'1=!%V47B1>N%](7]Q@;&$`891B*&*\8U1CZ&2`911EK&9$9MQG=&@0:*AI1 M&G<:GAK%&NP;%!L[&V,;BANR&]H<`APJ'%(<>QRC',P<]1T>'4<=:AZ4'KX>Z1\3'SX?:1^4'[\?ZB`5($$@;""8(,0@\"$<(4@A=2&A M(B>K)]PH#2@_*'$HHBC4*08I."EK*9TIT"H" M*C4J:"J;*L\K`BLV*VDKG2O1+`4L.2QN+*(LURT,+4$M=BVK+>$N%BY,+H(N MMR[N+R0O6B^1+\<-]1B)&9T:K1O!'-4=[1\!(!4A+2)%(UTD=26-)J4GP M2C=*?4K$2PQ+4TN:2^),*DQR3+I-`DU*39--W$XE3FY.MT\`3TE/DT_=4"=0 M<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4VU4H5755PE8/5EQ6J5;W M5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N56^5<-5R&7-9=)UUX7 M&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB\&-#8Y=CZV1`9)1DZ64] M99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(:I]J]VM/:Z=K_VQ7;*]M M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5&YXS'DJ>8EYYWI&>J5[!'MC>\)\(7R!?.%] M07VA?@%^8G["?R-_A'_E@$>`J($*@6N!S8(P@I*"](-7@[J$'82`A..%1X6K MA@Z&I+CDTV3MI0@E(J4])5?EA MMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H4JC$J3>IJ:H_R#W(O,DZR;G*.,JWRS;+ MMLPUS+7--:6YQ_GJ>@RZ+SI1NG0ZEOJY>MPZ_OLANT1[9SN*.ZT M[T#OS/!8\.7Q'EZA8:'B(F*E)66EYB9FJ2EIJ>HJ:JTM;:WN+FZ MQ,7&Q\C)RM35UM?8V=KDY>;GZ.GJ]/7V]_CY^A$``@$#`@0$`P4$!`0&!@5M M`0(#$00A$@4Q!@`B$T%1!S)A%'$(0H$CD152H6(6,PFQ),'10W+P%^&"-"62 M4QAC1/&BLB8U&50V160G"G.#DT9TPM+B\E5E=58WA(6CL\/3X_,I&I2DM,34 MY/25I;7%U>7U*$=79CAVAI:FML;6YO9G=X>7I[?'U^?W2%AH>(B8J+C(V.CX M.4E9:7F)F:FYR=GI^2HZ2EIJ>HJ:JKK*VNKZ_]H`#`,!``(1`Q$`/P#?X]^Z M]U[W[KW21VEOK;.^&W0-LY.GR:[/W;E]CYR2GFIY5I=R8%:49G'.L,TDL$V. MJ:GPR),L4GD1B%,91W(=CYFV/F-MWCV?<(YYK"\EM;A596:*:)BKH^DFAJ/6 MHRK`.KJJ^^VN_P!M%DU]:O$+F!9H]0IJB_=>ZX22)$CRRND<<:-)))(P1(T0%G=W8A515%R3P![J[I&C22,%C4 M$DDT``R22>`'F>J22)$CRRN%B4$DDT``R22<``9)/#I'[7[#V1O3,;ZV_M7< M^&SV:ZSW-!L[?N,QE=!5U>U=S5.W<'NRGP^7BA=S2UDNWMR452%/T6;2;.CJ MI?MVZ6VYON4=NMRT#U*D:U5'-"C,*:77!(9357564@&M_L^Y[9;;/>7]E M)%:[A;&XMF92JS0K/-;-)&2!J07%M/"6%1XD3K6JGI9^S+HMZ][]U[KWOW7N MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][] MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U M[KWOW7NO>_=>Z][]U[KWOW7NO__0W^/?NO=$7^<7S*VQ\3^OYDI,IC,CV_O" M.*'8&TZN3'3-04L];28JOWGEZ&HR.%#[=P`DDG2.6IB-?5H81+%3I4U%)!7O MK[PV/M/RQ=-;2^/SC>QR"R@'AL4(C-;F5"5/TT!76Y.HLQTXC#M',/LK[5W7 MN-S1']?%<_U0MY-=U*B,=(6,LMO&40DR3%/.K#6=)U&*,T6_RZOF;D^B^WX] MM;SS$M9L'O+>>WZ/>4K/CGDQ6_\`=F2V3@L3OQGDS&7JH:.3*YN>'-A*:FCI MZ$S5DQBCH)$Q>$'W?/>+>>1N=+G;>9+F9]BWF^C%S+(Q`6X/C+]3&DJ(D2MX M2P2QDK,ZQLD4+2Q)#;9F^]GLI#SWRBDO+44L>_;%:2&VB72JM9VQED^EC$D4 M8FD>.()%&A:5AX:PM-++$USM;HXD!90X`>1/7&\9O&[1L0LBJQ0LITM;2ZV9 M2003U25@X)`-*D9!'`D'!`QC!X$4()!!ZYG(XD!90:5(R".!(."`:5&#P849 M25()Y^[=7Z][]U[HEWS<^7FU/B?U/D,Q)7457V=NC'92BZPVB]3315^3R\-( M3+FYX*J.2./"[<\JSSF50M1+XZ2/5//%&T%^^?O%:^UG*4%W8A9>:]Q#)8V[ M*VMGT@F0Q$!J1%T#(^ABSJ@#/^FTO>T'M-N?NAOQMR9;?ENW8?57*IX@35A( MU`(!>1J`FI6*/5,_8F=?;X7?-RO^/7>F\MV;[SF0RVQ^Y-QUF0[:KZ=L74Y' M^*5F4WS7KV%3T9W1GHYEI89FK:658XGFD%*]^]<@0K*XC_`,:A7P2-4)N-46E9 MM8B"A>K&W;IM^Z[?:;OMEZMSMMRJO')'WJRO0*5*CAYDGXJ]F_T M]S:-%<1-X;KI?7KUD=ZFI4J2%:@555=3`4=BZ^S'IGKWOW7NO>_=>Z][]U[K MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_= M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=> MZ][]U[KWOW7NO__1WN>V.Q=N=/\`5G9?;6\)Z^EVCU=L#>78NZ:G%4?\0RE/ MMS9.WUEGG@MI9%CC MT^)(R(S!(]=4UN0%34-.HC5BO1WRSRSNO.G,?+_)VP@'?-VOH+*WJR(/'NI5 M@AJTGZ:CQ'7N?L'%L`]:3':?R.WIW=V'G>S-]TO8DN?W-N=8 MKY'O9E7PUDNH5$43DS16Z!0=%O"]S#&ID=68^*\OAZ9GL.QW*7MAM_*6SPL7O>NZ*)ML4=) M64N[8::3^NI(1`$CBD%1<1[R_ZQ4Z@97*4&$QF1S.5JHZ'%XB M@K,IDJV;4(:.@H*>2KK*J4J&;QT]/$SM8$V'M+>WEMMUE=[A>RB.S@B>21J$ MZ412S-0`DT4$T`)]!TKL+&[W.^L]ML(&EOKB5(HT'%Y)&"(HKYLQ`'S/6D7\ MK?E#4?)#Y(=X=CO%V`^!DSFUMM[(PDF%W=F*':6S:;JO##$XV5J*"@QVV*?/ M2[IGW$89&KX)Z;)9/)&6.FBR%`O'+W>Y\B]R.>=RYTBL$BL)8*0!Y(U,UM;3 MS)$RQS^+^H\=O.TO9"@9E@,4A;3N/8_V_P#:+_6]]M.1=K)LTO1;M-/*YM;8 MSS37UQ(S?J3W#S/$MHEG$T8A,KP6\2QK-):7#`CD=XFK;)R2X[LA6GF>&1:[ MKSL3&+KFBW-%&^9CJLA)%C\C&NXV^]-4)GC:#,-5O(V.S!K(N2SM[,>.&M7D M6(DJ+B%ZB,AG6,/&Z$$PW(U`D.`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`&ID6/P;G6SJ&50+>8ZB"(W-% M,Q?=[$+>^7M,D\$4D;;_`&2Z9`"I+3H%HIM[K6^HCPX_II_$DTH(G+:3IZ8^ MDEEBQ\!QU5/!5UN(9H8J%I(J^6-=C"!8XO[A9!):U?XQ(%;_`"PL*T6$_P!R M1F>*]TR7#WIN7A8+J*$OXAH?J'UM6Y:E9""`#+J[7US-/2_ZD%$9X9?!F>4R MSQ@K+I+#_&-4,1^I!5QH75PI2.L7PMP4,:2*0MM?,41*W1!C\-7D M_0.G1&Q%G],)]NME_E,PY1/F1A88J*LI\;3[`[(JJP_:M2TB/+D\ECH75C0; M,")4-0)"\`IJ\-+1J&IXC2QKB,B/NA0O>>[B2"-3+GWFWL8_:599)--[<7-HJ%I03.%57)C7QYM2ID@EI M"&,L@<^,\L^T[%^D^B6/]V;TRN)&/[TEG#"64"*0>I%N-*$#2MM(ZGAV<:F0 MJ:TIC@,`]I(R!7USW`-4=YHS:CEV-0=3=IXHM1I0JNE*:0`WR MEHLK7_';O"DPGW$>4GZDW_'2SQ32)%%?`SM,LD<50&:1Z='*O]O6A%5[TU2& M-)41G[QPW\_M?[@Q[8KF\.R7E*$4*^$2Z:34%W0,J'0U,BJZNX;^V\<,ON/R M/'<`"%]PA4LRO)'1IHAI,49\1Y'X1%%#H0=,L)(8Z-NW<;2P5W8LU-B4AJ'R MVUZBMDCIXY`*J;I/#U,4M8T>)RCTTM91T<51`SQX=GIH5J`M8JC/^^-S2S16 MVU,AA6X6&1442%$TI>ZU1)?$B)A20R'Q0;@:M4HNF:-FV[M)S`\_[NY2\=;I M85MV5#(YTA7W2IH M65J2*CBWW#3450[;"H&A:DBQ81!_D@@6C8!*<4]L,C@9(!%+:O#]28T/Q^'K M*FV8587(*H'U$G2-!!8>"83^[@I&B0AT2&:.-;B,4,M=!D-L620?4D-+(6)K M^,F0E)S/_CIY?Y/F):G^9>V1A<0E-34.?^4$V9@G$KTN*J$H\A M!N/(113QRU&.$4E2T9QN(D84$V2GW7K:ZN/?#E>ZCE?7'LSM+ICPT0M!$I=B M(RBJ6M1$/!4%=)K(K+=7<7?>ZN%;VPW6*\DF2[6TV,*LQ\1RHBA6*,51"C+$ MCDW`1A,B!%N[U29FV[_?5;KE-U[W[KW7O?NO=:7?_"GK?_8FP?D#\1J#8G8W M8&RZ"KZ>WFN5&V=[;QPU#&D'9.SZ&GR>Y8L/N''G)R3?=>&&JEAKIU(DB+*U M3'3UV8?W9;#:I]BYG-]M]M+,+NW">(L1DDI3LC:25&.FIU*:@^(#W`.C`3G7 M>'M[VR1Y=$D[@HB:4,LGB!BL86:%4"JI#*P6(F2)%U_V+[AG6,8AZUZ]A`G` MBV/M.,"IJI:ZI`3`8]0*BMGJ*R>LG`'KE>65Y&NQ=B;G$K!(STN M/:'IWKWOW7NM43_A4]O[?6Q.LOAT^QM^[YV14Y'L7M"2N_N;NG/[7.17'8?8 M;4;5U3@04TZ(Z4X4T)3AH7@!9M+2/M6V/,6,IMXRQ-:DE!6M4C-:\:QH:_@7X0:GV% MNC#KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N MO>_=>ZZ)M^">0+"WY(!/)`L!R?=)'9%!6-G.H"@I6A(!/<0**#J.:T!TAFHI MV/MZTK/GW\P_YB'\P+^9GNGX#_`7L3-=:;(Z8Q79>,GJ-A=DY7K8=D5FVMM[ M,7?F^]Z;UHLIBJJKVGM;/;L@P,&)BIJB.6HK:>HB:)*NGRAS`]MN7O;OD3V^ ML.?.;I+*?=;^0RM#/"+R>%4D5+:2UC%U&88A2-[@B)M3SP@LE)$FC+F'<=\W M7F&/EWE^8IX*H\L@)T)^HCZ)P%0ZI$5A&JS$R)XBO$J,EQ%QH_\`A.[_`#3M MXPY&7LC^8QAL?6UR9(^>B[+^2FZ*S[])\W04W!*2Z'5+:-V\-" M\\J"".V=;9^9K@I;W=Q;G;H5\:-!+*RM=.6U*8WA*PK&([8_51EI[EU75%;I M:HD[/NO^2S_.V^,6.K=_]"?,>N['J]GX[^+XW`];=^=XX'?687`TV/HX<3_` MM^S-MW<]95425,Z0SULYJ!++3-#4NSKDU%I[R>RG,L]M#OW)<,=V]5+W5I"\ M`:1XE)5TF=X0R)5F$1\.K,&9E/BI9^6N8$L(TLMR$%P("K)#)(J:C&B:8JU$ M2+I/A%8RR/I>A!FBFNU_D$_/GL;YT_#_`"DO=V0S>X>[>D-X5/7^]]Z9A-MT M\F\L5D)]'*>Q\ MM\U)=)(!`LR2B.6TN)K.&21(FE,T0)@G2&2$P1G'*E M]_= M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z__3WQ>Q M]A[?[3Z\WYUCNR`U6UNQ]F;HV'N6F6.EE:HV_N_!UVW\S`L5?35M#*9L=D9% M"S0RQ->SHRW4D_,.T+S!L&^;"]U)`E]9S6YDC-)(Q-&T9="*$.FK4IJ*,`>C M?E_?-QY9W[9.9-HG:+=MONX;F!U+*R302++&P92K*5=%(*L&!%00<]:4_P`B M/CUWS\5=]3]<]F[0V560S5IR&UMR8_?=!CMM;_PF/DH(L9DZ-,YU?)-0UL$A MI::N-0E2*67)UTA$\-'6'+\=/<_VVO\`VRWR'E_F^]#SO;HZ3^'+)',6JTKP MR/)$DC++)*2C+'ID%MXI,=Q>S#KSR%SQ[9^Y5@V_;#O6Y!(9?#FC%N[74*21 M1R.K1QWH\*K-=^"T;RPS_1VJ1ND[I'MQ:<^=]5V"I*+$;:Q,R5>\-CT,K8O= M=7DLA/KW+MZ.E$6`VGLNEW#-FZK&1(8X'JUC+Y+(1U4K4^.S#Y,'0RVGU\Q: M=Y=RB231&$<-]1IE94#W,U169I/@"WU!`T%+Z:Z\*3=EM.6%OXIY]SNC?FUW M#0KP1*I(M7(4&XNW1(EFD8&;PF\7P+/Z2)+B>R6SVTOY87POW7\:=B9??W;^ M*V]B^YNS,5A8\IA,%40Y&+9&`C,V:DVP^4@PN!@ER$N7R)6L2*!X5%#3K')X MT2"#IK]V_P!E[CVVLMWYCWV)!S#N<<*1H166VLXU!CAE8CLG!7AC M2)O#C15Y8_>,]U-OYZYD_7PFY)ZG<6UZO'5L3Q05L,[)08PU M#S5^6@R<'(#W<]M+SVRYP.QI'<+LH5_H93&[+)";HSQPJ\$B2GZ:2>VCF=HS M(\TL\D;&9+",]BO;#W1Y=]V/;SE._GW3<4YEVZV^FNXO!\2);@W,]U(8S'/$ M5MYWF@,1F\0PI->``VMHUO*6/(5NZUGJ%R&V-K4U1XX-;?Z0,!7O28XT]6(U MII*;KFB&3IZ.CK*K[&2G--%4Q8V@-.(5R6._A4.6S;9%JGM;\!DC5F;PIT.D M,AC:3PYR476L)8+JTN]QX!+0[;XP]^CY7B-Q#8;MN+*MPPC_`,5D*$J]&5V6 M^96>1TM_%DJ0C3WID6;Z6Z^LV-OY,GP[WITWUKNOOOM'8^$V=O\`[:W7NN79 M>T:+==7F*?`]6Y#L'+Y9=PUTXVCBJ)-P[Q^XER=(^/UXVNQ$E$T28M:N>BI> ME/W8?:FVV/:1[C7=Q++>;OM]FD`D@:VGA@@_C`:FF?1"5$8$;6T457N/$>63 M!3[YGNSRUS9S1M?)?(V^W6X;'M5I;17%S-&D9DN([6WA,"-'-)XT5L(EC=Y5 MU_41O26Y$:W<]YOO+GK"/KWOW7NO>_=>ZTAO^%5L^4@^1_Q$J:6&@-!C.EM_ MU=145534IHGE[,VDJ1U&.2`X_+4;04SW-0TSTHULD)I9,@XS6^ZF9AMG,D*U M%K-<*CD+,[A],8C5%C&A-:/-JF:2)HV6)E$M"$CWG>6."2PUO*L(XACDI:9LW_`(4E_P`K_:VSMF;;K-R=_?=8;:&% MQTO_`!@7LC(,K8?;6+D<5%;5P35CU%2D@C@^Z85596+)3J)*N.:)(LN_NY>Y M\^XNHVRS5YS+(!&["%0C*64-H*1T\1?#C=@[(&*JRQR%1(G,6V+&GC3>'*%C MU(Y36IE)5`P#$$LX*`J2K."JDFE5?+_PI<_E>P_<:]R][?Y-)+%-X^AMZS6E MB_B?[:>&-_-)-_"9/"$U&?RTWCU?>4GFU_P,ONF:4LK/()'ZZ\!6I^'@*&I^ M1].KGF':E\35<@:75&X8=M.E3G#-K32IR=2T'<*\?^@E[^5Y]\<=_>7O?[D, ML9/^@/>XI?(V3;$B(5YB^Q:7SJ9B@DU"@M6D?9D3EA?NV^Z#3RVXL+?6D:N2 M9"$TNSH-,A3PV(9&#*K%DJA<*)(RV_ZP;5J"?4KXGB:*5&K7H\33IK75X9UT MI4IW#`)ZU]_Y]O\`-+^-7\PS97QDP7QBK-YY>GZXW9V/F=]?W_VCN;KMJ0;@ MP.Q8L"<519?#U5+F)_LX\C%5&26G-#(KPS*\0KTAG3V4]KN?O;K=+Z7T7VV6K6X:6_ M660*=,/A!%1Q<(\\A8QN655\,1O&RK,]V1;6\LT.T=^?'7XY;.ZXZMDW3E=IIN#+4_1NU\QN;.Y#.5.VMU[AI-M[1QU.) M*IVQTU7-45%+2G1-4JZX^V_MQNGN1[D^XVW[))(K%:B:7P8R+9 M):>*^E"Z*8T6I36WA12BB;>X-CY>V*6VMS,94@2)*JI9=`=V_15XZQP+)($B M!5RGAQ?$O1.DIXJNCDI-7^W^T?+"\R[)N\ M5]>\S06Y6"6UN%N;/ZL?4+H=VAVZ3P%*VSNZI(]9IH%4_3">Z=MI^:+B\MYF MM(DVV45(9@KPJ",%567Q)G#5-)!$H32#50\XDP]3?\*=Z%)ZNH^3O\L[-2TB MFKAQL.#[%I8LJT454TN)*R?'2DDHA72MIIYS6_Y+JI_+]P*6H;)FUYN_W<&C MECV[E7?O%"$QM+(L8>5JZ4F=+JY\*!*"LD=O/,0['PR8U62\=KS1%-&YW&*6 M$*P96T@DT0*X9($S5"67X:S.00L<:=!KUK_.$^?WQR^9G1?P;_F6_%/JK&[C M[RW/L79.U^[^B=T;NIML9#-]B9_!;%V]G-O;=R.#W=1[QV5)V'F5I*JLHWEIJEG:;VBVKF/DZZYYY$W=FVNSVUY[J"=S+-ED\,&$B0!W0B1U(F$, M#4U!A*94KX[N MRW:.VB: MVW>P?Y=/QMP65FRI.U-5>: MV>!1').R)-(EJK79C_R*9H%+16L,Y=3196:@!4E:FV-0PU*30$*!I(9]4:.[ M1[$_X4@?#_851WAV"/@-\L]C;$I:S,]F[&ZW@W[M_<\.U*>OIJS.[FQ]57[- MZQ-'1[V.U_=RYLG;:MLO-[VK<9)XQ$]SH6 M,JQ57!:-K_4Z`R2)&RP^,RQ0B>,R-(J2ZN>;-JMYIS:P7MO%"[=K,LS%(R57 M0L01VE=15ET!-9"Q/H&L(^@?YPO\SO\`FDYZLZ]_EY?'+XV])5/7&P=C9GY` M]I=^]A;NWQ@-A[SWY5]AXW"8W:6,Q6R]LY+<^`KVV@*B#7C!7:J*OAG6G:"' M[M+O/MARC[87-@?<6>ZOK.Y@B;_%OJ+:42-&KND$<]F+:[2.3].63]XV\T,, MD?Y@WPT^7/5WPS_`)G_ M`$'TKFZ7M;?&)P^VODSTKN[<.W,0VT]Z[VQFU,%NRAV/4;2W!'OC`[9S.>@H MLC*7VI7T]'$U=4448BJ5CHWM5LW-^T&6NVWB,169K=:;IKMU5$%UR&&CQHIC5O)44T59]L1^U_M(_ MN)M?-.[R;LUI!ML>I:PR/',_AR2,DL\0D:T10B%I3;W!*NQBBE=/#97S3S2^ MP7&U6-M;Q2WUX6$:N^C4R-&2@J`E9$+HC&0$3F%2C(\CQ%_VWU]_PJ#W3M_9 M^Y*_OW^6SL:HS&V]OY?,;-R^#["7<.!R&6IH(CNOW;K8WD!Y56,SK`TCQPORVG-DRN$W.&)C$`&"K_::7!8Q-%)0:F#:1<.*QHH8` MR&3CF=E?\*A=AX3([IA[>_ER]SRX*JPF23K;;='NK%[MWEBZ;)TJ9W;^%S&Y M.F^LMI8[+U>'8M'45F0IH7G@F*>`5=/%CT]S<_=XW)5V_:=OWFPNI;J%?J;H M:XH[FIZ^/;VZLA'A]P;G+ MO=?VE@]OX-NWW8M\.X\KWDICBE,9PWA*^94#6[Z@6*%'!.DZ5)1RE^7M_CWV M%+6Z>+]YHH>3Z=Y#$=+BC))1#H9A32258K+"3)XYE\:V7;;@":X+10VMOU<3M`]A[MI\#A**CSFYYJZ6A MV9D:/&3U]3+)55TN+6H<*LJ4T$L\\\^7?NKN'*UF=K$-_$!;B5Y?%DF,IB5? M%9(HETQ%=$1$33>#H6>6XF5II`YM6TV?+5IN,@N?T'=IY&8(H#4K([$!1W$% MV+'2I)5!'$J1I6+\:OYF'\Y+^:M!V+N'X-=4?#;XS=?==9;$8.KW)WEN3LGL ME)\]E\7ELE)M^7TM_HY%B'B)"+VY2=PRB:-%5Y2;;= MYWW?XWOMM%LEFK=J%B6)**0DL@5U`&KQ`T2,)%>(I(8@7F'+&=)_\*C:7#82 MCK_EW_+3R>5I,914F;RD^$WO%-EJ^&-XJW*Q+1?$NBH**>M#.ZQI2>"&9X"$ M:.EGBR3,>\?=N<0F[Y8W]92U'\$*B!51@)(TEW.=]4CA7,3S$0AB@FF\+5,< M7D7,LU[>W5O<6\5O)/KCA4D)%&6C)B#R0RRLJA&"LS%RLK*S:E250N[Q_F._ MSAOY7F4ZVW%_,#ZA^+7R#^/F]NP=K[+SG<'QOE[#V_4[;@R]=A5RDD5-D\,: MD;NH,.V4.YIOB7EHL=KW?>HH/W;*Q13& M9&DUZ@$`!0*[N&!\$4"VEM?![HP,NTZ_"538BIHMQC*:3,TL-H0L5,TU374GA M?]D?;'E_G:\YBM.91>HEHRZA%*!+&)1TML]Z[BSW96_NUMD9"CW-2;?RN7R%-TGND M[;Q>X\?F,3F,9/38G'LLV.$VK)8NJC6L4S[/[.\B;CS#RYS3-<[UN-K*T8EM MDDCJPDNE*!3<0);O&L5D9)&-^H:XO+=8&,$-UT617?-.Y7+M'MZ6FVZ(F1GD M0R,2H>12JI,I6I,3#L(`\2.1M0"0.T'_`.%,WQ]V3N[N+-=G_P`OKO';.QJ! M]PYGKC8V`WL^\,CMW'5:U^>DPHR74O6=$]71X.&JT>3)^D24Y9)31U$F176< M?W>.8[ZRY?VRPWNROKN:WB2YN'2.&-I)=,S.$EO2H2,UA!1UEDT132VD9>[5 M+>Q\[V5BTUMXVT,SW$4 M7[Q MJ]_[PR._Z;'YO/X'(5U+F8]AU.1R*XO(T$:TU?3;>H\9D125-E6*>DJ2?WO* M/M+[=W&Z[)[@33;AO$5TZQFPN&ED$:A=/U=M)%91VKG#F&.\NR-;Q>/6'4Z: M.^YAW:&:3;UCAMI:+#*-,BA&4L+D,6_47(58O#%9$J7:*3Q(Q)V_TK_PJ.HE M5."'6R4\ MS*[4U2N4+K3>/NY%(3N'*N_^-]1*&\(H%%N))1;O1[]F:=X?`-PFJ.(3&7P6 M$:JKF%]!S%=O.]M=16JF)`JQL&&M8H@S5EMY2NN6-V))<`3R,L:J(88@F[6_ MFI?S6OY7^X=FT?\`,L^.'Q^[NZ@WSN-L!@N]?C5O#NVW-FR,=G=K M9"AI=RXG;!S62H-OY6CP@R\,4")EXTI,I5P&7+/M=RC[L17TG(MR^V75K-*& MAFDDNI3"TD*65+0I!'^OXKRQE5WO>Y;+?,V\30C;6"T(# M"G]K558J`6HHFEC3JX]P%^Z+K]]_N&J_6_5? M3USIU^)X?\.K3J_HUI^&N.A?]3!]+]9XB_3>'KU5%---5:UI2F:UI3-:=?_4 MW^/?NO=%F^5OQEVE\I>K*_8V=:/$[CH9(LOL3>4<=1_$-J[AHZNCKX7$M#4T M-=-@\K+CXH9[7>HD:7;V5H[B'M(EBD1HVH)%9#( M@;SS=NW-'- M]F]I:;%N/@+:J5C+W44:R%)9("K21KXRF>*L=O,`EM)`]L#;P9?_`'A?=^QL MN3]EVCE":)-RWZU,TLB`>(FWW"245ZJ&CDO([B0,,L$>Y74WB^)(+_\`/M_F M7[S^#W26SNKNF):'"_([OA]Z?W;WA20KF,GU'U]A:6?#YGLC;45;AJBDCW[D MEST-%C6FIIZ>BDFJWM5/#!%5]E_8#VTV?G/F"XO-]@;^KUB?$>-%-)I&$DFD MA`68:AJE4`:S(JO(C2H).;'-6]W6U6T"6"+)?RG"G43X:4+L%0$T`HNK.G4" MB32>'!+\_K>&Y=S[_P!Y5O8&_MP5.]]Z9W$YG+9G?>\:$BN9'>^5&I(+T1^-91`;B47ESN2- MF]P.6;NRWRU(W$1MX%XT026!T\`A=?T<9\`L6$P/Q1EI!I8,T1YLNZWNVS3R M?O-S%IU2"=+AR@->XH4MD6+Q9&*N43]*!UU&-2+/Z-G=74/5OSB^--#!C)J& MIPO8FR,%OCJ;?0Q]50UV&CW%@8LMMC.8_P"XI:3,8RERF$RW@JJ=XD9Z*KFA MEA.IHSQY]X?:NR]RN5]VY/YF@2+>XC)X4M2YM;L`HS(]%9D+#1**+XL=0R@T MTY.^T_N%<^W6][=S3L-I&]E);HKVY*B.:$*6@1_#+(1`["6$HS*D@K&U&)-( MWP,^"63[+[_[(7O7;&3IMH=![OJ,%N;:V0J,K38_+"FQ\GO%M_+G(^SW?*%X1'$*NR.@9D7PXDM]FN&EIJ=JAZ>G@@>KF6HJGAACB:IG2 MFIZ-)ZAD53-,E)211!FNPCB1;Z5`'3V...&..&&-4B10%4````4``&``,`#` M'7.HDDDDYZS^[]:Z][]U[KWOW7NM(_\`X55P"H^17P]9U=Z>DZ@W^:J?Q4TL MV,IJSLO9:R28R&HIIFK)V`CLS))+H`HM5K'+X@,[^!*8T MC(`C8$G5*[:4T>,FP3L7^31_*VR6Q]FY#(_!KH&>OK]E8=:Z9=KRE)ERVVL) M1Y6G6U33C[.NH\=3P21^-$D@IXHR@2-%7'.[]U_<-]P6[/.$\MS"9%CFTH&" M.5U^&6C#QK)H0LHTUTKJ%5%!?;[59BVM$FLD$B*IH6:32X0J2)'[G(#,OB,` MS!FK\1'2Q;^3+_*S9:M&^#W1+)7QSQ5RMMRJ*UD55+DYZF.K4Y&U1'439JL> M0/<.U7,3W.8V>S0LAJ MI(K0T*U'H=)(J/(D<">N(_DQ_P`K%9Y*E?@YT0M3,T+RU`VW4B>5Z?+3Y^G> M249#R.T&=JI:U"22M7(TPM(Q8LCW9]Q5NWOUYKN1?-&L9DHGB&-69E0OHU%% M9W95)TAF8@58UV=LL"R.;1"Z@@&F0&TZ@#Y!M*UIQTK7@.M:O_A1U\'_`(E_ M$/K3XKY'XS_'[8?2]1O'?/8>.W37[&QCXN#+4FWML;(_@=!D0TDBM)04U/>E M*RQ>&GI6_0L25-'DS]W+G;FWFW=M_M^8^9)+N&/Z31%*"^HF8DF,"&10ZA-1 M9AJ"!](`+R1QS[AVEE;IM<\?AI<#Q0.XJY6B.S#]>(:4*(S'2=#:)!-::#=1 M@]_.^:OK?C'_`"/ML4E%!7&7X=[8K*#"5-%20TU5GI.L>B\#B_/]WAZ2`I$F M5EI&BDI8ECAK98?'$*EZ6L-_9>0C?O>N2:Z4V3;OZM,E^0'_"GS'8QXJ3X7_&=3CZ6MIJ?'XO(;&ACIH,;3;ACHOX1%_I MJJ*3[F48Q(Q!KDID"6A>H67'G*Q)N6U_=EN7N[B#F'<)KX&22$SM=*K3,+D+ MXLJ[=-)&G<@,R12RZ64M$Y\=)!@LO-KB:W-MX9>%4$BF!560>*&D5"TS*ITQ ML`WC@!T'A527J=3?(3_A3W)]GK^'7QJC\T5,\OBR>SA]O,_]WM-%2_>]S4&J MBJ?OCKDJ?M9(?)^XL/@R'\*;@V+[K$/TNC?-Q'A*L:5284C/TVNNBR[*:'K' M'V-I>A'^+Z-F[YM?QO\`=:ZZYHV%7M^U/T=8/G M:ZG-'35/DHJS#=$]Y9VAH,S5P4U9`%@R(IZ^/S5-)XG:G1(HA4R?Q@_V!IXO MNJ[Y-!,J'QYE)TQU`:XA4@&15[W5VB.B4,8YB`KNL<;:NK**]YV@,\+/';:) M%5Y.W6\;@3+&))"2AB"1J\4*H_CRJTCDE=R+WA[U(/0:]RTL=9U!VO1R0)41 MUG6V^:>6G?2$J5GVMDX6AD+93!J5E0Z3>MHQ;_=\7^<4TY<$%OS!M$Q"(#>P ML[8%:.@U,?.BJ!4\%4#@!TS=2)%;3R2R!8DC8DDT"@`DDDX`&23P''K5C_X2 M7;=I*7IWYG[P2DQ\5;N?M/J#&-508NHQN3FQ6V>N*YL=1959L?AP7QE9G*Q$ MC>E^X@=I$DD5?'14.4'WK75-RY&L!%(CPV4FH$C15C%F,"*(4(459>TC2H5" MA!!G)-LD<-].SPO;,2Q/$DDG)Z'1)/$]:BO_"G M&AHJ;N7^63N.*M:GR\796\L?KH?/_$*"BBWUT9D8)JAUF2"EHJZJC>T_EQ\E M.M)-.*F,0_?8S+O[M@,O+7NC$]H'C%JC!G/9@/JT5':R`*SE2-9,`>2'2GB1 MMSQK7<=C:)D:=A*54Z`P,8#ZHZ:Y6:NEQ&+:\0R0Q-X4;+XG1P_YPO\`,SZY M^&O8?3'3NS/B5U1\C/DK5;I<3D=R8*@V?1[1HZ7;\S[A:6-Y8):[:+G<6=DAE>$OX`;!DDT:VC#"@* M"1=9(4R!`\J$RP/SJ_X4O[HV1M;.4'\NWK?!4>3V/A\FF$R^P\G@\G)4Y'$Y MZMGQFXMM;E[%Q6XMLO1_;1P&BEQ5)74RQI#-1_<-`,F)K+D/[O;[9')S-SK* MF[7`I<0F]BNC;O()%:,36UFT%R4=D$DRE[=ROC*_@:PS%SN/--[,1=;.SH\\ MGB5,1#Q,:+XFN1R[:9`90I34T4Q5F4Q).KMT?S*?^%!G4D,6_>UOY9FR5$%7C]W5E;'P)=9\2BZ5E,M9HU8OJ M9F:A^5S;2^Q7*2Q7,;%MSVY ME$$0\`H-LN5J+CP%!:*BQJJRD2?J.R#2BQ(>3+95W_=Y#:-%+$LJ8S%1I5&B M)B*DQF'2VDX3PD=8_#CM;7>B]X1]2CU[W[KW7O?NO=5'[1_F\?"GOGJ/YZ[J MBQ>]:GK[X38S-[?[\Q7:.QL7C,'O6+)5G9&T*?;&V<=593.1[IH]]93KZMQU M/35U-3FMCR%'>%HJM+R7?^V/-FRWW*%NA5]RW:=DMEB%P)%>-HJ.P>&-E!\5 M9(V35JBI.OZ3Q22!VWYFVVX@WN>0-';V!?Q6;0ZT35J(,3R"M$),3%9DP)(D M+*#1KTO_`#:_YF/=D'8__#9G\K;HC;O5.$W)D:'7M;:E=)24&;&'W!4T^,WK MG]N9/KO8V8ST5%!!7"3%4]0WEJ8$$=1$].F6G+>O:CV[VJ;;9_=#W8OCN]P" M=,NM;@HSRZ6TM%>/&IE^)I2L.HRLLS4+=!NTWW?)3M<^V\N`6UU<2>/2+0T: MA2(FD+R1$.J(BR'1('"TC8?HK(.&!^;G_"F44<,U7_+ZZHR%3.^WS3Q9?`&C M5J62?:L^4^\AHNXL/)2Y&9,I)$1))3P)")M9IIDJ7Q)>O(GWN=^[`W)FDW;!F<3O#"5FY(<-AWGHY,9]](3C`JT M$<:U+XH]Y+]K.4;;=^6>(#;YFB""2CM-:Z MH/[7ZC;WT7MJ3[GOM_=;9/==;>U@-DJR:&!U*(P\Q4,A=8O MIPJ_&T<:@LJFXBU*I:YMO&GVSE]F$37-PD:U9*^(TH5O!C(GCB(E,9:1#>.K M*B1E)_&0GI. MA4QPQQ^*7HH&HT!:@&3I"K4TJ=*A:\`!0=.>3I'K\;D*&.1(9*VAJZ1)I!5, MD3U-/)"LCK0UN-K2B,]R(:BGEL/1(C68>AE>":*>.GB(P85`85!J*JP*D5X@ M@@\"".O2Q1SQ2031AX74JRD5!!%""/,$8(ZT0OYD?\L'<'\K?^6EN[9B]V2] MSX3O;YA](9J:"FZ_HMG4^SDV=TMW#0B@E?\`O-N.;,4^5R=>8PT>/5I#3P`E M87AQ)SG]MO<6R]UN?_K7Y:@V^[V_8[I45)'E$ID$2'3&+*M]VBUY;Y>2P2\A-YVS7[DV3687+Y+;U?FGE[5 MI\F[Y#'+'525!I7K:J5F8Q2R5%#_`!4&\[[;]W7=>9^9;KFK>-P',,\LD5V! M'(,I]0M-(LM!-2OZ1_20LOEXX-&"_BE M'\1GBC+`B)@\BUKP:[II#H^ID M4A)8?IVJ^W1,6,**TFH%X'$D<4LX2VG)JL_-45PB-:O)"/$!;7!3O>,ICL:D M:.Z_A($3AA.S)(Y1_FIU)_PH)^?O3M#TCWS\,>CI]IT6^]D;XQV0VENG8>W- MRG(;4[2KZ?'PUZY-XYH6@B=+Q3"?'U-'53X8:\A\P?=^]OMW;>N M7>:MQANYX2LP9)WC9BEN@9T^B43&/2[*SU`*N`C(854NNXN9]TL;:QO+":,& M*CNDMN)`S*BFC`@8,KN7C$9#V_:A5U5[[3T#WF?Y%P^+AVMF#\F!_*;_`-`8 MV6=P8G^\`[U_V3T]=?W8&Z_N?X&,S_?TFD_B/F^U\Q\VOQ^KW`+[]M3^\T?- M[W49VM.:/K5G*5"Q_6&3Q@GTU1^DS'2+2NDE/I\F+H9>$XVXVX4Z_!TTKYZ: M4X^O]+\_/K__U=_CW[KW7%D5P`ZJX#(X#`,`T;!T8`@C4CJ"#]01?WL$J:J2 M#3_#@_M&.J21QRJ%EC5E#`T(!%5(93GS5@&!X@@$9'1)OB'\ANN^Z)/D!4[= MFVYBVPW?F:I(HJ::**HW'A\CA]FT6UMZS5$U94C+C=E3:"EJ8F,$OBBBIM4( M@>2$O:+GCDWGEN?[;EZT5);/?IC,KJNN9F*-'>'M!*R,A6$L-<:P(E:(C&8/ M=3DOF7E%.3?WXPD#[2B!T^%&2:X7Z=@/A>-0`0P#-0E@)!*B:G?_``JJZ[WS M1?)3XW]SU+4E9U7N?IW/=6X*J:%!1T&_]EYS?6X=Q8N2OFSRTQSC8G=$%;%" M\,$M61OMS64DDM7B35KA,C41B/#Q1SFK_P!(5&06B_B;5G\0CII5 M1J<@TTD=I/3E46,3J(;E.=-C_>%V'AT;H%58]K12C[AMS1^')+-)>J(-,,=V M\"-'4T]/3&@K9GP^%BI(L?C`C/E)8=GKY*$4>6>IGJ)YXFB>F@2I"3 M3AJ6^C&LQQ9&\L[;ERZWN_#6D-JWC4@M%\5EDM"DELOBS?3VJL)&\`?42R,R M*MRK1*L[%PC&UN7&XB,P(LBZH[9!\-N@$DEM+WH5T-&L%)X1X$G?(++7]5K^ M6QUEO'IKX"?#WK#L)H_[\[.^//6&+W-$D;0R461.VJ.K?&54'WV1IX*S%"I^ MVGCI9/L(YXG6D2*F$42=SM-XYXYEW"&:UEN'E"M)`OAI*D9:-)8XRSO% M!*RR201/))X2L8_%D96D;(S;;=K3;K*V*A0D8%%72HH!A5J0H&`!4T%.G#XN M=Z=:]L]@_)[!;.PF/PV?V7VT]/F*VE)5][8?^%4V"Q^[T@EFD:G3^/[Z%CL,Z2/9;T6+H%\.:.2)(HYHW4!9` MSVTJE@OX`6:0MXKS'[DHHZ][]U[KWOW7NO>_=>ZTCO\`A4UA=T[C^1'PRS>TH:[* MT%-TMV!7XBLPFW,EN%YIY>R]@U%3487+8J5X8A)1M2-)&`HF9J699340T<%1 MF=]U^'<6V/F5["XABMWO;>.?7%$^M&D@[-4EQ`R!H/JH056;2]PLA0K&8IXR MY^>S2[V5+G;YI8I7'B,J*T?AQL&"RJ4;6Q9BD,9)JTC/%&]PD(.YKU9#'3=8 M][ MC.+G<+ZY$S2"29VU,`K-J8G457M4M6I`P":#'4B6?C_1VGU2@7/AKK`%`&TC M4``\@`!KCQ)*<-;?$5Y[1]*>O>_=>ZU%/^%8N$W;ENOOA#)MW'UN1HHNP^W: M+)18_:F>W#.M=DL;UF,&'K\+4I%@XJB>EFA5JB&0S5$D7V[+51PQ3Y7_`'6; M>_N=RYE3;;RWBE6;;WE$MO#/XELDTK3QQ>)<6[02FB%+@>/%'I(DMY)&@T@3 MW#5GV&,6]O(UZMPC*RM*550KJ0884,DA,C0MK5U:"-)98D><1-&+'SP_EE=A M_//^5!_+SRO4-5BH^_/CO\7>J,OM'9M9C<#ALGV2<_\`'O9^)S.U<'EJW)#! M[CKJR*JJUBHJ;[NG MQ9C/]WG:N99KN\]M^<8[FP>*26.!C`[LJL-,4R<;&E+D3AXG=9HL_E)IZNCJL]3QF!(2U06'VY MF,]$M6167W9^;7O)+/=.8=IMY!&S!4E:>1RIH0D:(#)33)J$1=D,9#HNI2=V M7N!MM]I$6U[@C:78AH#VA&9>_P`,R:&9DD5$:C,T;`"IC#@;M;^8?_-H_F?? M+GXOK\2NDNQ_B)\0=L=B[#WSVANS_5&=[!7>F^-TQ0;2W.3U MT,C38[;NVJ.H>9\X))\@8OX?5R+.;/;?V\]K^3^8OZQ\Z6LW-\EM(D06)+@Q MRQO&]8PMTJ6\31^+!<3W2&2)AXMMWQ-#._M_,6Y;Q?"*TVEUMT>,MJ+QN8I& ME02:)(HS@Q@Z"RMB4A740M.Q]Y8#?U1_PJ\Z+RLM'6U^V/[L]D^,7?%5DZ//[IR&4R!W$1EZ>MK(ZS'PT--11+]HL,C)FJHG>T^,_W6=W MN+&^M8[>&Z*SI+&6D9VN65O!EAFC>(NL]H%5X9DI'.LS/#MM\BA9US+JM9_=C*?:EDVZ\>X'43Z;BA9:PC_,D2:?9WRU3^L>P:@2OUL% M?+_15\\_X#TW-_8R_P"E/^#K6+_X2>8//X7XU_*I=PX:NQE;4]U[!9Y\IM,[ M3RE1+#T]MB*2GRE-!65.,KJZF0)+YJ=(HU@J8XX]=,E/(T^?>8%XF_6/W;Q$.7O=`^-!'/X-JQ,LBG5%'([2(D`9'61D+)#=:G\*>2(I!. M%EAD`7.JVYN.7C?VKS;8;G1*J%M3"2BK&BM'):^*[Z1%+>(T$#@,T;E@`'G\ MZGXZ?*7H?^8-\8?YGWQYZOA[WZOV-MSJILSMW:_7N7W;BMN[QZUW'3?P^FR< M&U\O75VVMC[SVG5P)ALA!0U:TF64-Y7J8<9!4EOLWO\`;[_R=S![9[SS':;? M:R0MH)ME,SK-/;O=-',]VFMA#%(J6R1AAJ$Y:X$;0-7FRTECWVWWFRVV2:*) M-:*2TB_IO\$FE5"N"\4B.B2&0Q2-],\L-KH''9G_``J?Z8J-L8[)=D?"WY*[ M8SZX6BGST.VJC86Y<''ETARBY2FQ>0K,_@JZ:@@KL)6&)YX(F%.MY`DD%?'1 M%M[]V??X8H]SL.8MJ(EC0L)Y$BGC4C4JS>`]W"-!FC#-'@Q`PC5'JE$D:@1W$I\4M&-2Q2R(^9K_A3#BM MY_P7:/QG^`'R:[6[;W5GL%MW;>UU'6X^[UN/+UM+O7.7,5O#RY%=6\;R6BM81&9%?P%, M4*,MQ-*K2+';B22CO$T1HKZQDW=9;.4(+9VL4M/!B$T?B-]5<@T\6X\.UK5C;V4,!>A)RC?277, M_,#I"XLW7BT,\5)(V",E73PVH.QG++.7C9&0Q)%H8ODU\<_GS_)M_F+=C_-C MX;=387Y%]>?)23N'^+5-3TKO#>]'M':V]L_U7V'O?8.\HNN-\X+,[7W)2938 M=#4;?W'458H\G''D(Y<;%245/'3DO+N_#=QBX%O?,MO+;?MBO9;C:[..:S:`I&H0*L=& M4U(UJ31%T*JN$E M&PT(S2#M;P8\OI^H:(@>%XA0-,]MU_T%+=_3Y*DQ]'\!Z6:0I7UM9%_>KL$3 M"CI=WRX1J2!'V!%*V2Q]-2-3U&F.5355,+62H4XUTB_=IV-]XW#;VW_=(K:V MM;6C%X MW2B$Z4=5*ECXC`B-7\,RZ76/5,JPR)AO^%&G\R3L:;#Q]*_`_K[)Y?.24J;< MJ_\`1AW]VA+64.2?:4]7BL=CML[DV77Y3(.:KQO]K,8VGJJ0HDZI2G*F<7W< M?;2POY8>8><+V-H4JZ&;;K=E#JND^,[SH%#,)7`5F\*(@A#)&ZVAY_WMX%GD MV">#9R6>0.LNJD9DTRE0`H*QJYTL"W>X4U^G2]%_X4_RG_ECN'^4!_,$VMN; M,X/97RP_F#T<&]<+L[>.S:6*KP>&VKNS.;FP6"WG@)MP[;Q&(K>W,A79Z#'T MSU*X'"T.1HY:B.J5:ZE>-MV]Q=MV3G_DN.'>OWILFQI)X4WZ@2)[V+4VB,7$ MS2VUAO/WCMBPQ7%VTD2Z"JZ08YE&AB MRPRH7`>-<12?J@,6UN57^7G_`#>^VOY3O46X?AS\G/@SVGD#L+>.[\[MFMVK MB)]B[RCDW!6;BW%N"EWV-\2#`[N89'%U*T&;Q\U'%_#(X34Q.E/6U\4P^X?L MYM'NQN\?.O)?-L)AG4+-5XIT+^(Z(84M6)@4J*R(ZC2Q+NQD,I!;ROS$=MBD MV*_VVXCNHJ2#].7*3R,5U,T:EF!-&=ZR.JF:;1*+B*"R3&_\*F?C;E,;33TW MQ(^4L^4J:'&,,=14NP\C3QY?*08EH:!ZRCW++5&B:HSE*D=2M(7F2>)UA/W% M(M1#\'W9>=IKJTMWW;:X7DF"-&\ZF:(Z1(4E6'Q85F1!+K1;AXM<$B1SR=C. MO@]Q=KN#.8=NO'CC"!M$3.Z,S,I$D2@N@4JV2"W8]44-;F>K_P#FV?S+OD9_ M,_\`@COB@ZI^!W8757QLZWWYT_N_?O<_:N-Q^[LU4[MK]R;"I]@;?ZRQYDPN MQFS\F0WX@:4UN86II:B.=!3PM2/DASRI[26?(^\FT'N):S:&) M;>Z@FG-]#=7D7B0*EO),7U6-YTH5(]_\*#]O]@9_XP?RA5PPKZB#&8RH7/8F M38<^8B_O/2]/;$HB&H,Q7TV4VUD,7&,A]_2Y9))&AA-+(]/#_%"Z[V#N;+^M MGNG<0>$MF999F8O(LILR+IDTNA2%`7:!UN(HY)E77X4!6198##?HK[:.4^6E MW.U-QS2 MT]/#,/+2U%#+:6-7__A! MGOG]\(.P^D=E[IPNS^QL/7T'9O6N6W-0C(;8FWGL['YF.DPFXHVRV$6EQ&XL M7EJNADJFJ5BI&J%FE2:%)(9)(]K>=X.0N99MVNHU^EGLIK9W:-91")@*3^$U M/$$3*K/&'C:1-2"12U>BC>=A3F*WAV\K(S^*"JH%U,Q5D"C4C\=="H4B0?IN M'B=T;7B^,O\`-K^;/\KKJ6B^)_SP_E]=F;SV?U'AI]H;!WIMK'5>V\]-UUCI M=XU.+H]P97<4NY^O^V<$U'2_P_%Y3&U>&C@Q].@R$,DZY&:DR$WOV@Y8]P]W M',O(_N':IN%U=/(R*%*B5I'9"@2YEGCG2,0M=R2%EDE:6[1H8BL$84V[>;_; M=N:3<]B=9(TB0FDLCF,,5*,1&\LK0DR:6"M',"LJN!*YC.)BO^%3OQTR&,FD MG^(7REI<_%F<[M[^`Q4>S:S3E<1FUPE.)JM&:#?=N3;'FE3Q)G:%M$,LL3S:"K#P9%@EN;:4R"*YM?"EC MDU2>&MW]P]NCOI[1MIO]*B'2W@/J=Y0S%5B($U(U1RS:#_9RC2"L8E++V_\` MS@/YD'\R"3;'2_\`+7^*G<_1G]Y=V[)KLQW+58NJJ\WA*)JO;,E?3[BWU#$W M5FS=B_95=0,KE96RDL]`T?V""I6D^_&EM[/\B^W=O+O'/?-ME=7]OJ*VTH7P MW5'C+QK;BX6[>66)I!!)H$<*-1/;]_7FX7]W8[+M[0S=S,TD31B5D M\)0RR&FI`/TFD6.73I0DA?"6;9S'5OR$'P-_T*CN;)CY7?[*.>K_`/9AAC\< M,S_LPQZ<.U3W1_"OO/X3_%#V2?XX:?[C[?S>CR:/5[QFCO\`EV+G([O%LI7E M8[J;CZ4>$&^G:Y,K0U$?@ZVC)4MX7AEB24H=/0Y*N8=!65TCCC1I)))&")&B`L[N[$*J*HN2>`/=7=(T:21@L:@DDF@`&22 M3P`\SU221(D>65PL2@DDF@`&223@`#))X=4L?S,_F_-LJDR?QQZLST,^[\_4 MTN/[%S6+QF1F.R]N5LFTXIMHRU:8G=%!E,[N2GSDGWJI2DTF/J8X7A>HEACJ ML(?O/^_K;%;[K[;\J2_[LY(PEW<1NKM&DJ2@V\0CF62*XU",2.ZGP8W-8RTD M(DS!^[S[-0[E+:\]\Y6T2[8`)+%)9%"F2,R.MS/#J1WMU,$FE"Z^-I9BK0!Y M%I%^,WR8W'\1>S]C]J8F1TVQ+N+9.U^R\/'3TU*N8ZUW5N7JG"[LTFJV]B*3 M)Y;&8O+R9'#0-D4>;+QPHDS&L#9C$;VAY[NO;/GFRW^UOIEV9"1^JIQ6YMO-421305,8,=5$Z3 M0QRQA8NV/MO[D;AL,NV\X\E[S%-:S*'5EJ8)XB20CJ&#$%28WHR.*R*/#U,H MX[FD!HWCD#H5)UC*T4NII(C%DHKBFF5WI_P`)I?YA M.R>TX]N]*5_6G>W6-1C,_+B>RJO=>)ZRK\33?W\Q4N#QF[MJ[CRM970[[?!9 M"6>2IQ,&2QKT-'5P_3&7Q!% M*LR&&:*R:**2`QR1S6ZS,)D-LUO&EQ'/%FZP]E?(#YQ;VV?V?O+97\&SVS MND]@T^2EZWPVZ<=C\0N-S._,OG5%7NW*X*OH'J#14RC&RU3A9Y\A&M3+D8O] MROO"S[O;7NP.*@R>/&Q<#N3;F:JJ?\`NWX(,P])N;/4F-EFB=Z@/CJ% MQ+%/Y=590\E/O+?>`M.6=KON1.2]X!YGGB`N[B!JO8V\L<<@,1PKW4\$JO&L MZ[;SGS$@CV.VN(Y+>)]`^K>.XCBU%9)(RULL MNJ,NH=))XW@H[J89*+>C>]=]_&GL^G[2ZZDCILKBIJ^FSF+?%3T^)W=M[[S> M]5D-NY**FV!B)H<#4_PB(M`K4KP34D4JK3FD48;`_P!N^?K_`-M^;MGYKVYY M=5HL;3Q`]L]OX<<+6\A:=U=U0SF,JFJ!UJ4C162SS;Y^Y2V/W&Y9NN6]VNXF M666-DD5E++.?`5;FW4W%(XPDP4QL29/&#`2&1?J=PGHSO#8OR"ZMVYVSL.O$ M^W-P3Y;&-'4LL59BMP[=W!D-I[AV]DH7T2TN4Q&Y<544DD,JQS"1`&16.D=C M.2.UN(B31HKJ*2.6$@G4LBCXL=##[%W05 MZ][]U[KWOW7NHT%91U4%/4TM735--5TRUE)403Q3055&Z1R)5T\L;-'-3/', MC"125(8&]B/=9'2&&6XE8+`@JS$T50`22Q.`*`FI/`$^75/$3Q4@UCQF!(6O M<0I4$@<2`64$C@64'B.DUA>P-A[DJ&I-N[VVCGZM*.3(O387C'<-KW/:;8WNZ[=/:V8_P!$EC>-,`L>YP%PH)X\`3P'2N]K M^D/7O?NO=(V'L7KZIR:X6GWULV?,O.*5,3#N?"2Y-ZEOX7IIUH$KFJFG;^-T M5D":C]Y!Q^['J*3O^Q"\7;CO5H-P+`"+QH_$)8`J`FK54@@@4J013CT;7&P[ MY:V[W5ULMW':KQ=X9%05-!5BH`R0,GCCI7130SJ7@ECF19)H6>*19%$U--)3 MU$19"0)(*B)D=?JKJ5-B"/9J"&%5((K_`(,']AQT621R1,%EC96*@T((-&`9 M3GR92&!X$$$8/7&6IIX'IHIYX89:R9J:CCEE2-ZJH6GGK&@ID=@T\RTE++*4 M6[".-FMI4D;ZIT$M'O7H*/(QYC'[MZ?3+U4QJ8LI1Y[9:Y&HJ,Q_#;SQUT%6 M*F:;*?WGH_6&+3_Q&'EO.FLJ_P!<'8_H_P!W_P!=[3Z#_?7UD?A_%J^#Q-/Q M=W#XL\>CS^J?,FK7_5J^U^OT\M?VZ.A4Q^1Q^7H:/*8FNH\GC,A34];09''U M4%;0UU'5PI44M71U=,\M/4TU33RJ\1X9XF252058$$$&A!!R"#@@\#U,]O]-])3-[\ MV-MK)4N&W'O/:FW\O74JUU%BLWN+$8K)5E$^1H\.E92T-?605512MELA3THD M12AJ9XX[ZW522[AS)R[M-Y!M^Z[]96U_+&TB12SQ1R/&C*KNJ.P9D1G168`J MK.H)!85,;'9]WW-)I-MVNYN(XRHLN!WKLW M=3%-L;MVSN-UA2I9<#GL5F&6GDIZ&K2ERE-*'_28ZF)KVD0E?9W M]CN,*W&WWL4]N>#1NKJO2BCFAE:9(I8Y'II!#4)'(KM!,T,50L4RJ28I#3SHX5K'0ZM]" M#[5`@D@$5!S\O/\`P$'I(\ M'29;BW;1IG0ZG9!1AEUU:E&Y\7@:^DQ4- M35?*"'F M6TN+K3I51<1R-I1)RCS%$97CY8O5+G4Q%M*-1``U,0F M3I4"IS0`<`.A%BR%!-1TN0AKJ.6@K4HY**NBJ89*.K3(-$E`]+4JYAJ$KGJ( MQ"48B4NH6]Q.56A<`JP(*L&II((P0U10CC44Z*4BED8I'&S.`Q( M`)("@LQH/)5!9CY`$G`ZF>W.F^H5=DL=BX34Y.OHL=3@3L9ZZJ@I(0M+25.0 MJ6,M1)&EJ>@HYIY#?T0Q.YLJL1YNR&XN'Q;PH7D8X5$!`+.W!5!(!8D"I`KD M=>\P/,G'SZ:\/N[:FXI'BV_N?;V=EC-:)(L/FL;DY$.-JQC\B'2BJ9V4T%>P M@FN/VICH:S<>T-AN>V[I&\VV;A!UZMJ#GP5=()"-!2CG:]HI"I->=QB,^W[3=3P!J:HXG=:BA(JJD5`( M-..1TU2]N]3P^7S=G]>1?;_<>?R[UVW'X?M/XO\`=^75DAX_M?[OU_DO;1]C M47MX9-*;^M_*7_34;=_V4P_]!]*_ZK2.9U:S"X<@\$^Q?)N6XRI-% M+?S-%)\8+L0U':0:@31OU&9\U[V9OB)/0?"(""%%1\OR_P`&.I&X=S;;VCB: MK/[KW!A-L8*BDI(:W-;ARM!A<322U]53T%#%59')5%-1T\E;75<4,2NX,DLJ M(MV8`AW1HI MC*L-905,-92RM!-)3S".HIWDAIGMSIOI+ M9;?&RL#-34^+6VN*?#++'&W^\NP/\`+I?8;5NFZP1W.U[;<7-LZ!U> M*-Y%9&+!6#(""K%6`8&A*L`<'IXAS&)J<3%GZ?*8Z?!3XZ/,09J&NII<3-B9 M:85L64BR22M1R8Z2C82K.',1B.H-IY]F8(8!E(*D8/2.2.2&22&:-DE1B&4@ M@@@T((.00<$'(/3C[WU3H/9^Q+N4\BOX;S*)9 M')8*^@MJ=B6?2U":EJ')Z5OLM]/MTEY)M,K[05*M(8F,)4G05+%=%">T@FA/ M:?3I0YS=VU-L2446Y-S[>V]+DBPQT64J\=CW%$E?4T[512OR])`= M`:TU5"GZI$#-W^Y[;M<:3;GN$%M$S4#2R)&":5H"Y`)H":#-!U>RVO<]R,@V M[;I[@I35X<;OIK6E=(-*T-*\:'TZ<_XIC/X9_&OXC0_P?['^*?Q;[NG_`(9_ M#/M_N_XC]_Y/M?L?M?W?-K\?C]5[<^U'U-O]/]9XZ?2:->O4-&BFK5JKITZ< MZJTIFM.D5#730ZJ\.O_7WA/D]V%D.IOCCWMV7B,C+B,UL;J3L#X%/&DDDBHP*]R-YNN7O;_G3> MK"\^GW&WVRY:"7]+].?PF$#_`*X:'ME*$F8&(`5D!35T,_;G8K;FCG_DGER\ M2-K2^W6U@=9)OIT=99T1HVGHP@$@)3QB-,6K6Q"J2-'B7'9?*U-3F,GV=GJG M+Y?.SY;)UF4Q'5N>R\];N"J@KJW*5&0W)13R9AL=59E2T63F`?\`A4:S!EJ] MPA>,&Z[A=W%]N>X7>WS75[<.SS2/-=5D<&5&,Q81'*12^(5"$127T86#";?V M8M][VZT&V6PY1MQ;6Y/P"_"!(0BJNF.5=9F%O(?#51&IN7:)]0VP])#=.#KC MM^GJ8][9IY(-R[0J6Q%#C-F4-54TDFY=MU,](R[Q9&[%HW+=L&-M?CQ7-RRH3:R(C_KW443R,T3O$C:H89)]5NDK) MM4+[`'\F;O3=6*WGN'XY[@W1F-V[7R.TY]R;+AGHMII3;9SF`W%N1]T52P[. MJ32XVFWK39".KG_8CH8:B*GBIEAAFI7KLQ?N>^X^_3;SN?M]N#?[H7A>XLXI M"0;?PQ&TJ0,RDR12BXCDBA\27P8D+EZ,&N,&_O<[+LGN)86,=INB,(I MT47+AX9-/@H9)W9@UJVI%,ZBYG21C+(Q@"KL4@W_`*_4CD$?0D'@@&UQP?S[ MZ"1R+(I90P`8C(*FJDJ<,`:5&#P84925()P&(ITA^R=[4776PMZ[XKUD-+L_ M9^Y-V5!^VEEIQ3[>QLM?-]S.'IZ6FB&D%VFG@18@\C.D<U0SD40ZBJ-IQ7)`)]ROL4W,F_P"R;)#37=WD,`'B M1HQ,KZ>WQ&`K2H!R-153W.H;1"WKOK>?=?;7=G;&]-T[D&Z-[[UVSGLM79## M=CVV(L>-;R"6HE6GRT&/I:?C/S'S3S+ MS?NEMO7--S)=;Y-&XD=7D0PN+MHU@T6ZN@EB#02@^&I0I8*L3-&(;WM9MMKR M_P`J\@^W7*^S;?;SV%MMFB-?#O89(/\`=AN!D\;3,6\22:X^NTSJHE3PPX-H M;J25NK]O5`-3%_I`R=>B3TU6)8-O]3XT5K4GWE3)$[8G'T\]`:J7#O'/!0@T MW^YB1:1GCI-OW#-G=2M)$%VJ2(>&`");E@-9B51$`)36,20M"Y#,@AVXH9G1 M1?7',%E*+QX^5H(VEG.D-]?VHVI0XU3.L>@7",D1J#]*AN2CGMF?WT;ZYV=>]^Z]U[W[KW6NS_.BWIO[( M;YZ9ZWI>QM][)ZGW;L*?/Y/"X:AVSB:3.9>;=,6#R,V5EWI!3A+P_$U21DN8BZLP@D,Z(]N(NZ/BY_+5ZMW'TWOC9ORL[*^/N^VV?FTVA MNKJ+LC!Y');RAHH,)35>;W+AL_UQV)MB/=$,U!%#2P-C,X$^S[E,GU$4EK>&0W'A+;B1);CZ>1Q&YE0_3%K=9]V^ZOOWS;M?-6V[U[9[=O_+CR0--#>VT`4'6&)XFHH:\/3JJ#^#%W[W/, MF^\N>W&W/M)G2SN-SB2X>(E:HJO)'%+(K(\4,DJH9'1T9Q&+?6@G+KDM]UG9 M>7MV]P-PFY@VFVOA:;=)-#;SL=$LBN@*>'&#M=7_BA;&E.0/:2P^[QMWN3#?1)[A3PPA7-[X;/<">**6W M6-"@6J5,Q013Z&=IKN.-Y)ADG;>Y'NO:^_.Y*G,]V8N?<&[ M2\FHEJ:N>NHL1MK#TE'1U,K^6JHJ>*614=V1)"R(K$\.^4>79NZX M(F9)JC;6X(86!I(U65\-7:#)/D"F.ID4B_DJ'C@#`:V"DWD3F5-7+^]NUQX< M:6<[,=,;@KX+KW))VN`2'T5745`8Z-8,([-V\CUOA MS4Q"HR^)AZRJL#F,OD*8U-,CO5RSWH,,]1*K5$NXD7C=R+L-K>VN_P"X3>V< M5[9[:D,T[2W(MXTT=N`R2F.5$3ZA[J4%3!%8E;6OY+^U]R5> M]^T=\X;NA$Z]I-O8O;]9\?8ZZEJ?L,I7"CR^*WF^,A]%+X8I)Z'^)!Y)JUX& M$J4U2]=#[R:^Y)MTYO.8KJWYO!L[5#')9+,S&X+E/#NY+=HHXDC54"QRQ(D_ MBM,LQ".L*8T?>RNMKMMFY=VV?DH2/"C%!&K, M8P\(@8;#?OHGU@IUKB_S>=M5VY_F9\6:"#"UFXZ>3K_[-]L)DJ&*DW=4Y'L^ MDIZ?;-1B\L*2B^TJ6'W%77T]=0Y"FAIA`)X*&KR$\?/K[W%E'N_N3[;[$MG! M(K))))H,22)T`^ZON4=A[1^XB3W#VZ MR;JFFX9)&2"EH_B31-$\;"=5*1>"[/!.9XI&475K9"1);0_EU_+WN6WID*;#UZK#CZZFHL M>^2I#'6G36Y6(!WE7[M_NA!SIM._[1RO:\KPP);N'7<9KA0\;5E5A#.ESJGB M'@R@2>&%DE49E$EN9[C]X/VIVOEG=-OWZY_KGNCHZ)'/PIW@D<"&=39H#$DD6S#31/!3P02U,U9+##%%)65*TZU%4\:*CU,ZT<%+2+ M-.PU.(HHXPQ.E56P'2?KG9U4]_.!WAV/M[XQ;9J.N=Z;SV%193MNFPF^X<;2(:J@CBK)76!Z.JUM#!6XR_>UWG M>M@]M;*WVII1^\-SM[:9H9I$989H9I/[2W+/4E53P]+@R,(Y(I#6"3*K[H=G MR]<^XV[7>][-!>W5KM4KVHE^H/@3O-#`+E(X6C5Y(5E.DSNT$8Y:'Y%Y_/[DQNZ\U1;SV#NG<.XJRN["WIMW>]36QY M7#8O';7I]C9?%^#$##+CZ6&FQ7VLAK*)\G538H\]\CY>__/7+G,') M%E)[?C:[66"SDM;N*VBABM[2:V:.KBXDEO!(HN3*;J:0S221*LB1/'LA_P`O M[?.^.R?A_P!'[S[#S60W'N?*[:KHJC/9>2.;-9BAQF?RV)Q%;G)5,TM1EUQ= M!%'-432R5=:4^YJ]%5--%%G/[#[WOG,_M5R9O_,%_//N,T$P9I2C/(JW$B1/ M(PMX-;+$BJ)%73*I,K/.6$IY^>^&S[!L/NAS5MO+4(CVL21N(PFA8GEACEDB M1*G0J.Y'AE4,)!AT+X>31;TB:?9V[(%BK9VFVSGHE@QK.F1F:3%U2"*@:.BR M4BULA-HBM/4,)"+1N?291W9_"VK.XI#XTBO'>I-=KCNA,;2$LY4W&N.UC$(C:6[9Y%1HE82$S2&- M"D4LBAA%),3*\:,D$>B(@.Y52Q"WU,H.:*J6#D$445-2!Y@8!.3G@*FE32@) M&'JH6$C`BBBIJ0/,#`)!8U(PM32K4T@D4/?SBOE-G:'%)\5.M^PGV'5;CPZY M+N+<6%IMJY+-T^W,QBLU)A=DO3[LH,I3T6-SRT:U&1FHJ.IR"TTE,D3(T\=+ MD,%?O<>\LNR+;^VG+I26YE@:7\\YVUU+W5@MC08O=M?M/"[0VIMCMU/XS2*L-)A-LX M>D6HW/EUK,;62QRSQI_N+9+8I*2H(&^[?[@^"-8YU-P MI2]1&D$)EA'GWA.0]Z]P?;/;.UED@=$U?6758K&W,(@D4*9BMV9FGO!-(=G^-2B(C2/*RHJM+($ M#R%0`9'$21QAW(N=*JMSP`./?1]%*HJLY8@`5-*GYF@`J>)H`/0#KG!&I1$1 MI"[``%C2IIYG2`M3Q-`!Z`#'5_<^[-NY2H[0Q/2>ZY=N[H MH,I4056!K-H;/W)5;=J<5CSC\MBJFII:JIE9DJ:#(K,[HS02R04@BQP][?:+ MVTY@L>9^?^8MB>XYCLMM+J[3S1PL(XY!%&P\>WA*:\R+')'/0C2ZN\=<@?9_ MW>YRY6W'D[D_:)[6+EV3>[>2=#$M;@//%XJ32ZXI!'(BK&Y2:!O#4*)HQJ;J MI/\`E<_#SH_Y0TOR'R?-J MH:W/S4[&LH:[(9*.FI_MOMEBA2CE]XP_=A]G?;_W#VWF9><^44GN-N>!$G6Y MN!XPN8)#(KJDB1GPB5>&6-%[6C9)9D599,I/O+>\7-_M_=\G;=R;);68D$\E MQ(8VEEN&1H=*.MS)+%'"J$(IM(;<,WBZW>99-&T#24E+04M-0T5/#245%3PT ME)24T20T]+2T\:PT]/!#&%CBAAB0*BJ`%4`#CWTIMK>&TMX+2W33;Q(J**DT M50`HJ22:``5))/F>N;Q)8ECQ)ZJE_G34U14_!;<7V]=D:(P=K]*5$HQCM%+6 M4\?8N%%11U,M/B,UD$QCQ,7JE@BC\M.CQ3ST](]1/'CO]ZMH1[.;TDZ0:))H MUU2@E(R0])*!T!93\%=;*Q#1133K%$V3GW0988O>_:#-#;O7:]T"^,L3T8[= MN%TJVU6[!:L0JL M@*HFK/AH"%C!9Z(%`DE'ZC11[O2>-[H<^S"V:%7W2=A&7G?PPSDB,/=*MPRH M"%0S5DT!=3R'O89NYLQN;;W4':N?V4Q3>.#ZWWQE]INM+1US)N7&[9R=;@W6 MAR$D5!6NF3AB(AG=(92-+LJDD"WF^]W/;>5>8]PV9%;=H+&>2(,<>(D;,IPD ME2"*A=#!B`IH#4!?E:TVZ_YFY=L=WD1-JFOH$F9Y/"41/*BR%I37PE"$ZI*' M0*M0TIUK,_R]^D/CS\ELKW?N3Y<=LYS=V\:G$8O^!?WXWSM;;TT%-DZ?);JW M-O&FRU+;,UNX,!D)8HON*ZND2IIJ.26MIIJB7*ZN;WW>^5_;WW=N>;=X]W7$ MO,-M)!VMGR?M M'M)RO;V.U2F?Q3!9RR'7#].FC3))*D:.`[KH@B&F1OIY3`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`NJ19/%FC%_M?RUR+LJ\ MQW_M[MUN.5]]\">-8[C<"EBJ1LJ+;2RWC2-)<)*3/!=I/-;LRMXT;Q6WB[4/ MVO\`SA1]E_$'_P"R6OM?XK>NU_\`,IO%_$+_`,)_B6O_`'9_P!\]_P#=&K]O MWU!\;_F"_C_3#_E5]7A]E/\`<&NC^TT?T?[71_PRG=US=U3_`.O5K\&X^I_K M371K;Q]7U_PZ]&OQ:XUZ-6O.BN.O_]#:L:E^-7<^8%! M3PTM1/DC@-@YW.?PR*"NH\E0RODOX=X-,]+5P'R6D@G35$\>^Z^WS[G[=1^+H:-:,XL!HU-!XOMX_&(13M_!>*+PQQ1SR6EBTT$J$A ML,*`7"#+VZ40(GB532*12-IBDC`L>HBJ8#;6X^I5(WF;4(]?A_[D`.I:W9Y) MY-1R0VJBZYI3./KT3O#34[02'[PU+IFME$8IWFK[JF>ZRD:J@HQ5;L@449PZ M^6^-C:#[9'4TGVSU&`.+*`6^ZOIMF42LX+7Y6BW:):R*HBW`UH(XTUVU\H(D_Q5B\VLJ:2T==*EKOZA8-RN'_E! M[1RVYOE5D]XTR1UN&Z_Z]W4^5R5574U;/05NZ]RYN@P^-H!-G-V3:,Q'/5U; M2PR4S@1->=TG>3*Y'_<]L))?1:,]1+$JQRR.$"HK,6\`/)(2 MDG92KRW.*/WI=RBLO:S:]M:20RW-Y!&L901J@CA$C%!]/$6":56@6(!Y9`4' MA"*'9YIXWBC99*F>J8SU4@EJ$@214FJ9I8Z9134]-&8*.-Q#$2ID:)%+O(Y: M1NHT=)%.@9^1FUJ[?O27:FPL/05& M1SFZ.O=TTV'I(Q7P1S5T5'&*6- M]FFYBY)YOV&W+BXO=LNH%T$*VJ6%T4!B"`26`J13.>A;R!NEELO._*6Z[E!% M)MT&XP-*LBAD\,2+K)#%5JJU92Q`#`$X'6B_@YZF+)]E4=7#EL:Z9K;5)_N0 MDIZ3^+&BZ5Q&-FFC,.9A?A:-C('8^/J:XC:DD0&O0;8":2EM17HM5%:J->IK< MPD6-@G\FG:^8W=\L6W#'2YFFQVPJ_P"1FZZZ>=J90QSV[)=I4.4JUILS]G*N M\X_=>Z][]U[H*^U^DNJ^\<'_ M`';[7V5A=ZX5::OIHJ7*0%*FD7(FD-3+CAA+:UL^:MFBO+:"021AQ1HY%9662.5-,L;`H`?#D4.I9)`RFG0 MEY6YRYJY)W%]TY5WZ>RN7CT.$T%)!J5AXB.K*^DK@$::,P(-10L/6/\`+1^& MW4F_\5V?M+J>&;>N#P69V_A\INC.9O>%/C*3/_W7?)55'AMS5N3PD.5>JVK% M+'5"G\L)J)XHRL#I#&">7?87VLY8W$[IM_*\;W(NK>XC\5GD$,MJTK6YAU'4 MGA>,RIW$JBQ(#IBC"C_F'[P7O'S-RONO)VY<\SKL5Z5,R10VL+.4CFB74\<" MN5T3RAHR3%)K/BQN`*'R]S#U#?2=W7M+:^^MOY#:N\]OXC=&V\J*89#"9V@I MLEC:IJ*KI\C0S24M5')$*G'Y&DAJ:>4`24]3#'+&RR(K`NW?:-LW[;;S9]YL M8[G:[A"DD<@U*RGU'J"`5(H58!E(8`A?MFZ;CLU]!N>U7DEO?Q$Z70T(U*58 M?-71F1U-5=&9&!5B"1>+^5G\)*;<3[EI.IJJDJSD1DXJ*#>^]_X323";%S"" MCQTN?EAIZ1&H)A'&O$`K93%XVBHS2PC#]V'V6@W*XW$&I44A9F@PGZ=(XM$NWOWBO>/<+.6PNN<";=U(;3;6:$@\1J2W4YX-0 M@D$@U#,">O:VU\%LK;V)VIMC&46%V[@:1,=A,/C:.CQ^.Q.+@+"BQM#1T%/3 M4T%)0P%8HP$UE%!=GWVNT[/8PVNV0+ICBB18XT6I.E$0*JBI M/`9.34DDQ+N^[7^^[E=[ONEPTVXSMJD=F9F=Z`%V+%C5B*D`A16B*J!5#GD* M"ERE!78RM1Y:+(T=305<<0W)G]Q393&81(5Q<4YSV0R`@:B M9)-'@$*B.;PV^W@I(:>.>3?:'V]Y`GW2?E+8!:+>H5F3QIY8G5B"1X4TLD:U MI3M457L/8J*H^YR]TN=/<"VL;?FWI``A,2 M.%$C2O(R]5?";X[]*]BIVMUOM+*;;WN<)D-NU60I-V[G3&Y##Y+^%M-CJW;< M>4CVU+CJ:7%J])1K2+14%XTIH8HZ2@2D*N6/8?VMY*Y@7FGE/EMK#?%+`21W M%R5T2']2,PR3/`8W%1I,1T8,1C9(RBKFCW?]PN=-EBY>YFW[ZO:U='TO#!J, MD:E4D\01B17"'2=#(KC4SJSR2LYL/0!=#^(H*HZJZB0!]#AD+JCLI:.,H/^6? M<[G/E#ESF#E3E_<88=FW1U:X5K:VE=PL4L)02312.D MQMT`.O>_=>Z2N\MD[7[!P=1M?>>%QFY-LUXGBRVW\UC,;E<5EZ6HHJNB>DKJ M;)4=7IC7[ORJ\!AG62-;2:"Z.6;SLNT\P[9>;-OFWQ76U7"%)(I%#(RGU!\_ M,$4*FA4@@'HUV7?=YYSW*,]LD3LC#U!*D54THRFJL,,",=$=VK M_*O^#FSLYD,WB.FXR,GD,YD:O"56Z-UR;8GESN4H\U+%4[>BS$.-R%/19.E: M>!:I)R9I3)*99(Z=X8(5$-13F18Y25UQNE_U*PN#<@,"IK0C[/YC(_+K49I,=796OIFEBW)E5X4F=VJ#+-+%O+GLI[9+W%YKDV6 M;>^8FDDVZY6XMRL4*-'.M#XH=(PY;4H8*S&-#VQHB*J+RZ0^''0WQTSF4W!U M!M[.[5KL-'3HT9G9$*QQTR4ZG MDKVB]OO;S<)MTY1V-[6]EMA!(?J;J19(U-4UI+.Z,T9Q&VFL:?IK2,!`DYT] MT^=_<"QM]OYHW5+B&"35"?`MQ)"I*EXTE\+Q-,H1%E9V>5@@/B!B[,:/W)74 M>]%-Q_PB^-^/[,J^WGV-+F-\Y'*[ERV3K]S9[.;HQV3FW91[BQ^9@KMO[@KL MC@9J62AW+/%&OVP:$!F1@]36M519![*>V,'-=WSL>5DFYEG>1WEGEN+@%Y00 M["*>62$$ABJTC`C4D1A`S5D2;W6Y\EY?BY93?##M*``+#%#`VD%65-<*(P4, MBDZ2"^F-9"ZPPK'S[)^$GQK[8W%B=T;QZ^!RV&Q]=C*1]LYW/[&I7I:_<\.[ MI'J:+962P%+/D(*`/I7A%5;"24\55)`<:F)?Y6]X?E)EE#.&-'CJ/^'8^AQ_W-76_8T=+1_>5\JSUU7]K`D'W M-;,D<235<^C7(P50SDD`?3W*=K;0V5K;6=LA6WAC5$%2U%4!5%6)8T`&6))X MDD]1Q-*\\TL\FGQ'8L:*JBI-315`51Z*H"@8``QTT;QVIAM][1W3LC<4+U.W M]X[=S6ULY312>*2HP^X,;4XK)0))I8(TM%5NH)!'/((X]IMUVNRWO;;[:-Q1 MVL+F)HY%622(LCBC*'B9)%U`D$JP-"16AZ4;??WFU7]EN>WSF*_MY4EC<4JD MD;!D85!%58`BH.1T$'1GQ=Z5^-TV\)NGMJS;8._),+/N<3YS-YY\E4;??-?P MNIDK-P5^3R'FA@SDL;DS'S%?+)JJ))YI@GR+[9\D^VMON-KR7LOT<-W(LDOZ ML\Q=E!526GDD(H"1@BN6:K$DBCG#W!YLY\.V?UGW3QX[*-DA4)'&D8?27TK& MJ@:RJFGPH`L<82)$13!>QYT"^@>[UZ'ZS^2'7==U9VW@Y=Q;,R&6V]G*C&Q9 M"MQKG*;6S5%G\)5+44,T,H>BRE!%*E[Z74.NF14=0YS5REL'.NTR;'S)8FXV MQG#%-(DDCUK M0AHIHVBFB=34-'+$[(ZGR:H(8`A9;"V-M[K39^"V)M*GJ*/;6V:1L=A*.KK* MG)5%'CA4334]')D:Z2?(9`TJ3>,3U4L]7,%#SRRS,\C+]DV7;.7-HVW8=FM1 M#M5I"L42:F;2B"B@L[,[&G%G9F8U9F))/1)NFYWF\[C>[KN#HU]<2%Y"D<<2 MEFR2(XE2-:G-$517RZ5_LTZ0=$6[%_EM?#7L_XE>1I#;220*YE"B35"C"`EBD;EO"UB2-9%8.-1F;:?O!^[^RV-IMMCSB_ MT<"*B"2"UF8*OP@R2PO*U!@:G.,<*#HP?2WQ^ZD^/FWY-M]3[/QVUZ&JIL5! ME:N-?N\YGI,+32T=!5Y_/U8FS.8GIJ:9DA2>=H*5"5IXXD9E(]Y.]O\`D_D" MVO+/D_8X;&UG9^<>:><[Y-PYGWR: M[E0,$5@BQQEW:21HXXT15,CM5Z"ATK@4R,WL8]!OHL&X/AWT'N?N>F^069VG M65/:]#N+;^Z*#;R4SO,DEW8O3T3 M4L9W?L_[>W_.EM[AWFR22WB:,3))/!*P)JID>"6-G,>/!J: M0D!XPLM7-N4/=/GOD2RGV_E??#;VKS^-I:.*95D*>&S(DR2(K.@56<+KTKH# M!&=6'_\`NEMS^Z/]Q/X32?W1_NY_=+^!>,?8?W<_AG\&_A/B^GVG\,_9T_ZC MCV+_`-R6?[@_JY5_W?\`1_35J-?A^'X7&E-6GSI2N:>70-_>E[^]?WUXH_>/ MU'CZJ#^TU^)JTTT_%FE*>5*=?__1WZ\E'%+CJ^*?'_Q>&6BJHYL5HHY?XG$\ M$BR8_P`>0FIZ"3[U"8],\B0G59V5;D);VRLMRLKO;MQM(KC;[B)XY8I$5XY( MW4J\N\^LNL-OUGQ\W?FZ:CQF)Q^VL/7#K[)YS(4E/+L2KA_N M9N2M_@F1.8S(Q,TB3PR192HH9$DGFEBS/+[[RWM/NWMMO0YOV;=IY.7MRN9- M(9BD=I,!'(D9<.&)5+:%K:NIIFM0'+.BQS=0_8O[PO,7N1M\.V;_`,V;E-SS M:H#*?JIUFNDC#%;A'^JC4RUBLUD8+XB2V]O,:+'#+9UK8SIG#]HU^RMF[5VI M@ZG>^\^Q^O<'M`Q[5,Z9'=<^\=E5"%*`L(Z2&& M"$03JS0W5SD%_77=^5[+>M]W7>+R/9+/;-P:#Z6:(01QS2RPL3&D($ M3*&F\&SMK6*.X2V%ANE_$#XD=7?$/J^EV9L/:FU<7N;+14=3V+O#![:P6"R> M]\S0-6C'MD:C#T%"U1@=M4U?)18.C94@Q>-"000P)JC'6_VI]L-L]K>6HMGM MKI[O=IM,EU=2'5)-,06Z'NWSA[O;ZV]O;QR3?3V\UP\Z6PFE,DQAU.P7ZB6LSG#M51)W(`IK$01@JI<@O(_KD>0W MD=I&`:1F8(&8Z5OI1;*H```DM5"`@$TJ3DD\22;XP>PL+M2DQM+2T>"RIP^-W/4=>X?(15,2T$'\;56D99T@K: M7FE]Z'VMWWEKF"YYOV+;83R?>*%$<&N)+>2@65;G2\4213&XO'6122$FND<1 MH(Y8>E'W;/?"]YEY:V#VTOM]N+;=MIMI8XRUR];Z*6[N[M@J++$\DD45U=0, MKK/_`(O(X+B!YK:6K.FZPPU=DAAL%UQBWRDV47$8.@IMI8^*ICR(J-PTN(Q< M47MRJK'$DDCRW M,TI"M&(TG+GQ&NKA:(K2.UU26X"B@_@^UJ`4M!+'30T6/K:^FJ:R.DB M6K93UQ]B/;N?D3D.QAWZU3^NEW2:^N`S-+.VIG@224A)66VB=8!$X"1L)50, MCEY.5OW@?=*Y]WO<3<]Y;<;VXV6U$5O:27$TDDDL<")6H7Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][] MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K__2W^/?NO=(/LGK MK:?:FQMS]>[VQ+9S:^\*,8W,XYI17 MMRM=ZV:YFBW.&=)$='HR,"HU#4P`4`:F088:NUF8AJIOY;/P:CZ'[%[L[%WK M3T.Z@Z_R@I85(VI0T6WJFIWI0PZ*."AR>X:*O6FJ9&C>J*0SHCZ9 MYFK,6ON[>P\?)?-'-G,G,`2;>+"]GM+29M6MU**9;MZH/U+E'54`>18T9U+& M1IIILJ?O#^\UMS?RMR9R]L7BM;W4$-]=J&IHED9T%NZ2,758&+S!2^EHC"\" MRH8"+E?>8G6)?7O?NO=>]^Z]TE-\[,VGV)M'<&QM\[?H-U;3W1C*C%9O;V2C M62FRE),FLP@F2!X*J.2-9()HY(IJ>9$EC='174IWS:-FYAVN\Y=Y@MXIMJOX MV@DCD)`D5E8LHTD/J"AG!C(D33K0@J"%NW[MN>PWMOO6S3RQ[I:L)(FB(#AU MR-)8JM2>VCD(:T8Z2>JA?@!_+^Q'3W=O>6^MXTM7GJ3KK>-;U[TCD<@:.BF; M&+)6Y/+;IR=-B2D5?G5QN2QL-'5:RE,ZRE5CJ(HXJ'%+V%]CX^5..7G7E;E+EV MP@EMH+^RBO+X:CW2NBHD<+ZRZ1QNDK:E\,NS*Y"OK+W2`6O]>3_=> MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW M7NO>_=>Z][]U[KWOW7NO_]/?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>] M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^ MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7 HO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7_V3\_ ` end